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IABSTRACT
The work described in this thesis involved the production of antibodies to several defined antigens and 
the chemical synthesis of bispecific antibodies
Monoclonal antibodies against glial fibrillary acidic protein (anti-GFAP), and against a GFAP-like protein 
on the human anaplastic astrocytoma cell line, G-CCM (anti-G-CCM) were produced by electrofusion and 
by fusion using polyethylene glycol, respectively These antibodies were purified with saturated ammonium 
sulphate (S AS) and protein A These antibodies were fully characterised by ELISA, Isotyping, SDS-PAGE, 
Immunocylochemisiry, Dot Blot, Western immunoblotting, BIAcore, HPLC, Immunofluoresence and 
FACS An attempt was made to clone and express the variable regions of the anti-G-CCM monoclonal 
antibody in Escherichia coh
Iodinated Bolton-Hunter reagent (IBHR) was conjugated to bovine serum albumin (BSA), ovalbumin and 
keyhole limpet haemocyanin (KLH) These IBHR-protein conjugates were characterised by the iodide 
assay and the Bradford protein assay The IBHR-BSA conjugate was used to immunise six mice and a 
rabbit to produce anti-IBHR antibodies A monoclonal anti-IBHR antibody was not obtained However, 
a polyclonal anti-IBHR antibody was produced and was purified by SAS, protein A and CNBr-activated 
sepharose affinity chromatography This antibody was characterised by ELISA, SDS-PAGE and HPLC 
Bispecific antibodies were chemically generated using (1) anti-GFAP and ana-IBHR and (u) anti-G-CCM 
and anti-IBHR Ricin is a highly cytotoxic compound Bispecific antibodies were made using an acquired 
anti-Ricm A chain monoclonal antibody together with anti-G-CCM and anti-GFAP These bispecific 
antibodies were characterised by ELISA, SDS-PAGE, HPLC and FACS and may be used to target 
radioactive compounds and toxins to astrocytoma cells, in vivo
A catalytic monoclonal antibody was generated using a transition state analogue-KLH conjugate as an 
immunogen in six mice This antibody was precipitated using sodium sulphate and purified by protein G 
affinity chromatography This antibody catalysed the hydrolysis of the corresponding carbonate and its rate 
kinetics were determined
i
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SECTION 1 INTRODUCTION
1 1  Introduction
Cancer represents a complex group of diseases characterised by a common feature the 
failure of the malignant cell to respond to the usual homeostatic growth control 
mechanisms of the host This results in autonomous cancer cell proliferation that is 
passed on to all daughter cells by their malignant progenitors Thus, cancer may well 
be perceived, primarily, as a genetic problem Studies of cancer tissue have, however, 
involved multiple areas of biological research Early studies included investigations of 
the metabolic properties of tumour cells and, subsequently, a search for constituents, or 
properties, that might be unique to tumour tissue
Conventional cancer therapies exploit the fact that neoplastic cells and tissues are more 
rapidly dividing and usually more vascular than normal cells However, other healthy 
cells such as liver cells, bone marrow and germ cells also divide rapidly and are often 
killed non-selectively as a side-effect of such therapies (Britton et a l , 1991) An 
alternative therapeutic approach is to exploit the differences in the proteins and 
carbohydrate antigens which are present on the surface of cancerous and healthy cells 
If there was a way to direct drugs and other molecules selectively to target cells, many 
diseases could be treated without affecting non-diseased tissues (Smyth et a l , 1993) 
Such a selective therapy would allow the drug dosage to be reduced, the harmful side 
effects to be minimised and, thus, the efficacy of the drug could be improved Selective 
delivery systems would have wide applications, including use as vaccines to treat 
malaria (Coppel, 1986), against viral infections such as AIDS and hepatitis (Co et a l , 
1991), against autoimmune diseases such as arthritis (Sany, 1990), and would be 
especially useful in locating and perhaps treating cancer (reviewed by Goldenberg, 
1993)
Although enormous advances in our understanding of monoclonal antibodies have 
occurred m the last twenty years, their strategic applications still constitute a major 
growth area m biological, biotechnological and clinical science In 1986, Kohler and 
Milstem were awarded the Nobel Prize in recognition of the importance of their 
contribution to the development of means for the production of monoclonal antibodies 
(Kohler and Milstem, 1975) Their true prize must be the realisation that their pioneering 
work has led to an explosive improvement in our understanding of immunology and has 
produced new possibilities for the investigation, diagnosis and treatment of many 
hitherto poorly understood diseases
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With these advances in immunology, it was inevitable that the concepts and technology 
of this rapidly expanding field would be applied to studies in cancer research One such 
approach would be to use highly specific monoclonal antibodies which would selectively 
recognise the altered protein or carbohydrate antigens on tumour cells and could 
therefore, form the basis of selective diagnostic and therapeutic systems (Smyth et a l , 
1993)
Researchers involved in monoclonal antibody technology are currently looking at new 
ways of generating murine, human and genetically engineered monoclonal antibodies 
(Roguska et a l , 1994) (Figure 1 1 )  Immunoconjugates, which are monoclonal 
antibodies which are chemically and genetically conjugated to drugs, toxins and isotopes, 
have being developed Novel ways of treating diseases, such as cancer, with monoclonal 
antibodies alone and with immunoconjugates are being investigated (reviewed by Hand 
et a l , 1994)
The targeting of immunoconjugates to tumour cells has been a major goal in immu­
nology and the various ways in which monoclonal antibodies may be used to achieve 
this aim is the focus of this review
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Figure 1.1. Structure of an IgG antibody which consists of heavy (H) or light (L) 
chains joined together by disulphide linkages The light chains can be either k or X and 
can be further divided into variable (V) or constant (C) regions Various antibody 
subunits or fragments can be produced, including the Fc fragment which does not bind 
to antigen, or the F(ab')2, F(ab) and Fv fragments, which can bind to the antigen
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1.2. Historical background
The development of target-specific diagnostic or therapeutic agents have been the goal 
of medicine for over 2000 years, for it was first noted in the medical writings of Grecian 
scientists, three centuries B  C (Baas, 1889)
Attempts to use antibodies made against malignant tissues for cancer treatment can be 
traced back to the late nineteenth century In 1895, Hencourt and Richet, prepared 
antisera against a human osteogenic sarcoma in an ass and two dogs and claimed that 
these sera were effective in reducing two different neoplasms, a fibrosarcoma of the 
chest wall and a cancer of the stomach
At the turn of the century, the German bacteriologist and immunologist Paul Ehrlich 
proposed that antibodies might somehow serve to deliver chemically coupled toxic 
agents to specific cells, coining the term "magic bullet" for such an approach He 
suggested that the anti gem c expression of tumours differed from that of normal cells, 
encouraging work to raise antibodies which would selectively localise to neoplasms 
(Ehrlich et a l , 1904) The development of truly specific antibodies against tumour cells 
was hampered by the absence of antigens truly specific to tumours (Section 1 9 )  Ehr­
lich used his "magic bullet” technique to destroy the leptospira of syphilis without 
seriously affecting other tissues (Ehrlich et a l , 1904)
Primary immunisation of isolated lymphoid tissue was first performed in 1912 by Carrel 
and Ingebritsen In 1929, Witebsky first described the antigenic character of neoplasms 
The complexity of the antigens and their respective antibodies is augmented through 
cross-reactivity with other proteins and the fact that tumour-associated antigens can be 
found m normal tissues It was not until 1948 that Pressman and Keighley successfully 
labelled antibodies with radioactive isotopes They showed that rabbit antibodies to rat 
kidney could be labelled with Iodine-131 (131I) without loss of affinity and that, after 
mtra-venous injection, they would localise in the kidneys of living rats Since this 
important discovery, a series of investigators produced antibodies that appeared to have 
relative specifity for various tumours (Section 1 9 ) ,  but these antibodies were later 
shown to react with fibrin produced in association with rapidly proliferating cancers, 
and, therefore, were not tumour-specific
In 1957, Pressman and co-workeis demonstrated, using a ’’paired labelling" technique, 
that anti-tumour antibodies specifically localised in tumours but that radiolabelled rabbit 
IgG did not Such localisation could be determined by means of radionuclide imaging
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(Section 113 ) At this point in time, there were two major limitations to successful 
diagnostic imaging,
(a) tumour-specific or tumour-associated antigens had not been completely defined and
(b) techniques for producing and purifying large quantities of highly specific antibodies 
to these antigens needed refinement
The first problem was resolved following the immunochemical elucidation of tumour 
associated antigens, such as carcinoembryonic antigen (CEA) (Gold and Freedman, 
1965) and a-fetoprotein, (Section 1 9 )  Table 1 1 outlines the potential uses for any 
marker of human tumour growth The second problem was solved following the 
development of hybridoma technology
In 1965, Gold and Freedman reported the discovery of a component of human 
gastrointestinal carcinomas, using radiolabelled polyclonal antisera, which was present 
in the fetal digestive system but was absent from normal gut and cancers of other 
tissues, this was termed CEA Subsequently CEA has been found to be present m a wide 
variety of malignant and normal tissues but there is no doubt that it is quantitatively 
increased in the majority of gastrointestinal cancers (Jaffe, 1990) (Table 1 1 )  Micheál 
Potter then induced myelomas m mice which produced large amounts of monoclonal 
immunoglobulins (Potter and Boyce, 1962) However, it was not possible at this time 
to induce tumours to synthesise antibodies to an injected antigen Eventually, Kenko 
Honbata and A W Harris were able to establish a number of lines which they 
distributed to other laboratories
Table 1 X Potential uses for human tumour markers 
PO TEN TIAL USES FOR HUMAN TUMOUR M A RK ERS
Population screening 
Adjunct m the diagnosis of cancer 
Preoperative indicator of tumour burden 
Indicator of therapeutic success 
Evidence of postoperative success 
Use in tumour localisation
Cesar Milstem subjected a line derived from one of Potter's tumours to intensive study
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The problem of propagating a particular clone of B lymphocytes dedicated to the 
synthesis of a particular antibody was overcome by the development of hybndoma 
technology by George Kohler and Cesar Milstein in Cambridge Kohler devised a way 
to fuse B lymphocytes with the related, but malignant, myeloma cells The resulting 
hybrid cells, or hybridomas, are like B cells in that each produces a single antibody, and 
like myeloma cells in that they can be grown indefinitely in culture A single hybndoma 
cell can be grown into a clone of identical cells, which serves as a continuing source of 
a ’'monoclonal" antibody against a specific antigen Such a culture can be made to 
produce any required antibody for as long as it is needed Using Kohler and Milstein’s 
technique, an antigen against which an antibody is required, is injected into a mouse or 
rat Later, the spleen cells, which are producing the antibody against the antigen are 
isolated and fused with fast-growing cells in culture The resulting hybndoma (Kohler 
and Milstein, 1975), properly tended, will go 011 producing the desired antibody 
mdefmately Such hybridomas are screened for the production of monoclonal antibodies 
that bind to taiget cells in culture or to their membranes, but do not bind effectively to 
a panel of control cells or membranes Murine antibody production is further discussed 
in Section 2 3 13
The advent of hybndoma technology represented a quantum leap in the field of tumour 
immunology and since its discovery nearly 20 years ago, many murine monoclonal 
antibodies to human tumour cells have been made and many antigens have been 
identified (Section 1 9 )  Most of these monoclonal antibodies were, however, derived 
from spleen cells of mice or rats immunised with whole human tumour cells or cell 
extracts Thus, the results obtained may not directly reflect the intrinsic immunogenicity 
of human tumour cell antigens in a tumour-bearing host The difficulties which are 
encountered in producing stable human hybridomas prompted several researchers to 'by­
pass’ hybndoma technology and, 111 some instances, animal immunisation altogether 
(Ward et a l , 1989) The use of mouse-human chimaeric monoclonal antibodies, 
humanised monoclonal antibodies and their production in non-myeloma cells, yeast, 
bacteria and e\ en plants has renewed interest in monoclonal technology (reviewed by 
Griffiths, 1993) This is discussed in further detail m Sections 1 2 1 , 1 22 and 1 23 
The first publication describing the generation of true human-human hybridomas 
secreting specific antibody appeared in 1980 (Olsson and Kaplan, 1980) Croce and co- 
workers (1980) showed that human hybridomas producing monoclonal antibodies could
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be produced by fusing human B-cells which secreted the required antibodies, with 
human myeloma fusion partners However, this technology has taken longer to establish 
than the corresponding murine technology Hurdles which have limited the development 
of human monoclonal antibodies include the source of B-lymphocytes, immunisation 
strategies used, techniques used to immortalise the immunised B-cells, screening 
methods and problems encountered with large-scale production of human monoclonal 
antibodies (re\ lewed by Hand et a l , 1994)
1.3 Antibody structure and function
The basic structure of an antibody is shown in Figure 1 1 ,  a more detailed structure is 
shown in Figure 5 2 1 An antibody is a glycoprotein that consists of two identical heavy
(H) and light (L) chains, either kappa (k) or lambda (X), which are joined together by 
disulphide linkages (Roitt et a l , 1985) Each chain is made up of a variable region (V) 
and a constant region (C) known as domains The variable region is responsible for 
antigenic binding and the constant region for effector functions such as complement 
fixation and antibody dependant cell cytotoxicity (ADCC) There is a hinge region in 
the heavy chains which facilitates conformational changes in the antibody which occur 
during circulation in the organism or following binding to antigens The binding site of 
the antibody is situated in the variable legion at the -NH end of both the H and L  
chains The constant regions of the antibody chain provide a backbone structure The 
specificity for antigen binding is determined by the three-dimensional structure of the 
antibody combining site and the precise interaction depends on the ammo acid residues 
that react with the antigen (O'Kennedy and Roben, 1991)
An antibody has a molecular weight of approximately 150,000 -  160,000 daltons The 
light and heavy chain variable regions (VL and VH, respectively) consist of a highly 
conserved framework structure linked by three hypervariable loops, known as 
complementarity-determining regions (CDRs), on each of the VL and VH chains, which 
are involved in defining the binding specificity of the antibody The Fc portion of the 
antibody is in\ olved in binding to surface receptors and contains carbohydrates and has 
important physiological roles Antibody fragments, e g Fab' and F(ab,)2 portions, may 
be produced by enzymatic cleavage and genetic engineering These have advantages over 
the whole molecule in certain applications (Cahill et a l , in press)
1 4  The genetics of antibody diversity.
The human body can produce over 200 million antibodies, which is sufficient for every 
known antigen it may encounter (Roitt et a l , 1985) The basis of such a vast diversity 
of antibody molecules is genetic It has been mentioned that antibody light chains can 
be classified into two main types, k and X, based on the ammo acid sequence of their 
constant regions (Section 1 3 )  There are three X types and one k , and any B cell 
produces only one type of light chain The genes for X,  K  and heavy chains are 
genetically unlinked However, at each locus, the variable (V) genes are linked to their 
respective constant (C) genes In humans, the location of the X and k  light chain genes 
and heavy chain genes are on chromosomes 2, 22 and 14, respectively The genetic basis 
of antibody diversity has been reviewed by O’Kennedy and Roben (1991)
1 5 Production of antibodies
When an animal has been immunised with an antigen, on obtaining an immune response, 
the animal may be bled for polyclonal antiserum or, if a monoclonal is required, a fusion 
may be earned out (Section 2 3 13) Production of polyclonal antibodies rather than 
monoclonal antibodies are often more practical They have the advantages that they can 
be synthesised quickly and relatively cheaply and do not require the same amount of 
time or level of expertise associated with the production of monoclonal antibodies At 
present the major production methods for monoclonal antibodies involve the use of 
ascites fluid generation (Section 2 3 17 ) and large scale cell culture The production of 
ascites fluid gives good yields but there are difficulties with the large number of animals 
required, ethical considerations, high labour costs, the presence of endogenous antibody, 
and the possibility of contaminating viruses The methods of antibody production, 
isolation and punfication have been reviewed by Cahill et al (in press)
While large scale cell culture is technologically advanced, the costs are high, mainly due 
to media requirements This has resulted in research aimed at the generation of 
antibodies by genetic means using a range of systems including yeast, bactena and 
baculovirus expression systems (Section 1 21 ) and plants (Hiatt and Ma, 1993) 
Humanising rodent antibodies is an important development which can be achieved 
through genetic engineenng (Section 1 23 ) and has consequences for human therapy and 
tumour imaging (Section 1 7 )
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1 6 Monoclonal antibodies in clinical situations.
It became apparent soon after the discovery of monoclonal antibodies that their 
selectively and sensitivity would be of medical importance and they have been used to 
diagnose and treat a variety of diseases Monoclonal antibodies have been used to treat 
autoimmune disorders such as rheumatoid arthritis (Sany, 1990) They have been used 
as vaccines to treat malaria (Coppel, 1986), as anti-viral agents (Co et a l , 1991) and 
to catalyse the breakdown of cocaine (Landry et a l , 1993) They have also been used 
to diagnose non-specific infections and myocardial necrosis (Strauss et a l , 1991) 
Particular interest has been expressed, however, in the application of monclonal antibody 
technology to the detection and treatment of cancer (reviewed by Goldenberg, 1993) 
The current uses of monoclonal antibodies m oncology are presented in Table 1 2 
Several factors influence the type of monoclonal antibody or conjugate which can be 
used in a particular clinical application (Prosser et a l , 1991) These factors include 
tumour cell heterogenity (Section 1 8 ) ,  the intended usage of the antibody (whether for 
detection or therapy), the antigen target, the antibody unit used, (whether whole 
antibody, F(ab')2 or Fv fragment) (Figure 1 1 ) ,  and the distribution and pharmokinetics 
of the monoclonal antibody when administered to patients
A more fundamental understanding of cell growth regulation could also provide novel 
approaches for detecting, preventing and treating different cancers (reviewed by Bast, 
1993) Activation of protooncogenes or loss of tumour suppressor genes can have both 
a prognostic and therapeutic importance Bast, (1993) envisages that ultimately, 
molecular analysis of individual cancers will guide the application of specific therapies 
to inhibit activated oncogenes or restore the function of tumour-suppressor genes 
Circulating growth factors, oncogene products, and tumour-associated antigens may 
provide markers for earlier detection of some cancers
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Table 1 2 Current applications of monoclonal antibodies in oncology
Current applications of monoclonal antibodies in oncology 
Diagnosis and detection.
Immunohistopathology for detecting and classifying cell types by the presence or 
absence of markers in tissues and cell smears
Analysis of body fluids (serum, urine, effusions, etc) for the presence of marker 
substances by immunoassays
Nuclear imaging with radiolabelled monoclonal antibodies
Intraoperative use of y-detection probes with radiolabelled monoclonal antibodies 
Treatment
Direct cytotoxicity of monoclonal antibodies (complement- or ADCC-mediated) 
Inhibition of growth-factor receptors 
Immunoconjugates (drugs, toxins, isotopes)
Ex vivo purging of tumour cells from harvested bone marrow 
Anti-idiotype monoclonal antibodies vaccines
1 7 Antibody biodistribution and targeting
The use of monoclonal antibodies in cancer detection and therapy in humans requires 
considerable testing for sterility, pyrogemcity, adventitious viruses of the host cells, and 
general safety, as prescribed by guidelines from the Food and Drug Administration m 
the U S A (Hoffman et a l , 1985)
When an antibody is injected into the bloodstream it passes through a number of 
campartments including the vascular and extravascular spaces (Table 1 3 ) as it is 
metabolised and excreted The journey and potential barriers for an injected antibody 
which is required to target a tumour paitially explain why such a small portion of the 
injected lmmunogloublin, between 0 0007% and 0 01% of the injected dose per gram 
of tissue, targets to tumour (Epenetos et a l , 1985) After injection into the bloodpool, 
the initial problem is whether the immunoglobulin binds with circulating antigen or with 
antigen on blood cells, which would result in antigen-antibody complexes that could 
reduce the available immunoglobulin and possibly evoke deleterious immune complex 
disease Initial experience with the injection of anti-CEA immunoglobulin into patients 
with high blood CEA levels confirmed the formation of CEA-anti-CEA complexes, but
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did not show any effect on tumour targeting or adverse réactions (Primus and Goldberg, 
1980) Anothei form of antigen-antibody complexation, involving the sensitisation of 
patients with the foreign, murine immunogloublin, can have more significant effects on 
targeting After exposure to whole murine immunogloublin, or repeated injections of 
immuno-globulin fragments, patients show the formation of human anti-mouse 
antibodies (HAMA), which increase a patient’s risk for serum sickness and anaphylactoid 
reactions and prevent targeting of the immunoglobulin by complexing it and causing its 
degradation and excretion The anti-antibodies can be detected in some patients as early 
as three weeks after injection and in some circumstances can be present for months or 
years later There is considerable variability in such responses among different patients 
receiving the same monoclonal antibody Some immunogloublins have shown binding 
to tumour antigen present m certain normal organs, such as the liver, thus interfering 
with specific tumour targeting Other factors influencing immunoglobulin targeting are 
discussed in Section 1 8
1 8 Barriers to targeting of immunoconjugates to tumour cells
Tumour vascularisation and vascular permeability are factors that can affect antibody 
targeting, and it has been found in tumour model studies that blood flow and vascular 
permeability can vary between tumour hosts and between tumours m different sites of 
the same animal The location and density of the antigen being targeted by antibody are 
also important factors Although current precepts assume that the antigen target needs 
to be on the cell surface to be accessible, examples of successful targeting when the 
antigen is present in the external milieu or intracellularly are known (Blumenthal et a l , 
1989) It is generally believed that increased antigen density on the tumour cell results 
in increased antibody targeting Also of importance is the nature of the antibody’s 
avidity, or binding capacity, for the antigen, which determines the amount and duration 
of antibody attachment to tumour The normal physiologic and/or anatomic barriers to 
successful targeting are given in Table 1 3
A major problem in effectively treating cancer is that of tumour cell heterogeneity The 
cellular heterogeneity of neoplasms has been known since the last century, when 
historical studies first identified moiphological differences, among cells within the same 
tumour In 1954, Foulds formally documented the existence of distinct morphologies in 
different areas of a mammary tumour Since then, the use of increasingly sophisticated
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methods, and clonal analysis in particular, has revealed extensive heterogeneity in the 
expression of various phenotypic properties by tumour cells m both primary and 
metastatic lesions in the same host These include differences in karyotype, function, 
differentiation, degree of malignancy, antigenicity, immunogenicity, biochemical 
properties, growth behaviour, susceptibility to destruction by chemotherapeutic drugs and 
radiation, and the ability to evade the humoral and/or cell-mediated immune reactions 
mounted by the host
There may be hundreds of subpopulations of cells within a single tumour because of 
tumour cell heterogeneity which has profound implications for the use of antibodies as 
targeting ligands (Smyth et a l , 1993) Indeed, many tumours are composed of only 
small proportions of malignant cells, the remainder being supportive connective tissue 
and infiltrative elements, including different blood cells Tumour heterogeneity can be 
overcome in therapy with radioactive antibodies, since the higher-energy isotopes can 
kill from a distance of several cell diameters, thus affecting antigen-negative cells 
within a mixed tumour cell population (Section 1 1 3 )
Finally, tumours at diffeient sites of the body may be amenable to improved targeting 
when the monoclonal antibodies are administered by the most direct route for tumour 
accretion The intravenous route has been the most popular means used to target 
disseminated disease, but when the malignancy is limited to a site or body cavity, 
mtralesioal or intracavitary application, such as mtrapentoneal or intrathecal injection, 
has proven efficacious, both for imaging and therapy
These various barriers and impediments to monoclonal antibody targeting reduce the 
absolute amount of immunoglobulin accumulated by the tumour, which is a major 
problem when monoclonal antibodies are used to deliver a therapeutic agent For tumour 
imaging, however, it is only the relative amount of radioactivity deposited in tumour, 
as compared with that deposed m adjacent tissues, that is responsible for producing the 
lesion's image The process of cancer imaging with radioactive monoclonal antibodies 
is gaining m usefulness and acceptability (Goldenberg, 1993)
13
Table 1.3. Barriers to immunoconjugate targeting in vivo.
HOST TUMOUR H ETERO G EN EITY
Endothelium and basal lamina Phenotypic drift/cellular instability
Plasma membrane Inherent sensitivity to drug
Basement membrane Development of drug resistance
Blood-brain barrier Antigenic drift
Epithelial membranes Membrane transport
Reticuloendothelial system (RES) Metastatic potential
Immune system (non-RES)
Inactivating enzymes
Biodegrading enzymes
1.9. Cocktails of monoclonal antibodies.
Tumour cell heterogeneity, particularly with regard to antigen expression, can be 
mitigated by the combined use of a "cocktail” of different antibodies directed against 
different tumour-associated antigens (Blumenthal et a l ., 1991).
Hybridoma technology has resulted in the identification of a considerable number of new 
tumour-associated antigens (reviewed by Goldenberg, 1993) and also in antibodies 
against different epitopes of the same antigen. In lung cancer, for example, more than 
50 monoclonal antibodies have been described (Stein and Goldenberg, 1991). 
Nevertheless, no truly tumour-specific antibody or antigen has, as yet, been elucidated. 
Most tumour antigens identified by anti-tumour antibodies appear to be quantitatively 
increased in neoplasia and frequently react with a wide range of carcinomas so that their 
antibodies are considered to be pancarcinomic in specificity. Indeed, it is rare to find a 
monoclonal antibody that is specifically reactive with a single organ or tissue type, 
whether normal or neoplastic. Despite these limitations, numerous applications of 
monoclonal antibodies in cancer diagnosis, detection, monitoring, therapy and 
prognostication have been identified or proposed (Dillman, 1989), as summarized in 
Table 1.2.
The applicability of monoclonal antibodies in diagnostic histopathology is particularly 
widespread and can be used for classifying tissues and tumours according to their 
expression of certain defined markers that reflect differences in cellular genesis,
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differentiation and biology (Jaffe, 1990) Immunohistochemical identification of 
neuroendocnnc differentiation in some cases of non-small-cell lung cancers has been 
positively correlated with response to chemotherapy (Mulshine et a l , 1991) Of 
particular interest is the determination of the organ or tissue of origin of undifferentiated 
metastases Monoclonal antibodies against certain organ-associated antigens, such as 
prostate-specific antigen, prostatic acid phosphatase, placental alkaline phosphatase, 
human chorionic gonadotropin, a-fetoprotein, CEA and others, can assist the pathologist 
in making a diagnosis (Jaffe, 1990) Unfortunately, immunohistology has not enabled 
a differentiation to be made between malignant and benign lesions, but antibodies can 
assist in distinguishing primary from metastatic tumours, such as in the lungs 
(Goldenberg et a l , 1983) The detection of occult metastases by immunocytologic 
analysis of bone marrow and other tissue aspirates, as well as lymph nodes and various 
body fluids, has also proved feasible with selected monoclonal antibodies 
The most established application of anti-tumour monoclonal antibodies has been for the 
measurement of circulating tumour-associated markers, such as CEA, in body fluid 
immunoassays The lack of tumour specificity of these markers precludes their general 
use in cancer screening and diagnosis, but they have shown value as diagnostic aids in 
high-risk groups and to monitor disease absence or recurrence in treated patients 
(Herberman and Mercer, 1990)
Without the knowledge of markers for all tumour cells, a "typing panel" of receptors 
will be necessary Avner and co-workers (1989) have shown that it is possible to create 
therapeutic monoclonal antibodies to an individual patient's tumours within a 6 -  to 9 -  
month time-frame Their panel consisted of 20 distinct antibodies that bind to different 
cancer cell surface molecules and epitopes, and antibodies from this panel were used to 
type patient biopsies These antibodies may be used to create a customised "cocktail" 
of antibodies, if required, that could be conjugated to chemotherapeutic drugs, toxins or 
radioactively labelled nucleotides Effective targeting will probably require such 
cocktails of different antibodies, with different cocktails needed to treat tumours m 
different patients (Poste, 1986)
A monoclonal antibody cocktail could be composed of different IgG isotopes, such as 
IgGl or IgG2 to manipulate different host effector functions IgM and IgG m 
combination may prove useful, as would a cocktail of high and low affinity antibodies, 
these would also be designed to manipulate tumoui antigens to augment the host’s ability
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to destroy these cells lmmunologically Combinations of the above may prove to be 
more effective The human Fc portion may interact more efficiently with human 
complement and/or effector cells It is currently undetermined whether IgG l, IgG2, IgG3 
and IgG4, either individually or m various combinations, will have any clinical value, 
or whether whole antibody, F(ab')2, F(ab) or Fv (Figure 1 1 )  fragments would be more 
effective The IgM class of antibodies are much larger than the IgGs (Section 3 19 ) and 
may not traffic as well, but a combination of an IgM variable region with an IgG heavy 
^  chain may circumvent this problem (Glassy and Dillman, 1988) Clinical trials using
cocktails of murine monoclonal antibodies are already m progress and those with human 
monoclonal antibodies will be commencing in the near future (reviewed by McKearn, 
1993)
Techniques of molecular biology may be useful to class switch the heavy chains of 
human monoclonal antibodies (Section 1 2 1 ) (Shimizu and Honjo, 1984) which could 
be of some clinical significance for using monoclonal antibodies alone (Section 119  ) 
There are differences in the cytotoxic effects resulting from interactions with 
complement binding and cytotoxicity, IgM is superior to IgG l, which is greater than 
IgG3, which is greater than IgG2, IgG4 has no apparent activity (Shakib, 1986)
110  Targeting of drug lmmunoconjugates to tumour cells
Most of the drugs used in cancer treatment non-specifically kill all growing cells, 
resulting in often unacceptable side effects However, considerable ingenuity has been 
devoted over the past decade to the development of systems for improved drug delivery 
m cancer treatment These range from efforts to reduce toxicity using (a) rate controlled 
release preparations and implantable devices, (b) to improving the effectiveness of anti- 
tumour drugs by using new formulations with improved pharmokinetic and/or 
pharmacodynamic profiles, (c) to introducing chemical groups for conjugation well 
separated from the active site which allow covalent linkage of the drug to the antibody 
without affecting the drug potency or toxicity, (d) to using active groups or carrier 
molecules such as dextran, polyannnoacids or human serum albumin to minimise 
reduction in drug potency
Each monoclonal antibody usually has several drug molecules attached to it in order to 
deliver a potent dose of drug to the selected cell Even when very active drug 
lmmunoconjugates are targeted to the most drug-sensitive tumour cells, between 106 to
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107 drug molecules must be accumulated in a tumour area to mediate tumour killing 
(Reisfeld and Schrappe, 1990) Johnson et al (1987) showed that many of the
t
commonly used drugs lose much of their activity following binding to proteins This loss 
in activity has been attributed to steric hindrance, altered mechanisms of cellular uptake 
and reduction in the drug half-life following linkage
The target for these drugs is every tumour cell in the patient, since any remaining 
tumour cells cause recurrence Potential targets for drug targeting to tumour cells include 
tumour-associated antigens, growth factor receptors and attachment molecules on 
tumour cell surfaces Other targets include oncogenes, oncogene products and the organ 
or tissue where the tumour resides
Khawh et al (1994) developed seven novel vasoactive immunoconjugates that 
selectively alter vascular permeability and/or blood volume of tumours in vivo in order 
to enhance monoclonal antibody uptake m tumours These immunoconjugates were 
composed of IL-1 p, IL-2, tumour necrosis factor-a, physalaemin leukotnene B4, 
histamine and bradykmm chemically linked to TNT-1, a murine monoclonal antibody 
that binds necrotic regions in tumours All of these immunoconjugates showed specific 
enhancement of monoclonal antibody uptake in tumours with no changes seen in normal 
tissues These studies of Khawh et al (1994) indicate that pretreatment with vasoactive 
immunoconjugates may improve monoclonal antibody uptake in tumours significantly 
and, thereby, increase the therapeutic index of monoclonal antibody-directed 
immunotherapy
Seelig et al (1994) developed a method for predicting the ability of drugs to cross the 
blood-brain barrier The tight endothelium of brain capillaries constitutes the permeabil­
ity barrier for the passive diffusion of substances from the blood stream into the central 
nervous system To reach the brain, a molecule has first to be absorbed from the blood 
into the endothelial cell, where it is then released into the brain A prequisite for a 
substance to diffuse through the blood-bram barrier is therefore a certain degree of lipid 
solubility They propose an approach which takes advantage of the surface activity of 
the molecule of interest Three properties of a drug molecule have been suggested to 
determine its ability to cross the blood-brain bamei, (i) the number of lipophilic groups, 
(11) the number of charged groups and their extent of ionisation, and (ill) the molecular 
size Their study suggests a method of predicting the potential of drugs to cross the 
blood-bram barrier
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Many researchers have abandoned the use of conventional drugs and are beginning to 
produce new drugs specifically designed for monoclonal antibody conjugation These 
drugs have been termed structure-activity-relationship (SAR) compounds, and have 
been designed with both the potency of the drug and the immunoreactivity of the 
antibody in mind The developments of new SAR drugs such as KS1/4 -  DAVLB, a 
vinblastine derivative (Koppel, 1990), mark the beginning of SAR immunoconjugates
111 Targeting of toxin immunoconjugates to tumour cells
Cytotoxic drugs frequently will be less potent than plant or bacterial toxins Toxms were 
proposed as suitable agents for immunotherapy because of their extreme cytotoxivity 
A wide array of toxins have been conjugated to monoclonal antibodies for the 
production of lmmunotoxins (Vitetta and Thorpe, 1991) Many of the toxms consist of 
two protein chains a B-cham for cell binding and an A-chain that inhibits protein 
synthesis Ricin, from the castor bean, is the prototype toxin, whose B-cham is replaced 
by the monoclonal antibodies to which the A-chain is conjugated Toxins, such as ricin, 
abrin, pokeweed antiviral protein, gelonin, saporin, diphtheria toxin, and Pseudomonas 
exotoxin, are considerably more toxic on a molecular basis than most chemotherapeutic 
agents, but most of these toxins are much larger in size For example, ricin A-chain has 
a molecular weight of 32,000, whereas most chemotherapeutic agents have molecular 
weights less that 1,000 (e g doxorubicin has a molecular weight of 544) Most natural 
toxms are themselves immunogenic, thus enhancing the immune response to the 
immunotoxm These immunotoxins exeit their action in the cytoplasm, where they 
inhibit protein synthesis After binding to cell surface antigens, they are endocytosed into 
the cell and incorporated into endosomes (Vitetta and Thorpe, 1991) Some toxin 
fragments, such as diphtheria toxin, translocate across the membrane of the endosome, 
whereas others, such as ricin, are transported to the trans-Golgi network, from where 
they enter the ^cytoplasm However, most are routed to lysosmes, which degrade the 
toxins In the cytoplasm, the toxms act on adenosine diphosphate-ribosylate elongation 
factor 2 (e g , Pseudomonas exotoxin) or inactivate the 60S nbosomal subunit, affecting 
its binding to elongation factor 2 (e g ricin) It has been estimated that less than 10 
toxin moleculcs in the cytoplasm are sufficient to kill a cell (Waldmann, 1991), but 
considerably more must bind to the cell surface in order for this minimal number to be 
internalized and translocated
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There have been a number of clinical trials in patients with cancer with the initial group 
of immunotoxins, which were generally unstable in vivo Among 127 patients treated in 
10 clinical trials with immunotoxins against breast, colorectal, ovarian, and lymphoid 
malignancies, only 2 complete and 8 partial remissions were observed (Waldmann, 
1991) Ricin A-chain conjugated to an IgG2a monoclonal antibody directed against a 
high-molecular-weight glycoprotein expressed by melanomal cells was given to 
melanoma patients over a 5-day schedule, and 3 partial responses out of 43 patients 
treated were reported However, moie promising results have been obtained with 
modified, or second generation, immunotoxins in cancer patients, or when benign 
diseases were treated with these agents Since one of the problems of using native ricin 
A-chain, even when bound to monoclonal antibody, is its binding to liver cells via its 
carbohydrate residues, second-generation deglycosylated A-chain ricin lmmuno- 
conjugates are preferably used in clinical trials For example, Vitetta et al (1991) 
recently reported partial responses in 38% of 14 evaluable patients with B-cell 
lymphomas, and in patients with antigen-positive tumour cells, half of the patients 
achieved a transient, partial response, lasting between 1 and 4 months At doses of 
75mg/m2 or greater in this phase I trial, three of four patients achieved a partial 
response Dose-related toxicities included vascular leak syndrome, fever, anorexia, and 
myalgia, while dose-hmiting toxicities involved pulmonary edema and/or effusion, 
expressive aphasia and rhabdomyolysis with reversible kidney failure There was no 
liver dysfunction noted, supporting the value of using a deglycosylated ricin A-cham 
Four of 14 patients (29%), however, made antibody to the immunotoxins, 3 to the ricin, 
and 1 to both ricin and murine antibody (Vitetta et a l , 1991)
Even when the ideal antibody and toxin are selected, there still remain the problems of 
conjugating the toxin to the monoclonal antibody, large-scale production of the 
immunotoxm, the evocation of human antibodies against the monoclonal antibody and 
against the toxin, and a dose-limiting capillary leak syndrome, manifested by normal 
liver function with hypoalbuminemia and edema
Kuzel et al (1993) conducted a phase I clinical tual of a diphtheria toxin/IL-2 fusion 
protein This is a construct m which the native diphtheria toxin-receptor binding- 
domam has been replaced with human IL-2 This molecule is specifically cytotoxic in 
vitro withm 30 minutes for cells that expiess the high affinity IL-2  receptor The 
purpose of the study was to investigate the biologic activity of the fusion protein, when
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administered three times daily, in terms of toxicity, pharmacokinetics and anti-tumour 
effects in patients with IL-2 expressing malignancies, such as mycosis fungoides, and 
other non-Hodgkin's lymphomas Biologic activity was noted in patients with mycosis 
fungoides, with skm lesions clearing
Siegall et al (1994) showed that a single chain immunotoxm fusion protein could cure 
human breast carcinoma xenografts in athymic mice and rats The immunotoxm was 
targeted to the tumour cells using an antibody, and was rapidly internalised into these 
cells
EGF-receptor is amplified or overexpressed in many malignant gliomas and other 
primary brain tumours, but is low or undctectable m normal brain In a study of Phillips 
et al (1994), this differential expression has been exploited for targeting brain tumours 
using a transforming growth iaoXox-a-Pseudomonas exotoxin, a recombinant toxin 
Treatment of nude mice bearing glioblastoma or medulloblastoma subcutaneous 
xenografts with this toxin produced tumour regression and growth delay Their results 
suggested that the fusion protein was active against primary human brain tumours which 
had moderate to high EGF-receptor expression For intracranial tumours, they suggest 
a better method would be direct delivery of the fusion protein into the brain tumours by 
controlled-relcase biodegradable polymers or mtratumoural implantable catheters, which 
may represent clinically useful applications of recombinant toxin therapy in tumours 
with high EGF-receptor expression
Another phase I trial of this diphtheria toxin/IL-2 fusion protein has been reported 
(Tepler et a l , 1994) This fusion protein was given as a brief infusion m 15 patients 
with refractory lymphoid malignancies One complete response was observed m a patient 
with Hodgkin's disease in relapse and the patient remained free of disease more than two 
years after completion of therapy The dramatic anti-tumour response seen in one 
patient and the relative tolerance of the fusion protein in the other patients, indicated the 
potential utility of this target agent in IL-2-expressmg haematologic malignancies 
Fishwild eta l (1994) conjugated gelomn and ricm A-chain, both nbosomal inactivating 
proteins, to monoclonal antibodies which bind to specific cells and, upon internalisaion, 
inhibit protein synthesis, ultimately resulting m cell death This study reported that 
gelomn anti-'l cell monoclonal antibodies conjugates were more cytotoxic than their 
ncin A-chain counterparts when tested against human peripheral blood mononuclear 
cells Gelomn is more toxic than the ncin A-chain Fishwild et al (1994) showed that
a 10 minute exposure to a gelomn immunoconjugate was as effective as a 90 hour 
exposure to the ncin A-chain immunoconjugate in vitro These properties of gelomn 
might be advantageous for immunoconjugates made with other monoclonal antibodies 
or receptor-binding molecules
112  Adverse effects of monoclonal antibody therapy
Several limitations occur with delivery systems themselves and in order to have an 
effective immunoconjugate targeting system several criteria must be satisfied (Table 
1 4 )
Toxic reactions to the administration of monoclonal antibodies are foremost immune 
reactions, particularly to foreign antibodies, such as murine monoclonal antibodies The 
nature of the immune reactions is governed by (1) whether it is the monoclonal antibody 
binding to its antigen target, particularly when it is a circulating antigen and (2) if the 
administered monoclonal antibody evokes host antibodies (HAMA) (Catane and Longo, 
1988) The clinical manifestations of both mechanisms can be quite similar, thus making 
a differentiation difficult In the first instance, fever, chills, urticaria, dyspnea, 
hypotension and diarrhoea can occur They aie observed fairly soon after monoclonal 
antibody infusion, are dose-related, and are affected by rate of administration In the 
case of HAMA, the reactions usually aie unrelated to dose and rate of administration 
and and can be manifested by anaphylaxis, serum sickness, urticaria, fever and 
hypotension HAMA responses can alter monoclonal antibody pharmcokinetics, 
impairing targeting and therapy and enhancing monoclonal antibody clearance The 
HAMA response can involve the production of anti-framework, anti-isotypic and anti- 
ldiotypic antibodies, depending on the particular monoclonal antibody and the dosage 
schedule Even monoclonal antibodies can evoke anti-allotypic and anti-idiotypic 
antibody responses
When a toxin is conjugated to a monoclonal antibody, it too can be immunogenic Other 
adverse clinical manifestations have included flu—like, capillary leak symptoms and 
hepatic enzyme elevations (Vitetta and Thorpe, 1991) Despite the diverse reactions to 
unlabelled and conjugated monoclonal antibodies, the clinical experiences to date have 
indicated that these are relatively safe cancer therapies, and the adverse reactions 
generally have been easy to control, such as by changing antibody dose, changing 
infusion rate, administering corticosteroids and antihistamines or possibly treating with
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cytoxic immunosuppressants (Goldenberg, 1993)
Another major obstacle to effective cancer chemotherapy is the resistance of tumour 
cells to cytostatic agents Tumour cells frequently express a multidrug-resistance 
phenotype Efferth and Volm (1992) have shown that multidrug resistant tumour cells 
can be effectively killed by monoclonal antibodies, toxins or bispecific antibodies This 
study has shown that an antibody-directed therapeutic approach to eradication of 
multidrug-resistant cells might be a promising adjunct to conventional chemotherapy of 
cancer patients
Table 1 4 Requirements for an immunoconjugate delivery system 
REQ U IREM EN TS FOR AN IM M UNOCONJUGATE D ELIVERY SY STEM
Recognition and interaction of carrier and target 
Localisation to target tissue/organ
Delivery of therapeutic concentiations without significant uptake by non-target 
tissues
Protection of immunoconjugate from premature biodégradation 
Protection of immunoconjugate from premature inactivation 
Carrier must be able to incorporate a broad spectrum of immunoconjugates 
without loss of activity
Release of drug/toxin in a controlled predetermined manner once the îmmuno- 
conjugate-carrier is at the target 
Biodegradable 
Biologically inert
Immunogenic, only if required for targeting 
Production should be straightforward and reproducible 
Clinically cost effective
113  Radioimmunoconjugates
Isotopes conjugated to monoclonal antibodies (radioimmunoconjugates) have distinct 
clinical applications, either in diagnosis by immunoscmtigraphy or treatment by 
radioimmunotherapy (O'Kennedy et a l , 1993) The aim of radioimmunotherapy is to 
irradiate and kill antigen-bearing tumour deposits throughout the body with minimal
radiation to normal tissues
The limited success of radioimmunotherapy in vivo has been attributed to inability to 
target sufficient doses of isotope to the tumour Britton and colleagues (1991) reported 
that one day after the administration of a radioimmunoconjugate, approximately 30% 
of the administrated radioactivity has been excreted They also reported that an average 
of 1% of the administered activity is actually located to the tumour site, while 69% 
accumulates in normal tissues (liver, kidneys, bone marrow and with lodinated 
compounds, the thyroid) This leads to extensive lethal irradiation of non-specific 
tissues In many cases far less than 1% of the administered radiation may reach the 
tumour site Therefore, tumour selection and the route of administration are important 
parameters in effective radioimmunotherapy
Although tumour imaging only requires a high target/nontarget ratio of counts for
optimal results radioimmunotherapy depends on a high concentration of tissue reactivity
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for a long duration In contrast to drug and toxin immunoconjugates, radiolabelled 
monoclonal antibodies can kill cells that are at a distance from the targeting, depending 
on the choice of radionuclide, without the monoclonal antibodies conjugate being 
internalised Therefore radiolabelled monoclonal antibodies can distribute their cytotoxic 
energy to antigen-negative cells in the neighbourhood of antigen-positive cells The 
attractive feature of radioimmunotheiapy is the prospect that most normal tissues are 
spared intensive radiation As in the case of other immunoconjugates, the radionuclide 
should be linked tightly to the monoclonal antibody without affecting targeting 
Technically, depending on the choice of radionuclide, considerable progress has been 
made in the chemistry of antibody radiolabelling Some radionuclides, such as the 
isotopes of iodine, can be conjugated directly to the antibodies, while others are linked 
by an intermediate group, such as chelating groups for radiometals 
The fact that tumours can accumulate globulins and other macromolecules non- 
specifically was first reported by Duran-Reynolds in 1939 This phenomenon has 
already been used effectively in brain tumour imaging with 131I labelled human serum 
albumin (Chou et a l , 1951) The success of this method of brain tumour visualisation 
depended on the intact blood-brain barrier excluding the protein from normal 
surrounding biain The absence of such a barrier in other tissues has made it difficult 
to image tumours with non-specific proteins elsewhere in the body since tumour 
concentrations, although high, did not exceed background (Goodwin et a l , 1988)
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Lastoria et al (1993) demonstrated that using 131I-metaiodobenzylguamdine scintigraphy 
was successful m localising the majority of neuroblastoma lesions in children They 
showed that since the spread of neuroblastoma is unpredictable, this type of imaging was 
more sensitive than computed tomography or ultrasonography in localising the majority 
of neuroblastoma lesions
Immunoscintigraphy has been the most successful application of immunoconjugates in 
oncology It aims to detect tumours in vivo, rather than kill these tumours, uses lower 
levels of radiation (gamma, y) by using lower energy isotopes such as inIn and 
" mTechnetium (99mTc) and smaller doses of radiolabelled monoclonal antibody conjugate 
than radioimmunotherapy Typically, patients are administered between 0 5 and 2 Omg 
of radiolabel for diagnostic purposes, but are administered with up to 500mg of 
radiolabelled monoclonal antibodies for therapeutic purposes (Britton et a l , 1991) 
While radioimmunotherapy is more successful on very small and diffuse tumours, 
immunoscintigraphy has been most effective on large tumours with larger surface areas 
to bind antibodies
114  Immunocytokines
Another method to treat cancer has been to look at the body's natural mechanism for 
fighting disease and to redirect the natural cellular molecules called biological response 
modifiers to kill cancer cells (reviewed by Tanneberger and Pannuti, 1993) Biological 
response modifiers are defined as 'agents or approaches that alter interactions between 
tumours and host toward therapeutic advantage, primarily through modification of host 
response to tumours’ (Mihich, 1985) Such modifiers include interferons (Weiner et a l , 
1988), interleukins (IL-1, IL-2), colony-stimulating factors, human granulocyte colony- 
stimulating factor and tumour necrosis factor (Reisfeld and Schrappe, 1990) and all have 
been conjugated to monoclonal antibodies and used in cancer treatment 
Jinno et al (1993) used a drug immunoconjugate targeted against a growth factor 
receptor This targeted therapy showed selective cytotoxicity to cancer cells with 
expression of the growth factor receptor Moreover, the cytotoxic effect was positively 
correlated with the expression level of the receptor
Ferrim and colleagues (1990) noted that immunologists are only beginning to unravel 
the complex reactions of biological response modifiers, cytokines and growth factors 
They recogmscd that many of these moleculcs have pluripotcnt effects on many cells
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of the immune system and, therefore, the efficiency of biological response modifiers- 
monoclonal antibody conjugates on tumour cells is more difficult to monitor than other 
immunoconjugates, such as those with drugs, toxins or isotopes Research aimed at 
directing biological response modifiers to specific cells may help to elucidate these 
pluripotent effects
115 Bispeciflc antibodies
Today, hybndomas producing antibodies of a variety of specificities exist in almost 
limitless quantities In recent years, however, advances in hybndoma production 
techniques, recombinant DNA manipulation and gene transfection technology have made 
possible the pioduction of entirely novel bispecific antibodies (Williams, 1988) Most 
naturally occurring antibodies have two antigen combining sites which both recognise 
the same antigenic determinant (Figure 1 1 )
Bifunctional antibodies have potential for many uses including imaging, therapy (Section
116 and 1 1 7 )  and diagnostic kits Bispecific antibodies have been produced by 
chemical reassociation, heterogeneous aggregation and cell fusion (reviewed by Nolan 
and O’Kennedy, 1990) These methods will be briefly discussed As the name suggests, 
in bispecific antibodies produced by chemical reassociation, monovalent fragments 
derived from two monoclonal antibodies are chemically recombined There are some 
technical disadvantages with this method It may be difficult to dissociate the 
immunoglobulin chains without some protein denaturation and subsequent loss of 
antibody activity Unorthodox disulphide bonds, within chains, may be created when the 
antibody heavy chains are allowed to reassociate An alternative method of preparation 
involves the covalent attachment of whole monovalent antibodies of different 
specificities using a heterobifunctional cross-lmker such as SPDP (N-succimmidyl-3- 
(2-pyridyldithiol) propionate) Such reagents can be used in the targeting of cytotoxic 
T cells (Section 1 16 and 5 1 )  (Perez et a1 , 1986)
A third method for the preparation of bispecific monoclonal antibodies, cell fusion, was 
described in 1984 by Milstein and Cuello A so-called hybrid hybndoma', obtained by 
fusion of two hybndoma cells, each producing its own antibody, contains the genetic 
information necessary for the production of two different antibodies The antibody genes 
are codominantly expressed (i e light and heavy chains from both antibody types are 
expressed) These protein chains recombine m the cisternal space to produce parental
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and hybrid antibody molecules Although only a small proportion of light and heavy 
chain associations yield bispecific molecules (Milstein and Cuello, 1984)
DeSutter and Fiers (1993) reported the genetic engineering of a murine human 
chimaeric antibody, directed against the tumour marker human alkaline phosphatase, in 
which one antigen-binding arm had been replaced by Escherichia coh p-lactamase The 
mutated (3-lactamase gene was fused, in phase, to the cDNA sequence encoding the 
hmge region, CH2 and CH3 of the human IgG3 heavy chain (Figure 5 2 1 )  Approxi­
mately 200ng/ml of correctly assembled bifunctional antibody-(3-lactamase lmmuno- 
conjugates were detected in culture supernatant This bifunctional immunoconjugate 
could be of therapeutic value for the activation of cephalosporin-based anti-cancer 
prodrugs at the tumour site (DeSutter and Fiers, 1993)
In the future, it may also be possible to create tn- and multi-functional antibodies using 
antibody engineering (Section 1 2 1 ) One of the most innovative and far-reaching areas 
opened up by this technology is that of catalytic antibodies (Section 6)
Morelh et al (1994) have modulated drug induced cytotoxicity by a bispecific 
monoclonal antibody, that recognised the EGF and doxorubicin, which was produced by 
somatic hybridisation of two hybndomas The bispecific monoclonal antibody obtained 
was able to retarget doxorubicin cytotoxicity in vitro specifically on EGF-receptor 
positive cells
Progress towards an understanding of the construction and use of bispecific antibodies 
in the therapy of tumours has been considerable, this area has been reviewed by Fanger 
et al (1993) The importance of accessory adhesion molecules (Section 1 1 7 )  as well 
as the requirement for cell killing and the mechanisms by which cytotoxicity is mediated 
(Section 1 16) are being are also being clarified As clinical trials have demonstrated 
little toxicity and, in some instances, promising responses and long-term survivals, it 
seems likely that bispecific antibodies will be very useful tools for therapy of tumours 
Bispecific antibodies are further discussed in Sections 1 16 , 117 and Section 5 1
116  T  cell killing
Much work has been done recently on the use of hybrid antibodies to the T-cell 
receptor complex activating T-cells for target cell killing, raising the hope that T-cell 
killing mechanisms might be recruited as an additional effector mechanism for 
antibody-directed killing of tumour cells in vivo
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Effective cell-cell interactions are known to be required for cell-mediated cytolysis, 
Lotze and co-workers (1987) detailed possible models of tumour targeting and focusing 
of lymphoid effectors Human peripheral blood T-cells can be induced to lyse either 
cultured or fresh tumour cells in vitro, by coating them with heteroaggregates containing 
anti-T3 cross-lmked to anti-tumour antibody Such heteroaggregates bridge the effector 
cells to the tumour target cells and activate the T-cell lytic mechanism In order to 
trigger lysis, the anti-T cell portion of the heteroaggregate must be directed against an 
activation molecule on the T-cell surface such as a component of the T cell receptor 
complex -  T3 or Ti or CD2 (in man) and Ly6 (in mouse) to redirect the specificity of
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cytotoxic T cells (Segal et a l , 1988) Lysis mediated by targeted T - and K-cells is 
enhanced by incubating the effector cells with IL-2, whereas killing by monocytes and 
neutrophils is boosted by mterferon-X By contrast, the anti-target cell antibody can be 
directed against any cell surface epitope on the tumour cell, as long as it is expressed 
at a sufficient density for conjugate formation and T-cell triggering In vitro, the 
cytotoxic activity of targeted T cells resides in the T8+ subset and is rapidly augumented 
after exposure to IL-2 (Segal et a l , 1988) In vivo, targeted T - and K-cells can also 
block tumour growth Specific target cell lysis has been achieved by retargeting T-cells 
with the use of chemically produced antibody heteroaggregates with dual specificity for 
target and T-cell receptor complexes (Starez et a l , 1985)
In a study by Duke-Cohan et a l  (1993), they used a bispecific antibody-toxm conjugate 
directed against CD4 and CD29 antigens simultaneously, as binding through both these 
antigens would predispose toward endocytosis and delivery of the toxin to the cell 
interior They demonstrated that the potency of the immunotoxin is not only a function 
of its affinity but also of its propensity to internalise, and that this property is influenced 
by the degree of bivalent binding These results have opened up the possibility of 
engineering bispecific antibody-toxm conjugates for use as therapeutic immunotoxms 
for selective removal of restricted T cell subsets
Weiner et a l  (1994) developed an anti-CD3 x anti-tumour bispecific antibody that can 
retarget T cell-mediated lysis in a major histocompatability fashion and can prevent 
tumour growth in a mouse model They also studied the use of bifunctional constructs 
which differed in the presence or absence of Fc They showed that the use of 
bifunctional constructs that lack functional Fc allows for separate manipulation of T cell 
retargeting and T cell activation, allowing a new method of potential immunotherapy for
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malignancy
117  Effector cell retargeting
Heteroconjugates of monoclonal antibodies, as well as hybrid monoclonal antibodies 
were found to induce T cells to act against a target site Hybrid monoclonal antibodies 
consist of one of the antibody component binding sites (first specificity) being directed 
against a tumour-associated antigen and the other component binding site (second 
specificity) is directed against an activation molecule on the T cell surface, (e g T3) 
(Perez et a l , 1986) In addition, there have been reports of hybrid hybndomas that 
secrete bispecific antibodies that can also mediate what is termed "effector cell 
retargeting" To optimise the potential in vivo applicability of effector cell retargeting, 
the hybrid antibodies should promote high levels of specific cell killing of the desired 
target with mimmium killing of the effector T cells (Clarke and Waldmann, 1987) 
Beun et al (1993) investigated the ability of bispecific anti-T cell receptor x anti­
tumour antibodies, destined for the study of T cell retargeting in a rat colon carcinoma 
model They found by cocultivating with recombinant IL-2, at concentrations as low as 
lU/ml, tumour neutralisation by retargeted effector cells was promoted This non-toxic 
regimen of IL-2 administration strongly enhanced natural killer—like activity as well as 
retargeted anti-tumour activity and enabled retargeted effector cells to prevent tumour 
growth in the majority of animals m this study
1.18 Immunophotodynamic therapy
Chemoimmunoconjugates (Section 110) ,  immunotoxins (Section 1 1 1 )  and radio- 
lmmunoconjugates (Section 1 13) have all been of limited success in vivo, mainly due 
to non-specific uptake of conjugate by non-tumour tissue To overcome this problem, 
researchers use a two step system by administering the conjugate to the patient and 
allowing the clearance of the monoclonal before activation of the drug or isotope Novel 
therapy systems such as immunophotodynamic therapy may be a better solution to this 
problem
The use of photochemicals in the diagnosis and treatment of certain cancers has received 
a considerable amount of attention (Mew et a l , 1985) Tumour phototherapy, or 
photodynamic therapy, is when light is used in combination with a group of photoactive 
drugs called photosensitisers to destroy tumour tissue and normal tissue is left relatively
28
unharmed All forms of photochemical therapy rely on chemical reactions triggered by 
light The photosensitisers produce singlet oxygen when activated by light By 
administering photosensitisers such as hematoporphyrin, hematoporphyrin derivatives, 
chlorines and benzoporphyrins (reviewed by Nelson et a l , 1988) and then irradiating 
those areas of their body with tumour masses using light focused from a laser light or 
other source, significant reductions in the mass of these tumours have been observed 
This area has been reviewed by Yarmush et al (1993)
119  Uncoiyugated monoclonal antibodies in therapy
Unconjugated monoclonal antibodies can play a vital role in vivo by stimulating and 
manipulating the immune system by mimicking a patient’s own antibodies This role is 
often forgotten m the race to find effective immunoconjugates Unconjugated 
monoclonal antibodies can achieve an anti-tumour response by the following mechan­
isms (reviewed by Mellstedt, 1990), (i) complement-dependent cytotoxicity, (11) 
antibody-dependent cell-mediated cytotoxicity, (111) anti-idiotypic antibodies, (iv) non- 
specific-effector cell activation and (v) interaction with receptors on malignant cells
1 20 Catalytic antibodies
The discovery that antibodies can catalyse a range of reactions such as acyl-transfer and 
peptide-bond formations has led to renewed interest in catalytic antibody technology 
(Hams, 1991) Green and Tawfik (1989) outlined several roles for catalytic antibodies 
They can act as catalysts m organic, synthetic and sterospecific synthesis Catalytic 
antibodies may also be used as biosensors and as cleavage systems in protein 
engineering In addition, catalytic antibodies have several potential clinical applications 
(Landy et a l , 1993) These applications include, (i) catalysis of breakdown of bacterial 
toxins -  it was suggested that catalytic antibodies with proteolytic activity would act 
more speedily and with lower overall dose than unconjugated antibodies, (11) similarity, 
catalytic antibody vaccines' may passively immunise against toxins, bacteria, virus and 
potentially cancer cells, (111) catalytic antibodies may be used to replace enzymes which 
are deficient m a patient and (iv) these antibodies may replace monoclonal antibody- 
enzyme conjugates in prodrug activation
The applications of catalytic antibodies in the field of drug targeting has, as yet, not 
been pursued However, some of the applications of catalytic antibodies include
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esterolytic antibodies, which have already been put to work in the production of a 
biosensor (Blackburn et a l , 1990) These catalytic antibodies are proving to be an 
important new class of biomolecule in which the binding sites are continually 
regenerated by the catalytic reaction of the substrate In this study, Blackburn et al 
(1990) introduced the use of catalytic antibodies as the molecular recognition element 
m a reversible potentiometric immunobiosensor Catalytic antibodies have several major 
advantages over natural enzymes m biosensor applications
The importance of the catalytic activity of antibodies in the body was demonstrated by 
an anti-vasoactive intestinal peptide antibody found naturally This antibody hydrolysed 
the vasoactive intestinal peptide, a bronchorelaxant In a study by Ollerenshaw et al
i
(1989), they demonstrated that both healthy people and asthma sufferers were shown to 
have similar levels of the anti-vasoactive intestinal peptide antibody However, they 
found that the asthma patients had a 50-fold higher affinity for the peptide and thus had 
less vasoactive intestinal peptide In light of these results, it has been suggested that 
these antibodies have a role in the airway hyper-responsiveness of asthma (Ollerenshaw 
et a l , 1989)
Hirschmann et al (1994) have developed a monoclonal antibody, which when induced 
with a phosphonate diester hapten, catalysed the coupling of p-mtrophenyl esters of N -  
acetyl valine, leucme and phenylalanine with tiyptophan amide to form the correspon­
ding dipeptides These results represent a first step toward generating antibodies capable 
of coupling unprotected amino acids and peptide fragments
Addiction to cocaine afflicts Western populations in epidemic proportions, and the 
exceptional reinforcing effect of cocaine renders abuse of this stimulant resistant to 
treatment Landy et al (1993) have developed one of the most promising approaches in 
decades to treat this dependency In their study, Landy et al (1993) immunised mice 
with a phosphate monoester transition-state analogue of cocaine and obtained 
monoclonal antibodies capable of catalysing the hydrolysis of the cocaine benzoyl ester 
group Their monoclonal antibody can bind specifically to cocaine and then break it into 
two inert byproducts, ecognme methyl ester and benzoic acid They proposed that 
passive immunisation with such an artifical enzyme could provide a treatment for 
cocaine dependence by blunting withdrawal symptoms Richard Lerner, president of the 
Scnpps Research Institute has said of Landry's work, that it has the potential to "move 
catalytic antibodies into the treatment of human problems for the first time"
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The development of catalytic antiboclies of defined specificity promises to be of 
considerable value to biology, chemistry and medicine Catalytic antibodies may find a 
use as therapeutic agents to selectively hydrolyse the protem or carbohydrate coat of 
viruses, cancer cells or other physiological targets It may also be possible to selectively 
cleave or ligate complex biomolecules such as polynucleotides, carbohydrates and 
proteins, thereby facilitating structural/functional studies or allowing the synthesis of 
new biomolecules with novel properties The ready availability of large quantities of 
monoclonal antibodies may allow for their use as synthetic tools for the production of 
pharmaceuticals or new materials The ability to generate antibody combining sites with 
specific catalytic groups and/or microenvironments should also serve to test fundamental 
notions of enzymatic catalysis Catalytic antibodies and their applications are further 
discussed in Section 6
1 21 Antibody engineering
The first advance from hybndoma technology was through the somatic mutation of the 
cells to produce mutants that could be selected (Rudikoff et a l , 1982), allowing their 
functional properties to be changcd by switching the heavy chain constant regions 
(Radbruch, 1986) Gene technology expanded the scope of engineering, and has allowed 
the synthesis of new antibodies almost to order It may soon be possible to bypass 
hybridomas entirely with the direct gene transfection from lymphocytes to bacteria 
(Ward e t a l ,  1989)
An antibody is an ideal agent for protein engineering It can be broken into fragments 
which can be used alone or can be transplanted and swapped from one antibody to 
another (Jones et a l , 1986) to make the most suitable antibody For example, m humans 
the constant regions determine the lysing capacity of the antibody, yl isotype is highly 
effective in both complement-dependent cytolysis (CDC) and ADCC and, as such, 
would be useful m therapy (Reichmann et a l , 1988) while the y4 isotype is inactive so 
could be used in diagnostic imaging (Van der Zee et a l , 1986)
Antibody engineering has been used to convert mouse monoclonal antibodies into 
"human" ones by joining the entire immunoglobulin V domains from the mouse 
antibody to human C domains (Morrison et a l , 1984) or by transplanting the 
complementarity-determining regions (CDRs) of the mouse antibodies into human 
myeloma proteins (Jones et a l , 1986) Thus, the iearranged immunoglobulin V genes
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provide the raw material for engineering and have been derived by cloning from 
genomic DNA (Oi et a l , 1983) or cDNA (Neuberger et a l , 1984)
The advent of PCR technology has aided m this field (Saiki et a l , 1985) PCR has been 
used for genomic (Scharf et a l , 1986) and cDNA cloning (Saiki et a l , 1988) It 
involves repeated rounds of extension from two primers specific for regions at each end 
of the gene The primer sequence need not match the gene sequence exactly, and when 
restriction sites are incorporated within the primers, DNA can be cloned directly for 
expression in mammalian cells (Orlandi et a l , 1989) or bacteria (Ward et a l , 1989) 
Lu et al (1994) demonstrated the improved quantitative analysis of PCR amplified 
products using an automated system that combines capillary-gel electrophoresis for 
highly efficient separation and laser-mducer fluorescence for highly sensitive detection 
which will further expand the applications of PCR
1 22 Clinical applications of antibody enginenng
An example of the use of chimaeric antibodies is a chimaeric anti-colorectal cancer 
monoclonal antibody (Steplewski et a l , 1988) The murine VH was combined with a 
human constant region, while VL was joined to CK In a bid to optimize effector 
function, the VH was joined to each IgG isotype in turn and IgGl was found to be the 
most clinically effective
Liu et al (1987) demonstrated the ability to select monoclonal antibodies with desired 
specificity and engineered antibody molecules with desirable biologic functions In this 
study, a mouse-human chimaeric monoclonal was made by substituting the mouse 
constant domains of the mouse monoclonal antibody with the human y l  and K domains 
which bound to the cluster of designation 20 (CD20) antigen of normal and neoplastic 
B cells The mouse variable domains were retained This new antibody has the same 
binding specilicities as the original mouse monoclonal but is highly effective in 
mediating ADCC with human effector cells and CDC with human complement The 
CD20 antigen of normal and neoplastic B cells may be a suitable candidate for targeting 
of B cell lymphomas as hemopoietic stem cells do not express CD20 and, also, as CD20 
does not internalise after monoclonal antibody binding
DeSutter and Fiers (1993) reported the genetic engineering of a murine human 
chimaeric antibody, directed against the tumour marker human alkaline phosphatase 
(Section 1 9 )
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Ten patients were tested in clinical trials of a murine-human chimaeric antibody specific 
to a gastrointestinal-tumour antigen (LoBuglio et a l , 1989) Four patients were given 
single infusions while the other six received three infusions, one every fortnight 
Although the plasma half-life of the antibody was on average six weeks longer than a 
non-chimaeric one and only one person had an antibody response, no tumour regression 
was reported and all patients' tumours showed signs of progression within a three month 
period (LoBuglio et a l , 1989) The clinical applications of antibody enginering has been 
reviewed by Hand et al (1994)
1 23 Humanised antibodies
Humanisation or "reshaping" of murine antibodies is an attempt to transfer the full 
antigen specificity and binding avidity of murine monoclonal antibodies to a human 
antibody by grafting the murine CDRs onto a human variable region framework 
(Reichmann et a l , 1988) Using Campath-1, a rat antibody capable of recognising an 
antigen on human lymphocytes, the humanised antibody acted in a similar manner to the 
parent mouse monoclonal antibody Two patients with non-Hodgkins lymphoma were 
treated with this humanized Campath-1 (1-20 mg/day for up to 43 days) Neither 
showed an immune response and the tumours showed signs of regression (Hale et a l , 
1988)
Other humanized antibodies aie showing equally positive signs Celltech, the British 
biotechnology company, are conducting research on antibodies against septic shock, 
heart disease (Newell, 1989, Queen et a l , 1989) and on anti-Tac antibody, which blocks 
binding of interleukm-2 to its receptor (Queen et a l , 1989) However, to preserve the 
binding affinity, the majority of the CDR-grafted antibodies require additional ammo 
acid changes in the framework region, because such ammo acids are conformationally 
important or are in direct contact with the antigen (Foote and Winter, 1992) Such 
necessary framework changes may introduce new antigentic epitopes and, if many 
changes are needed, the advantages of CDR grafting over chimaeric antibody constructs 
would be lost
A solution to this problem was proposed by Roguska et al (1994), by maintaining the 
CDRs and the core of the murine variable region framework but replacing the surface 
residues of the framework region with those from a human variable region by a process 
they called "resurfacing" A premise to this approach is that the immunogenicity of
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munne antibody variable regions originates with the surface residues and, hence, that 
the surface will carry most, if not all, of the antigenic potential of the protein 
Masat et al (1994) isolated a murine antibody that is highly specific for a molecule 
expressed by human cells of the melanocytic lineage This antibody consists only of a 
kappa light chain and only in the monomeric form does this kappa light chain 
specifically bind to its cognate antigen Masat suggests that there may be numerous 
other examples of monomeric light chain antibodies among the hundreds of thousands 
of hybndomas generated since the fusion method was described (Kohler and Milstein, 
1975) Thus, it might be feasible to use conventional techniques to generate naturally 
occurring monomeric light chain antibodies for many antigenic specificities 
For serotherapy, human monoclonal antibodies are preferred There are, however, 
considerable difficulties in making human monoclonal antibodies of the required 
specificity by hybndoma technology (Carson and Freimark, 1986) One way of 
minimizing these undesirable responses in therapy was provided by antibody engineering 
with the creation of chimaeric and 'humanised' antibodies (Figure 5 2 1)
Pedersen et al (1994) have made a systematic analysis of the known antibody structures 
to determine the relevant solvent accessibility distributions of ammo acid residues in 
murine and human antibody variable regions and have shown that the sequence 
alignment positions of surface ammo acids for human and murine variable region heavy 
( V h ) and (V J  chains are conserved with 98% fidelity across species While the ammo 
acid usage at the surface positions creates surface residue patterns that are conserved 
within species, there are no identical patterns across species However, Roguska et al 
(1994) have shown that surprisingly few amino acid changes need to be made to convert 
a murine variable region surface pattern to that characteristic of a human surface They 
have "resurfaced" two murine monoclonal antibodies which maintained their parental 
affinities for their cell surface ligands This experiment provides evidence that, despite 
the differences m the surfaces of mouse and human variable regions, it is possible to 
substitute one for the other while retaining full antigen binding activity
1 24 Second generation recombinant monoclonal antibodies
Mallender and Voss (1994) reported the design, construction and expression of a 
bivalent, bispecific, single-chain antibody protein in Escherichia coh, which was based 
on two previously constructed monovalent, single-chain antibodies possessing distinct
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specificities Construction of such a model bivalent, bispecific molecule provides a 
foundation for future assembly of similar molecules designed to identify parameters 
involved in enhanced binding of antibodies due to avidity and dual specificity 
Hand et al (1994) reviewed the development of novel immunoglobulin forms They 
proposed that the genetic modifications may result in more useful diagnostic reagents 
and in the production of more stable immunoconjugates with the characteristic of more 
efficient tumour cell killing
125  Future developments
During the past decade, the marriage of cancer research and molecular biology has 
produced a much better understanding of the many biochemical changes underlying 
cancer development Only recently, however, have researchers begun to apply that 
growing body of knowledge to the search for better therapies for cancer Two reports 
have brought one potential treatment aimed at correcting a biochemical alteration of 
cancer cells a step closer to reality (Kohl et a l , 1993, James et a l , 1993)
A so-called oncogene, ras , may contribute to as many as one-fifth of all human 
cancers, including more than half of such common ones as colon cancer A great deal 
of work has shown that the proteins encoded by ras genes occupy a central position in 
the signaling pathway used by cells to respond to growth factors What apparently 
happens in cancerous tumours is that as a result of mutations in the genes, Ras proteins 
are always turned on, so that they constantly promote cell division, even in the absence 
of stimulation by growth factors However, before either the normal or mutated Ras 
proteins can function, they have to undergo a series of modifications that enable them 
to settle on the cell membrane, from which they relay growth signals to the cell interior 
These two reports (James et a l , 1993, Kohl et a l , 1993) have described compounds 
which interfere with the modification of the Ras protein which might be able to keep 
the proteins from attaching to the membrane and, thus, might be able to keep the growth 
of the cell switched off and prevent uncontrolled cell division In theory, drugs designed 
on this principle might prove more powerful and have fewer side effects than 
conventional chemotherapeutic drugs, which attack rapidly dividing cells, whether they 
are cancerous or not
Another hopeful development was made recently (Marasco et a l , 1993) A  team of 
researchers, using a combination of antibody engineering and gene therapy, have
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directed an antibody to a specific location inside a cell The antibody Marasco and his 
colleagues put into cells was able to interfere with the assembly of the AIDS virus, 
thereby reducing both its cell-killing potential and its mfectivity This achievement 
raises the possibility of using antibodies within cells to block the construction of viruses 
or harmful proteins, such as the oncoproteins whose activity contributes to the 
uncontrolled growth of cancer cells If this proves correct, then antibodies may prove 
as important inside cells as outside
126  Thesis outline
The work described in this thesis was designed to exploit the potential of antibodies to 
perform analytical, targeting and catalytical functions This involved the production of 
several antibodies to defined antigens and the chemical synthesis of bispecific 
antibodies In the introduction, the major areas of monoclonal antibody technology for 
the detection and treatment of cancer have been discussed (Figure 1 2 )  The areas in 
which experimental work was undertaken during this thesis are boxed in Figure 1 2
In this thesis, the following aspects of antibody technology were explored,
(l) a monoclonal antibody to a protein, Glial Fibrillary Acidic Protein (GFAP),
which is associated with human astrocytomas (Section 3 )  was produced 
(n) a monoclonal to a human astrocytoma cell line, called G-CCM, which also reacts
with commercial GFAP (Section 3 )  was produced 
(in) monoclonal and polyclonal antibodies to Iodinated Bolton-Hunter Reagent 
(IBHR) (Section 4 ) were developed
(iv) bispecific antibodies were produced between the anti-GFAP and anti-G-CCM  
and anti-Ricin~A chain and the polyclonal anti-IBHR (Section 5 1 )
(vi) a method to genetically clone and express the variable regions of the anti-GFAP 
antibody in Escherichia coh (Section 5 2 )  was examined
(v) a monoclonal antibody was produced which catalysed a chemical reaction, e g 
to catalyse a prodrug ->  drug reaction (Section 6 )
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Figure 1.2. Summary o f the major areas of research in the production and application 
o f monoclonal antibodies for the detection and treatment of cancer The boxed headings 
indicate areas in which experimental work was undertaken
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SECTION 2 : MATERIALS AND METHODS
2.1. Materials.
Reagents used in experimental work were of analytical grade and were obtained from 
Sigma Chemical Co., Poole, Dorset, England; BDH Chemicals Ltd., Poole, Dorset, 
England and Riedel de Häen, AG, Seelze, Hannover, Germany. Cell culture media, 
supplements, sera and disposable plasticware were supplied by Flow Laboratories, 
Woodcock Hill, Harefield Road, Hertz, WD3 1PQ, England, ICN Biomedicals Ltd., 
Irvine, Ayrshire KA12 8NB, England; Greiner, The Science Centre Ltd., 159 Lower 
Rathmines Road, Dublin 6 and Medical Supply Company, Unit 9, Santry Hall Industrial 
Estate, Santry, Dublin 9. Stains used for cytogenetic and histological analysis were 
obtained from BDH Chemicals Ltd., Poole, Dorset, England. Genetic reagents were 
obtained from Pharmacia, Unitech, United Drug House, Belgard Road, Tallaght, Dublin 
24. Restriction enzymes were obtained from New England Biolabs, 32 Tozer Road, 
Beverly, MA 01915, U .S.A . and from Promega Corporation, 2800 Wood Hollow 
Road, Madison, WI 53711-5399, U .S.A .
A number of specific reagents, which were obtained from various suppliers are listed. 
Balb/c mice were obtained initially from Trinity College, Dublin 2 and subsequently 
from Harlan Olac Limited, Shaw’s Farm, Blackthorn, Bicester 0 X 6  OTP, England. 
Bolton-Hunter reagent (3-(4-hydroxyphenyl)propionic acid N-hydroxy succinimide ester) 
and dimethylsulphoxide (Sure Seal) were obtained from Aldrich Chemical Company, 
Gillingham, Dorset, England.
Borosilicate glass tubes (16x100mm) were obtained from Corning Glass Works, 
Corning, New York 14831, U .S.A .
Bradford reagent was obtained from Bio-Rad Laboratories Ltd., Richmond, California, 
U .S.A .
BriClone was obtained from Dr. Kenneth Carroll, National Cell and Tissue Culture 
Centre (NCTCC), Dublin City University.
Dulbecco’s Modification of Eagle’s Medium (DMEM) with 3.70g/L of sodium 
bicarbonate without glutamate was obtained from Flow/ICN Flow laboratories, Irvine, 
Scotland KA12 8NB.
DNA Primers were obtained from the Department of Genetics, Trinity College, Dublin. 
Ethanol was obtained from Merck, Darmstadt, Germany.
Millex-GV and Millex-HA 0.22^m single use filter units were obtained from Millipore, 
France through Medical Supply Company Ltd. NUNC Immunopiates Maxisorp-96 well
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non-sterile (certified) were also obtained from the Medical Supply Company.
Hoechst 33258 was obtained from Calbiochem, Bering Diagnostics, La Jolla, CA 
92037.
Hybond-C-Super supported pure nitrocellulose paper (0.45^m, 30cmx3m) was supplied 
by Amersham International, Amersham, Buckinghamshire, HP7 9NA, England. 
Liquid Carbon Dioxide was obtained from Irish Industrial Gases, Bluebell, Dublin 12. 
Liquid Nitrogen was obtained from Cooper Cryoservice Limited, 6 Chalet Gardens, 
Lucan, Co. Dublin.
New Zealand White Rabbits were obtained from Ballina Laboratories, Carrentrila, 
Ballina, Co. Mayo.
NuSieveR GTG Agarose was obtained from FMC BioProducts, 191 Thomaston Street, 
Rockland, ME 04841, U .S.A .
Phosphate buffered saline (Dulbecco A) (PBS) tablets were obtained from Oxoid 
Limited, England.
Polyethylene Glycol 1500 was obtained from Boehringer Mannhiem, Hannover, 
Germany.
PAGELR precast polyacrylamide gels for electrophoresis were obtained from ATTO 
Corporation, 2-3 Hongo 7-Chrome, Bunkyo-ku, Tokyo, Japan.
Protein A columns and BCA Reagent were obtained from Pierce and Warriner (U .K.) 
Limited, 44 Upper Northgate Street, Chester, Cheshire, CHI 4EF, England.
Protein G-Sepharose 4 Fast Flow column (5 ml) and Sephadex G-25 Medium were 
obtained from Pharmacia, address as above.
Rapi-Diff II, a triple stain pack for rapid Romanowsky staining was obtained from 
DiaCHEM, Diagnostic Developments, Units 2-4, 50 Everton Road, Birkdale, 
Southport, Merseyside PR8 4BT, England.
Sterile Needles (Microlance 2) were obtained from Becton Dickinson and Company 
Limited, Dun Laoghaire, Co. Dublin.
Trypsin/EDTA (0.05%, v/v /0.02%, w/v) in PBS (without Ca++ or M g++), Penicil­
lin/Streptomycin (10,000units/ml and 10,000/xg/ml, respectively) and Gentamicin 
(20,000^g/ml) were purchased from Seromed, Biochrom KG, Leonorenstra/?e 2-6, D- 
1000 Berlin 46, Germany.
Ultrogel AcA44 was obtained from IBF Biotechnics, Villeneuve-La-Garenne, France. 
Several commercial kits were used for analytical purposes; these are given in Table 2.1.
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Table 2.1. Summary of commercial kits used.
Name Source Address
QuickPrep™ mRNA 
Purification Kit
SEROTEC Isotyping Kit
Pharmacia Unitech Limited, 
United Drug House, 
Tallaght,
Dublin 24
Bicinchonic Acid (BCA) 
Protein Assay Kit
Pierce
Chemical Co
Rockford, 
IL 61105, 
U S A
CEL-PRIME IN VITRO 
Immunization for High 
IgG Yield
Immune Systems 
Ltd
P 0  BOX 99, 
Westbury on Trym, 
Bristol BS10 5NU, 
England
Sigma Mouse 
Monoclonal Antibody 
Isotyping Reagents
Sigma Immuno­
chemicals
P 0  BOX 14508,
St Louis, MO 63178, 
U S A
The animal cell lines used are summarised in Table 2 2 The antigens used in the 
enzyme-linked immunosorbant assays (ELISA) are detailed in Table 2 3 , while the 
antibodies used in immunocytochemistry, ELISA and fluorescence activated cell sorting 
(FACS) analysis are listed in Table 2 4
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Table 2.2. Animal cell cultures used m vitro and in vivo.
Cell Line Cell Type Catalog
No.
Supplier
MCF-7
LOVO
NRK
HL-60
A549
Human, breast 
adenocarcinoma 
Human, colon 
adenocarcinoma 
Rat, normal kidney 
Human, promyelocytic 
leukaemia
Human, lung carcinoma
HTB 22 
CCL 229 
CRL 6509
ATCC,
12301 Parklawn Dr , 
Rockville, Maryland 
20852, U S A
EJ-138
NSO/1
G-CCM
G-UVW
UK(t)
Human, bladder 
carcinoma
Mouse, balb/c myeloma 
Human, astrocytoma 
Human, astrocytoma 
Human, astrocytoma
8511412
84112004
86022702
86022703
86022704
EC ACC,
PHLS Porton Down, 
Salisbury,
Wiltshire SP4 0JG, U K
T-24 Human, bladder Dr J Tager, 
Amsterdam University, 
1105AZ, Netherlands
H5683
B21
Human, brain 
Human, brain
Dr Alice Redmond, 
Dr Geraldine Grant, 
NCTCC, D C U
K562
SP2/0-Agl4
Human, erythroleukaemia 
Mouse balb/c myeloma
- Laboratory Stocks, 
Dublin City University
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Table 2.3. Antigens used in ELISAs.
Antigen Supplier
GFAP, (code 77-106) 
from bovine spinal cord
ICN Immunobiologicals, 
P 0  Box 1200,
Lisle, IL 60532
IBHR-BSA, IBHR-KLH, 
IBHR-oval
Produced during thesis 
research
PHOS-KLH Dr Gerry Gallacher, 
Division of Chemistry, 
University of Brighton, 
Brighton BN2 4GJ
Ricin-A chain Dr Denis Thatcher, 
Zeneca Corporation, 
England
Anti-recombinant ncin-A 
chain monoclonal anti­
body (608/7)
Dr Malcolm V Pimm, 
University of Nottingham, 
University Park, 
Nottingham NG7 2RD
Cell lines See Table 2 2
Permission to use anti-ncin-A chain antibody was gratefully obtained from Dr Partick 
Trown, Xoma Corporation, 2910 Seventh Street, Berkeley, California 94710, U S A
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Table 2 4. Monoclonal antibodies used in lmmunocytochemistry, ELISA and FACS 
analysis, (alk. ph. = alkaline phosphatase).
Antibodies used Label Dilution Code Supplier
Goat anti-mouse 
IgG (whole 
molecule)
Fab specific
No label 
alk ph 
peroxidase 
FITC
10^g/ml
1/9500
1/1000
1/32
M-8642
A-5153
A-4416
F-4018
Sigma Immunochemical 
Co , P O Box 14508, 
St Louis,
MO 63178, U S  A
Monoclonal anti- 
GFAP, 
clone G-A-5
No label 1/200 69-110 ICN Immunobiologicals, 
P 0  Box 1200, Lisle,
IL 60532, U S A
Goat anti-mouse 
ig
No label 1/500 083-67 ATAB, P 0  Box 60, 
Scarborough,
MG 04074, U S A
Monoclonal 
alk ph anti- 
alk ph (APA- 
AP)
alk ph Neat A-2806 Sigma, as above
Goat anti-mouse 
IgM
FITC 1/32 F-2031 Sigma, as above
Goat anti-mouse 
IgM (fx chain)
alk ph 1/1000 A-7784 Sigma, as above
Mouse IgMk M-2770 Sigma, as above
Mouse IgG Sigma, as above
Anti-Ricin-A
chain
1/100 608/7 Prof Malcolm V 
Pimm,
Umv of Nottingham
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Table 2.5. Subtrates used m unmunocytochemisty, ELISA and FACS.
Substrate Reagents Cone. Supplier
Code
5-bromo-4-
chloro-3-indoyl phosp­
hate (BCIP),
Disodium salt
0 1M Ammo-methyl- 
propanol (5mM MgCl,
0 01 % v/v Tnton X- 
405, 0 01% w/v NaN3), 
pH 10 25
1/xg/ml Sigma,
B-6149
o-phenylene-diamine 
[50fil 20% (v/v) 
H2S 0 4 used to stop 
reaction]
0 1M Citrate buffer, 
pH5 0, 50^1 1% (v/v)
h 2o 2
2mg/ml Sigma,
P-9029
Fast red TR/ 
Naphthol AS-MX 
phosphate 
(when 1 tablet is 
dissolved in 10ml 
H20 )
Fast red TR 
Naphthol AS-MX 
Levamisole 
0 1M Tns/HCl buffer, 
pH 8 2
1 Omg/rnl 
0 4mg/ml 
0 15mg/ml
Sigma,
F-0900
p-Nitrophenyl
Phosphate
10% (v/v) diethanolam- 
me, 0 5mM MgCl2, pH 
9 8
1 mg/ml Sigma,
P-2765
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2.2. Equipment.
Cells m culture were examined using a Nikon type ELWD 0 3 inverted phase contrast 
microscope A Nikon Optiphot microscope was used for fluorescence and phase contrast 
microscopy
A Holten LaminAir HB 2448 K laminar flow was used for all cell culture work 
The temperature and carbon dioxide controlled incubators used for cell culture were 
Jouan EG 115 IR and Heraeus Instruments B 5060EK/C02 
Cell counts were performed on a Neubauer Hemocytometer slide 
A Heraeus Christ Labofuge 600 and Labofuge GC were used to centrifuge universal 
tubes (1 - 20ml) A Heraeus Biofuge A was used for smaller volumes ( 0 - 1  5ml) The 
higher speed centrifuges and rotors used were SorvallRRC-5B Refrigerated Superspeed 
Centnfuge with SorvallRGSA (13000rpm max ) and SorvallR SS-34 (20500rpm max) 
rotors A Beckman J2-21 centnfuge with a Beckman JA  20 rotor were used in the 
extraction of mRNA A Beckman L8-70M Ultracentnfuge with Ty 70-1 TI rotor was 
used in the punfication of cell membranes for Western blotting 
Slides of cells in suspension were prepared using a Heraeus Sepatech Labofuge Ae with 
disposable inserts used for each slide prepared
A Biohit ProlineR Electronic 250 automatic octopipette was used in cloning work and 
with ELISAs
A Kika-Werk, Ultra-Turrax homogemzer was used to prepare stable adjuvant-antigen 
suspensions pnor to injection
Electrofusion for hybndoma production was performed using a Biojet CF electrofusion 
apparatus supplied by B Braun, Amsterdam, Holland
A Hetosicc CD-52 freeze dner was used to lyophilise IBHR conjugates and was 
supplied by Heto Laboratory Equipment, Leopardstown Road, Foxrock, Dublin 18 A 
Vitns Consol 4 5 from The Vitns Company Incorporated, Gardiner, N Y 12525, 
U S A  was used to lyophilise cell membranes for Western blotting analysis and to 
lyophilise DNA pnmers
Absorbances in 96 well plates (e g from ELISAs) were read using the Titertek 
TwinPlus Microplate Reader and the Titertek Multiscan PLUS M K11 
A Shimadzu UV-160A UV-Visible Recording Spectrophotometer was used to measure 
the absorbance of solutions
The HPLC system used was Beckmann System Gold supplied by B M Browne,
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Sandyford Industrial Estate, Foxrock, Dublin 18 and serviced by Brennan and Co , 61 
Stillorgan Industrial Park, Stillorgan, Co Dublin The column used was a 10^m Protein 
Pak SW 300 column with a mobile phase of 0 1M phosphate buffer, pH 7 0 
A LKB Bromma 2050 Midget Electrophoresis Unit was used in the preparation of SDS- 
PAGE gels and a Bio Rad Trans-Blot SD semi-dry transfer cell was used in Western 
immunoblotting PAGELR precast polyacrylamide gels for electrophoresis were also 
used These gels were run using the ATTO model AE-6100 mini gel apparatus using 
an ATTO Crosspower 3500 power supply
Electroporation of E  coll cells was earned out on a ProGenetor Pulse Controller from 
Hoefer Scientific Instruments, which was fitted with a Gene Pulse Cuvette Unit (Bio- 
Rad)
The PCR machines used were LEP Scientific Prem™ and Hybaid Omni Gene 
Photographs for immunocytochemistry and immunofluorescence were taken using a 
Nikon FX-35 WA camera An NCB10 filter was used with colour film and an ND2 
filter was used with black and white film The automatic timed exposure apparatus used 
was a Nikon Model HFX-IIA The colour film used was Kodak Gold II ISO/ASA 100 
colour film and Ilford HP5 Plus400 black and white film ISO/ASA 400 
Photographs for genetics work were taken using an Olympus OM-20 camera using T- 
max 100 film (Kodak) and an A003 red filter (Cokin, France) which blocks UV light 
Vivitar close-up lenses were used when required
2.3. Techniques involved in the production, purification and characterisation of 
monoclonal antibodies.
2.3.1. Routme culture of cells in suspension.
All tissue culture was performed in a laminar flow All matenals used were stenlised 
by either autoclavmg, filter stenlisation (using a 0 22¿¿m filters) or were purchased 
stenle The cell lines used were maintained in DMEM-S10 [Dulbecco’s Modification of 
Eagle’s Medium containing 7 5% (v/v) sodium bicarbonate, supplemented with L- 
glutamme (2mM), Hepes (ImM) and FCS 10%, v/v] Media for the MCF-7 (and MCF- 
7 brain vanant) breast adenocarcinoma cell line was further supplemented with sodium 
pyruvate (ImM) Cultures were initiated at cell densities of 2x10s cells/ml using 7ml 
o f medium per 25ml culture flask or 12ml of medium per 75cm2 culture flask Cells
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were harvested, when approximately 75% confluent, by flushing them from culture 
surfaces using a stenie pasteur pipette All animal cells in culture were incubated in a 
humid, 5% C 0 2 atmosphere at 37°C
2.3.2. Routine cell culture of adherent cell hnes.
The G-CCM, G-UVW, IJK(t), T-24, MCF-7, A549, HL-60, H5683, B21 and EJ-138 
cell lines are strongly adherent and required trypsimzation to release them during 
harvesting and subcultunng procedures All of the culture medium was decanted and 
4ml of a trypsin EDTA solution [0 05%, v/v 0 0004%, w/v in sterile 0 01M PBS, pH 
7 3] was added to the flasks After 1 minute this trypsin was removed and a further 4- 
5ml o f trypsin EDTA solution was added and incubated at 37°C for 10 minutes The 
cell suspension was decanted into 5-10ml of complete culture medium to inactivate the 
trypsin and centrifuged at l,200rpm for 10 minutes in universal tubes Cells were 
resuspended m 36ml o f culture medium and divided into 3x75cm2 stenie flasks The 
MCF-7 and UK(t) cell lines do not adhere to plastic as strongly as the above cell lines 
and require a more dilute trypsin solution (0 05%, w/v) trypsin,0 02%, w/v, EDTA in 
0 01M PBS, pH 7 3) to minimise surface antigen losses (Sasaki, et a l , 1981)
Stenie 0 01M PBS was prepared by dissolving 8 Og NaCl, 0 2g KC1, 1 44g Na2H P04 
and 0 24g KH2P 0 4 in 800ml of distilled water The pH was adjusted to 7 3 and the 
volume of water was adjusted to 1 litre This solution was dispensed in convenient 
volumes, stenlised by autoclaving and stored at room temperature Phosphate buffered 
saline (PBS), 0 01M, pH 7 3 was routinely prepared by dissolving one PBS tablet in 
100ml ddH20
2.3.3. Cell counts and viability staining.
Cell counts were performed on a Neubauer Hemocytometer slide Acndine orange/ethi- 
dium bromide and/or trypan blue were routinely used to determine cell viabilities 
(Mishell et al , 1980)
The acndine orange/ethidium bromide stain solution contained 0 lmg acndine orange 
and 0 lmg ethidium bromide in 100ml 0 01M PBS, pH 7 3 An equal volume of stain 
was added to a known volume of cells and examined by UV fluorescence microscopy 
Live cells stain green while dead cells stain orange
For trypan blue staining, a known volume of cells was added to an equal volume of
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stain (0 2%, w/v), left for one minute and were then examined by light microscopy 
Live cells excluded the dye and remained white while dead cells stained blue Longer 
incubation periods with stains leads to non-specific uptake o f dye and inaccurate results 
The total number of cells (T) in the cell suspension was calculated using the number of 
cells counted on the gnd (C), as follows,
T =  C x D x l 0 4 x V  
where D is the dilution factor, in the case of a 1 1 dilution, D = 2 , V is the volume of 
cell suspension available and 104 is the conversion factor used
2.3.4. Long term storage and recovery of animal cells.
Cryopreservation methods descnbed by Reid and Cour (1985) and Pnce (1985) were 
used Stocks of cells were maintained in liquid-mtrogen freezers Washed cells were 
resuspended to the desired concentration (usually lxlOVml) in FCS supplemented with 
5% (v/v) dimethylsulphoxide (DMSO, cryoprotectorant) Aliquots of 1ml were placed 
in sterile cryotubes (ICN-Flow) and frozen at a rate of approximately -1°C per minute 
to -70°C on a freezing tray (Union Carbide) before being immersed in liquid nitrogen 
Recovery of cells from liquid nitrogen was achieved by thawing the cells rapidly to 
37°C (Care must be taken to wear a face mask due the possibility of a vial exploding ) 
The cells were then added to 10ml of DMEM at 37°C, pelleted by centrifugation at 
500g for 10mm and resuspended in 10ml fresh DMEMS10 culture medium in 25cm2 
culture flasks Cells recovered from liquid nitrogen were approximately 90% viable
2 3.4.1. Antibiotics used in culturmg cells.
A sterile penicillin/streptomycin stock solution (lOOx) of 10,000umts/ml and 10,000 
¿tg/ml, respectively, was purchased (Section 2 1 ) and was used to give protection 
against bacterial infection This solution was aliquoted asceptically to single use 
volumes and stored at -20°C The usual working concentration used was lOOumts/ml 
penicillin and 100/xg/ml streptomycin
Gentamicin was occasionally used when a broader spectrum antibiotic than pemcil- 
lin/streptomycm was required This was bought as a lOOx sterile stock solution 
(20,000^g/ml) (Section 2 1 )  which was aliquoted aseptically to single use volumes and 
stored at 4°C The stock solution is very stable The usual working concentration used 
was 200/ig/ml
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2.3.5. Mycoplasma detection using the Hoechst 33258 fluorescence assay.
Since mycoplasma contamination affects the growth and viability of cell cultures, all 
cell lines used were routinely checked using the DNA-intercalating agent bisbenzimid 
(Hoechst 33258) which detected the presence of mycoplasma in the cellular cytoplasm 
The detection method used was further described by Carroll and O’Kennedy, (1988) 
Cultures of mycoplasma-free normal rat kidney (NRK) cells were established on glass 
coverslips using 5 xlO3 cells in 1ml of DMEM containing 6% (v/v) FCS and cultured 
overnight Supernatants from cultures to be tested were then added to the NRK cells, 
which were reincubated for a further 3 to 4 days or until the cells were approximately 
70% confluent Duplicate NRK cultures were fed with fresh media and used as a 
negative control Positive controls, previously prepared and stored at 4°C were 
included The coverslips were then washed three times in 0 01M PBS, pH 7 3, (taking 
care to keep the cells on the uppermost surface at all times) and fixed for exactly six 
minutes in 1 1 methanol acetone solution at -20°C The coverslip preparations were then 
nnsed three times m 0 01M PBS, pH 7 3, and stained for 10 minutes m Hoechst 33258 
(0 05^g/ml in 0 01M PBS, pH 7 3)(toxic) The stain was washed from the cells using 
0 01M PBS, pH 7 3, and the coverslips air-dned and mounted on clean slides Slides 
were stored in the dark until viewed under UV light on a Nikon fluorescence 
microscope at 100X magnification with a B2 combination filter (Nikon) The 
membranes of contaminated NRK cells had areas of fluorescent DNA which could be 
associated with mycoplasma while no such fluorescence was found in negative and 
control slides
2.3.6. Use of adjuvants to stimulate an immune response.
Adjuvants are non-specific stimulators of the immune response Used properly, they 
allow a much stronger immune response to be generated (Cahill et al , m press) The 
most commonly used adjuvants are Freund’s complete and incomplete adjuvants (CFA 
and IFA, respectively) Both CFA and IFA consist of nonbiodegradable mineral oils 
CFA also contains killed Mycobacterium tuberculosum and is only used for the initial 
immunisation, all subsequent immunisations are given with IFA The effect o f the 
adjuvant is to cause a local lmtation leading to an mflamation response which attracts 
large numbers of immune effector cells to the site of injection The antigen, which has 
been emulsified in the oil using a Kika-Werk Ultra-Turrax homogemser, is released
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slowly to give a prolonged exposure to the immune system M tuberculosum contains 
muramyl dipeptide in its extracellular matrix which is a potent stimulator o f immune 
cell function dunng primary immunisations It stimulates the release of various 
lymphokmes which play a crucial role m the development of the immune response 
Freund’s adjuvant was always given intrapentioneally and must never be given 
intravenously
2 .3 .6 .1 . Types, doses and preparation of antigens for injection with and without 
adjuvant.
Soluble proteins, such as glial fibrillary acidic protein (GFAP), îodinated Bolton-Hunter 
reagent-BSA conjugate (IBH-BSA) or phosphogen-KLH (PHOS-KLH) when used to 
immunise mice, were always given in the presence of an adjuvant (Section 2 3 6 ) If 
the antigen is in short supply, such as GFAP, it can be given at doses of 20pcg to 60ptg 
per mouse Where a large amount of the antigen is available, 50/ig to 200^g per mouse 
may be given It is seldom worthwhile to administer larger amounts 
To reconstitute GFAP (250fig), 100/xl of sterile ultrapure H20  was added to dissolve 
the protein, then 145^1 of DMEMS10 was added to prevent the protein adhering to the 
glass when reconstituted, lastly 5/a1 of gentamycin was added to eliminate contamina­
tion
To prepare for administration the antigen is made up in a bijou at a concentration of 
50fjig in 100/xl of 0 01M PBS, pH 7 3 per mouse 200/xl of the appropriate Freund’s 
adjuvant per mouse is added to the antigen solution and the mixture is emulsified using 
an homogenisor Emulsification is achieved, when the two solutions do not separate if 
left standing at room temperature 300^1 of this solution is administered intrapentionally 
per mouse using a 1ml sterile syringe and a 26xG3/8 gauge needle Particulate antigens 
include whole cells, such as G-CCM, which make good antigens, because they are 
readily phagocytosed by the antigen-processing cells of the immune system Live cells 
are given at 105 to 107 cells per injection, mtrapentoneally (i p ) in 300/d of 0 01M 
PBS, pH 7 3, which had been warmed to 37°C
2.3 .6 .2 . Immunisation protocol of mice for the production of monoclonal 
antibodies.
Male balb/c mice were used for the production o f monoclonal antibodies Mice bred in
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the animal house facility at Dublin City University were used, mitally However, 
subsequently, because of the problem of mouse hepatitis virus (MHV) contamination 
and IgM production, certified mice were obtained from Harlan Olac Limited Normally 
five mice were immunised at a time 
Four types of immunogens were used
(I ) a human anaplastic astrocytoma cell line, G-CCM, m order to produce anti-G-CCM 
monoclonal antibodies (Section 3 )
(I I ) Glial Fibrillary Acidic Protein (GFAP), a commercially produced pure protein, in 
order to obtain anti-GFAP monoclonal antibodies (Section 3 )
(I I I ) an 1BHR-BSA conjugate to obtain monoclonal and polyclonal anti-IBHR antibodies 
(Section 4 ), and
(iv) a Phosphogen-KLH conjugate in order to obtain monoclonal antibodies which 
would react with the phosphogen and hydrolyse the corresponding amide (Section 6 )
All injections were given i p , except for the final GFAP injection (50/ig), which was 
given i v in 100/xl of warmed stenle 0 01M PBS, pH 7 3, through the pre-warmed tail 
vein of a mouse The following immunisation protocol was used for the production of 
monoclonal antibodies,
Day 1 (l) The protein antigen-adjuvant emulsion was prepared (Section 2 3 6 ) in CFA 
using 50/xg of antigen per 200/xl of emulsion or (1 1) 5 x ltf G-CCM cells were 
resuspended in 500/U of 0 01M PBS, pH 7 3
Day 14 Reimmunise as in (i), except IFA is used in place of CFA for this, and
succeeding immunisations
Day 28 Repeat immunisation as on Day 14
Day 42 Repeat immunisation as on Day 14
Day 49 Each mouse that had been immunised was tail bled (Section 2 3 8 ) and the
specific antibody titre checked by ELISA (Section 2 3 16 ) against the appropriate
antigen or alternative conjugate for specific antibody production
Day 56 If the titre obtained from day 49 was low, the mice were boosted as on Day
14
The mice with the strongest immune response to the antigen were either,
(l) selected and reimmunised by an i p injection or,
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(n) as was the case with the protein antigens, boosted with an 1 v injection or,
(1 1 1) the mouse was sacrificed and a splenectomy performed (Section 2 3 9 ) in 
order to perform a fusion (Section 2 3 13 ) or,
(iv) the mouse was sacnficed three days pnor to a fusion and a splenectomy 
carried out (Section 2 3 9 ) in order to perpare for an in vitro immunisation (Section 
2 3 1 1 ) Routinely three fusions were performed separately on the same day
2.3.6.3. Specific immunisation protocol for mice immunised with G-CCM cells. 
Care was taken when preparing G-CCM cells for immunisation These cells are 
adherent and 0 05% (w/v) trypsin in 0 01M PBS (Section 2 3 2 ) was used to detach 
the cells from the tissue culture flask The cells were incubated in this trypsin solution 
for as short a time as possible as, otherwise, surface antigens may be removed by the 
trypsin The immunisation protocol is detailed in Section 2 3 6 3 Five mice were 
immunised with G-CCM cells in 0 5ml of PBS, per mouse, as outlined in Table 2 6
Table 2.6. Immunisation schedule of balb/c mice immunised with G-CCM cells in 
0.01M PBS, pH 7.3.
Day NUMBER OF CELLS 
(x 106) injected
1 1
16 4
31 1
48 2
65 1
On day 56, the mice were tail bled and their sera were tested by ELISA on G-CCM-
i
and GFAP-coated plates The results obtained are shown m Table 3 1 and Figure 3 1
2.3.7. Procedures for the production of anti-G-CCM monoclonal antibodies.
From the results of the screening of the sera obtained from G-CCM immunised mice 
(Table 3 1 ), the mouse which gave the best result was sacnficed and the spleen cells
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used in electrofusion as described m Section 2 3 132  8x10s spleen cells were harvested 
(Section 2 3 9 ) and 1 7xl07 SP2/0 cells were obtained from culture (Section 2 3 1 )  
The spleen and myeloma cells were mixed m a l l  ratio
Following the electrofusion, the cells were seeded at 1x10* cells per well in sterile 96 
well culture plates Three electrofusions were performed and the resulting hybndomas 
were cared for as outlined in Section 2 3 14 with the fused cells were selected using 
hypozantme 8-azaguamne (HA) The positives were selected by ELISA (Section 
2 3 1 6 ) against an anti-mouse IgG antibody in order to select for clones which were 
secreting antibody (Section 2 3 16 5 ) The supernatant from these antibody-producing 
clones were further screened by ELISA against G-CCM (Section 2 3 16 1 )  and, finally, 
against GFAP (Section 2 3 16 3 ) This was to find an antibody that would react with 
a GFAP-like antigen on G-CCM cells
The anti-G-CCM antibodies were then isotyped by the various methods outlined in 
Section 2 3 18 All of the monoclonal antibodies produced isotyped as IgM This, at 
first, appeared to be an extraordinary result as the mice had been immunised four times 
over a penod of two months and had been given an in vivo or in vitro boost in some 
cases
However, on examination of the immunisation records of these mice, it was noticed that 
a number of the immunised mice, of all ages, died between January and Feburary 1991 
These were the first of such immunised mice to die In July and August of 1991, when, 
on isotyping, only IgM monoclonal antibodies were obtained and on discussing with 
other colleagues attempting to produce monoclonal antibodies using mice from our 
animal house, five co-workers had produced an IgM antibody in the previous 6 months, 
and no IgG monoclonal antibodies were produced within this period 
As suspecion grew of some viral contaminant of the mice colony in D C U , the mice 
were screened for immunodeficiency viruses which would either kill these mice, as had 
happened,or would render them incapable of mounting an IgG response to an injected 
antigen and would only allow them to produce an IgM response 
Two of the ten mice screened came up positive for the mouse hepatitis virus (MHV) 
These mice tested negative for Sendai, PVM and MVM viruses Although this was only 
a small sample, it demonstrated that our balb/c colony was contaminated with the MHV 
virus From the animal house records, it was shown that the supplier o f our balb/c mice
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had changed in December 1990, and from that time mice were obtained from a source 
which was known by the supplier to be MHV contaminated, but the supplier did not 
inform our animal house personnel until questioned when the screening results were 
obtained
The assistance and support of Ms Carolyn Wilson is acknowledged and appreciated 
during this period
When the monoclonal antibodies obtained from these fusions isotyped as IgM, attempts 
were made to repeat immunisations in isolation facilities in Tnmty College, Dublin, 
along with immunising mice there to produce catalytic antibodies (Section 6 ) Certified 
disease- and virus-free mice were imported from Harlan Olac Ltd (Section 2 1 )  and 
were brought directly to isolators in Tnmty Such attempts were without success as 
there was a shortage of trained technicians to care for these mice in the isolators in 
Tnmty College Due to the inability to keep these mice m the isolators for the required 
length of time for a sufficient immunisation schedule, the mice were returned to D C 
U without being immunised
2.3.7.I. Procedures for the production of anti-GFAP monoclonal antibodies.
The GFAP used (Table 2 3) was determined to be 98% pure by SDS-PAGE Its source 
was from bovine spinal cord and its molecular weight (Mr) was 52,000 Due to the 
expense of GFAP, only three mice were immunised with GFAP as outlined in Section 
2 3 6 The immunisation schedule is given in Table 2 7
Table 2.7. Immunisation schedule of balb/c mice immunised with GFAP.
Day GFAP Otg/ml) irejected
1 50
21 50
40 50
58 50
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On day 48, the mice were tail bled and their sera were tested by ELISA on GFAP and 
G-CCM coated plates The results obtained are shown in Table 3 2 and Figure 3 2 
One mouse was given an l v injection, on day 58, of filter sterilised GFAP m PBS 
maintained at 37°C This solution was filter sterilised using the low protein-bmding 
0 22fim filters from Becton Dickinson Only 15/xg were administered i v and the 
remaining 35fxg were administered i p The mouse was bled and sacrificed on day 61 
The sera obtained was used as a positive control for ELIS As and throughout the 
experiment A splenectomy was performed (Section 2 3 9 ), 1 24x10s spleen cells were 
harvested, washed with red cell lysis buffer (Section 2 3 1 1 4 )  and resusdended in 8ml
DMEMSo 2ml (i e 3 lxlO7 cells) of this solution was used in the immunisation as
follows,
5 ml DMEMS0
5 ml sTCM
100/xl lOOx 2-Mercaptoethanol
50fi\ Gentomycin (5^1/ml)
12/il GFAP (luglfx 1)
This solution was dispensed at SxlO6 cells per well of a 6 well stenie tissue culture 
plate and was incubated for 3 days in 5% C 0 2 at 37°C The spleen cells were then 
resuspended, pooled and counted Using the PEG method (Section 2 3 13 1), 1x10s 
spleen cells were fused with 3xl07 SP2/0 cells (i e a 3 33 1 ratio of spleen cells to 
myeloma cells) The fused cells were plated onto 15 plates which were monitored for 
growth of clones after 10 days These clones were screened for anti-GFAP antibodies 
by ELISA (Section 2 3 1 6 ) and the antibody-producing hybndomas were expanded 
according to Section 2 3 14
Employing the in vitro immunisation method again, a second mouse was used 6 72x107 
cells were incubated with GFAP as above and according to Section 2 3 115  After 3 
days, 6x l06 cells were electrofused (Section 2 3 13 2 ) with 6X106 SP2/0 cells The 
parameters used in the electrofusion are detailed in Section 2 3 13 2
2.3.8. Tail bleeding of mice.
The serum of each immunised mouse was tested in order to monitor the response to the 
injected antigen This was done by placing the mouse under an infrared lamp for 5 
minutes to warm it up and increase the blood flow to its tail veins making them easier
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to visualise The lower tail vein was swabbed with 70% (v/v) alcohol, nicked close to 
the tip of the tail using a sterile scalpel blade and the drops of blood were collected 
The blood was then placed at 37°C for 1 hour and the clot was released by tapping the 
tube against the bench The tube was placed at 4°C overnight and then centrifuged at 
1000g for 10 minutes The serum was collected using a pipette and the pellet discarded 
The serum was then tested by ELISA to determine the titre o f antigen-specific antibody 
present (Section 2 3  16 ) 0 02% (w/v) sodium azide was added to the serum and stored 
in 50/xl lots at -20°C
2.3.9. Isolation of immunised splenocytes for cell fusion.
The mouse was sacrificed by cervical dislocation A scissors, forceps and tissue 
dissociation sieve were autoclaved and when in use they were immersed in 70% (v/v) 
alcohol The sacrificed mouse was immersed in a beaker of 70% (v/v) alcohol, and then 
transferred onto a stenle dissection board in a laminar flow All subsequent steps were 
earned out under aseptic conditions The mouse was pinned down on its nght hand side 
and using stenle instruments, the skin was cut away from the abdomen to expose the 
pentoneal membrane which was sprayed with 70% (v/v) alcohol The peritoneal 
membrane was dissected and the spleen removed carefully, ensunng that the spleen was 
not torn and the gut, or any other tissue, was not pierced
The spleen was placed in a stenle petn dish containing 20ml of warmed DM EM -S10 
A stenle tissue dissociation sieve (Sigma) was placed in a second petn dish and 10ml 
of medium was poured into it The spleen was transferred to the sieve and, using a 
stenle pestle, the spleen was pressed through the sieve into the medium to produce a 
cell suspension The medium can be collected using a 20ml synnge and passed through 
the sieve a number of times to ensure a uniform cell suspension This medium was 
collected into a 50ml centnfuge tube and the large clumps were allowed to settle The 
supernatant was then transferred to a fresh tube and the cells washed once in DMEM- 
S10 The red blood cells were lysed using filter-stenlised red cell lysis buffer (Section 
2 3 1 1 4 )  The cells were washed in DMEM-SI0, stained using trypan blue (Section 
2 3 3 ) and counted The viability should be greater than 95 % The cells were then 
washed twice m DMEM-S0 It is important for the success of the fusion that no protein 
is present in the medium at this stage as it would interfere with the polyethylene glycol 
(PEG) The cells were left at 37°C and used as soon as possible
I
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2.3.10. Preparation of myeloma cells for fusion.
Both NSO/1 (NSO) and SP2/0-Agl4 (SP2/0) cells were used in cell fusions, NSO were 
used initially, but it was subsequently found that using SP2/0 gave a 10-fold, or greater, 
number of clones NSO and SP2/0 cells were maintained in the exponential phase of 
growth for 7 days prior to fusion, by dividing a suspension of the cells every two days 
and the day before the fusion was to be undertaken Both NSO and SP2/0 cell lines 
were tested for the presence of mycoplasma (Section 2 3 5 ) These cell lines were also 
checked for the presence of any type of contamination by cultunng them in antibiotic- 
free medium for 7 days prior to fusion The NSO cell line was pretested for HAT 
sensitivity by confirming their inability to grow in DMEM-S10 containing HAT (100/xM 
hypoxanthane, 1M aminoptenn and 60juM thymidine) Similarly, the SP2/0 cells were 
pretested for their inability to grow in DMEM-S10containmg HA (100/iM hypoxanthane 
and 2/xg/ml 8-azaguanme)
2.3.11. In vitro immunisation.
In vitro immunisation is used where an antigen is toxic or is very expensive, as with 
GFAP, or where it was available in only minute quantities, as was the case with Phos- 
KLH This method is an alternative to in vivo immunisations (Section 2 3 6 ), where 
isolated lymphocytes can be sensitised to antigens in vitro These cells can then be used 
in cell fusions for monoclonal antibody production (Section 2 3 13 )
In vitro immunisations offer the following distinct advantages,
(i) only very small amounts of antigen are needed, i e fxg instead of the mg quantities 
required in vivo
(1 1) the normal controls of the immune system are absent in vitro allowing responses 
against self antigens to be generated and
(in) the methods are simple and rapid Immunisations are complete in 3 to 5 days as 
opposed to several weeks in vivo
The major disadvantage associated with the in vitro response is that most of the 
responses obtained are primary responses consisting mainly of IgM class antibodies 
Secondary responses are not normally seen unless the donor lymphocytes have had 
some pnor exposure to the relevant antigen in vivo, or special kits are used such as the 
CEL-PRIME in vitro immunisation kit for high IgG yield from Immune Systems Ltd 
(Table 2 1 ) It has been demonstrated, however, that a secondary response is obtained
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if the animals used as a source of lymphocytes are given an in vivo immunisation 28 
days prior to the in vitro immunisation (DeBoer et a l , 1988)
The methods described here are essentially those of Ossendorp et al (1986) in which 
isolated munne lymphocytes are immunised in vitro in a serum-free medium called 
LINO This medium was first described by Yssel et al (1984) and was designed for 
the culture of lymphocytes For successful in vitro immunisations a rich source of B- 
cells is required, which usually come from a mouse spleen and a source of T-cell 
denved growth factors These factors were supplied in the form of a T-cell-conditioned 
medium (sTCM) Mouse thymocytes were cultured for 48 hours in LINO during which 
time they secrete a variety of lymphokmes and other growth factors (Ossendorp et al , 
1986) These factors play a crucial role in the development of the immune response
2.3.11.1. Preparation of LINO.
The basal medium used was Iscove’s DMEM (IMEM) (Flow laboratories) The order 
of addition of the components of LINO is very important The proteins must be fully 
dissolved before adding any lipids
1 litre o f LINO was prepared as follows, although this may be scaled down for smaller 
volumes 2 5g of BSA was added to 50ml of IMEM and allowed to fully dissolve 5mg 
of bovine insulin (25umts/mg) was dissolved in 2ml of 0 01N HC1 and added to the 
medium 26mg of human transferrin was dissolved in 2ml of 0 01M PBS, pH 7 3, and 
added A 1 1000 dilution (v/v) of 100% ethanolamine m 0 01M PBS, pH 7 3 was 
prepared and 2ml of this solution was then added 10ml of penicillin (10,000umts/ml) 
streptamycin (10,000/xg/ml) solution was added to the medium 5mg of linoleic acid 
was dissolved in 1ml of absolute alcohol and 0 2ml of this was added 5mg of palmitic 
acid was dissolved in 1ml of absolute alcohol and 0 2ml of this solution was added to 
the medium 5mg of oleic acid was dissolved in 1ml of absolute alcohol and 0 2ml was 
added to the medium The medium was then filter sterilized using a 0 22fim filter and 
adjusted to 1 litre with IMEM, and it was then dispensed into 50ml lots and stored at - 
20°C 1% L-glutamine (v/v) and 50/iM 2-mercaptoethanol (Section 2 3 1 1 2 )  were 
added to the medium just before use
2.3.11.2. Preparation of a stock solution of 2-mercaptoethanol.
0 5ml of 2-mercaptoethanol was added to 6 6ml of ddH20  and 5ml of this solution was
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added to 95ml of ddH20  This was filter sterilized, aliquoted and stored at -20°C The 
stock concentration was 5xlO~2M and this was used at a dilution o f 1 1000 Once 
thawed, it should not be refrozen
2.3.11.3. Preparation of sTCM in LINO.
Scissors, forceps and a tissue dissociation sieve were autoclaved and placed in 70% 
alcohol in a laminar flow 30ml of DMEM was placed m a stenie 50ml tube and kept 
at 37°C Five ummmumsed female balb/c mice, 5 to 6 weeks old, were sacrificed by 
cervical dislocation and placed m alcohol One of these mice was then pinned onto a 
dissection board The skin was cut away from the abdomen and a wide flap from the 
abdomen to the shoulders was cut to expose the nb cage The entire mouse was sprayed 
with alcohol The nb cage was cut from the zyphoid process to the axillary region and 
the flap was pulled up over the head The thymus, which is a small, white, bi-lobed 
organ just anterior to the heart is then visible The thymus was then carefully lifted out 
and placed m the tube containing DMEM This procedure was performed on each of 
the mice and their thymuses were pooled These were then transferred to a stenie tissue 
dissociation sieve in a petn dish and 25ml of DMEM was added The thymuses were 
pressed through the sieve to get a uniform cell suspension using a pestle The remaining 
tissue in the sieve was discarded The cells were washed twice in DMEM and once in 
LINO and the cells were resuspended at 5xl06 cells per ml in LINO The medium was 
dispensed in 25ml lots into 75cm2 culture flasks and incubated at 37°C in 5% C 0 2 for 
48 hours The culture supernatants were harvested and centnfuged at 300rpm for 10 
minutes The final supernatant was filter stenlized and stored in 10ml lots at -80°C
2.3.11.4. Preparation and use of red cell lysis buffer.
0 874g of NH4CI, 0 lg  KHCO3 and 3 67mg of EDTA were dissolved in a final volume 
of 100ml of ddH20  The pH was adjusted to 7 4 with IN NaOH, filter sterilized and 
stored at room temperature The cell pellet, for example splenocytes, was resuspended 
in 15ml o f lysis buffer Lysis should be complete in 2 to 3 minutes and the cells were 
then washed in 15ml of DMEM-S10 If lysis was incomplete, ( 1  e the pellet was still 
red), the pellet can be re-washed in DMEM-S10
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2.3.11.5. In vitro immunisation of isolated murme splenocytes.
The in vitro immunisation medium was prepared as follows, 50ml of LINO (Section 
2 3 11 1 ) was thawed by warming to 37°C, 2-mercaptoethanol (Section 2 3 1 1 2 )  was 
added to a final concentration of 5x10 5M and L-glutamine was added at a concentration 
of 1% (v/v) 25ml of sTCM (Section 2 3 1 1 3 )  was thawed by warming to 37°C and 
added to an equal volume of LINO This is the immunisation medium All media were 
kept at 37°C while not in use A balb/c mouse was sacrificed, the spleen was removed 
and a cell suspension prepared (Section 2 3 9 ) The red blood cells were lysed (Section 
2 3 1 1 4 )  and the final cell preparation was washed in LINO The cells were 
resuspended to SxlO6 cells per ml in the immunisation medium The antigen was 
prepared (Section 2 3 6 1 ) and added at concentrations from 0 1 to 5^g/ml If this is 
the first immunisation with an antigen, it is recommended that a range of antigen 
concentrations from lng/ml to 10jtg/ml be used Generally, most antigens will give a 
good response at around 1 jug/ml, but this is very dependent on the antigen in question 
2ml lots were then dispensed aseptically into the wells of 6 well culture trays, wrapped 
in parafilm and incubated at 37°C in 5% C 0 2 These cells can be harvested after 3 days 
for use in cell fusions (Section 2 3 13 ) Blasts of activated B-cells are seen after 4 to 
5 days of culture
2.3.11.6. In vitro immunisation using the Immune Systems’ Cel-Prime ‘High IgG 
Yield’ kit.
The instructions accompanying the kit were followed throughout this procedure Sterile 
antigen was prepared as descnbed in Section 2 3 6 1 The vial of support cells and 
support cell medium provided were thawed and the contents of the vial were 
resuspended in 5ml of the support cell medium and aseptically transferred to a 25cm2 
flask These cells are incubated at 37°C with 5 % C 0 2 for 24 hours The medium was 
then discarded and replaced with 5ml of fresh support medium with 30fig o f sterile 
antigen (Section 2 3 6 1 ) added and incubated for 48 hours The bottles of 
immunisation medium and splenocyte medium provided were thawed at room 
temperature and these media were heated to 37°C The spleen was removed from a 10- 
12 week balb/c mouse (Section 2 3 9 ) and placed in a petn dish with 5ml o f splenocyte 
medium and the spleen treated to produce a single cell suspension These cells were 
centrifuged for 5mm and the splenocyte cell pellet was resuspended m 5 ml
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temperature and these media were heated to 37°C. The spleen was removed from a 10- 
12 week balb/c mouse (Section 2.3.9.) and placed in a petri dish with 5ml o f splenocyte 
medium and the spleen treated to produce a single cell suspension. These cells were 
centrifuged for 5min and the splenocyte cell pellet was resuspended in 5ml 
immunisation medium. The medium from the support cells was discarded and the 
splenocyte suspension transferred to this flask. The remaining immunisation medium 
was added to this flask, along with 30¡ig of fresh, sterile antigen. The lid of the vented 
flask was firmly tightened and the flask was placed horizontally on the incubator and 
left undisturbed for 3-4 days at 37°C with 5% C 0 2. After this time, the primed 
splenocyte culture is ready for fusion to myeloma cells (Section 2.3.13.1).
2.3.12. ELISA-spot assay: assessment of in vitro immunisation.
To assess the efficacy of an in vitro immunisation experiment, one must be able to 
enumerate the numbers of specific antigen-reactive B-cells generated during the 
immunisation. A measure of the success of the immunisation is the number of antigen- 
reactive hybridomas obtained in subsequent cell fusions. However, it can take several 
weeks and a lot of work before such information is available. A simpler and more rapid 
approach is to use an ELISA-spot assay. The principles of this assay are based on 
standard ELISA technology. Two major differences in this assay, however, are that (i) 
cells are incubated with fixed antigen and (ii) the substrate solution is provided in a 
solid-phase rather than an aqueous phase (Sedgewick and Holt, 1983; Czerkinksy et al., 
1983).
The antigen to which the antibodies had been raised, was coated onto 6 well trays in 
the normal fashion. An aliquot of the cells from the in vitro immunisation (Section
2.3.11.5.) were incubated with the antigen. During the incubation period, the cells 
secrete their antibody onto the antigen-coated surface. If the cells were producing 
specific anti-antigen antibodies, then this antibody would bind to the antigen in the area 
around the cell. Non-specific antibodies do not bind and will disperse into the 
surrounding medium.
The cells were then washed from the plates leaving the antigen-coated well with small 
areas of specifically bound antibody which correspond to the antigen reactive cells. An 
anti-mouse antibody linked to alkaline phosphatase (Table 2.4.) was then added which 
binds the first antibody. The excess antibody is removed by washing and the enzyme
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substrate is added in a solid-phase of agarose Colour development was only obtained 
in those areas which correspond to the locations of the original antigen reactive cells 
because both the antibody and the substrate are fixed in position A measure of the 
number of antigen reactive cells generated in the in vitro immunisation can be obtained 
by counting the number of colour spots
2.3.12.1. Preparation of reagents for the ELISA-spot assay.
To prepare carbonate buffer, 0 15g of sodium carbonate and 0 293g sodium bicarbonate 
were dissolved in 100ml of ddH20  and was brought to pH 9 6 using conc HC1 and 5M 
NaOH, as appropriate Phosphate buffered saline (PBS), 0 01M, pH 7 3 (Section 
2 3 3 ) was routinely prepared by dissolving one PBS tablet in 100ml ddH20  The wash 
buffer was prepared by adding 0 1 % (v/v) Tween-20 to PBS Amino-methyl-propanol 
buffer (0 1M) was prepared by dissolving 150mg magnesium chlonde (5mM), 0 1ml 
Tnton X-405 (0 01%, v/v) and 1 Og sodium azide (0 1%, w/v) (highly toxic) was 
dissolved in 30ml of ddH20  95 8ml of amino-methyl-propanol was added with stirring 
The pH was adjusted to 10 25 with conc HC1 This solution was left overnight at room 
temperature and then the pH was readjusted to 10 25 The final volume was brought 
to 1 litre and stored at 4°C To prepare BCIP substrate, 0 05g of 5-Bromo-3-chloro- 
mdoyl-phosphate (BCIP, 2 3mM) was dissolved m 50ml of amino-methyl-propanol 
buffer (0 1%, w/v) and left for 1 hour at room temperature This was then filtered 
through 0 45ptm filters to remove any undissolved material and warmed to 40°C 3% 
(w/v) o f 36°C gelling agarose was prepared in ddH20 , boiled to dissolve the agarose 
and subsequently cooled to 60°C 12 5ml of the 3 % (w/v) warmed agarose (final concentra­
tion is 0 6%, w/v) was added to the BCIP solution and was kept at 40PC until required
2.3.12.2. ELISA-spot assay.
100 to 200/xg/ml of antigen in 1 5ml of carbonate buffer, pH 9 6, was added to each 
well of a 6 well tissue culture plate and incubated overnight at 4°C The wells were 
washeci twice with wash buffer, PBS-Tween This was prepared by adding 0 05 % (v/v) 
Tween-20 to 0 01M PBS, pH 7 3 Tween-20 is polyoxethylenesorbitan monolaurate 
(Section 2 3 16 2 ) 2 5ml of 1 % (w/v) BSA in 0 01M PBS, pH 7 3, was added to each 
well to block unbound sites and incubated for 1 hour at 37°C The plate was washed as 
before Previously washed in wro-immunised lymphocytes (Section 2 3 1 1 5 )  were
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before Previously washed in vz/roimmumsed lymphocytes (Section 2 3 1 1 5 )  were 
prepared at concentrations of 1x10*, lx l0 5 and lxlO6 cells/ml in DM EM S10 1ml of 
these cell solutions was added to duplicate wells of the 6 well plate which was then 
incubated on a level surface for 2 hours at 37°C in a vibration-free incubator The plates 
were washed twice m 0 01M PBS, pH 7 3 Then 2 0ml/well of cold 0 01M PBS, pH 
7 3, with lOmM EDTA was added and left at room temperature for 10 minutes The 
plate was washed four times in wash buffer 6ml of a 1 7000 dilution of anti-mouse Ig- 
alkaline phosphatase-conjugated antibody (Table 2 4 )  was prepared in Tns-buffered 
saline (TBS) [2M Tns-HCl, pH 9 5, 5M NaCl and 1M MgCl2, made up to 1L in 
ultrapure H20 ] lml/well of this solution was added to the plate and incubated at 37°C 
for 2 hours or overnight at 4°C The plates were four washed times in TBS buffer and 
rinsed once in amino-methyl-propanol buffer 1 5ml of BCIP substrate in 0 6% agarose 
(w/v) was added on a level surface and the agarose allowed to solidify The plates were 
transferred to a 37°C incubator Blue spots began to appear after 60 to 90 minutes and 
were counted with the lOx objective of an inverted microscope
2.3.13. Fusion protocols used in the production of monoclonal antibodies.
The fusions performed were based on the technique descnbed by Kohler and Milstein 
(1975)
2.3.13.1. Hybndoma cell production by PEG-mediated cell fusion.
The media and solutions used throughout this procedure were sterile and were kept at 
37°C The mouse spleen and myeloma cells, NS0/1 or SP2/0, were counted (Section 
2 3 3) and the cells were combined in a 50ml centnfuge tube in a 5 1 spleen myeloma 
ratio However, ratios of 10 1 and 2 1 have also been used successfully This cell 
mixture was then washed twice in serum-free DMEM (DMEM-Sq) Cells were spun at 
4,000rpm for 10 minutes and the supernatant was fully decanted The cells were fused 
in PEG-1500 as follows, one ml of the PEG solution was added to the pelleted cells 
over one minute with gentle mixing, ensuring the temperature was kept constant at 37°C 
by keeping the tube in a 37°C water bath in the laminar flow throughout the procedure 
This was left for a further minute while the tube was mixed with a continuous gentle 
swirling motion The PEG was then slowly diluted by the drop wise addition of 3 ml of 
DMEM-S0 over three minutes, followed by 10ml of medium over a further 10 minutes
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The cells were incubated at 37°C for 30 minutes to allow the hybrid cell membranes to 
form The cells were then pelleted and resuspended at a concentration of 2x10s cells/ml 
of DMEM-S10 supplemented with either lx hypoxanthine, aminoptenn and thymidine 
(HAT) if  fused with NSO or hypoxanthine 8-azaguanine (HA) if SP2/0 cells were used, 
plus 5% (v/v) BRIclone, and lx  HIPO HIPO supports the growth of hybndomas and 
consists of HEPES (1M), insulin (20iu/ml), sodium pyruvate (5mg/ml) and oxaloacetic 
acid (15mg/ml)
200/xl of this solution was added to 11 rows of a sterile 96 well culture plate The 
parent myeloma cells in selective media were added to the 12th row in order to confirm 
that these cells were sensitive to the selective media The myeloma cells died out in 7-8 
days The spleen cells die in 3-4 days Therefore, any cells growing after 10 days are 
hybrid cells or hybndomas The cells were left undisturbed for seven days and 
subsequently fed with DMEM-S10 containing HAT or HA Plates were checked for the 
presence of clones after 14 days and the supernatant was checked for specific antibody 
production by the sandwich ELISA (Section 2 3 16 4 ), "supernatant" ELISA (Section 
2 3 16 5 ), cell fixation ELISA (Section 2 3 16 1 ) or antigen ELISA (2 3 16 3 ), as 
appropriate, when the cells in the wells were 70% confluent The hybndomas grown 
in HAT were weaned off this medium after 2 weeks in culture by replacing it with lx 
hypoxanthine and thymidine (HT) medium After 4 weeks all hybndomas were cultured 
and expanded in DMEM-S10 without HT or HA
2.3.13.2. Generation of hybndomas by electrofusion.
The basis of this technique is discussed in Section 2 3 13 2 Immunised splenocytes 
were collected from either an immunised mouse (Section 2 3 9 ) or from in vitro 
immunised splenocytes (Section 2 3 11 ) The SP2/0 myeloma cells were harvested 
from a culture in log-phase of growth (Section 2 3 10 ) The spleen and myeloma cells 
were prepared as descnbed (Sections 2 3 9 and 2 3 1 0 ) counted, and the viability 
assessed using trypan blue (Section 2 3 3 ) The cells were mixed in a 1 1 ratio to give 
6xl06 cells/ml total and then pelleted If SP2/0 cells were used, the cells were 
resuspended m pronase solution (0 05mg/ml pronase in DMEM-S0) for 3 mins This 
reduces the surface charges for the cells, thus aiding and increasing cell fusion One ml 
of the pronase solution was used per lxlO6 cells 1ml of FCS was added to stop the 
action of the pronase If NS0/1 cells were used the pronase step was omitted as it
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caused these cells to clump The cells were then washed three times in 10ml of fusion 
medium (0 225M sucrose, 0 2mM calcium chloride and 0 2mM magnesium chlonde) 
at room temperature The cells were then resuspended at 6x l06 cells/ml in fusion 
medium and transferred into a stenle eppendorf or bijou 250/xl of this cell suspension
was drawn into the stenle cell fusion chamber and the electnc field was applied to the
chamber for inducing dielectrophoresis, followed by high voltage pulses to induce 
fusion Dielectrophoresis is induced by a field strength of 250V/cm and amplitude of 
1MHz Fusion of the myeloma and spleen cells was induced by 3 consecutive pulses 
o f 3kV/cm and 15/*sec duration The pulse interval was 1 second The electrical 
conditions for an electrode gap width were set as follows,
(l) Dielectrophoresis
Frequency 1 5MHz
Amplitude 1 0V
Amplitude 2 5V
Duration (delay 1) 0V
Duration (ramp) Osec
Duration (delay 2) 30sec
(n) Fusion Conditions
Pulse strength 40V
Pulse duration 15/xsec
Pulse number 3
Pulse interval lsec
Alignment-off time 10msec
(1 1 1) Post-Alignment Conditions
Frequency 1 5MHz
Alignment time 30sec
Alignment time (constant/ramp) constant
The cells were then removed from the chamber and pipetted into 5ml o f warmed 
DM EM -S10 and incubated at 37°C for 30 minutes From this point the procedure is the 
same as for PEG fusions (Section 2 3 13 1)
2.3.14. Expansion of the antibody-producing hybndomas.
The clones were initially screened for specific antibody production by sandwich and
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supernatant ELISA (Section 2 3 16 5 ) when they became 70% confluent in the 96 well 
plate Those cells that test positive were expanded into 24 well plates and were re- 
screened to ensure that they continue to produce and secrete the relevant antibody using 
the antigen-specific ELISA (Section 2 3 16 3 ) Positive clones from this second 
screening were transferred to 6 well plates when they reached 80% confluency Samples 
were also frozen in liquid nitrogen as back-ups in case of contamination (Section 
2 3 4 ) The remaining cells were expanded to 25cm2 flasks and, subsequently, used in 
the cloning procedure (Section 2 3 15 )
2.3.15. Cloning of suspension cells by limited dilution.
Hybndoma cultures, in exponential growth phase, were cloned by limiting dilution in 
96 well plates in order to ensure monoclonality of cells The cloning medium was 
prepared prior to cell cloning, and consisted of culture medium supplemented with 10% 
(v/v) FCS, 5% (v/v) BRIclone and 1% (v/v) HIPO Cells were removed from culture 
flasks, 24 well plates or 6 well plates, and a very accurate count of the viable cells was 
obtained (Section 2 3 3 ) The cells were diluted to a stock concentration of 50 cells/ml 
in cloning medium and 200/xl/well were plated over 6 rows of a 96 well plate (i e 10 
hybndoma cells per well) This stock medium was further diluted to 5 cells/ml and 2 5 
cells/ml to give a final concentration of 1 and 0 5 hybndomas per well when plated out 
at 200/tl/well The 96 well plates were incubated for 5-6 days and then examined 
microscopically for clone formation Wells containing one clone per well should 
represent monoclonal cultures of hybndomas and were allowed to grow to 70% 
confluency, expanded and checked for maintenance of antibody production by antigen- 
specific ELISA This cloning procedure was repeated to ensure monoclonality 
Eventually, following sequential cloning by limited dilution, the cells were tested for 
mycoplasma contamination, expanded into 25 cm2 flasks and frozen as back-up stocks 
in liquid nitrogen (Section 2 3 4 )
2.3.16. Enzyme-Linked Immunosorbent Assay (ELISA).
ELISAs were used to determine if the vanous monoclonal and polyclonal antibodies 
produced, bound to their respective antigens The antigens used in the various ELISAs 
performed are outlined in Table 2 3 and the secondary antibodies used are given in 
Table 2 4
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2.3.16.1 Cell fixation for use m ELISA.
Two methods are described for the setting up and performance of a solid-phase enzyme- 
linked immunosorbant assay (ELISA) for use with fixed cells as antigens
Method 1.
In this method, adherent cells to be fixed onto 96 well plates were obtained from 
actively growing cultures This procedure was used with the following adherent cell 
lines, G-CCM, G-UVW, UK<t), A549, H5683, MCF-7, EJ-138, LOVO and T-24 Flat 
bottomed flexible (NUNC) plates were washed 3 times in 0 01M PBS, pH 7 3, 
followed by the addition of 100/d/well of 0 1 % (w/v) poly-L-lysine in 0 01M PBS, pH 
7 3
After incubating for 1 5 hours at 37°C, the poly-L-lysine was removed This solution 
may be re-used up to 10 times The plates were re-washed three times in 0 01M PBS, 
pH 7 3 The cells to be fixed to the plates were obtained by trypsimsation (Section 
2 3 2 ) They were washed in 0 01M PBS, pH 7 3 and 100/d of a suspension of 5x10s- 
SxlO6 cells per ml m 0 01M PBS, pH 7 3, was added to each well After 1 5 hours at 
4°C, 150/tl of 0 1% (v/v) glutaraldehyde in 0 01M PBS, pH 7 3, was added to each 
well to give a final concentration of 0 075% (v/v) glutaraldehyde (Carroll et al , 1990) 
It is important that the cell layer was not disturbed and that no air bubbles were present 
in any of the wells, dunng the addition of glutaraldehyde After a maximium of 10 
minutes at 4°C, the plates were washed three times in 0 01M PBS, pH 7 3 100/xl of 
lOOmM glycine m 0 01M PBS, pH 7 3, was added to the wells to block any remaining 
unreacted glutaraldehyde Following incubation at 37°C for 30 minutes, the plates were 
again re-washed three times in 0 01M PBS, pH 7 3 150/d of storage/blocking buffer, 
[1% (w/v) BSA in 0 01M PBS, pH 7 3, containing 0 1% (w/v) sodium azide as 
preservative], was then added to each well The plates were thoroughly sealed using 
Parafilm and tin foil to prevent evaporation of the storage/blocking buffer and then 
stored at 4°C Under these conditions it was possible to store the plates for up to six 
months with no apparent loss of activity The plates were checked regularly for 
evaporation of buffer The remaining steps are as described for an ELISA (Section 
2 3 16 3 ) after the plates have been blocked 
Method 2.
A second method of fixation was used mainly for non-adherent cell lines such as K562
68
and HL-60 and may also be used for adherent cell lines which grow quickly in culture, 
such as EJ-138, H5683 and T-24 Pelleted cells were resuspended m complete culture 
medium at a concentration of 5x10* cells/ml Each well of a 96 well plate received 
100fil o f this suspension The plates were sealed and placed in an incubator (5%, v/v, 
C 0 2 at 37°C) and examined daily They were grown to approximately 75 % confluency 
and this time interval depended on the growth rate of the cell line Cells were usually 
ready for fixing after 2-3 days The medium was then removed and the wells were 
washed three times with 0 01M PBS, pH 7 3 150/xl of 0 1% (v/v) glutaraldehyde in 
0 01M PBS, pH 7 3, were added to each well to give a working concentration of 
0 075% (v/v) glutaraldehyde (Carroll et a l ,  1990) The remaining steps in this 
procedure were exactly as those of method 1
2.3.16.2. Preparation of reagents for an ELISA.
All solutions were stored at 4°C, unless otherwise stated
(i) Carbonate buffer was made by dissolving 1 06g of Na2C 0 3 and 2 94g N aH C03 in 
dH20 , adjusting the pH to 9 6 with conc HC1 or 5M NaOH, as appropriate, and 
adjusting the volume to 1 litre with dH20
(1 1) 0 01M Phosphate buffered saline, pH 9 0, was prepared by dissolving 1 42g 
Na2H P04and 8 76g NaCl in 900ml dH20  The pH was adjusted to pH 9 0 with 0 1M 
NaOH and made up to 1 litre
(m) Washing solutions were prepared as follows, (a) 0 01M Phosphate Buffered Saline 
(Dulbecco’s A), pH 7 3 (PBS) was prepared by dissolving 1 PBS tablet into 100ml 
distilled (dH20) or ultrapure water, routinely ultrapure H20 was used PBS-Tween was 
prepared by adding 0 05% (v/v) Tween-20 to the 0 01M PBS, pH 7 3, solution with 
stimng
(iv) Blocking solutions were prepared as follows, (a) 0 05% (w/v) porcine gelatin in 
0 01M PBS, pH 9 0, was heated to 40°C while stimng This solution was allowed to 
cool at 4°C and was then checked to ensure it did not solidify at this temperature and 
was fully dissolved If it was not fully dissolved, it was heated again (b) 1 % (w/v) 
BSA was made up in 0 01M PBS, pH 9 0, and dissolved by gentle stirring
(v) Amino-methyl-propanol buffer was prepared by dissolving 150mg magnesium 
chloride (5mM), 0 1ml Triton X-405 (0 01%, v/v), 1 Og sodium azide (0 1%, w/v) in 
30ml dH20 95 8ml of amino-methy 1-propanol (0 1M) was added with stimng The pH
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was adjusted to 10 25 with conc HC1 This was left overnight at room temperature, 
and the pH was readjusted to 10 25 and the final volume brought to 1 litre with dH20 
(vi) The various secondary antibodies used and their dilutions are outlined in Table 2 4 
The secondary antibodies used were alkaline phosphatase-conjugated and the 
manufacturers’ instructions were routinely followed
(vi) The substrates used to develop the colour of the labelled secondary antibodies in 
ELISAs are outlined in Table 2 5 (a) The substrate used routinely for ELISA was 5- 
bromo-4-chloro-3-indol-phosphate, disodium salt (BCIP) made up at lmg/ml (w/v) in 
amino-methy 1-propanol buffer The substrate was prepared just before use and was 
dissolved by gentie stimng in the dark Both the secondary antibody and the substrate 
were checked for activity by mixing in a 1 1 ratio in the dark, where a deep blue colour 
developed after approximately 5 minutes (b) O-phenylenediamine (OPD) was also used 
and was freshly prepared just before use, as follows, 20mg OPD was added to 10ml 
0 1M sodium citrate buffer, pH 5, and stirred gently This is light sensitive and was 
kept in the dark Directly before use 2 Oytxl of 30% (v/v) H20 2 was added and the 
absorbances determined at 492nm
2.3.16.3. ELISA for the detection of antibodies to protein or hapten-protem 
antigens.
In this indirect, non-competitive ELISA system the antigen is coated onto a microtitre 
plate and the antibody binding is detected using a labelled secondary antibody The 
antigen solution is made up in carbonate buffer (0 05M Na2C 0 3, pH 9 5) (Section 
2 3 16 2 ) at a concentration range of l-10^tg/ml A concentration of lOptg/ml at 
100jid/well was generally used (Table 2 3 )  Following addition of the antigen , the 
plates were left at 37°C for 2 hours or at 4°C overnight Following the incubation 
period, the antigen solution was decanted and the plates were then washed using 0 01M 
PBS, pH 7 3 The antigen solution may be used up to 8 times if stored with 0 005% 
(w/v) sodium azide After pounng the wash solution onto the plate, the plates were 
tapped, then inverted and tapped onto tissue paper to remove any remaining liquid This 
procedure was repeated four times Non-specific binding sites were blocked with 1 % 
(w/v) BSA in 0 01M PBS, pH 7 3, or 0 25% (w/v) gelatin in 0 01M PBS, pH 7 3, 
(200-250^1/well) for one hour at 37°C or overnight at 4°C If sodium azide is added to 
the blocking solution, the plates, if tightly sealed, may be stored at 4°C for a number
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of weeks at this stage Otherwise, the blocking solution was decanted and the plates 
were then washed four times with PBS-Tween and once with PBS, as already described 
100/xl/well of the samples to be tested were added to the wells on the plate in duplicate 
or triplicate Examples of the samples added include appropriately diluted ascitic fluid, 
culture supernatant, dilutions of test sera, sera from pre-immunised mice as a negative 
control and sera from immunised mice as a positive control The plates were left at 
37°C for 2 hours The samples were decanted and the plates were washed four times 
with PBS-Tween and once with PBS, as before The appropriate secondary antibody 
(usually alkaline phosphatase-conjugated secondary antibody) (Table 2 4) diluted in 
(TBS) [2M Tns-HCl, pH 9 5, 5M NaCl and 1M MgCl2, made up to 1L in ultrapure 
H20 ] was added to the plates (100^1/well) and incubated at 37°C for one hour After 
a thorough washing of the plates to remove unbound conjugate, 100/xl of substrate 
(BCIP in amino-methyl-propanol buffer) was added to each well When sufficient colour 
had developed, (which took up to an hour,) the plate was ’blanked’ against one of the 
negative controls (a well which had 0 01M PBS, pH 7 3, added instead of a sample) 
and the absorbance was recorded at 620nm on a Titertek TwmPlus Microplate Reader 
(ICN-Flow) Table 2 3 gives an outline of the many different ELISAs performed
2 3.16.4. Sandwich ELISA.
The sandwich ELISA was used in the initial screening stage of fusions where a large 
number of clones or 96 well plates had to be screened for antibody production Here 
the 96 well ELISA plate was coated with 10^g/ml anti-mouse IgG (whole molecule) 
(Table 2 4 ) as the antigen The plate was blocked as previously described (Section 
2 3 16 3 ) and supernatant from wells containing clones were added at 100/xl/well, the 
remainder of the ELISA is as described in Section 2 3 16 3 where the alkaline 
phosphatase-conjugated antibody, m TBS, and BCIP were subsequently added
2 3 16.5. ‘Supernatant5 ELISA.
This ELISA was developed to minimise use of expensive or scarce antigen and to 
confirm that hybndomas continued to produceantibody having been initially 
characterised by ELISA (Section 2 3 16 1) This involved coating the wells with 
supernatant at 100/nl/well, the wells were then blocked and secondary antibody and 
substrate added as described m Section 2 3.16 3.
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2.3.17, Generation of monoclonal antibody-containing ascitic fluid from mice.
Once the monoclonal antibody has been initially characterised, large quantities can be 
produced as ascitic fluid m mice by injection of the hybndoma cells into the peritoneum 
of the mouse
Before injection o f the hybndoma cells, the mice were pnmed This was done by 
injecting 0 5ml of FIA or pnstane 7 days pnor to injecting lxlO6 hybndoma cells i p 
in 0 01M PBS, pH 7 3, at 37°C The ascitic fluid was recovered by sacnficing the 
mouse when the abdomen became enlarged The skin covenng the abdominal area was 
removed, the pentoneum was punctured and the ascitic fluid removed The monoclonal 
antibodies were recovered by centnfugmg the ascitic fluid at 1200rpm and collecting 
the supernatant This was aliquoted and stored at -20’C This method may also be used 
to produce large numbers of hybndoma cells In this instance, the removal of the ascitic 
fluid was performed under aseptic conditions and on spinning down the fluid the pellet 
is also retained This pellet contains the hybndoma cells, which may be resuspended 
in culture medium and grown in culture (Section 2 3 1) This procedure also has the 
advantage of removing any mycoplasma contamination from the hybndoma cells 
(Carroll and O’Kennedy, 1988)
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Table 2.8. Outline of the different ELISAs to characterise the various monoclonal, 
polyclonal and bispecific antibodies produced, (alk. ph. = alkaline phosphatase).
Antigen Cone. Desired Antibody 2° Antibody
IBHR-BSA
IBHR-KLH
IBHR-OVAL
10^g/ml
IBHR
Monoclonal and
Polyclonal
Anti-IBHR
Anti-Mouse 
and -Rabbit 
IgG alk ph
PHOS-KLH
PHOS-BSA
lO^xg/ml Monoclonal
Anti-Phos
Anti-Mouse/ 
IgG alk ph
GFAP
G-CCM
G-UVW
10/xg/ml
5x10s
cells/ml
Monoclonal Anti- 
GFAP and Anti- 
GFAP/G-CCM
Anti-Mouse 
IgG/IgM 
alk ph
T-24, HL-60 
MCF-7, EJ-138 
H5683, A549 
LOVO, K562
5x10s
cells/ml
Monoclonal 
Anti-GFAP and 
Anti-GFAP/G-CCM
Anti-Mouse 
IgG/IgM 
alk ph
RICIN-A
CHAIN
10/ig/ml Monoclonal Anti- 
Ricin-A chain
Anti-Mouse 
IgG alk ph
KLH
BSA
OVALBUMIN
lOfig/ml Monoclonal Anti-Phos 
Monoclonal or 
Polyclonal Anti-IBHR
Anti-Mouse/ 
Sheep IgG 
alk ph
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2.3.18. Isotyping of the monoclonal antibodies.
The isotype of the antibodies produced was performed using two kits, one from Sigma 
ImmunoChemicals and one from SEROTEC (Table 2.1.).
2.3.18.1. Procedure for antigen-mediated ELISA  for isotyping.
The Sigma Immunochemicals’ kit was used for this procedure. 0.1ml of appropriately 
diluted antigen was used to coat each of 12 wells of a microtitre plate which was then 
incubated for 1 hour at 37°C. The coating solution was removed and the plate washed 
3 times using 0.01M PBS, pH 7.3, containing 0.05% (v/v) Tween-20 (washing buffer). 
The coating solution may be used again up to 5 times, if stored in borosilicate glass 
tubes at -20°C. If plastic tubes were used for storage of the antigen, a precentage of the 
protein adheres to the sides of the tubes and would be lost. This does not happen when 
borosilicate glass tubes were used. This was important in the case of GFAP, as it was 
particularly expensive. The monoclonal antibody to be tested was applied to a 96 well 
ELISA plate, at an appropriate dilution, in 0.01M PBS, pH 7.3. 0.1ml of undiluted 
cultured supernatant was added to each of 12 wells. The plate was incubated for 2 hours 
at room temperature and was washed 3 times with washing buffer. 0.2ml of a 1:1000 
dilution of the isotype specific reagents supplied with the kit, in 0.01M PBS, pH 7.3, 
were required for each sample being tested. 0 .1ml of each of the diluted isotype specific 
reagents were added in duplicate to the coated wells. The plate was incubated at room 
temperature for 30 minutes and washed as before. 0 .1ml of a peroxidase-labelled rabbit 
anti-goat IgG, at a 1:5000 dilution in washing buffer, was added to each well and this 
was incubated at room temperature for 15mins and then washed as before. The o- 
phenylenediamine substrate was freshly prepared as outlined in Table 2.5. 0.1ml was 
added to each well. After 30mins, development of a yellow colour indicated a positive 
result and the reaction was stopped using 50^1 of 20% (v/v) H2S 0 4.
2.3.18.2. Procedure for indirect ELISA  for the determination of antibody isotype.
The Sigma Immunochemicals’ kit was also used in this procedure. The antibody to be 
tested was diluted in 0.01M PBS, pH 7.3. A 1:5000 dilution was used to isotype ascitic 
fluid and 1:1000 dilution was used for a purified antibody. 0.1ml of undiluted culture 
supernatant was added to each of 12 wells. The covered plate was incubated for 1 hour 
at 37°C and the coating solution was removed. The plate was washed three times with
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washing buffer (0 01M PBS, pH 7 3, containing 0 05%, v/v Tween 20) The following 
steps were as those outlined in Section 2 3 18 1 from where the diluted isotype specific 
reagents, in PBS, were added to duplicate wells
2.3.18.3. Procedure for isotyping monoclonal antibodies using isotypmg strips.
These strips were obtained from Sigma and each stnp was placed in a 30ml stenle 
universal 10ml of supernatant, from the hybndoma to be isotyped, was added to the 
universal and left shaking for 20min The stnp was washed in 0 01M PBS, pH 7 3, 
blocked as before, re-washed and 10ml of the provided secondary antibody, diluted in 
0 01M PBS, pH 7 3, was added and left shaking at room temperature for 20min The 
stnp in the universal was washed with PBS, as before, for 5min and the substrate 
provided was added A dark brown band appeared over the isotype of the antibody 
tested after 10mm The reaction was stopped by placing the stnp in ultrapure H20  and 
then allowing it to air dry
2 3 18.4. Procedure for isotyping monoclonal antibodies using the SEROTEC kit.
The anti-mouse monoclonal isotyping kit from Serotec has been specifically designed 
to identify the class and subclass of monoclonal antibodies in tissue culture super­
natants The pnnciple of this test system is based on red cell agglutination A positive, 
agglutinated result is produced when highly specific antibody, which is coupled onto 
sheep red blood cells, recognises and binds to the particular isotype to which it is 
directed This binding forms a lattice on the bottom of the microtitre plate well, termed 
agglutination The sensitivity of the reagent cells in detecting mouse immunoglobulins 
has been developed to optimally detect antibody concentrations within the normal range 
found in tissue culture supernatants, i e l-20pig/ml
To reconstitute the freeze dned reagents supplied in the kit, 1ml of reconstitution 
diluent was added to each reagent vial to be used The vials were then recapped and 
after overnight storage at 4°C, the reagents were fully reconstituted The vials were 
stored at 4°C and are stable for 6 months In this procedure, only stenle tissue culture 
supernatants with no visible contamination should be used The test procedure should 
be performed on a vibration free bench at room temperature 
A 1 50 dilution of the supernatant to be tested was made and was mixed by inversion 
If it was suspected that the antibody concentration in the supernatant was low, it was
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used at a 1:10 dilution. 30/*l of the diluted supernatant to be tested was placed into each 
of eight wells across the microtitre plate provided. The reagent bottles containing the 
resuspended cells were inverted gently and 30/zl of each specific isotyping reagent was 
added to one of the wells containing the supernatant to be tested. This was done for 
IgG l, IgG2a, IgG2b, IgG3, IgA, IgM and for positive and negative controls. The plate 
was covered with the lid provided and holding the lid firmly the plate was tapped gently 
at the side to mix the reagents. The plate was left on a cool flat surface, with as little 
vibration as possible, for one hour for the results to develop. A partial or full carpet of 
agglutination is a positive result and a small, red button is a negative result. The final 
result should show one agglutinated well for the positive control and only one other 
agglutinated well, thereby indicating the isotype of the mouse monoclonal antibody 
tested.
2 .3.19. Purification of the monoclonal antibodies.
The ascitic fluid was purified by saturated ammonium sulphate (SAS) precipitation 
according to Knutson et al. (1991). In this procedure, the thawed ascitic fliud was 
clarified by centrifugation at 10,000g for 5mins at 4°C. The protein concentration was 
then adjusted to 10-12mg/ml with 20mM Tris, pH 8.0. A saturated ammonium sulphate 
solution, which had been adjusted to pH 7.4 with ammonium hydroxide and was at 4°C, 
was slowly added to the diluted ascitic fluid with stirring to achieve 45 % saturation of 
ammonium sulphate. After 1 hour at 4°C, the suspension was centrifuged at 10,OOOg 
for 5mins at 4°C. The pellet was resuspended to the same volume as the original diluted 
ascitic fluid with lOOmM Tris, 150mM NaCl at 4°C and exhaustively dialysed against 
the same buffer. Following dialysis, the sample was subjected to centrifugation at 
10,OOOg for 15mins at 4°C, to remove precipitated proteins. The SAS-treated ascitic 
fluid was further purified by protein A affinity chromatography or protein G 
purification. These methods are described in Section 2.4.13. and Section 2 .6 .3 ., 
respectively.
2.3.20. Characterisation of monoclonal antibodies.
2 .3 .20.1. Preparation of reagents for High Pressure Liquid Chromatography 
(HPLC).
The column used was a 10¡urn Protein Pak SW 300 column with a mobile phase of
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0 .1M phosphate buffer, pH 7.0 with a flow rate of 0.5ml/min. This column was a size 
exclusion column where molecules of greater molecular weight are eluted and detected 
before molecules of lower molecular weight. 0.1M sodium phosphate buffer was 
prepared by adding 13.8g NaH2P 0 4 and 14.2g Na2P 0 4 to 900ml ultrapure H20 , 
adjusting the pH to 7.0 and the volume to 1 litre with ultrapure H20 . All buffers were 
filtered and sonicated for 30mins before use. The protein standards and samples were 
made up at 1 mg/ml in 0 .1M phosphate bufffer, pH 7.0. Absorbance due to protein was 
detected at 280nm. After use, the column was washed and stored in 0.1M phosphate 
buffer, pH 7.0 containing 0.05% (w/v) sodium azide.
2.3.20.2. Cytospin preparation of cells.
Cytospins were prepared by adding 100/xl of a 5X104 cells/ml in 0.01M PBS, pH 7.3., 
to the cytospin chambers placed over slides. The cells were centrifuged onto these slides 
at lOOOrpm for 2mins at room temperature. The cytospin preparations were air dried 
and stored at -20°C in tin foil in a slide holder.
These slides were thawed by removing them from the freezer and leaving to stand at 
room temperature, wrapped in tin foil, for 20mins. Thereafter the slides were not 
allowed to dry when being used in APAAP or FITC-conjugate labelling. If required, 
slides were fixed by immersion for 30sec in a solution of acetone: absolute alco­
hol formaldehyde in a 19:19:2 ratio, respectively.
2.3.20.3. Staining of cytospin preparations.
Rapi-Diffll, a triple stain pack for Romanowsky staining from DiaCHEM (Section 2.1.) 
was used to examine the cellular and nuclear morphology of myeloma cells. The kit 
consists of three solutions: solution A was the fixing solution, thiazine dye in methanol; 
solution B was the acid dye, eosin Y in phosphate buffer and solution C was the basic 
dye, methylene blue (polychromed) in phosphate buffer. Optimal results were obtained 
when the slides were immersed in solution A for 30secs, solution B for 35secs and then 
solution C for 45secs. The slides were rinsed briefly in buffered water, pH 6.8, allowed 
to dry and were then viewed under a microscope.
2.3.20.4. The alkaline phosphatase anti-alkaline phosphatase (APAAP) detection 
system.
Using the APAAP system, the slides were treated like an ELISA, the primary antibody,
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blocking solution (Goat/FCS/Tns buffer), anti-mouse IgG, APAAP and substrate were 
each incubated for 30mins, with four washes in Tns buffer between each step The 
substrate used was a BCIP and mtro blue tetrazolium (NBT) which generates an intense 
black-purple precipitate at the site of enzyme binding The reaction proceeds at a steady 
rate, which allows accurate control of the development of the reaction by the length of 
incubation
The following three stock solutions were prepared pnor to developing the cell staining 
(1) NBT was prepared by dissolving 0 5g of NBT in 10ml 70% (v/v) dimethyl- 
formamide (2) BCIP was prepared by dissolving 0 5g of BCIP (disodium salt) in 10ml 
of 100% dimethylformamide (3) When using the APAAP system for the detection of 
antibody binding on slides the following recipe was used to make 10ml of the alkaline 
phosphatase buffer solution, 0 5ml of 2M Tns-HCl, pH 9 5, 0 2ml of 5M NaCl, 50/xl 
o f 1M MgCl2 and 9 25ml of dH20  All stocks are stable at 4°C for at least one year 
Immediately before use, the substrate was prepared by adding 66^1 NBT stock to 10ml 
of alkaline phosphatase buffer This was mixed well and 33/xl o f BCIP stock was then 
added and used within 1 hour 100^1 of this solution was added to each slide which was 
developed at room temperature in the dark A typical incubation was approximately 20 - 
30min The reaction was stopped by nnsing the slide with 0 01M PBS, pH 7 3, 
containing 20mM EDTA The slides were counterstained and mounted in DPX 
(Sections 2 3 20 5 and 2 3 20 6 , respectively)
2.3.20.5. Methyl green counterstauung of alkaline phosphatase/BCEP-stained shdes.
The slides were counterstained with 2 0% (w/v) methyl green for lmin and were then 
washed in 0 01M PBS, pH 7 3 The slides were either mounted in DPX (Section 
2 3 20 6 ) or were dehydrated in 95% (v/v) alcohol followed by 100% absolute ethanol 
and cleared in xylene before mounting in DPX
2.3.20.6. Mountants for shdes.
DPX is named for its components, lOg of distrene 80, 5ml of dibutyl phthalate and 
35ml of xylene DPX mountant was used to mount slides by allowing the slides to dry, 
but not overdry, adding a drop of DPX mountant and then quickly placing a coverslip 
on top, avoiding air bubbles
Slides can also be mounted using glycerol jelly, which is an aqueous mountant It
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consisted of lOg of gelatine power dissolved in H20  by warming and then 70ml of 
glycerol was added One drop of phenol or sodium merthiolate was added as an 
antibacterial agent This was stored at 4°C and must be melted and freed of air bubbles 
before use which is conveniently done in a vacuum-embedding chamber Because of the 
low refractive index (1 42) many unstained structures remain visible in this medium
2.3.20.7. Detection of antibody binding using the ’eppendorph5 ELISA,
This was used primarily with FITC-labelled primary antibodies (Carroll et al , 1990) 
The eppendorphs were coated with 2% (w/v) BSA in 0 01M PBS, pH 9 0 for 2hrs at 
room temperature or at 4°C overnight This solution was then discarded and lxlO6 cells 
in 0 01M PBS, pH 7 3, containing 3% (v/v) FCS and 0 01 % (w/v) sodium azide From 
this step, everything was kept at 4°C in the dark The cells were centnfuged and 0 1ml 
of the FITC-conjugated primary antibody at a suitable dilution was added, as was the 
negative control, PBS These were incubated for 30min and the cells were washed three 
times in ice cold 0 01M PBS, pH 7 3, containing 3% (v/v) FCS and 0 01% (w/v) 
sodium azide The slides were kept in the dark and photographed immediately as the 
fluorescence fades
2.3.20.8. Fluorescence Activated Cell Sorting (FACS) analysis to determine 
antibody specificity.
The interest and assistance of Mrs Kate Cotter, University of Maynooth, in the FACS 
analysis is gratefully acknowledged and appreciated
The cells were removed from culture (Section 2 3 1 , 2  3 2 ) and brought to a cell 
count of lxlO6 (Section 2 3 3 ) The eppendorphs to be used were coated with 2% 
(w/v) BSA in 0 01M PBS, pH 9 0, for 2hrs at room temperature or at 4°C overnight 
This solution was then discarded and lxlO6 cells in 0 01M PBS, pH 7 3, containing 3% 
(v/v) FCS and 0 01% (w/v) sodium azide From this step, everything was kept at 4°C 
m the dark The cells were centnfuged and 0 1ml of the pnmary antibody, at a suitable 
dilution, was added, as was the negative control, 0 01M PBS, pH 7 3 These were 
incubated for 30min and the cells were washed three times in ice cold 0 01M PBS, pH 
7 1, containing 3% (v/v) FCS and 0 01 % (w/v) sodium azide After this step, the cells 
were blocked with 2% (v/v) goat serum (Sigma) in PBS/FCS/azide to block any Fc 
receptors on cells The appropnate anti-mouse FITC-conjugated antibody (Table 2 4 )
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was then added. The cells were pelleted by centrifugation at 1080rpm for 5min and 
resuspended in the PBS/FCS/azide solution. 1ml of 70% paraformaldehyde (Section
2.3.20.9.) was added dropwise, to fix the cells and was left at room temperature for 
30mins. The cells were pelleted again at 1080rpm for 5mins and washed twice in the 
PBS/FCS/azide solution. The cells were finally resuspended in this solution, stored in 
the dark at 4°C and read in a FACS Scan IV machine from Becton Dickinson as soon 
as possible. The cells were resuspended in FACS fluid before being analysed.
2.3.20.9. Preparation of paraformaldehyde for use in FA CS.
Paraformaldehyde (70%, w/v) was prepared by adding 25ml 0.01% sodium 
azide/O.OlM PBS, pH 7.3, to 3.5g paraformaldehyde. This was heated to 60°C. Four 
drops of 1M NaOH was added and the solution should clarify. The volume was made 
up to 50ml with 0.01% sodium azide/O.OlM PBS, pH 7.3. The solution was filtered 
and stored at 4°C.
2.3.21. Dot immunoblotting.
Care was taken to use gloves and forceps when handling the Hybond-C-Super 
nitrocellulose membrane used in this procedure. A 5cm2 grid was scored on the 
membrane using a fine pencil, leaving a margin around the edges to handle the 
membrane.
The membrane was soaked in 0.01 M PBS, pH 7.3, for 5min in a small container 
ensuring the entire membrane was wet. The PBS solution was poured off and the 
membrane was allowed to air-dry. O.lmg/ml of antigen in 0.01M PBS, pH 7.3, was 
prepared and 1-2/¿I of this solution was applied to duplicate squares.
Negative and positive controls were prepared in a similar manner. A positive control 
was a square coated with GFAP where the primary antibody was commercial anti- 
GFAP diluted in 0.01M PBS, pH 7.3. A negative control was a square without antigen 
and was incubated with the same dilution of the primary antibody, for example anti- 
GFAP in 0.01M PBS, pH 7.3.
The antigen was left to bind for 30min at room temperature. The wash buffer used was 
lOmM Tris, 150mM NaCl and 0.5% Tween-20, w/v, this solution was adjusted to pH 
7.5 and brought to 2.5L with ultrapure H20 . The blot was washed twice in wash buffer 
and the sites not bound by antigen were blocked with 20ml of 1 % (w/v) BSA in 0.01M
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PBS, pH 7 3, ensunng the whole membrane was completely immersed The blot was 
immersed in the blocking solution for 30min at room temperature and was gently 
shaken at intervals The blocking solution was poured off and the membrane was 
washed three times with wash buffer and twice with PBS, as before 
\-2fA o f sample, e g supernatant or ascitic fluid diluted in 0 01M PBS, pH 7 3, with 
2% (w/v) BSA and 0 1% (v/v) Tween-20, was added to the blot and left at room 
temperature for 2 hours The plate was washed, as before, and 20ml of a 0 l^g/m l of 
anti-mouse IgG (whole molecule) alkaline phosphatase-conjugated secondary antibody 
(Table 2 4 ) ,  diluted in TBS with 2% (w/v) BSA and 0 1% (v/v) Tween-20 was then 
added to the blot
The blot was left shaking for 30min at room temperature and was then washed three 
times, for 5min each, in 0 01M PBS, pH 7 3, containing 0 1% (v/v) Tween-20 and 
three times in 0 01M PBS, pH 7 3 10 3ml of the BCIP/NBT substrate solution (Section 
2 3 20 4) was made up and the substrate solution was added to the dot blot container 
and left to develop for 5-10min When the colour had developed, the reaction was 
stopped by pouring off the substrate and washing the membrane in distilled water This 
was then poured off and the membrane left to air dry The blots were stored in the dark 
at room temperature to prevent fading and photographed as soon as possible 
The dot blots in Figure 3 4 1 were performed as follows, 2/xl of a 10/^g/ml solution 
of GFAP from lot 16 (GFAP "A") was used as the antigen on the upper portion of each 
dot blot and the same quantity of GFAP from lot 17 (GFAP "B") was used on the 
bottom portion In Figure 3 4 1 (a) was treated with 10ml of a 1 1000 dilution of 
commercially available anti-GFAP in 0 01M PBS, pH 7 3, (b) the negative control for 
commercially available anti-GFAP, 0 01M PBS, pH 7 3, (c) examined with 2DH5 clone 
A10 supernatant (1 5 dilution in 0 01M PBS, pH 7 3) and (d) the negative control the 
negative control which had DMEMS10, added instead of hybndoma supernatant These 
results are discussed in Section 3
2.3.22. Preparation of cell membranes for Western immunoblotting.
This procedure was performed according to Barrand and Twentyman (1992) Lysis 
buffer was prepared by adding lOmM KC1, 1 5mM MgCl2 and lOmM Tns-HCl to 1L 
of ultrapure H20  and the pH was brought to 7 4 using conc HC1 or 5M NaOH, as 
appropnate The lysis buffer was kept on ice Immediately before use, 2mM of a
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protease inhibitor, phenyl-methyl-sulphonal fluoride (PMSF) (toxic), was dissolved in 
a minimium volume of acetone and added to 40ml of boiling lysis buffer When 
dissolved, this 40ml was added to the remainder of the lysis buffer and kept on ice 
Cell membranes were prepared for Western immunoblotting by first washing 108 cells 
obtained from cell culture (Sections 2 3 1 and 2 3 2 ) with 0 01M PBS, pH 7 3, three 
times at 2000rpm for 5mm The cells were resuspended in 5ml of ice cold lysis buffer 
and sonicating using a Braun Labsonic U sonicator with a repeating duty cycle of 0 5 
and low speed The cell membranes were kept on ice throughout the procedure These 
membranes were then checked at intervals during the somcation to ensure the correct 
amount of cell fragmentation was obtained by microscopic examination The cell 
membranes were transferred to centrifuge tubes and centrifuged in a SorvallR RC-5B 
refngerated Superspeed Centrifuge using a SorvallR GSA rotor at 7,800rpm for 15mm 
at 4°C The plasma membrane ennched-supernatant was retained and centrifuged again 
using a Beckman Optima XL-80 Ultracentnfuge at 38,500rpm for lhr 15min at 4°C 
The pellet was resuspended m 500/xl of ice-cold lysis buffer, sonicated for 2-3 seconds 
and was kept at 4°C 3x100^1 of this solution was divided into eppendorphs and 50/il 
o f this solution was retained to perform a BCA protein assay (Section 2 4 9 3 ) 
Parafilm was placed over the eppendorphs which were kept on ice throughout These 
eppendorphs were frozen quickly by placing in a -70°C freezer for 15mm They were 
then placed in a Vitns Consol 4 5 freeze dryer overnight and were stored at -20°C until 
required for use in Western blots (Section 2 3 22 )
2 3 22.1. Procedure for Western immunoblotting.
The electrophoresis mini-gels used for the Western blots were made-up according to 
Table 2 9 The molecular weight markers used are given in Table 2 10 15/xl of a 
lng/ml sample was prepared in reducing Laemmli loading buffer This buffer consisted 
of 2 5ml of 1 25M Tns-HCl pH 6 8, 0 5ml 10% (w/v) SDS, 2 9ml mercaptoethanol, 
8 7% (v/v) glycerol, adjusted to 50ml with ultrapure H20  The cell membrane samples 
(Section 2 3 22 ) were mixed by vortexing and 3-5/xl of each sample was taken for use 
in a dot blot (Section 2 3 2 1 )  0 1  mg of bromophenol blue (BDH chemicals Ltd ) was 
added to the remaining 10-12^1 of each cell membrane sample Laemmli running buffer 
was placed between the gel and the container and 10/il of each sample (not boiled) and 
of the boiled molecular weight markers were loaded per well When the gel was loaded,
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more running buffer was added Gels were run on a LKB 2050 Midget electrophoresis 
unit at 40 milliamperes (250 volts) until the first bromophenol blue band was near the 
bottom of the gel
A square of Hybond-C-Super nitrocellulose paper the size of the mim-gel was carefully 
cut out, taking care not to touch the paper and to wear gloves This paper was 
moistened by placing gently on blotting buffer (25mM Tns, 192mM glycine, pH 8 3 
in 500ml ultrapure H20  - no methanol) and was allowed to wet by capillary action from 
the bottom and left to soak for 10mm
The Bio Rad Trans-Blot Semi-dry transfer cell system was used to transfer the proteins 
from the gel to the nitrocellulose paper, as proteins go toward the anode in this system 
This system was set up by placing four sheets of filter paper pre-soaked in blotting 
buffer on the anode Any air bubbles were removed using a glass pasteur pipette The 
moistened nitrocellulose paper was positioned on top of the filter paper The gel was 
placed on top of the nitrocellulose paper and four sheets of moistened filter paper were 
placed on top of the gel
The dryer was set at 15 volts maximum and the limit for the current was 0 340 
amperes Transfer took 30min On transfer, the membrane was treated in a similar 
manner to the dot blot, from the stage of the dot blot protocol where the antigen was 
added to the membrane (Section 2 3 21 ) The variations m this procedure are briefly 
outlined All the antibodies were diluted in TBS [0 1 % (w/v) Tween-20 in 2M Tns- 
HC1, pH 9 5, 5M NaCl and 1M MgCl2, made up to 1L in ultrapure H20 ] The washing 
buffer was 0 5 % (v/v) Tween in TBS The blots were blocked at room temperature for 
1 5 hours with 5 % (w/v) Blotto in TBS The primary antibodies were left at 37°C for 
1 5 hours The secondary antibodies at a 1 1000 dilution of alkaline phosphatase- 
conjugated anti-mouse IgG or IgM in TBS, as appropriate, were incubated for 1 hour 
at 37°C (Table 2 4 )  BCIP/NBT in TBS was added until colour developed This was 
approximately 5-10mins
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Table 2.9. Composition of resolving and stacking electrophoresis gels for Western 
blots.
Gel constituents 7.5% Resolving mini- 
gel
Stackmg Gel
29 1 % (w/v) Acrylamide - 
0 9% (w/v) Bisacrylamide 
Stock
3 8ml 0 8 ml
Tns-HCl 3 0ml
(1 875M, pH 8 8)
0 5 ml
(1 25M, pH 6 8)
Ultra Pure Water 8 0ml 3 6ml
Ammonium Persulphate 
(added last)
50/d 20/d
SDS (10%, w/v) 150/wl 50/d
TEMED 7 5/d 5/d
Table 2.10. Molecular weight markers used m Western lmmunoblotting.
Molecular weight 
marker
Molecular weight
Myosin 205,000
6-galactosidase 116,000
Phosphorylase 97,400
BSA 66,000
Ovalbumin 45,000
Carbonic anhydrase 29,000
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2.3.23. Conjugation of fluorescein isothiocyanate (FITC) to proteins and antibodies.
Fluorescein isothiocyanate (Isomer I) was conjugated to (i) the proteins IBHR-BSA and 
IBHR-KLH and (ii) antibodies using a modification of Goding (1976). FITC was 
conjugated to IBHR-BSA and IBHR-KLH to facilitate the detection of bispecific 
antibodies containing the anti-IBHR polyclonal antibody (Section 5.1.) by FACS 
analysis. The anti-G-CCM and anti-GFAP antibodies were directly labelled to facilitate 
the detection of these antibodies by FACS and immunofluorescence.
Antibody concentrations of equal to or greater than lOmg/ml relative to fluorochrome 
concentrations of 10-20/jg/mg of antibody, favour conjugation to antibody (up to 70%). 
Satisfactory conjugation of FITC to antibody solutions of lower concentrations, for 
example 1 mg/ml, can be obtained if the fluorochrome concentration is correspondingly 
increased (100/*g/mg antibody). Protein concentrations of the purified ascitic fluid or 
protein solution used were determined using the BCA assay (Section 2 .4.9.3.)
The protein and purified antibody preparation from ascitic fluid samples were dialysed 
overnight against freshly prepared 0 .1M sodium carbonate buffer, pH 9.5. This dialysis 
helps to remove extraneous nucleophiles such as Tris, amino acids, ammonium ions or 
azide that might inhibit conjugation. At pH 9.5, a large fraction of the e-amino groups 
on lysine are unprotonated enabling thiourea bonds to form with the thiocyanate groups 
of the fluorochrome.
A stock solution of FITC (lmg/ml) was dissolved in pure DMSO to prevent hydrolysis. 
The appropriate volume of the fluorochrome solution to add to the protein or ascitic 
fluid solution was calculated as follows;
(i) when the protein or ascitic fluid solution had a concentration of greater than or equal 
to lOmg/ml, 10/xg of the fluorochrome solution was added per mg of protein or 
antibody solution used, (ii) when the concentration of protein or antibody solution was 
less than lOmg/ml, 100/xg of the fluorochrome solution was added per mg of protein 
or antibody.
The fluorochrome solution was added in 20/xl amounts to the protein or antibody 
solution with gentle stirring. This was left in the dark for 3-4 hours at room tempera­
ture. The free fluorochrome was separated from the FITC-protein conjugate on a 
Sephadex G-50 column in 0.01M PBS, pH 7.0, with 0.01% (w/v) sodium azide. The 
size of the column was 32cm x 3.2cm and the exclusion limit was between 20,000 and 
50,000. According to Goding (1976), the first coloured band to be eluted is the
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conjugated antibody This was stored at 4°C in the dark
2.3.23.1, Calculation of the fluorescein:protein (F:P) ratio.
The fluorescein coupling 1 e the ratio of fluorescein to protein, can be estimated by 
measuring the absorbance at 495nm and 280nm The difference in absorbance (A) for 
fluorescein (495nm-280nm) should be between 0 3 and 1 0, all the FITC-protein 
conjugates and the FITC-labelled antibody solutions prepared dunng this project were 
m this range
Ratios below these yield low signals, while higher ratios show high backgrounds 
(Harlow and Lane, 1988) If the ratios are too low, the conjugation would have to be 
repeated using lower levels of antibody and higher levels of label If higher levels were 
found the labelling procedure would have to be repeated with appropriate changes or 
the labelled protein could be further purified on a DEAE column 
The F P ratio for the fluorescein conjugates can be calculated using a simple formula 
proposed by The and Feltkamp (1970a, b) They included a correction for the 
contribution of FITC to the total absorbance at 280nm Mouse [IgG] represents the 
mouse IgG concentration
F P ratio =  2 87 x A495
A2 8 0 ~ 0 35 x A495
Mouse [Ig G] =  A280 - 0 35 x A495
-----------------  mg/ml
0 69
Using either of these methods the ratio of FITC conjugated to a protein or antibody 
may be calculated
2.3.23.2. Indirect immunofluorescence and its use m antibody characterisation.
In this system, binding of test antibody to the antigen is detected using a second 
antibody which is fluorescently labelled When immunofluorescence is earned out on 
live cells only cell surface components are recognised If immunofluorescence is 
performed on fixed cells or on frozen tissue sections, intracellular antigens are also 
detectable
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The cells to be tested were adjusted to a concentration of lx l0 6/ml in DMEM-S10 and 
lOOftl of the cell suspension was pipetted into each eppendorph tube lOOpcl of the test 
antibody, either ascitic fluid diluted 1 100 in DMEM-S10, purified antibody preparation 
from ascitic fluid, supernatant or positive and negative controls was added to each tube 
The negative control in each case was DMEM-S10 and the positive control was serum 
from immunised mice or commercially available anti-GFAP antibody 
The tubes were mixed gently and incubated for 30 minutes at 4°C The cells were then 
washed three times in 0 01M PBS, pH 7 3, containing 0 1% (w/v) sodium azide (PBS- 
azide) The cells were incubated for 30 minutes at 4°C with 100/¿I of a dilution of fluor- 
escein-isothiocyanate (FITC)-hnked anti-mouse IgG or IgM at appropriate dilutions 
(1 32 and 1 28, respectively) with DMEM-S10 The cells were then washed three times 
in PBS-azide and the supernatant aspirated from the cell pellet Each cell pellet was 
resuspended in a mimmium amount of PBS-azide 10/xl of this cell suspension was 
placed on a microscope slide, covered and observed for fluorescence Samples may be 
stored (if required) away from the light at 4°C
2.3.24. Characterising antibody affinity using BlAcore.
In the BlAcore system the optical phenomenon used for detection of antibody-antigen 
binding is surface plasmon resonance, (SPR) This is discussed in Section 3 15
2.3.24.1. Preparation of samples for BlAcore.
Antigen samples should be resuspended in 0 01M PBS, pH 7 3, H20  or other 
physiological buffer It is important that the antigen be pure and at a concentration of 
50/ig/ml or greater Only 300^1-500/il is needed normally, but in cases where the 
antigen immobilises poorly, more may be needed If the antigen is a conjugate, the 
molecular weight of the protein and hapten is required along with how many haptens 
are conjugated per protein molecule BlAcore works better with BSA-conjugates than 
some antigens alone as sometimes when using unconjugated antigens the epitope on the 
antigen may be concealed
In the case of the antibody, it must also be pure and at as high a concentration as 
possible, e g 0 5ml of 500/xg/ml would be sufficient This should also be in a low salt 
buffer, like 0 01M PBS, pH 7 3
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2.3.30. Molecular biology techniques.
2.3.30.1. Treatment of plastics for use with mRNA and DNA.
All plasticware was treated by washing with chloroform (toxic) in a fume hood and 
autoclaving. Plastic tips were only used if the container had been previously unopened. 
These were also chloroform washed and autoclaved. Gloves were worn at all times 
when handling these tips, even before the chloroform wash.
2.3.30.2. DEPC-treatment of solutions for use with mRNA and DNA.
Diethylpyrocarbonate (DEPC, toxic) was used to inhibit RNases in the preparation of 
solutions for RNA manipulation. DEPC (0.2%, v/v) was added to the solution which 
was left at room temperature for at least 20 minutes and then autoclaved to inactivate 
the DEPC. DEPC was not added directly to solutions containing Tris as it is highly 
unstable in these solutions decomposing rapidly into ethanol and carbon dioxide 
(Sambrook et a l ., 1989). Gloves were worn at all times, and changed frequently, when 
preparing solutions for the manipulation of RNA to avoid the introduction of RNases.
2.3.30.3. Purification of mRNA from cultured cells.
Gloves were worn at all times when isolating, purifying or handling mRNA as it can 
be easily degraded by RNases.
(a) Extraction o f cultured cells.
Polyadenylated RNA was extracted from the exponentially growing anti-G-CCM 
hybridoma, 3BH2 clone A3 cells, using the QuickPrep™ mRNA purification kit (Table
2.1.). Thirty minutes before use, the kit was removed from storage at 4°C and left to 
equilibrate to room temperature. The extraction buffer was placed at 37°C at this time. 
The extraction buffer was shaken periodically and when all the crystalline material had 
dissolved, it was cooled to room temperature. mRNA was extracted from the 3BH2A3 
hybridoma and these cells, which grow in suspension, were stained using trypan blue 
exclusion, counted and their viability determined (Section 2.3.3.). The cells were 
pelleted by centrifugation and the supernatant was decanted and discarded. 1.5ml of 
extraction buffer was added to the pelleted cells. The cells were disrupted using a 
homogenizer (Kika-Werk, Ultra-Turrax), to ensure a homogeneous extract.
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3ml of elution buffer was added to the cell extract to dilute the sample followed by 
thorough mixing The sample was homogenised briefly and then transferred into a 
stenle polypropylene centrifuge tube The remaining elution buffer was placed at 65°C 
until needed Having ensured each tube is counter-balanced, the diluted extract was 
centrifuged for 10mm at 12,000xg using a Beckman JA20 rotor in a Beckman J2-21 
centrifuge at room temperature
(b) Isolation ofmRNA
The 01igio(dT)-Cellulose Spun Column provided with the QuickPrep™ mRNA 
purification kit (Table 2 1 )  was inverted several times to resuspend the matrix The top 
and bottom closures were removed and the column was placed in a 15ml centrifuge tube 
and balanced against a counterweight This was centrifuged at 350xg for 2 mm 
(l,400rpm in a Heraeus Christ Labofuge 600 centrifuge) The column was removed 
from the centnfuge tube and the liquid m the tube was discarded The bottom closure 
on the drained column was put back on and the column was placed upright in a rack 
Using a stenle pipette, 4ml of the supernatant from the final step in the mRNA 
extraction procedure was transferred onto the surface of the column Dunng this 
transfer, disturbing the pelleted cellular material was avoided The top closure of the 
column was put back on and the column was inverted several times to resuspend the 
resin The column was gently mixed for 10mm by inverting the column manually The 
column was placed in a 15ml centnfuge tube and balanced against a counterweight 
leaving both top and bottom closures securely on This was centnfuged at 350g for 
2min, to separate the resin from the suspension The top closure was removed, the 
supernatant was decanted and discarded while taking care to avoid disturbing the resin 
3ml of high salt buffer provided was applied to the top of the resin and the top closure 
was replaced on the column The matnx was resuspended by gentle tapping of the 
bottom of the column The column was placed in a 15ml tube and centnfuged at 350g 
for 2mins The top closure was again removed, the supernatant was decanted and 
discarded The wash, using the high salt buffer, was repeated twice, exactly as 
descnbed above 3ml of the low salt buffer was applied to the column and the top 
closure was replaced The matnx was resuspended by gentle tapping of the bottom of 
the column The column was placed in a 15 ml centnfuge tube and centrifuged at 35Og 
for 2min. The top closure was removed, the supernatant was decanted and discarded
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The bottom closure was removed, 3ml of low salt buffer was applied to the top of the 
resin and centnfuged at 350g for 2min A sterile 1 5 ml screw-top microcentnfuge tube 
was placed inside a 15ml centrifuge tube so that the tip of the column was inside the 
opening of the screw-top microcentnfuge tube ("the collection tube")
The bound poly(A)+ RNA was eluted as follows, using three successive washes with 
the elution buffer provided which had been prewarmed to 65°C For each wash, 0 25ml 
of buffer was pipetted onto the top of the column, the column in its collection tube, was 
then centnfuged at 350g for 2mm The collection tube was not changed between washes 
in order that the entire 0 75ml eluate was collected in the same stenle tube The screw- 
top microcentnfuge tube was removed from the 15ml centnfuge tube using a sterile 
(autoclaved) forceps, which was flamed before use The collected sample and the 
remaining elution buffer was placed on ice
(c) Quantitation and precipitation ofmRNA
The concentration of RNA in the final eluate can be estimated by ethidium bromide 
fluorescence (Sambrook et a l , 1989) or by spectrophotometry, which was the method 
used and is descnbed below However, the disadvantage with the spectrophotometric 
procedure is that it consumes one-third of the sample
To protect the RNA sample from degradation by RNases, the 0 5ml quartz glass 
cuvettes used were pretreated by soaking in concentrated HC1 methanol (1 1) for 1 hour 
and then nnsing several times in DEPC-treated water DEPC-treated water was made 
by prepanng a 0 1 % (v/v) solution of DEPC in ultrapure H20  Stenle glassware was 
used throughout the procedure This was allowed to stand at room temperature 
overnight and was then autoclaved
0 25ml of the column eluate was placed in a stenle microcentnfuge tube and an equal 
volume of elution buffer was added The absorbance of the diluted sample was read at 
260nm (A260) m a Shimadzu UV-160A UV-Visible recording spectrophotometer using 
elution buffer as a blank This reading must be between 0 05 and 2 0 to reflect the 
RNA concentration accurately, if the absorbance was above 2, the sample would have 
been diluted further to determine the RNA concentration This diluted sample was 
discarded
Knowing that for RNA, 1 A260 unit =  40^g/ml, the concentration of the RNA present 
([RNA]) was calculated using the following formula
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[RNA] =  A260 x D x 40/ig/ml
where D =  final dilution factor In the simpliest case above, this would be 2 
If the absorbance of the diluted sample was greater than or equal to 0 5, the sample 
may be used directly for complementary DNA (cDNA) synthesis (Section 2 3 30 9 ) 
If the absorbance was less than 0 5, the sample must be precipitated and redissolved at 
a higher concentration to ensure efficient cDNA synthesis (Pharmacia, 1991)
2 3.30.4. Rules for generating primers.
The following rules were adhered to when designing primers 
There should be 100% homology at the 5 ’ end of the pnmer for the first 4 to 5 bases 
The pnmer should ideally be no more than 24 bases long The pnmer should not 
contain inverted repeats as this would form a secondary structure within the template 
DNA The G-C and A-T ratio should be equal and constant throughout the pnmer 
sequence The G-C content determines the melting temperature in the PCR reaction and 
this can be calculated according to Section 2 3 30 10 There can be no complementarity 
between the 3 ’ end of the forward pnmer and the 5 ’ end of the backward pnmer as this 
would result in pnmer dimers and stop the PCR reaction The pnmer must be 
absolutely specific for the region of the genome required The homology of a chosen 
region can be checked against DNA of that species stored in the GENBANK, which 
contains over 200,000,000 bases and 150,000 sequences The pnmer should also 
contain the required restnction enzyme sites for forced cloning, which should be in 
frame with the promoter in the vector and should not contain a stop codon, such as 
TAG, in frame If the pnmer sequence has to be modified to incorporate a specific site, 
only 2 or 3 bases in the middle of the pnmer should be changed and, if possible, the 
change should only be in the second or third base of a codon It would be better to 
check if there is another restnction enzyme available which does not require changing 
the sequence This can be checked easily and quickly using the SeqAid™ II, version 3 0 
or later, software analysis package which is currently available
2.3.30.5. Analysis of the DNA regions to be amplified by polymerase chain reaction 
(PCR) primers.
The first and most important step in engineenng antibodies is to generate PCR primers 
which will only amplify the DNA region of interest The protein regions of a mature
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antibody corresponding to the DNA regions amplified by the pnmers selected are 
shown m Figure 5 1 In order to do this, the target sequences of each of the primer 
pairs were compared with each other using the computer package SeqAid™, version 3 0 
and the following results were obtained,
The region which would be amplified by VKFOR and VKCBAC2 showed no alignment 
greater than 2 bases Therefore, a primer anywhere along this sequence could be used 
The region amplified by 1HEAVY and HCH1BAC2 was then analysed and alignment 
between position 30 of 1HEAVY and position 21 in HCH1BAC2 was observed It was 
important that the pnmers be specific for the region o f the first 30 nucleotides in 
1 HEAVY and the first 21 bases in HCH1BAC2
The region amplified by the postulated 1HEA V Y and HCH2 pnmers was compared and 
an alignment between position 24 of 1HEAVY and position 6 in HCH1BAC2 was 
observed, implying that it was important that the pnmers be specific for the region of 
the first 23 nucleotides in 1HEAVY and that the HCH2 primer be made from position 
1 In all cases the beginning and ends of the sequences were chosen as regions for 
pnmer sequences The target regions were also checked to ensure they did not form 
regions of hairpin loops, i e they were not complementary to themselves
2.3.30.6. Design of amplification primers to be used in PCR.
The munne hybndoma used was that producing the anti-G-CCM monoclonal antibody, 
3BH2A3 (Section 3 ), and isotyped as IgM with kappa (k) light chains 
In order to apply the PCR to the cloning and expression of these immunoglobulin 
genes, the conserved regions at each end of the nucleotide sequences encoding V 
domains of mouse immunoglobulin heavy (V„) and k light chain were identified 
Pnmers were then designed for the PCR amplification, which incorporated restnction 
sites for forced cloning into a suitable vector The five pnmers used in this project 
amplify up the nucleotide regions corresponding to the antibody protein segments shown 
in Figure 5 1 and were used in the combinations given in Table 5 11  The rules for 
the generation of pnmers (Section 2 3 30 4 ) were adhered to in order to generate these 
pnmers
In order to find the conserved sequences for both the heavy and light chains, the 
database o f Kabat et al (1987) was consulted The beginning o f the nucleotide 
sequences correspond to the mature N terminus of the protein As expected, the
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nucleotide sequences encoding the protein CDRs are variable and those corresponding 
to the J region segments are conserved However, there are several other conserved 
regions, in particular, those encoding the mature N terminus of both VH and V* 
domains
In order to find if the sequences obtained in Kabat et al (1987) were representative in 
light of the expanded database in the intervening years, the GENBANK database of 
known DNA sequences was searched Not all of the database was searched, only the 
list of sequences in the database which had the keywords ’mouse’ and ’immunoglobulin’ 
in the title of the paper or, if unpublished, in the keywords for the sequence The 
number of sequences m this subset was 3,555
When the primer regions were chosen, they were analysed using SeqAid to search for 
restriction enzyme sites in the primers If a necessary change in the DNA sequence was 
required, the ammo acid change was analysed to ensure that, where possible, the 
change resulted in a silent mutation
The primers pairs were also checked to see if there was any inverted repeats in the 
primer sequence or if the primer sequence of corresponding pnmers were inversions 
of each other as if this were the case they would form pnmer dimers This procedure 
was followed for each of the five regions of interest Figure 5 2 shows the antibody 
protein segments that these five primers would amplify corresponding to the regions of 
the DNA sequence Each of these pnmers are detailed below
Primer sequence o f Variable region, kappa light chain
This sequence was taken from sequence numbers 75 and 76 (Clark et al , 1985) 
obtained in Kabat et al (1987) This pnmer sequence was called V KFO R (Figure 5 1) 
Sequence number 76 was used to generate the database search 
The sequence chosen as VKFO R had one base pair change (in bold type), to introduce 
a Sac  I restnction site G A G CTIC , underlined in the pnmer sequence below Sac I cuts 
at position 1119 o f the pComb3 vector system for antibody expression (Section 5 )
V KFO R  GAC ATT GAG CTC ACC CAA TCT CCA
Pnmer sequence o f Variable region, heavy chain
This sequence was taken from sequence numbers 148 and 153 (Boersch-Supan et al ,
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1985) obtained in Kabat et al (1987) These sequences were both generated from 
hybndomas derived from balb/c mice Sequence number 153 was used to generate the 
database search The primer sequence obtained was called 1HEAVY 
The sequence chosen as 1HEAVY required no base pair changes to introduce a Pst I 
restriction site C TG C A IG , underlined below Pst I cuts at position 157 of the pComb3 
vector system
1HEAVY GAG GTT CAG CTG CAQ CAG TCT
These two primers are for the forward sequence and correspond to the 5 ’-»3 s reading 
of the genetic code To generate the primers for the complementary DNA strand, the 
sequence must be reversed in polarity (l e from 3’->5’ to 5 ’^ 3 ’) and the complemen­
tary strand made (i e substituting A for T, T for A, C for G and G for C)
Pnmer sequence o f Constant region, kappa light chain
This sequence was taken from sequence numbers 3 (Hieter et al , 1980), 4 (Max et al , 
1979), and 7 (Hamlyn et al , 1981) obtained in Kabat et al (1987) The primer 
sequence obtained was called VKCBAC2, as these sequences were identical, sequence 
number 3 was used to generate the database search The sequence chosen as 
VKCBAC2 had two base pair changes (in bold type and underlined) to introduce a Xba 
I restriction site T IC TA G A , underlined below Xba I cuts at position 1131 of the 
pComb3 vector system
VKCBAC2 CTC ATT CCT TCT AGA GCT CTT GAC complementary strand
Pnmer sequence o f Heavy Constant chain, CHI region
This sequence was taken from sequence numbers 18 (Kawakami et a l , 1980), and 19 
(Auffray and Rougeon, 1980) obtained in Kabat et a l , (1987) Both of these were of 
IgM sequences of newborn mouse genomic DNA This pnmer sequence was called 
HCH1BAC2, as these sequences were identical, sequence number 18 was used to 
generate the database search The sequence was chosen although HCH1BAC2 had three 
base pair changes (in bold type) to introduce a Spe I restnction site A I CTAGT, 
underlined below Spe I cuts at position 175 of the pComb3 vector system 
HCH1BAC2 ATG CAG ATC ACT AGT TTT GCC TCC complementary strand
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Pnmer sequence o f  Heavy Constant chain, CH2 region
This sequence was again taken from sequence numbers 18 (Kawakami et al , 1980), and 
19 (Auffray and Rougeon, 1980) obtained in Kabat et al (1987) Both of these were 
of IgM sequences of newborn mouse genomic DNA However, the CH2 region was 
analysed to generate this primer This primer sequence was called HCH2, as these 
sequences were identical, sequence number 18 was used to generate the database 
search The sequence was chosen although HCH2 had three base pair changes (in bold 
type) to introduce a Spe I restriction site A IC T A G T , underlined below As above, Spe 
I cuts at position 175 of the pComb3 vector system
HCH2 TAC ATT GGG A £ T  AGT CTC TGC GAC complementary strand
Amplification primers VKFOR and 1HEAVY were designed to be complementary to 
the mRNA m the beginning of the FR1 regions of VL and VH, respectively The primers 
VKCBAC2, HCH1BAC2 and HCH2 were designed to be complementary to the first- 
strand cDNA encoding the more conserved heavy chain constant regions, CL, CHj and 
CH2 (Figure 5 1) The restriction sites for forced cloning were incorporated in the 
middle or towards the 5 ’ end (the least conserved part) of the pnmers, and mismatches 
were minimised near the 3 ’ end The degree of complementarity of the 3 ’ end of each 
pnmer to each o f the entnes in the Kabat et al (1987) data base was checked with 
SeqAid For most entnes in Kabat et al (1987) and GENBANK, the pnmer regions 
proved to be perfectly homologous or had only one or two mismatches The restnction 
sites at each end of the mature antibody domains would allow the DNA segment to be 
excised and the amplified cDNA to be inserted into the pComb vector
2.3.30.7. Extraction of oligonucleotides from their synthesis columns.
As this procedure may be hazardous, care was taken to wear eye protection and to take 
all necessary precautions In a fume cupboard, 1ml of ammonium solution or 
[(NH4)2OH] in a 1ml synnge was passed through the column into another 1ml synnge 
attached to the other side of the column This was repeated 3-4 times and the 1ml of 
solution was then left in the column for at least 15min The 1ml was then eluted into 
a stenle 4ml bijou bottle The 1ml elution step was repeated twice more, and the elutate 
was put into the bijou after each 15mm in the column The bijou bottle was sealed 
tightly with parafilm and incubated at 55°C for at least 8hrs or overnight The
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ammonium solution containing the oligonucleotide was freeze dried and resuspended in 
200/xl of stenle Tns-EDTA, pH 7 5, or water The oligonucleotide was ethanol 
precipitated overnight by the addition of 1/10 the volume of 3M sodium acetate and 
twice the volume of ice-cold ethanol, at -20PC
The pellet was washed twice with ice-cold 70% ethanol by gently pouring the ethanol 
on and off the pellet, it is crucial at this stage that the pellet is not disturbed The pellet 
was resuspended in 300/il of stenle water and stored in aliquots at -20PC The pnmers 
were quantified as outlined in Section 2 3 30 8
2.3.30.8. Quantification of PCR primers.
To quantitate the pnmers, an aliquot was removed from -20°C and thawed The 
eppendorphs were spun at top speed for 30mm and the pellet was resuspended in 200/xl 
o f 70% ice-cold ethanol and spun for 10mm This eliminates contaminating salts, etc 
The pellet was then resuspended in 500/d of stenle water A 1 50 dilution (D) m water 
was then prepared (20/d pnmer solution 980/d stenle water) and the absorbance (A) 
was measured at 620nm The DNA concentration (/xg/ml) =  A x D x 20, where a 
reading of 400/xg/ml is expected The molanty of the DNA was calculated by 
multiplying the concentration by the weight of an average base (325) and then by the 
length o f the pnmer All the pnmers were used from a stock concentration of 
50pmol//d
The quantification of the VKFOR pnmer, 24 nucleotides in length, is calculated as an
example Since the approximate molecular weight of the VKFOR pnmer =  24 x 325g
=  7800g, then a 1M solution would be 7800g/L
1M =  7800g/L => ImM =  7 80g/L => lpM =  7 80x10 9g/L
=> lpM//d =  7 8 0 x l0 9g//d
=> 50pM//d =  3 9 0 x l0 7g//d
=  3 9 0 x l0 5g//d total DNA, if the pnmer is resuspended in 100ftl of stenle H20  
20ng of pnmer DNA is required per PCR reaction The amount of DNA (ng//d) is 
calculated as follows,
Total DNA =  39 0 x l0 6g//d => 39 0/*g DNA per /d This can be then simply diluted to 
20ng/ul and 1/d per PCR reaction can be used
2.3.30.9. Synthesis of cDNA.
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ammonium solution containing the oligonucleotide was freeze dned and resuspended in 
200jx\ o f stenle Tris-EDTA, pH 7 5, or water The oligonucleotide was ethanol 
precipitated overnight by the addition of 1/10 the volume of 3M sodium acetate and 
twice the volume of ice-cold ethanol, at -20°C
The pellet was washed twice with ice-cold 70% ethanol by gently pounng the ethanol 
on and off the pellet, it is crucial at this stage that the pellet is not disturbed The pellet 
was resuspended m 300/¿I of sterile water and stored in aliquots at -20°C The pnmers 
were quantified as outlined in Section 2 3 30 8
2.3.30.8, Quantification of PCR primers.
To quantitate the primers, an aliquot was removed from -20°C and thawed The 
eppendorphs were spun at top speed for 30min and the pellet was resuspended in 200/d 
o f 70% ice-cold ethanol and spun for 10mm This eliminates contaminating salts, etc 
The pellet was then resuspended in 500/xl of stenle water A 1 50 dilution (D) in water 
was then prepared (20/d pnmer solution 980/d stenle water) and the absorbance (A) 
was measured at 620nm The DNA concentration (fig/ml) =  A x D x 20, where a 
reading of 400/*g/ml is expected The molanty of the DNA was calculated by 
multiplying the concentration by the weight of an average base (325) and then by the 
length of the primer All the pnmers were used from a stock concentration of 
50pmol//d
The quantification of the VKFOR primer, 24 nucleotides in length, is calculated as an
example Since the approximate molecular weight of the VKFOR pnmer =  24 x 325g
=  7800g, then a 1M solution would be 7800g/L
1M =  7800g/L => ImM =  7 80g/L => lpM =  7 80x10 9g/L
=* lpM//d =  7 8 0 x l0 9g//d
=> 50pMifil =  3 9 0 x l0 7g//d
=  3 90x10 5g//d total DNA, if the pnmer is resuspended in 100/d of stenle H20  
20ng of pnmer DNA is required per PCR reaction The amount of DNA (ng//d) is 
calculated as follows, Total DNA =  39 0 x l0 6g//d =* 39 Ofig DNA per ¿d This can be 
then simply diluted to 20ng/ul and 1/d per PCR reaction can be used
2.3.30.9. Synthesis of cDNA.
Best results for the synthesis of cDNA were obtained when the cDNA was prepared
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immediately from the mRNA The pnmer pairs for the three cDNA, and subsequent 
PCR, reactions are shown in Table 5 11  cDNA was prepared by using 1 Ofxg RNA 
(Section 2 3 30 9 ) dissolved in 3/d of elution buffer from the mRNA isolation kit and 
2/d of a 10ng//d solution of the appropriate pnmer pairs was added (l e 20ng of DNA 
was used) This was heated to 70°C for 10mm and was then chilled quickly with ice 
water Then 5/d (20 units) of placental RNase inhibitor (RNase in), 5/d of lOx reverse 
transcnptase (RT) buffer, 1/d of a solution of dNTPs (dGTPs, dATPs, dTTPs, dCTPs) 
each at a concentration of 20mM, 5/xl of 0 1M DTT and 0 5/d of a 200units//d solution 
of single stranded munne reverse transcnptase was brought up to a total volume of 25/d 
with DEPC-treated stenle water This solution was mixed by gentle vortexing Any 
resulting bubbles may be eliminated by bnef centnfugation in a microcentnfuge 
Incubation at room temperature for 20min and at 42°C for 5min followed The reaction 
was then incubated at 90°C for 5min and left on ice for 10mm 1/d of RNase H was 
added and left at 37°C for 20min This mRNA-cDNA hybnd gave best results if used 
in PCR immediately Otherwise it was stored at -2(fC
2.3.30.10. Calculating the melting temperatures of primers.
The equation used to calculate the melting temperature (Tm) of the primers is as 
follows,
Tm =  81 5 - 16 6(log10[Na+]) +  0 41(96 G + C ) - (600/N), 
where N =  chain length (Sambrook et al , 1989) This equation predicts accurately the 
melting temperatures for oligonucleotides as short as 14 nucleotides and as long as 60- 
70 nucleotides
2.3.30.11. PCR protocol.
All PCR reactions were set up in a laminar flow under stenle conditions and the PCR 
ingredients were added in the order shown below, the template DNA was added last to 
each vial to prevent cross contamination The oligionucleotides were kept on ice at all 
times A typical PCR reaction was set up as follows,
78 5/d stenle water,
8 0/d dNTP mix (20mM each)
10 0/d of lOx Taq buffer 
0 5/d 5* pnmer (50pmol)
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0 5/d 3 ’ pnmer (50pmol)
0 5/d Thermus aquaticus (0 5 umts//d) (Taq)
2 0/d of template DNA (lOOng from Section 2 3 30 9 )
The total volume was 100/d, care was taken to keep the Taq polymerase on ice at all 
times and to minimise its time out of -20PC The reaction was mixed and centnfuged 
briefly to remove any bubbles, this was then layered over with 100/d mineral oil, to 
prevent evaporation of the small volume of liquid during the high temperatures involved 
in the PCR cycle The PCR cycle conditions were optimised for each individual 
expenment The product of a PCR reaction should be a fragment or fragments of DNA 
of defined length Following the PCR reaction, a 10/d sample with 2/d of 6x sample 
buffer (Section 2 3 30 25 ) with appropriate molecular weight marker were examined 
on an agarose gel of between 0 8%-4 0%, stained with ethidium bromide and view 
under UV light The PCR machine used was PREM™ LEP Scientific, supplied by the 
Medical Supply Company
2.3.30.12. Electrophoresis of nucleic acids.
Agarose (0 7%, w/v) in Tns-acetate-EDTA (TAE) was routinely used for the analysis 
of plasmid and chromosomal DNA Mini gels were run at 100V in TAE buffer on a 
Horizon 58 gel box system for approximately 1 hour, (while total DNA digests were 
run 40-50V on a Pharmacia GN-200 or BRL H4 gel box for 14-16 hours) 4% (w/v) 
NusieveRGTG (FMC) agarose or 1 5% (w/v) agarose in TAE were used to separate 
PCR products and primers These gels were run at 75V in the Horizon 58 or Horizon 
11 14 Midi gel systems for 1-2 hours NusieveR GTG agarose is a low gelling ( <  30°C) 
and low melting ( <  65°C) temperature agarose It finely resolves nucleic acid fragments 
less than lOOObp and can distinguish fragments as small as 8bp At a given Nusieve1* 
GTG agarose concentration, DNA electrophoresed in gels in the presence of tns-borate- 
EDTA (TBE) buffer runs more slowly than DNA electrophoresed in TAE buffer In 4% 
gels using TAE buffer, bromophenol blue migrates similanly to a 70bp fragment, while 
in TBE buffer this dye migrates similanly to 30bp (FMS Bioproducts, Denmark)
The following is the range of separation of DNA on agarose gels,
Agarose % Optimal range of separation of linear DNA (kb)
0 3 (run at 4°C) 60 0 - 5 0
0 6 (run at 4°C) 20 0 - 1 0
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0 9 7 0  - 0 8
1 2
1 5
6 0  - 0 4  
4 0  - 0 2
2 0 3 0 - 0 1
The molecular weight marker used m these gels was <£X174, restricted with Hind III 
which gave distinct bands at the following molecular weights,
2.3.30.13. Preparation of ethidium bromide to stam DNA.
One gram of ethidium bromide (highly mutagenic) was added to 100ml H20 and stirred 
for several hours to ensure the dye was dissolved, resulting in a stock concentration of 
lOmg/ml This was used at a final concentration of l^g/m l m dH20 The container was 
wrapped m tin foil and stored at 4°C Gloves were worn at all times when handling 
solutions or gels containing ethidium bromide Ethidium bromide waste was collected, 
treated with activated charcoal and filtered through 3MM Whatman filter paper The 
clear liquid was disposed normally and the solids contained on the filter paper were 
incinerated
2.3.30.14. Visualisation of nucleic acids.
All nucleic acid gels were stained in 1/xg/ml ethidium bromide for 15min, washed in 
dH20  for 15min and then visualised on a UV transilluminator Photographs were taken 
on an Olympus OM-20 camera using T-max 100 film (Kodak) and an A003 red filter 
(Cokin, France) which blocks UV light Vivitar close-up lenses were used as required
2.3.30.15. Development of black and white negatives.
The black and white photographic film used (Section 2 2 )  was loaded onto the spool 
o f a small tank developer, m complete darkness, and 250ml o f D76 developer was 
added Air bubbles were removed by tapping a few times off the bench After the 
required development time, the developer was removed and may be re-used The 
developer tank was rinsed twice with water, then 250ml of fixer was added, and left for 
an hour or overnight It was then removed and the negative was left to soak in water 
until all the pink colour was removed The negative was then dned and printed
2.3.30.16. Rapid purification of DNA fragments.
This was carried out using the Magic PCR Preps™ Purification System from Promega,
1,353, 1,078, 872, 603, 310, 281, 271, 234, 194, 118 and 72
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according to the instructions Briefly, one magic column was prepared for each PCR 
product purification required The column was prepared by attaching the syringe barrel 
from a 3ml disposable tube to the leur-lock extension of each mini-column 100^1 of 
direct purification buffer (50mM KC1, lOmM Tns-HCl, pH 8 8, at 25°C, 1 5mM 
MgCl2, 0 1% Triton X-100) was dispensed into a 12x75mm polyproplene tube 100/aI 
o f each PCR reaction was added to the polyproplene tube and mixed 1ml of the magic 
PCR resin was added to the tube and vortexed briefly 3 times over lmin The resin 
containing the bound DNA was pipetted into the syringe barrel The syringe plunger 
was inserted slowly and the slurry was gently pushed into the mini-column using the 
synnge plunger The mini-column was then washed with 2ml of magic PCR preps 
column wash solution (80% isopropanol) The synnge barrel was removed and the 
mini-column was transferred to a 1 5ml microcentrifuge tube The mini-column was 
spun for 20sec at 14,000g in a microcentnfuge to dry the resin The mini-column 
containing the resin-bound DNA was set at room temperature for 15mm to allow the 
evaporation of any isopropanol present The mim-column was transferred to a new 
microcentnfuge tube and 50/xl of Tns-EDTA buffer (lOmM Tns-HCl pH 7 5, lOmM 
EDTA) was applied to the column After lmin the bound DNA fragment was eluted by 
spinning the microcentnfuge tube containing the mim-column for 20sec at 14,000g The 
mim-column was removed and discarded The purified DNA was stored in the 
microcentnfuge at 4°C or at -20°C
2.3.30.17. Phenol extraction of DNA.
DNA was extracted from a PCR sample using phenol The PCR sample was removed 
from under the layer of mineral oil and an equal volume of the 
phenol chloroform isopropanol (25 24 1) mixture was added It was mixed by vortexing 
and then centnfuged at 14,000rpm in a microcentnfuge for lmin Two layers were 
formed The upper layer contains the DNA and was removed without disturbing the 
phenol layer underneath
2.3.30.18. Preparation of plasmid for hgation.
The restnction enzymes used were stored at -20°C and diluted according to the 
manufacturers’ instructions The PCR fragments were digested with their appropriate 
restnction enzymes and ligated to their respective plasmids The purified DNA from
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the heavy chain PCR reactions were ligated to the pTACOlH plasmid, which carries 
the carbenicillin resistance gene and the light chain DNA was ligated to pTCOl which 
carries the chloramphenicol resistance gene The plasmids were prepared for ligation 
by being cut with the appropriate restriction enzymes in a volume of 300/d at 37°C for 
2hrs The reaction mix was extracted with phenol/chloroform (Section 2 3 30 17 ) and 
ethanol precipitated Subsequently, this was treated with calf intestine alkaline 
phosphatase, which catalyses the removal of 5 ’-phosphate residues from single or 
double stranded DNA and RNA This enzyme was used to prevent vector DNA from 
re-ligating on itself by adding 0 5/d of calf intestine alkaline phosphatase (0 5 units) to 
12/d of vector DNA and incubating it at 37°C for 20min To stop the reaction the 
following were added and incubated at 65°C for 10mm,
lOxSTE (TNE) 10/il
lOmM Na2EDTA 10/tl
20% SDS 2 5/xl
Tns-EDTA, pH 7 5 100^1
H20 60/il
Following extraction of DNA from the reaction mixture (Section 2 3 30 17 ), the vector 
DNA was purified on a 0 8% agarose gel and the vector DNA band was excised and 
purified (Section 2 3 30 16 )
2 3.30.19. Ligation of vector and insert DNA.
The enzyme T4 DNA ligase catalyses the formation of a phosphodiester bond between 
adjacent 3 ’-OH and 5 ’-phosphate termini in double stranded DNA This enzyme was 
used in the ligation o f cohesive ended fragments to vector DNA Ligation reactions 
were earned out overnight at 16°C and were set up as follows,
insert DNA in H20  15 4/d
vector DNA 1 0/il
lOx ligation buffer 2 0/d
0 5M DTT 0 6/d
T4 DNA ligase 1 0/d
The total reaction volume was 20/d
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2.3.30.20. Preparation of electrocompetent E  coh cells.
Electroporation was the method used to introduce DNA into competent E  coh TGI 
cells and these cells were prepared by inoculating one litre of LB with 1% (v/v) of an 
E  coh culture, which had been grown overnight at 37°C This culture was shaken 
vigorously at 37°C to an A600mn of 0 5-0 8 The flask was chilled on ice for 15-30min 
and the cells were centrifuged at 4000graax, 4°C for 15min The cell pellets were 
resuspended slowly, in a shaking ice water bath, m one litre of ice-cold distilled water 
Centrifugation and resuspension was repeated, as previously, in 0 5L of ice-cold 
distilled water Following resupension, the cells were centnfuged as before and 
resuspended in 20ml of 10% (v/v) ice-cold glycerol The cells were again centnfuged 
and resuspended finally in 2-3ml of 10% (v/v) glycerol The competent cells were 
dispensed into 100/d aliquots and stored at -80°C for up to 6 months
2.3.30.21. Electroporation of E . coh cells.
Electroporation of electrocompetent cells was earned out using a BioRad Gene pulser™, 
set at 25¿¿Faradays capacitance, 2 5kV and 200 Ohms to deliver a single exponentially 
decaying pulse The electrocompetent cells were thawed on ice and 1-5/xl of plasmid 
DNA was added The DNA must be free of excess protein and salts to prevent arcing 
The mixture of cells and DNA was transferred to an ice-cold 0 2mm electroporation 
cuvette This was then quickly dned and tapped sharply to dislodge bubbles which can 
also cause arcing Immediately following the pulse, 1ml of SOC medium (Section 
2 3 30 25 5 ), at room temperature, was added to the cuvette and the cell suspension 
was placed at 37°C in a microfuge tube Following 30min recovery time, dilutions of 
the cells were plated onto selective medium and incubated at 37°C for 24 hours
2.3.30.22. Small scale plasmid preparation from E  coh cells.
This method was desenbed by Bimboim and Doly (1979) 1 5ml of overnight broth 
culture was pelleted at 14,000rpm and resuspended by vortexing in 100/d of solution 
1 (Section 2 3 30 25 3 ) and was incubated at room temperature for 5min 200/d of 
solution 2 (Section 2 3 30 25 3 ) was added and the samples were left on ice for a 
further 5mm 150/d of solution 3 (Section 2 3 30 25 3 ) was added, the samples were 
placed on ice for a further 10mm and then centnfuged at 14,000 for 5min The 
supernatant was removed and 400/d of Kirby mix added After thorough mixing, the
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samples were spun at 14,000rpm and the aqueous layer removed and precipitated with 
0 8ml of ice-cold ethanol Following 10mm at room temperature, the plasmid DNA was 
pelleted by centrifugation at 14,000rpm The pellet was washed twice in 70% (v/v) 
ethanol, dessicated and resuspended in 50/ul of TE
2.3.30.23. Antibiotics used in molecular biology techniques.
All antibiotics were purchased from Sigma and stock solutions were stored at 4°C and - 
20°C Carbemcillin stock solution (lOmg/ml) was made up in 50% (v/v) ethanol, stored 
in the dark and used with E  coh at a concentration of 100^g/ml Chloramphenicol was 
dissolved m 98% (v/v) ethanol and used at a working concentration of 20/ag/ml with 
E  coh
2 3.30.24. Growth conditions and storage of strains
E  coll strains were routinely grown shaking in LB at 37°C Long term storage o f E  
coh strains was in 50% (v/v) glycerol at -20°C TGI cells were kept on M9 minimal 
medium to prevent the loss of the lacZ phenotype
2.3.30.25. Preparation of buffers and solutions used in molecular biology.
All buffers were dispensed and stored at -20°C, unless otherwise stated 
TE buffer (5Qx)
Tns-HCl 50mM
Na*-EDTA ImM
This solution was adjusted to pH 8 0 using conc HC1, sterilised by filtration (0 22/*m 
filter) or autoclaved and stored in aliquots at 4°C
3M Sodium acetate, pH 5 2
Sodium acetate 3H20  (408 lg) was dissolved in 800ml H20 ,  the pH was adjusted to 5 2 
with glacial acetic acid and the volume brought up to 1 litre This solution can also be 
filter sterilised or autoclaved and stored at 4°C
05M ED TA  (pH 8 0 )
Disodium ethylene diamine tetraacetate 2H20  (181 6g) was added to 800ml of H20  and 
stirred vigorously The pH was adjusted to 8 0 with NaOH
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lQx PCR buffer 
500mM KC1
lOOmMTns-HCl (pH 8 3)
15mM MgCl2 
1 % (w/v) gelatin
2.3.30.25.1. Solutions used in electrophoresis.
1 Ox Tns Borate EDTA electrophoresis buffer (TBE)
Tns-HCl 108 Og
Na2-EDTA 9 3g
bone acid 55 Og
H20  to 1 0L
This solution was adjusted to pH 8 0 with conc HC1
5Qx Tns Acetic Acid EDTA electrophoresis buffer (TAE)
Tns-HCl 242 Og
0 5M Na2-EDTA (pH 8 0) 100 0ml
H20  to 1 0L
This solution was adjusted to pH 8 0 with conc HC1
6x Bromophenol blue 
bromophenol blue 0 25% (w/v) 
sucrose in H20  40 00% (w/v)
This was stored at 4°C DNA samples were mixed in a 5 1 ratio with bromophenol blue 
pnor to loading on agarose gels
2.3.30.25.2. Preparation of Sucrose, Triton X, EDTA, Tns (STET) buffer for lysis 
of E  coh transformants.
8% (w/v) sucrose 
5% (w/v) Tnton X 100 
50mM Na2 EDTA 
50mM Tns-HCl (pH 8 0)
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2.3.30.25.3. Solutions for gene clean procedure.
Solution 1
0 5M glucose 1 0ml
0 1M Na2EDTA 1 0ml
1 0M Tns-HCl (pH8 0) 0 25ml
H20  7 75ml
Solution 2
IN NaOH 2 0ml
10% (w/v) SDS 1 0ml
H20  7 0ml
Solution 3
5M potassium acetate 30 0ml
glacial acetic acid 5 75ml
H20  1 425ml
pH 4 8ml
5M potassium acetate
To prepare this solution, 60ml of 5M potassium acetate, 11 5ml of glacial acetic acid 
and 28 5ml H20  were mixed This solution was 3M with respect to potassium and 5M 
with respect to acetate This solution was used in the preparation of solution 3
Phenol/Chloroform (Kirby mix)
100g of AnalaR grade phenol was dissolved in 100ml chloroform 4ml of îsoamyl- 
alcohol and 0 8g of 8-hydroxyquinoline was then added and the mixture was stored 
under lOOmM Tns-HCl, pH 7 5 m a dark bottle at 4°C
2.3.30.25.4. Solutions used in ligations.
IQx STE/TNE
lOmM Tns-HCl (pH 8 0)
1M NaCl
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lOmM Na2EDTA This was used in the calf intestinal alkaline phosphatase reaction
lOx Nick translation buffer/Klenow reaction buffer 
0 5M Tns-HCl (pH 7 2)
0 1M M gS04 
ImM dithiothreitol
500^g/ml BSA (fraction V, Sigma)
lOx Ligation buffer 
200mM Tns-HCl (pH 7 6) 
lOOmM MgCl*
1 OOmMdithiothreitol 
6mM ATP
This was used for cohesive ended ligations 
Dithiothreitol (1M DTT)
DTT (3 09g) was dissolved in 0 01M Sodium acetate (pH 5 2) It was filter stenlised, 
dispensed and stored at -20°C
ATP (0 1M)
ATP (60mg) was dissolved in 800¿¿1 of stenle H20  and the pH adjusted to 7 0 with 
0 1M NaOH The volume was adjusted to 1ml with H20 , dispensed and stored at -
20°C
2.3.30.25.5. SOC medium for electroporation of E  coh
Tryptone 2 0% (w/v)
Yeast extract 0 5% (w/v)
NaCl 10 OmM
KC1 2 5mM
MgCl2
M gS04
Glucose 20 OmM
10 OmM
10 OmM
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2.4. Techniques involved in the production, purification and characterisation of 
lodinated Bolton-Hunter reagent (IBHR), and of polyclonal and monoclonal antibo­
dies against IBHR.
The problems associated with direct lodination and radiolabelhng of proteins can be 
minimised using a second molecule to carry the radioiodine (Section 4 ) One such 
molecule used was developed in 1973 by Bolton and Hunter The molecule they used 
was 3-(4-hydroxyphenyl) propionic acid N-hyroxysuccinimide ester, now known as 
Bolton-Hunter reagent (BHR) (Bolton and Hunter, 1973)
In order to produce antibodies to the BHR molecule or to lodinated-BHR (IBHR), as 
is too small to elicit an immune response on its own, it must be conjugated to a carrier 
protein, BSA (Section 2 4 5 ) To produce antibodies to IBHR, it is important, 
however, to allow for a large enough spacer arm between the IBHR molecule and 
protein in the conjugate to prevent any interference between these molecules The iodide 
in the IBHR-protein conjugate is detected using an iodide assay based on the Sandell- 
Kolthoff reaction, (Sandell and Kolthoff, 1934) The reaction involves the oxidation of 
arsenic (III) by cerium (IV) which is catalysed by trace amounts of iodide Sandell and 
Kolthoff (1934) first reported that a minute quantity of iodide could be detected by 
measuring its catalytic effect on the slow cenum(IV) - arsemc(III) reaction
2 Ce4+ +  As3+ -* 2 Ce3+ +  As5+
A microassay was developed and later optimised (O’Kennedy et al , 1989, O’Kennedy 
and Keating, 1993) (Section 2 4 9 2 ) Two methods were used to determine the 
concentration of protein in a sample, (a) a miniaturized Bradford assay (Bradford, 1976) 
and (b) a miniaturized Bicinchonmic Acid (BCA), protein assay (Smith et al , 1985) 
(Section 2 4 9 3 ) The IBHR molecule was chosen to work with in this project as in 
the radiolabelled form, iodine has the highest specific activity available commercially 
Monoclonal and polyclonal antibodies against IBHR were produced, purified and 
characterised (Section 4 )
2.4.1. Preparation of IBHR.
A 0 1M solution of Bolton-Hunter reagent (BHR) and a 2M solution of iodine 
monochlonde (IC1) (toxic) were made up m ethyl acetate IC1 was added to BHR at a 
2 1 molar ratio and allowed to react overnight at 4°C The resultant mixture, a white 
precipitate, was recovered by centrifugation and the pellet was then washed in ice cold
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ethyl acetate After recentnfugation, the IBHR was dried under nitrogen and stored at - 
70°C The punty of the preparation was tested by thm-layer chromatography on 
fluorescent silica gel plates developed in ethyl acetate toluene (1 1 , v/v) and compared 
to two previous lodinations of the same BHR IBHR is very sensitive to moisture When 
thawing from -20°C it should not be opened until it has reached room temperature 
Before using the IBHR for standards or conjugation, 4mg of IBHR was dissolved in 
40/d N,N'-dimethylformamide (DMF), 960/xl benzene was then added to bring the total 
volume to 1ml The solution was aliquoted at lmg per vial and dned under nitrogen in 
a fume cupboard lmg of IBHR was redissolved in a minimum volume (0 2ml) of 
DMF, ultrapure H20  was added to bnng the concentration to lmg/ml and this was used 
directly for conjugation or as standards Further dilutions were made up m 0 01M PBS, 
pH 7 3
2.4.2. Preparation of IBHR standards.
lmg of IBHR was dissolved in 0 2ml DMF before being diluted to give a final 
concentration of ljd/ml with ultrapure H20  Standards were prepared m the range 0- 
ljil/ml and these were used in the iodide assay to quantify the IBHR concentration of 
the IBHR-proteins conjugate produced
2.4.3. Preparation of protein standards to determine the protem concentration of 
k the IBHR-protein conjugates produced
BSA, KLH, ovalbumin and IgG used in Bradford assays were made up in 0 01M PBS, 
pH 7 3, to a final concentration of lmg/ml Further dilutions of these standards were 
also made up in 0 01M PBS, pH 7 3
BSA, KLH ovalbumin and IgG standards used in the ELISA were made up to a 
concentration of 10/xg/ml using sodium carbonate buffer, pH 9 0 BSA, KLH 
ovalbumin and Rabbit IgG standards used for electrophoresis, absorbtion spectrum 
analysis and HPLC analysis were made up in 0 01M PBS, pH 7 3, buffer up to a final 
concentration of lmg/ml
2.4.4. Preparation of 0.1M borate buffer for use m the conjugation of IBHR to 
protem.
9 54g of disodium tetraborate was dissolved m 250ml dH20 ,  and 1 5g o f bone acid was
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Vdissolved in 250ml dH20  In order to bnng the bone acid solution to pH 8 5, 54ml of 
the disodium tetraborate solution was added
2.4.4.1. Preparation of 20x 0.01M PBS, pH 9.0
34 8g of potassium hydrogen phosphate was dissolved in 500ml dH20  27 6g sodium 
dihydrogen phosphate 2-hydrate was dissolved in 500ml dH20  10ml of the potassium 
hydrogen phosphate solution was added to 400ml of the sodium dihydrogen phosphate 
2-hydrate solution The pH was adjusted to 9 using concentrated sodium hydroxide 
9 5g Sodium chlonde was added to the solution to give 0 01M 20x PBS, pH 9 0
2.4.5 Coryugation of 1BHR to BSA, KLH, and ovalbumin.
4mg of IBHR was dissolved in DMF, washed in benzene and then dned under nitrogen 
The IBHR was again dissolved in 800/d DMF and used for protein conjugation 4ml 
of a lmg/ml solution of BSA (grade V), KLH (type VIII) or ovalbumin (grade V), 
(Sigma) in 0 1ml borate buffer, pH 8 5, (Section 2 4 4 ) was added to the IBHR 
solution with thorough mixing The reaction was allowed to proceed on ice for two 
hours, with mixing The solution was then centnfuged at 13,000g for 2 minutes to 
remove any precipitate formed The unconjugated IBHR was removed from the 
conjugated IBHR initially using chromatography on Ultrogel AcA44 (Section 2 4 6 ) 
and subsequently, with dialysis against a large volume of 0 01M PBS, pH 7 3, 
overnight at 4°C, with mixing
2.4 6 Gel nitration usmg Ultrogel AcA44.
A 16mm internal diameter x 360mm column of Ultrogel AcA44 column was prepared 
by resuspending 100ml of Ultrogel in 50ml of 0 01M PBS, pH 9 0 The Ultrogel has 
a linear fractionation range of approximately 10,000-130,000 daltons and an exclusion 
limit of approximately 200,000 daltons The gel suspension was mixed gently with a 
glass rod and connected to a vacuum pump for 30min to remove air bubbles The 
column was poured and then washed with 3 column volumes (cv) (lev =  80ml) of 
0 01M PBS, pH 9 0, at a flow rate of lml/min The conjugated sample (Section 2 4 5 ) 
was added and 80 one ml fractions were collected at a flow rate of lml/min The 
protein content of the fractions obtained was determined using the Bio-Rad micro- 
Bradford assay using a protein standard curve in the range 0-100/xg/ml protein, read at
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a wavelength of 595nm (Section 2 4 9 3 ) The IBHR incorporation was determined 
using the iodide microassay using IBHR standards in the range 0 1-1 0^g/ml (Section 
2 4 9 2 ) Before the column was stored at 4°C, 0 02% (w/v) sodium azide was added 
to the wash buffer ensunng that at least lev of this was run through the column
2.4.7. Preparation of dialysis tubing.
Gloves were worn at all times when handling dialysis tubing Dialysis tubing (Sigma) 
was prepared by boiling it in 500ml of ultrapure H20  m a glass beaker for 20min after 
addition of 50mg of ethylene diamine tetraacetic acid (EDTA)
2.4.8. Concentration of dialysed samples.
After dialysis the conjugated sample, still in the tubing, was immersed in a trough 
containing crystalline sucrose at 4°C The sucrose removed the water in the sample by 
reverse osmosis The osmosis was continued until the desired sample volume was 
reached In order to remove any sucrose that may have entered the sample, the 
concentrate was again dialysed against PBS at 4°C for 1 hour
2.4 9. Characterisation of the IBHR-protein corrugates produced.
The conjugates were characterised according to O ’Kennedy et al (1989)
2.4.9.1. Preparation of cenc ammonium sulphate and arsenious acid for the iodide 
assay.
Cenc ammonium sulphate (0 1M) was made up in 2 5M H2S 0 4 Dilutions of this stock 
solution were made up fresh daily in 10% (v/v) H2S 0 4 to a final concentration of 
0 028M cenc ammonium sulphate Arsenious acid (0 075M) (toxic) was prepared by 
placing 14 84g of arsenious tnoxide (toxic, potential carcinogen) in 700ml of distilled 
water containing 28ml of concentrated sulphunc acid The mixture was heated carefully 
to near boiling with constant stimng until most of the arsenic tnoxide had dissolved 
Some precipitation of arsenious oxide may occur The solution was then allowed to cool 
to room temperature before being filtered The resulting solution was made up to 1L 
with distilled water
2.4.9.2. Iodide microassay procedure.
The Bolton-Hunter reagent used in this project was labelled with non-radioactive iodine
iIi
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which was detected using the Sandell-Kolthoff reaction (Sandell and Kolthoff, 1934) 
These standards, in duplicate or triplicate, were added to the wells of NUNC1 
Immunosorb Maxisorb microtitre plates to a final volume o f 100¡il Samples for 
analysis, in duplicate, were added to remaining wells with a final volume of 100^1 
Arsenious acid (60^1) was added to each well using a multichannel pipette Cenc 
ammonium sulphate solution (25/il) was added to all wells except to column 1 The 
plate was mixed and blanked against column 1 Absorbance readings were taken at 
precisely timed 1 minute intervals Wells incubated with 0 01M PBS, pH 7 3, served 
as zero controls These wells will have the highest absorbance values as no iodide is 
present to catalyse the Sandell-Kolthoff reaction The absorbance of each of the 
standards and samples were read every minute for five minutes at 414nm on a Titertek 
Twin Reader Plus
2.4.9.3. Protein concentration determination.
The two methods used to determine the concentration of protein in a sample are 
discussed The reagents for both assay systems were obtained in kit form from Pierce 
Chemical Company (Table 2 1 )
(a) Bradford Coomassie protein reagent kit procedure.
A miniaturized version of the assay kit was developed in order to minimise the amount 
of sample required The assay had the the advantage of providing a rapid indication of 
the protein level This is based on the fact that Coomassie Brilliant Blue G-250 exists 
in two different colour forms, red and blue When the dye binds to the protein, the red 
form is converted to the blue form which can be detected by monitoring the absorbance 
at 595nm In order for the dye to bind, the molecule must possess a macromolecular 
form and an active aromatic functional group This makes the assay suitable for protein 
determination, but BHR also satisfies this criteria This means that BHR interferes with 
the assay This assay was used for protein determination as iodine interferes to a greater 
extent with the BCA assay Aliquots of 10/lx1 of diluted standard (e g 0 01-0 lmg BSA, 
KLH, mouse IgG/IgM, as appropriate) or unknown protein samples were pipetted into 
a 96 well plate (NUNC), to which 200/xl of Pierce Protein assay reagent was added
i
The plate was mixed and the absorbance read after 5mms at room temperature, at 
595nm, on a Titertek Twin Reader Plus
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(b) BCA protein assay reagent kit procedure.
In this assay Cu++ combines with protein under alkaline conditions to form Cu+, which 
reacts with BCA to give a coloured product Two separate reagents consisting of an 
alkaline bicarbonate buffer Reagent A and Reagent B, 4% (w/v) copper sulphate
r
solution are supplied with the kit The BCA protein assay working reagent was made 
up by mixing 49 parts o f Reagent A with 1 part of Reagent B, and was stable for one 
week at room temperature Two different miniaturized protocols were followed One 
used incubation at 37°C for 30 minutes for protein concentrations in the range of 0 02-
1 5 mg/ml The second method used incubation at 60°C for 30 minutes for protein 
concentrations in the range of 0 001 - 0 25 mg/ml 10¡i\ o f each standard or unknown 
protein sample and 200^1 of BCA working reagent was added to each well of a 96 well 
plate For control wells, 10^1 of diluent was used The plates were incubated at the 
selected temperature and time Absorbance readings were taken at 562nm on a TitertekR 
TwinPlus Reader All samples and standards were prepared m duplicate or triplicate 
The BCA gave more accurate protein readings than the Bradford Assay for compounds 
which did not contain iodine, as less interference was obtained from detergents and 
chelating agents However, the assay system required incubation at preset temperatures 
and results were not as quickly obtained when the Micro-Bradford assay was used
2 4.9.4. Investigation of the interference of IBHR with the Bradford assay.
Two sets o f BSA standards were prepared (Section 2 4 9 5 ) m the range 0-20/<il/ml m 
triplicate One of these sets was spiked with a 2/ig/ml concentration of IBHR The 
Bradford assay was continued as in Section 2 4 9 3 and the absorbances read at 
595nm
i
i
2.4.10. Production of monoclonal anti-IBHR antibodies.
An attempt was made to produce monoclonal antibodies to IBHR Five balb/c mice 
were immunised with the IBHR-BSA conjugate as outlined in section 2 3 6 The 
immunisation schedule was as follows each mouse was immunised with 50/ug IBHR- 
BSA on days 1, 14 and 28 These mice were tail bled on day 35 and the results
t
obtained are shown in Table 4 2 An in vitro immunisation was performed (Section 2 3) 
using 20jLig IBHR-BSA (Ifiglfjil) in 0 01M PBS, pH 7 3
Following in vitro immunisation, the spleen cells were electrofused with NSO cells Thei
|
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clones obtained were screened for anti-IBHR antibodies by ELISA (Section 2 3 16 3 ) 
against the following, IBH-BSA, IBH-KLH, IBH-Ovalbumm, BSA, KLH, Ovalbumin 
(Table 2 3 )  The results are presented and discussed in Section 4 The antibody1- 
producing hybndomas were expanded according to Section 2 3 14
2.4.11. Production of polyclonal anti-IBHR antibodies.
As the production of a monoclonal anti-IBHR antibody was unsuccessful, the polyclonal 
approach was undertaken
Serum was obtained from a four month old male New Zealand white rabbit 7 days prior 
to immunisation, to determine the background response of the rabbit to the antigen The 
results are shown in Table 4 3 This rabbit was considered suitable for use in the 
production of polyclonal antibodies against IBHR as the non-specific binding of the 
serum to IBHR was low This serum was used as a negative control in ELISAs dunng 
all stages o f the purification o f the anti-IBHR polyclonal antibody 
The rabbit was immunised subcutaneously with IBHR-BSA along the back The initial 
injection was of IBHR-BSA suspended in FCA (Section 2 3 6 1 ), all subsequent 
injections were intramuscular using FIA, as outlined in Section 2 3 6 The immunisation 
schedule is given in Table 2 11
The injections administered after day 80 (Table 2 1 1 ), used 0 4mg IBHR-BSA in a
i
total volume of 0 4ml Test bleeds were performed 11 days after the third and 
subsequent injections using the marginal ear vein o f the rabbit The sera obtained were 
assayed for anti-IBHR polyclonal antibodies (Table 4 4 )  The rabbit was immunised 
over an 8 month period, bled at intervals and the serum obtained (Section 2 4 1 1 )  
ELISAs were performed to obtain the specific antibody titre (Table 4 4 )
Over the entire immunisation schedule the recommended amount of antigen to use for 
a rabbit is between 0 5 - 4  Omg of protein (Mayer and Walker, 1987) For polyspecific 
antisera, 4 Omg of antigen is preferable Antibodies are produced against the carrier
i
protein and the hapten when a conjugate is used as an immunogen In the case of the 
IBHR-BSA conjugate to separate the anti-BSA from the anti-IBHR antibodies, two 
different separation methods were undertaken and compared The methods used in 
producing, purifying and characterising the anti-IBHR polyclonal antibody are outlined
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Table 2.11. Immunisation schedule of a rabbit immunised with IBHR-BSA in order
t
to produce anti-IBHR polyclonal antibodies.
Day IBHR-BSA (mg) injected
1 0 2
30 0 3
50 0 4
80 0 4
2.4.11.1. Isolation of rabbit serum.
Eleven days after each immunisation, when the anti-IBHR antibody titre was greater 
than 1 10,000, the rabbit was bled from the marginal ear vein, having first used a lamp 
to warm the ear thereby stimulating the blood flow Serum was obtained by allowing 
the blood from the rabbit to stand at room temperature for 20mm in order that the 
blood would coagulate These clots were then gently broken up using a pipette tip and 
centrifuged at 3000rpm for 20mins The resulting serum was aliquoted and stored at - 
20°C This serum was precipitated with ammonium sulphate and further punfied by
either protein A or by an IBHR-KLH-CNBr affinity chromatography column The
i
reactivity of the punfied samples was also tested by ELISA against IBHR-KLH, KLH, 
IBHR-ovalbumin, ovalbumin, IBHR-BSA and BSA (Tables 4 8 1 - 4 8 3 )
2.4.11.2. Preparation of saturated ammonium sulphate. ■
1M saturated ammonium sulphate (SAS) was prepared by adding 761 Og ammonium
sulphate to 1L o f ultra pure water (4 1M solution at room temperature) with constanti
stimng at room temperature The solution may be warmed to 35°C to aid dissolution
i
Once dissolved, the solution was left at room temperature overnight to allow 
precipitation of excess salt The solution was then poured into a separate container, and 
deemed to be saturated A 50% (w/v) solution of the SAS was prepared by making a 
1 1 dilution of the 100% (w/v) saturated solution with ultrapure H20  1
2,4.11.3. Ammonium sulphate precipitation of rabbit serum or ascitic fluid from 
mice.
This method was described by Hudson and Hay (1980) The rabbit serum (or ascitic 
fluid from mice) was cooled to 4°C and the pH was adjusted to 7 2 with conc HC1 oi 
5M NaOH as appropriate An equal volume of 100% (w/v) SAS was added drop wise 
to the serum at 4°C, while stimng This was stirred for one hour at 4°C before being 
centrifuged at 10,000rpm for 20mins at 4°C The supernatant was discarded and the 
pellet was resuspended m a volume equivalent to that of the original sample with ice 
cold 0 01M PBS, pH 7 3 An equal volume of ice cold 50% (w/v) SAS was added 
dropwise with stimng and again centrifuged as before This step was repeated using 
45 % (w/v) SAS, with the final pellet being resuspended in a volume of 0 01M PBS, pH 
7 3, corresponding to half the volume of the original sample The resulting antibody 
solution was dialysed against several changes of ultrapure water and finally 0 01M PBS, 
pH 7 3 Following dialysis, the antibody solution was removed from the tubing and 
recovered by centrifugation at l,000g for 5mins at 4°C, in order to remove any debris 
A small sample was removed to determine the protein concentration and to check the 
purity of the antibody 0 02% (w/v) sodium azide was added to the final supernatant 
which was dispensed and stored at -20°C
2.4.12. CNBr-sepharose affinity chromatography of SAS-treated serum.
(a) Preparation of CNBr-sepharose affinity chromatography buffers.
Preparation o f coupling buffer, 100ml of a 0 1M sodium bicarbonate (NaHC03) 
solution was adjusted to pH 8 3 using 0 5M NaCl
Preparation o f blocking buffer, 0 2M glycine was adjusted to a final pH of 8 3 using 
coupling buffer
Preparation o f  washing and regeneration buffers, 0 1M sodium acetate was brought to 
pH 4 5 using 0 5M NaOH 0 1M Tns was brought to pH 8 5 using 0 5M NaOH 
0 01M PBS, pH 7 3, was prepared by dissolving one Dulbecco’s A tablet in 100ml of 
distilled water ,
Preparation o f dissociation buffer, 0 1M glycine was adjusted to pH 2 5 using conc 
HC1 I
Preparation ofpH-correction buffer, 12 1 lg  of tnzma base (tris[hydroxymethyl]amino- 
methane) was suspended in a mimmium volume of distilled water before its pH was
i
115
i
*
i
adjusted to pH 10 5 using conc HC1 This solution was then made up to 100ml and 
allowed to dissolve properly, (as tnsma base is difficult to dissolve in water at neutral 
pH)
(b) Preparation of unmunosorbant for CNBr-sepharose affinity chromatography.
0 4g of CNBr-activated sepharose was suspended in 3ml of 0 001M HC1 before being 
transferred to a sintered glass funnel to be washed for 15mins with 80ml of HC1 2ml 
of coupling buffer was then added to the activated sepharose 600/xl of a 10mg/ml 
solution of anti-rabbit antibody was diluted m coupling buffer to a final volume of 
2 8ml The activated sepharose was then added to the antibody and allowed to bind for 
2 hours on a shaking water bath at room temperature The conjugate was then washed 
with 5 ml of coupling buffer in a sintered glass funnel before being blocked with 3 ml 
blocking buffer for one hour at room temperature The resulting gel was washed with 
three alternating cycles of pH, 5ml of 0 1M acetate buffer, pH 4 5 followed by 0 1M 
Tns buffer, pH 8 5, before being resuspended in PBS, pH 7 3 
A 1ml syringe barrel was used as the column support in which a small piece of glass 
wool was inserted in the base to prevent gel leakage The CNBr-activated sepharose 
was carefully poured into the synnge barrel until the immunosorbant level reached the 
lml mark A little 0 01M PBS, pH 7 3, was added on top of the column to prevent the 
gel from drying out The column was covered with several layers of Parafilm and 
stored at room temperature
(c) Use of Immunosorbant.
After storage, the Parafilm was removed and the column was washed with 10ml of 
0 01M PBS, pH 7 3, in order to remove any protein that leaked during storage 2ml 
fractions were collected and each of these were tested for the presence o f protein using 
the BCA reagent (Section 2 4 9 3 ) Half of the purified antibody sample from the SAS- 
treated serum (Section 2 4 113) was applied to the column with a very slow flow rate 
( >  1 ml/hr from this column) lml fractions were collected and again tested for proteiri 
After application of the sample, the column was washed with 0 01M PBS, pH 7 3, until 
no protein was detected in the fractions The flow rate was increased using a peristaltic 
pump to wash the column and dissociating buffer was then added After lml was 
collected, the column was again sealed and left for 15mins to allow the rabbit antibody
i
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to dissociate from the anti-rabbit antibody in the gel The column was again opened and 
lml fractions were collected Each of these fractions was at a very low pH (dissociating 
buffer had a pH of 2 5) and hence 125/xl of 1M Tns buffer, pH of 8 5 was added in 
order to prevent antibody denaturation The fractions were also tested for the presence 
of protein (see (d) below) Those fractions which contained protein were pooled The 
column was regenerated by washing the column with 5ml o f 0 1M Tns-HCl buffer, pH
8 5, followed by 5ml of sodium acetate buffer, pH 4 5, and finally 5ml of 0 01M PBS,ii
pH 7 3 The column was sealed with several layers of Parafilm and stored at 4°C for 
further use
(d) Testing Fractions for Protein.
A NUNC 96 well microtitre plate was used in this test 200^1 of Bradford reagent 
(Section 2 4 9 3 ) (diluted 1/3 with water) was added to each of the 96 wells lO t^l of 
the fraction to be tested was added to a well If a blue colour resulted after 5mins, 
protein was deemed to be present The absorbances were also read at 595nm
2.4.13. Preparation of protein A affinity chromatography separation buffers.
Preparation o f start buffer, 0 6057g of Tns was suspended in a minimum volume of 
distilled water before its pH was corrected to 8 6 using conc HC1 This was then 
adjusted to a volume of 100ml
Preparation o f  elution buffer, 21g of citric acid was dissolved in 1L o f dH20  Solid 
disodium hydrogen phosphate was added until a final pH of 4 5 was obtained This gave 
a 0 15M solution o f citrate buffer This was diluted 2 3 to obtain a 0 1M solution 
Preparation o f pH-correction buffer, 12 1 lg  of Tns was suspended in a minimum 
volume o f distilled water before its pH was adjusted to 9 0 using conc HC1 The 
volume was brought to 100ml with dH20  and the Tns was allowed to dissolve | 
Carbonate buffer, this buffer was prepared by making up lOOmls of stock 0 01 ill 
solution of sodium carbonate and 0 035M solution of sodium hydrogen carbonate in 
ultrapure H20  These solutions were mixed in a 1 1 ratio and the pH was adjusted to
9 6 using conc HC1 or 5M NaOH as appropnate ,
iI
I
2.4.13.1. Separation of SAS-treated serum by protein A affinity chromatography.
Prepacked protein A affinity chromatography columns from Pierce were used Each lml
column contains protein A covalently linked to agarose beads which has a binding 
capacity of approximately 20mg IgG This system has a high salt buffer system which 
allows a better than usual yield of IgGl to be obtained The top stopper of the protein 
A column was removed and storage buffer was poured off The bottom stopper was 
removed and the column was equilibrated by running 5cv of the Immunopure IgG 
binding buffer provided, through the column This buffer was prepared by adding 
19 88g sodium phosphate (dibasic) to 800ml ultrapure H20, the pH was adjusted to 8 0 
with 80% phosphoric acid and brought to 1 litre 2ml samples were collected and tested 
to ensure that protein was not leaking from the column (Section 2 4 9 3 ) Half of the 
sample from the ammonium sulphate cut was diluted in Immunopure IgG binding buffer 
and was applied to the column with a slow flow rate (6ml/hr) This was allowed to run 
completely into the column which stops flowing automatically when the buffer level 
reaches the top fnt The column was washed down with 15cv of the Immunopure IgG 
binding buffer 1ml fractions were collected and tested for protein by monitoring the 
absorbance at 280nm, where an absorbance of 1 0 =  0 8mg/ml, or the protein 
concentration can be measured using the BCA assay Those samples with protein were 
pooled and were dialysed against 0 01M PBS, pH 7 3, overnight The column was 
regenerated by washing with 4cv of 0 1M citric acid adjusted to pH 2 3 with 6 Normal 
(N) NaOH Before storage, the column was washed with a further 2cv o f ultrapure H20  
containing 0 02% (w/v) sodium azide The column was stored at 4°C in the upright 
position, and is stable for up to 1 year Each column may be regenerated up to 10 
times ,
i
2.4.14. Preparation of porcine gelatin.
The preparation of this solution has been described in Section 2 3 16 2 The solution 
was used as the blocking solution in the following anti-IBHR antibody ELISAs
2.4.15. ELISA for the determination of the titre of anti-IBHR rabbit serum.
ELISAs were earned out as detailed in Section 2 3 Details relevant to the ELISAs used 
to screen the anti-IBHR antibody are desenbed |
24 wells of a microtitre plate were coated with 10/ul/ml of IBHR-ovalbumin conjugate 
made up with carbonate buffer (Section 2 3 12 1 ) , while the other 72 wells were coated 
with ovalbumin, IBH-KLH and KLH (Table 2 3 )  This was accomplished by addition
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of 100/xl/well of each preparation to a section of the plate, this was then stored at 4°C 
overnight The plate was then washed four times with 0 01M PBS, pH 7 3, before 
being blocked with porcine gelatin, (1/zg/ml, in 0 01M PBS, pH 7 3) at 200/xl/well for 
2 hours at 37°C
The plate was then washed four times with PBS/Tween-20 (0 1 %, w/v) and once with 
0 01M PBS, pH 7 3 Suitably diluted rabbit serum samples and positive and negative 
controls (lOO t^l) were added to wells of the plate, as appropriate, and left to incubate 
for 2 hours at 37°C or at 4°C overnight The wells were washed four times with PBS/ 
Tween-20 (0 1%, w/v) and once with 0 01M PBS, pH 7 3, as before and a 1 7000 
dilution o f alkaline phosphatase-conjugated secondary antibody in TBS (l e goat-anti- 
rabbit IgG) (Table 2 4 )  was added (lOO/d/well) and allowed to incubate for an hour at 
37°C
The wells were washed again as before and then the substrate, (BCIP in amino-methyl- 
propanol buffer, Table 2 5 ), at lOO/ul/well, was added The reaction was allowed to 
proceed at 37°C in the dark until a suitable colour had developed, which took 
approximately 45mins The absorbance was read at 620nm
2.4.15.1. Competitive ELISA to determine the anti-IBHR antibody specificity
A competitive ELISA was performed using the SAS-precipitated, protein A and CNBr- 
sepharose affinity chromatography-punfied antibodies by coating the wells of a 96 well 
microtitre NUNC plate with 10/xg/ml of the antigen in carbonate buffer, pH 9 6, 
incubated overnight at 4°C The plate was washed four times with 0 01M PBS, pH 7 3, 
and then blocked with 250/a1 of blocking solution [1% (w/v) BSA m 0 01M PBS, pH 
9 6] When IBHR was used the blocking solution was 2% (v/v) gelatin (Section 
2 3 16 2 ) m 0 01M PBS, pH 9 6 The plate was incubated at 37°C for two hours or 
overnight at 4°C The plate was washed four times with PBS-Tween and once with 
0 01M PBS, pH 7 3 25^1 of the antigen, at 10/xl/ml, and 75¡i\ o f a serial dilution of 
the test antibody, in blocking solution, was added to the test wells and incubated at 
37°C for two hours The secondary antibody and substrate were added, as detailed in 
Section 2 3 16 3 , and the absorbance was read at 620nm
2.4.16. Stability study of the purified antibodies.
A stability study of the protein A and CNBr-sepharose affimty-chromatography punfied
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antibodies (10/xg/ml) diluted in 0 01M PBS, pH 7 3, was established at 4°C and 25°C 
An aliquot of antibody, stored at each temperature, was taken regularly and its stability 
determined by direct ELISA (Section 2 3 16 3 ) The stability was estimated as a 
percentage of a control antibody (aliquoted and stored at -20°C)
2.4.17. SDS-polyacrylamide gel electrophoresis (PAGE) of purified antibodies.
Monoclonal, polyclonal and bispecific antibodies and their fragments were subjected to 
sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) using 
modifications of the method of Laemmli (1970) Proteins were separated on a resolving 
gel containing 7 5% (w/v) acrylamide (neurotoxin), 0 33% (w/v) bis-acrylamide, 0 75M 
Tns, 0 2% (w/v) SDS, 0 1% (v/v) TEMED and 0 1% (w/v) ammonium persulphate, 
pH 8 8 A stacking gel containing 3 5% (w/v) acrylamide and 0 08% (w/v) fresh 
ammonium persulphate, pH 6 8, was used The electrode buffer contained 0 025M Tns, 
0 192M glycme, 0 1 % (w/v) SDS in distilled water, pH 6 8 Samples for electrophore­
sis were resuspended m a buffer containing 0 062M Tns, 2 0% (w/v) SDS, 10% (v/v) 
glycerol and 0 001% (w/v) bromophenol blue 05%  (v/v) 2-mercaptoethanol was 
included only when reducing conditions were required The samples were prepared at 
a concentration of 0 1 mg/ml in the loading buffer and boiled for 2 minutes before being 
applied to the gel (10-20/d volumes were used) Electrophoresis was earned out at a 
constant current o f 40mA for about 30 minutes at 4°C using an LKB 2050 Midget 
Electrophoresis Unit Following electrophoresis, the gels were fixed by immersion in 
a methanol distilled water (1 2 ) solution containing 114%  (w/v) tnchloroacetic acid and 
3 4% (w/v) sulphosalicylic acid for one hour They were then stained with 0 25% (w/v) 
Coomassie Bnlliant blue R-250 in a 5 1 1 solution of methanol, acetic acid and distilled 
water for one hour Destaining was earned out overnight in a solution of ethanol, acetic 
acid and distilled water (1 3  6)
When premade Atto gradient gels were used, they were run at a constant current of 
75mAmps until the marker dye reached the bottom of the gel (approximately 2 h rs)
2.4.17.1. Preparation of electrophoresis reagents.
The acrylamide stock solution was a 30% (w/v) solution of acrylamide added to a 0 8% 
(w/v) solution of N,N-methylenebisacrylamide and then made up to 100ml with 
ultrapure H20
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The resolving gel buffer was made up by dissolving 9 085g of Tns in ultrapure H20  
and, usmg conc HC1, was brought to a pH of 8 8 The volume was then made up to 
100ml with ultrapure H20  to give a fined concentration of 0 75M The stacking gel 
buffer was made up by dissolving 3 0285g of Tns in conc HC1 until a final pH o f 6 8 
was reached The volume was then made up to 100ml with ultrapure H20  to give a final 
concentration of 0 25M
Ammonium persulphate had to be freshly prepared when needed This was done by 
making up 10ml o f a 10% (w/v) solution of ammomum persulphate in ultrapure H20  
lg  of sodium dodecyl sulphate (SDS) was dissolved in 10ml of ultrapure H20  to give 
a 10% (w/v) SDS solution
The sample buffer was prepared by dissolving 2g of SDS, 0 969g of Tns and 50mg of 
bromophenol blue in 10ml of glycerol, adding 5ml of /3-mercaptoethanol and making 
up to 100ml with ultrapure H20
The destain solution was made up by mixing together acetic acid, methanol and water 
with a ratio of 1 4 5 This was done by adding 100ml of acetic acid, 400ml of methanol 
and 500ml of ultrapure water Care must be taken when handling these reagents 
The staining solution consisted of lg  of Coomassie Bnlliant Blue R-250 dissolved in 
200ml of destain solution
The running buffer was prepared by dissolving 0 303g of Tns in 500ml ultra pure water 
and 0 144g of glycine in 500ml of ultrapure water The two solutions were mixed and 
the pH adjusted to 8 3 using conc HC1 SDS was then added to a final concentration 
of 0 1 % (w/v)
Table 2.12. Composition of resolving and stacking electrophoresis gels.
Gel Constituents Resolving Gel Stacking Gel
Acrylamide Stock 14 0ml 2 5ml
Tns-HCl 8 4ml (pH 8 8) 1 2ml (pH 6 8)
Ultra Pure Water 18 8ml 7 5ml
Ammonium Persulphate 200^1 80/xl
SDS 240/il 1(%1
TEMED 40/il 100/tl
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2 4,17.2. Electrophoresis of the purified polyclonal antibodies.
(a) Pouring the Gels.
There were two types of gels used in the separation of the bands, a resolving gel and 
a stacking gel The resolving gel is the one that actually separates the different bands 
from each other The stacking gel is used to allow the sample to be applied 
The composition of these gels are outlined in Table 2 12 The TEMED (N ,N ,N 'N '- 
tetramethylethylenediamme) acts as a catalyst for the polymerisation reaction and thus 
gels the solution It is for this reason that the TEMED was the last component to be 
added, just before the gels were poured The glass plates used to hold the gel were 
washed with H20  and acetone was used to wipe them down prior to pounng to remove 
any residual contaminants A small amount of Vaseline was smeared over the edges of 
the plates to about 0 5cm inside them This was to allow a water tight seal to form 
between the plates and the spacer The spacer was also lightly smeared with vaseline 
for the same reason
The spacer was carefully placed between the two plates Care was taken not to allow 
any Vaseline to enter the gel area The apparatus was then screwed tightly in place The 
area on which the plates stand was also lightly smeared with Vaseline before they were 
placed on it The apparatus was again screwed tightly down until a seal formed In 
order to test the seals, the space between the plates was filled with water If no water 
leaked, the seals were deemed to be water tight
The resolving gel was poured first The TEMED was added to the rest of the 
constituents and the solution was carefully poured into the inter-plate space until it 
reached a level just before the end of the comb space A thin layer of water was added 
on top of this to aid in the polymerisation reaction and to form an even uniform line at 
the top of the gel The resolving gel was allowed to set at room temperature for 
approximately 30min before the stacking gel was poured
The stacking gel was poured in the same manner as the resolving gel The spacer comb 
was then inserted This allowed the formation of wells at the top of the gel Care must 
be taken to ensure no air bubbles were trapped The stacking gel was allowed to set for 
approximately 15min at room temperature
(b) Preparation and apphcation of the samples.
200/,il of sample buffer was added to 200/xl of each of the samples to be run on the gel
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They were then placed in boiling water for lmin to allow the proteins to denature 
After boiling, 40/^1 of each sample was carefully applied into each separate well in the 
gel using a Hamilton Synnge
(c) Running the gel.
The gel was removed from the stand and placed in the electrophoresis apparatus and 
screwed in This apparatus was an LKB Bromma 2050 Midget electrophoresis unit with 
a 2197 power supply The running buffer was carefully added on top of the gel, 
ensuring that the samples were not disturbed, until it had gone over the level of the 
conducting wire The system was run at 30mA per gel until the bromophenol blue in 
the sample buffer reached the end of the gel, which took approximately 2 hours 
PAGELR precast polyacrylamide gels for electrophoresis were also used These were 
gradient gels with gel concentrations from 5% (w/v) to 20% (w/v) and were supplied 
by ATTO Corporation (Section 2 1 ) These gels were run using the ATTO model AE- 
6100 mini gel apparatus using an ATTO Crosspower 3500 power supply at 20mA per 
gel
(d) Staining and destaming the gel.
After electrophoresis, the gel was carefully removed from the plates Wet latex gloves 
were used by the operator during this procedure Wetting the gloves prevents the gel 
from adhering to them Care must be taken not to disrupt, break or tear the gel The 
gel was then completely immersed in the stain solution for 15-20min The staining 
solution was completely poured off and destaming solution added as before The destain 
was changed when it had become very blue The gel could be left with tin foil covering 
it for 3-4 days until it was photographed
2.4.17.3. Molecular weight markers used m electrophoresis
The prestained molecular weight markers (Sigma) used in SDS electrophoresis are 
detailed m Table 2 13
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Table 2,13. Molecular weight markers used m SDS electrophoresis- The apparent 
molecular weight is the weight of the molecule when it is conjugated to the dye
Molecular weight 
marker
Native molecular 
weight
Apparent molecular 
weight
jff-galactosidase 116,000 125,000
Fructose-6-phosphokin-
ase
84,000 86,000
Pyruvate kinase 58,000 65,000
<
Ovalbumin 45,000 48,000
Lactic dehydrogenase 36,500 38,000
Tnose phosphate 
isomerase
26,600 33,500
2.4.18. Examination of the absorption spectrum of purified antibodies and FITC- 
labelling of IBHR-protein conjugates.
A Shimadzu UV-160A UV-Visible recording spectrophotometer was used for this 
procedure The absorbance spectrum was monitored over the range 200-800nm for 
purified antibodies and over the range 200-560nm for FITC labelled IBHR-protein 
conjugates The appropriate buffers were used as blanks, i e , citrate buffer for the 
Protein A affinity chromatography samples, glycine for the CNBr-sepharose affinity 
sample and 0 01M PBS, pH 7 3, for the BSA, KLH, ovalbumin proteins and their 
conjugates, and for IgG and IgM standards and samples
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r2.5. Techniques used in the production and characterisation of heteroconjugate 
antibodies.
2.5.1. Preparation of heteroconj'ugate antibodies.
The preparation of heteroconjugate antibodies (Section 5 1 )  involves the linking of two 
complete antibodies via a heterobifunctional cross-linker such as N-succimmidyl-3-(2- 
pyndyldithio) propionate (SPDP) This is a very quick method and the procedure used 
was that o f Bush and Winkler, (1989)
Each of the antibodies used was dissolved in 0 01M PBS, pH 7 3, at a final concentra­
tion of 2 Omg/ml 9xlO"5mM of SPDP, a thiolatmg agent, in ethanol was added for 
every lmg of antibody The final ethanol concentration should be less than 10% (v/v) 
The addition of 80/d of a 2 25mM SPDP solution, with constant stirring, to 1ml of 
antibody solution (2mg/ml) satisfied this cntenon After 30mins at room temperature, 
each of the antibody solutions was desalted on a Sephadex G-25 column (32cm x 
3 2cm) to remove the excess reagent and products of low molecular The column was 
equilibrated with 0 1M sodium phosphate, 5mM EDTA, 0 15M NaCl, pH 6 0 In each 
case the fractions containing the antibody, as determined by BCA (Section 2 4 9 3 ), 
were pooled One of the parent antibodies was then reduced with 100/d of 1 5mM 
dithiothreitol (DTT, toxic) dissolved in the 0 1M sodium phosphate, 5mM EDTA, 
0 15M NaCl, pH 6 0 for 15min at room temperature This reduced sample was then 
desalted using the Sephadex G-25 column (32cm x 3 2cm) equilabrated, as before, to 
remove excess reducing agent and any 2-thiopyndone formed The heterodimers were 
produced by mixing the reduced parent antibody (following DTT treatment) with the 
non-reduced SPDP-treated parent antibody and incubating them together at 37°C for 1 
hour
Antibody 2mg/ml in 0 01M PBS, pH 7 3 
;
9 x  105mM SPDP in ethanol was added per lmg of antibody
4
Left for 30mins at room temperature 
I
Each antibody solution was desalted in a Sephadex G-25 column (32cm x 3 2cm)
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One of the antibodies was reduced with 100/xl of 1 5mM DTT 
for 15mins at room temperature 
I
This antibody was desalted using a Sephadex G-25 column (32cm x 3 2cm), as before
I
The antibody treated with DTT was mixed with the SPDP-treated parent antibody
and incubated at 37°C for 1 hour
2,5.2. Characterisation of the bispecific heterocoiyugate antibodies produced.
ELISAs were performed to assess the activity of the parent antibodies and the hetero­
conjugate as outlined in Section 2 3 16 3 The ELISAs chosen depended on the species 
of the antibodies (mouse or rabbit) and their target antigen These heteroconjugates 
were also examined by HPLC, FACS, SDS-PAGE and immunofluorescence The 
methods are given in Section 2 3 and the results are given m Section 5 1
2.6. Techniques utilised in the production and characterisation of catalytic 
antibodies.
In order to detect catalysis of the monoclonal antibodies produced dunng this project, 
it was first necessary to repeat the procedure outlined in Gallacher et al (1991) for the 
determination of the kinetics of the hydrolysis of the carbonate ester (Section 6 ) In 
order to determine the kinetics, the crude normal sheep serum and the serum from the 
immunised sheep 271 were isolated by sodium sulphate precipation and chromatography 
on Protein G-Sepharose (Gallacher et a l , 1991)
2.6 1. Purification of IgG from sheep 271 and from non-immumsed sheep.
This procedure was from Gallacher et al (1991) 180mg of anhydrous sodium sulphate 
(N aS04) was added to 1ml of serum, with vortex-mixing, (l) from sheep 271 and (11) 
to provide a negative control from a sheep that had not been immunised, i e normal 
sheep serum In each case, the resulting suspension was gently mixed for 30min and 
was then centrifuged at 3000g for 10mm at 25°C The supernatant was removed The 
precipitated IgG was then washed twice using 2ml of 18%, w/v, sodium sulphate The 
final pellet was re-dissolved in 2ml of 50mM sodium phosphate buffer, pH 7 5 The
I
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resulting solution (2ml) was subjected to chromatography on a Protein G-Sepharose 4 
Fast Flow column (5ml) (Section 2 6 3 ) and the absorbance (280nm) was monitored 
The adsorbed IgG was eluted with 0 1M glycine/HCl buffer, pH 2 7, and 2ml fractions 
of the eluate were collected in tubes containing 1M N aH C03 The fractions containing 
IgG were pooled and the buffer was exchanged with 50mM sodium phosphate buffer, 
pH 8 0, by chromatography on a Sephadex G-25 column (32cm x 3 2cm) (Section 
2 6 2 )
2.6.2. Preparation of Sephadex G-25 column
Sephadex G-25 medium was swollen in ultrapure H20  overnight at 4°C, where lg  of 
dry weight powder gives 4-6ml of swollen gel The size of the column prepared was 
32cm x 3 2cm column It was equilibrated with 50mM sodium phosphate buffer, pH 
8 0
2.6.3. Purification of antibodies usmg Protein G.
Separating IgG from sodium sulphate punfied sheep serum was earned out simply and 
effectively in a single step using Fast Flow protein G Sepharose 4 This is a valuable 
tool m the separation of monoclonal antibodies from ascitic fluid because of its binding 
charactenstics Protein G from Pharmacia LKB is a recombinant Streptococcal Fc 
receptor from which the albumin-binding region of the native molecule has been deleted 
genetically Compared with Protein A affinity chromatography, Protein G binds more 
strongly to polyclonal IgG from, for example, cow, sheep or horse Protein G binds to 
the Fc region of IgG from many species without affecting their antigen-binding sites 
Fast Flow Protein G Sepharose 4 was supplied preswollen in 20% (v/v) ethanol To 
pack the gel, the ethanol solution was first removed by washing with ultrapure H20  (pH 
7) on a sintered glass filter While the gel was still on the filter, it was resuspended in 
starting buffer, 20mM phosphate buffer, pH 7, and transferred to the column The 
column was packed and equilibrated with two cv (column bed volumes) of starting 
buffer and the column was then ready for use
The samples were brought to pH 7 0 to be the same pH as the starting buffer 
The IgG was eluted using 0 1M glycine-HCl buffer, pH 2 7, since the binding between 
the immobilised protein G and the IgG is strong In order to preserve the activity of the 
acid-labile IgG, a few drops of 1M Tns-HCl, pH 9 0, were added to those tubes which
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would contain the fractions containing IgG, so that the final pH of the fraction would 
be approximately neutral.
After elution, the column was re-equilibrated with starting buffer at 4°C, if it was to be 
used again in a short period. For longer periods of storage, the gel was stored at 4°C 
in 20% (v/v) ethanol to prevent microbial contamination.
2.6.4. Kinetics of the hydrolysis of the carbonate ester.
The release o f 4-nitrophenolate from the carbonate ester was monitored in 50mM 
sodium phosphate buffer, pH 8.0, containing 0.67% (v/v) acetonitrile at 25°C by 
recording the increase in the absorbance at 400nm (A ^ ) with the use of a Shimadzu 
UV-160A UV-Visible recording spectrophotometer and quantified by using e400 =  
l ^ x l O ^ c m ' 1. Stock solutions of the substrate were prepared in acetonitrile. The 
concentration of the stock solutions was adjusted in order that 20/zl of this solution in 
a final reaction volume of 3ml gave a final concentration in the range 0.2-16/xM. In 
some cases reaction mixtures also contained 0.2/iM IgG prepared from sheep 271 or 
0.2jnM IgG prepared from the non-immunised sheep, hybridoma serum or from mouse 
ascitic fluid, controls or sample. The concentration of IgG in the eluate from the 
Sephadex G-25 (32cm x 3.2cm) column was determined using e28o =  2 .0x l05M 1cm'1 and 
was usually 3/jlM.
Initial rates (i;) were determined from slopes of linear progression curves (Section 6.). 
Those for the reactions carried out in the absence of IgG, carboxylesterase, DMEMS0, 
control ascitic fluid, whole sera or in the presence of IgG prepared from non-immunised 
sheep increased linearily with increase in substrate concentration [S] and were closely 
similar at a given [S]. The initial rates obtained in the presence of IgG from non- 
immunised sheep were subtracted from those obtained at the same values o f [S] in the 
presence of the IgG prepared from sheep number 271 to provide the rates of the 
polyclonal catalytic antibody-catalysed reaction. Other parameters such as Vm&x and Km 
can be calculated (Gallacher et al., 1991). The catalytic activities of the monoclonal 
antibodies produced were also determined (Section 6.).
2.6.5. Immunisation schedule for the production of monoclonal catalytic antibodies.
Seven days prior to immunisation, blood was obtained from six balb/c mice by tail 
bleeding (Section 2.3.8.). This was used for negative controls. An amide conjugate
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between the carboxy group of the 4-nitrophenyl 4 ’-carboxy-methylphenyl phosphate and 
an amino group of KLH was synthesised (Gallacher et al., 1991). The phosphate 
immunogen (Phos-KLH) (XI) used was produced and supplied by Dr. Gerard Gallacher 
(Table 2.3). 6 male balb/c mice were immunised with Phos-KLH with the aim of 
producing catalytic monoclonal antibodies (Table 2.14.). The mice were tail bled 
(Section 2.3.8.) and their sera tested by ELISA on Phos-BSA and BSA-coated plates. 
The results obtained are shown in Table 6.1.
Table 2.14. Immunisation schedule of six balb/c mice immunised with the 
phosphate immunogen (Phos-KLH) (XI) (Gallacher et al., 1991).
Day
Concentration of 
Phos-KLH (/xg/inl) injected
1 100
19 50
32 100
On day 40, the mice were tail bled (Section 2.3.8.) and their sera were tested by 
ELISA on Phos-BSA and BSA coated plates. The results obtained are shown in Table 
6.1.
In order to screen the sera obtained, the NUNC Immunosorb Maxisorb microtitre plates 
used were coated at a range of Phos-BSA and BSA concentrations (10, 15, 20 and 
25jitg/ml) to determine the optimal coating concentration. lO/ng/ml gave the best result, 
with the least background and was the coating concentration used.
2.6.6. In vitro immunisation of isolated murine splenocytes with Phos-KLH.
In order to produce mouse anti-Phos monoclonal antibodies, an in vitro immunisation 
was performed (Section 2.3.11.5.) using mouse spleen cells which were in vitro 
immunised with Phos-KLH. The immunised spleen cells were fused with SP2/0 cells 
using the PEG method (Fusion 1) (Section 2.3.13.1.).
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1 lxlO8 spleen cells were harvested and these were washed with red cell lysis buffer 
(Section 2 3 1 1 4 )  and resuspended in 8ml DMEMS0 2ml (i e 3 lxlO7 cells) of this 
solution was used in the immunisation as follows,
5 ml DMEMSq 
5 ml sTCM 
100jtl 2-Mercaptoethanol 
50(xl Gentamycin (5/d/ml)
20(j\ Phos-KLH (l/xg//il)
This solution was dispensed at 5x10* cells per well of a 6 well stenie tissue culture 
plate and was incubated for 3 days in 5 % C 0 2 at 37°C The success of this in vitro 
immunisation was assessed using the ELISA-spot assay (Section 2 3 12 2) This assay 
showed that 131 hybndoma cells producing the desired antibody were obtained 
The spleen cells were then resuspended, pooled and counted (Section 2 3 3 ) Using the 
PEG method (Section 2 3 13 1), ratios of spleen myeloma cells between 2 1 and 10 1 
were successful The limiting factor was generally the number of myeloma cells The 
cells from each of these three fusions were plated onto 5 plates which were monitored 
for growth of clones after 10 days
The hybndomas were screened by ELISA against Phos-BSA, BSA, Phos-KLH and 
KLH (Section 2 3 16 3) The plates were washed with PBS-Tween 20 and PBS after 
each step The plates were blocked with 0 25% (w/v) porcine gelatin in 0 01M PBS, 
pH 7 3 (Section 2 4 14 ) 100/d of neat supernatant taken from a 24 well tissue culture 
plate and controls were added in duplicate to wells of the microtitre plate 100/^1/well 
o f a 1 4000 dilution in PBS of goat anti-mouse IgG Fab’ specific alkaline phosphatase 
conjugated antibody (Table 2 4 )  was added and incubated for 1 hour at 37°C The Fab’ 
specific goat anti-mouse secondary antibody was used in an effort to optimise the 
number of IgG-secreting hybndomas obtained A lmg/ml solution of BCIP in amino- 
methyl-propanol buffer (Section 2 3 16 2 ) was made up and 100^1/well added to the 
microtitre plate The plate was incubated at 37°C and read at 620nm after 30mins The 
antibody-producing hybndomas were expanded according to Section 2 3 14 and the 
results obtained using these antibodies are outlined in Section 6
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1SECTION 3 PRODUCTION AND CHARACTERISATION OF ANTI-G-CCM 
AND ANTI-GFAP MONOCLONAL ANTIBODIES
3 Outline
The mam purpose of the research described in this thesis was to develop a monoclonal 
antibody to a GFAP-like protein on a human anaplastic astrocytoma cell line, G-CCM  
(anti-G-CCM ) and a monoclonal antibody to commercially available glial fibrillary 
acidic protein (GFAP), known as anti-GFAP These monoclonal antibodies were 
produced, purified and fully characterised by ELISA, HPLC, isotypmg, SDS-PAGE, dot 
blot, western immunoblotting, BIAcore, immunocytochemistry, immunofluorescence and 
FACS
3 1  Introduction
Glial fibrillary acidic protein, a constituent protein of intermediate filaments of glial cells 
of the astrocyte lineage, occurs widely among vertebrates (Onteniente et a l , 1983) and 
invertebrates (Cardone and Roots, 1990) and is also generally present on primary glial 
brain tumours In general, intermediate filament proteins in the central nervous system 
(CNS) have been conserved through evolution Intermediate filaments are 8-10nm fibers 
that form part of the cytoskeleton of virtually all types of eucaryotes On the basis of 
their tissue restrictive distribution, intermediate filament proteins have been divided into 
five classes desmin, vimentin, GFAP, neurofilament proteins and keratins (Cardone and 
Roots, 1990) All intermediate filament proteins have the same structural organisation 
with a central a-helical rod domain flanked by amino and carboxy termini of variable 
sizes
Within one cell, chemical components of two intermediate filaments can exist, either as 
individual filaments, or as co-polymers in the same filament In astrocytes, filament 
subunits may vary in terms of ratios of component proteins and associated accessory 
proteins depending on the stage of astrocyte development In immature astrocytes, the 
dominant filament is vimentin, but with astrocyte maturation vimentin is replaced by 
GFAP
Brain tumours are classified into designated grades (I-IV), depending on the degree of 
malignant dedifferentiation present Designation of the higher grade malignancy is called 
anaplastic The term ',anaplasla', describes cellular pleomorphism, increased cellulanty, 
increased amount of mitotic activity, dedifferentiation, abnormal stromal reactions, 
especially vascular proliferation, and, finally necrosis formation with or without pseudo- 
palisading of nuclei or presence of mctastases
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The G-CCM  and G-UVW cell lines used in this study are both anaplastic astrocytomas 
of adult human origin G-CCM had been shown to be entirely GFAP-positive in that 
it is expressed throughout the cell cycle during all subcultunng stages (Frame et a l , 
1984) G -IJK ^ had only a minor component of GFAP-positive cells (Frame et a l , 
1984) In this latter study, it was shown that cell lines derived from histologically 
similar anaplastic astrocytomas showed considerable heterogemty of phenotypic 
expression This reflects the heterogenous nature of ceils m malignant astrocytomas with 
the inevitable selection of cells most suited to growth in culture The cell lines used in 
the study of Frame et al (1984) exhibited a range of morphologies and states of 
biochemical differentiation from highly differentiated, in the case of G-CCM  to 
undifferentiated, in the case of G-ATA The astrocyte marker protein, GFAP, was 
present in cultures derived from 12-16 weeks post-conception foetal brain and in the 
human glioma, G-CCM  and the rat glioma, C6 They demonstrated that highly 
differentiated astroglial cells are able to grow and divide in culture They showed that 
GFAP was consistently visualised in only two of the glioma lines G-CCM  was entirely 
GFAP-positive while C6 was 50-60% positive under standard culture conditions in 
sub-confluent cultures Of the remaining glioma lines studied, G -IJK ^ had only a minor 
component of GFAP-positive cells Cell lines derived from normal adult brain m this 
study were entirely GFAP negative With G-CCM, there was no visually detected 
increase in the number of GFAP-positive cells with increasing cell density 
The chemistry, neurobiology, molecular biology and immunology of GFAP have been 
reviewed by Eng and Shiurba, (1988) Extensive use of GFAP antibodies in neuro- 
biology has established GFAP as a prototype brain antigen m CNS immunochemistry 
and as a standard marker for neuroscience research (Eng and Shiurba, 1988)
3 2 Rational for producing monoclonal antibodies against GFAP and ’GFAP-like’ 
antigens
The production of monoclonal antibodies against antigenic structures makes it possible 
to tackle problems of direct clinical relevance in a well-defined syngemc system 
(Prosser et a l , 1991) In particular, it makes it feasible to investigate (a) the binding 
capability of conjugated monoclonal antibodies to glioma cells in vivo, (b) the fate of 
labelled monoclonal antibodies in vivo as they overcome the blood-brain barrier, and
(c) the applicability of drug-antibody complexes aimed at destroying glioma cells in
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vivo without seriously damaging the host (Stavrou et a l , 1983)
Monoclonal anti-GFAP antibodies have proven to be a valuable tool for use in 
immunocytochemical localisation of GFAP in normal CNS tissue and certain tumours 
and metastases of glial antigen as well as for immunofluorescent labelling of cultured 
mammalian cells Cell culture has become an established technique in oncology 
Although cell lines are reasonably stable, it is accepted that cell cultures change during 
long-term culture and this is especially true for gliomas Westphal et al (1990) stated 
that GFAP expression did not disadvantage the successful culturing of cells but that 
GFAP expression was an indicator that long-term survival of a cell line would be poor 
m most cases However, they had one cell line which started with 1% of GFAP positive 
cells and later developed into a 99% positive cell line
The research in this thesis is based m part on work done by Elizabeth Moran In her 
Ph D thesis, monoclonal antibodies against G-CCM  cells were produced and 
characterised One hybndoma, B110H appeared to be particularly interesting (Moran, 
1989) as it reacted with a 'GFAP-like' antigen which appeared to be present on the 
surface of glioma cells It was decided to attempt to produce additional anti-G-CCM  
and anti-GFAP monoclonal antibodies to further study this phenomenon The following 
sections report on the production, purification and characterisation of monoclonal 
antibodies against G-CCM  cells and against GFAP
3 3. Immunisation o f mice with G -C C M  cells
The immunisation protocol is detailed m Section 2 3 6 3 Care was taken when preparing 
these cells for immunisation to use low concentrations of trypsin (Section 2 3 2 ) , and 
for a minimum time to reduce damage to surface antigens Sera obtained from five mice 
immunised with G-CCM  were tested by ELISA on G -CC M - and GFAP-coated plates 
The results obtained are shown in Table 3 1
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Table 3 1 Testing of sera (1 100 dilution in 0 01M PBS, pH 7 3) from five mice 
immunised with G-CCM cells by ELISA against G-CCM- and GFAP-coated 
plates The absorbance was read at 620nm (A620) The results for the positive 
control (commercial anti-GFAP, 1 400 dilution in 0.01M PBS, pH 7 3) and the 
negative controls (0 01M PBS, pH 7 3), normal mouse serum (1 100 dilution in 
0 01M PBS, pH 7 3) and NSO supernatant are also given The data represents the 
mean values of triplicate determinations (n=3) and the SD are in brackets
G-CCM immunised 
mouse number
G-CCM-coated plates GFAP-coated plates
1 0 395 (0 005) 0 294 (0 004)
2 0 401 (0 008) 0 551 (0 001)
3 0 656 (0 001) 0 561 (0 002)
4 0 469 (0 010) 0 534 (0 009)
5 0 517 (0 000) 0 510 (0 004)
Commercial anti-GFAP 
(1 400 dilution)
0 062 (0 01) 0 153 (0 014)
PBS (0 01M, pH 7 3) 0032 (0 032) 0 030 (0 022)
Normal mouse serum 
(1 100 dilution)
0 034 (0 012) 0 029 (0 018)
NSO supernatant 0 029 (0 021) 0 033 (0 028)
3 4 Production of an anti-G-CCM monoclonal antibody
Mouse 3 was sacrificed, and a splenectomy and an electrofusion were performed 
(Section 2 3 7 )  The spleens from mice 4 and 5 were fused to NSO myeloma cells using 
PEG (Section 2 3 13 1 ) A scheme of the results of this procedure is outlined below,
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i15 plates made, 129 wells contained clones
1
115 wells were expanded into 24 well plates, all screened by ELISA using anti-mouse 
IgG as antigen
1
48 clones gave positive ELISA values against anti-mouse IgG (> 0 150), these were 
expanded and screened against G-CCM
i
21 clones were found to react positivly with G-CCM, these were expanded to 24-well 
plates, and screened against GFAP
i
1 clone became negative, 4 died out and the 9 hybridomas which reacted most strongly 
were 1BD5, 1BD11, 2AG5, 2BC11, 2BF11, 2BF12, 2DG7, 2ED10 and 3BH2
I
These were screened again against G-CCM and GFAP by ELISA and following this 
screening, five anti-G-CCM  clones were considered for further characterisation, 
1BD11, 2AG5, 2DG7, 2ED10 and 3BH2 These were screened for mycoplasma 
contamination (Section 2 3 5 )  and were negative
i
These five hybridomas were subcloned twice by limiting dilution (Section 2 3 15), 
screened for anti-G-CCM  and anti-GFAP activity by ELISA (Section 2 3 18 ) and 
isotyped (Section 2 3 18) 3BH2 was selected for further study as it reacts strongly with 
G-CCM  and GFAP and also binds to the astrocytoma cell line G-UVW The remaining 
hybridomas were stored in liquid nitrogen but were not further characterised
3BH2 was grown up as ascites (Section 2 3 17) in balb/c mice The ascitic fluid was 
punfied and characterised and this monoclonal antibody will be referred to as the 
anti-G-CCM  monoclonal antibody
3 FUSIONS (PEG or electrofusion)
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3.5. Immunisation of mice with GFAP.
Three mice were immunised with comercially available GFAP (Table 2.3.) in 0.5ml 
0.01M PBS, pH 7.3. (Section 2.3.7.I.). Following four immunisations, the mice were tail 
bled and their sera were tested by ELISA on GFAP and G-CCM-coated plates. The 
results obtained are shown in Table 3.2.
Table 3.2. Testing of sera (1:100 dilution in 0.01M PBS, pH 7.3) from three mice 
immunised with GFAP by ELISA  against G FA P- and G -C C M -coated plates. The 
absorbance was read at 620nm (A620)* The results for the positive control 
(commercial anti-GFAP, 1:400 dilution in 0.01M PBS, pH 7.3) and the negative 
controls (0.01M PBS, pH 7.3, normal mouse serum [1:100 dilution in 0.01M PBS, 
pH 7.3], NSO supernatant and DM EM S10 medium, are also given. The data 
represents the mean values of triplicate determinations (n=3) and the standard 
deviations are in brackets.
GFAP immunised 
Mouse number
G -CC M -coated plates GFAP-coated plates
20 0.075 (0.006) 0.312 (0.001)
34 0.062 (0.003) 0.275 (0.006)
37 0.050 (0.001) 0.304 (0.004)
Commercial anti-GFAP 
(1:400 dilution)
0.034 (0.012) 0.107 (0.007)
PBS (0.01M, pH 7.3) 0.003 (0.001) 0.008 (0.016)
Normal mouse serum 
(1:100 dilution)
0.030 (0.008) 0.037 (0.010)
NSO supernatant 0.024 (0.012) 0.035 (0.020)
DMEMS10 medium 
(1:400 dilution)
0.029 (0.009) 0.035 (0.018)
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On day 58, one mouse was given an 1 v injection of filter-sterilised GFAP in 0 01M 
PBS, pH7 3, which was maintained at 37°C (Section 2 3 7 1 )  The mouse was bled and 
sacrificed on day 61 The serum obtained was used as a positive control for ELIS As and 
throughout the antibody purification stages of the experiment An in vitro immunisation 
(Section 2 3 1 1 )  was performed and the details of this experiment are given in Section 
2 3 7 1
The remaining two mice were also in vitro immunised After 3 days, these spleen cells 
were electrofused (Section 2 3 13 2 )  with SP2/0 cells, as described in Section 2 3 7 1  
The resulting hybridomas were maintained as outlined in Section 2 14 and the fused 
cells were selected (Section 2 3 14) The positive clones were selected by ELISA 
(Section 2 3 1 6 )  against an anti-mouse IgG antibody, G-CCM  and finally GFAP in 
order to obtain an antibody which would react with a GFAP-like antigen on G-CCM  
cells
3 6 Production of the anti-GFAP monoclonal antibody
The results of the in vitro immunisations, fusion, screening and cloning of the mice 
immunised with commercially available GFAP are summarised, as follows,
IN VITRO IMMUNISATION
i
3 FUSIONS (PEG or electrofusion)
i
15 plates were made, 110 wells contained clones
i
96 clones wert expanded into 24 well plates, each of these clones were screened by 
ELISA using anti-mouse IgG as antigen
i
40 clones gave positive ELISA values (> 0 150), these were expanded and screened 
against GFAP
4
10 clones were found to react positively with against GFAP, these were expanded to 
24-well plates
4 clones became negative, 2 died out and 4 continued to produce The four hybridomas
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which reacted most strongly with GFAP were 1BC6, 2BC7, 2DH5 and 3EG7 These 
were subcloned twice by limiting dilution (Section 2 3 15), were screened for anti- 
GFAP antibody production by ELISA (Section 2 3 16) and isotyped (Section 2 3 18) 
These hybndomas were screened for mycoplasma contamination (Section 2 3 5 )  and 
were negative
1
The monoclonal antibody 2DH5 was chosen for further study as it reacted with the 
greatest specificity to GFAP, was the most stable to freeze-thawing and was the best 
producer of antibody It was grown as ascites in balb/c mice (Section 2 3 16 ) 1BC6, 
2BC7 and 3EG7 were stored m liquid nitrogen and were not further characterised The 
2DH5 monoclonal antibody was chosen for further study and will be referred to as the 
anti-GFAP monoclonal antibody
Initially the hybndomas from the GFAP immunised mice were screened with GFAP 
from lot 19 and very few positives were obtained It was then decided to screen these 
hybndomas using GFAP from lot 16 which was used as the immunogen 10 times as 
many positives were subsequently found and a lot variation in GFAP was noted which 
was confirmed by dot blot (Figure 3 4 1 ) The supplier (ICN Immunobiologicals, Table
2 3 )  confirmed a change of source of GFAP between lots 16 and 17
3 7 Screening of the 3BH2 and 2DH5 monoclonal antibodies against G-CCM, G- 
UVW and GFAP by ELISA
The 3BH2 and 2DH5 monoclonal antibodies were grown as ascites in balb/c mice Titres 
were determined by serial dilution of the ascitic fluid (1 10 -  1 106) These dilutions 
were screened by ELISA (Section 2 3 16 ) and a suitable working dilution was obtained 
for each antibody (Table 3 3 )  After titres and working dilutions had been determined 
against the immunogens, the monoclonal antibodies were screened against G-CCM , G - 
UVW and GFAP (Table 3 4 )  Following this initial characterisation, these two 
antibodies were screened by ELISA against other cell lines (Table 3 5 )  (Section 
2 3 16 1 )
It should be noted that the cell lines G-CCM and G-UVW and the other adherent cell 
lines used (Section 2 3 2 )  had been treated with trypsin to detach them from the culture 
flasks and they still retained antigenic reactivity Absorbance readings less than 0 1 were
1
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considered negative
Commercially available anti-GFAP antibody was tested by ELISA against GFAP and 
G-CCM , m order to compare the results with those obtained when 2DH5 was similarly 
screened The results obtained are shown in Table 3 4 The commercially available anti- 
GFAP antibody acted as a positive control throughout the characterisation of 2DH5, the 
'anti-GFAP' antibody
The cell line lJK ^ was used in each of these assays However, it was subsequently 
established that this cell line was contaminated with a rat glioma cell line C6 (PHLS, 
personal communication) For this reason, the results obtained using this cell line are not 
presented
The titre of the 3BH2 crude ascitic fluid against G-CCM was determined to be 1 50,000 
from Table 3 3 and the working dilution was 1 10,000 The working dilution of the 
SAS-treated 3BH2 ascitic fluid was 1 5,000 The titre of the 2DH5 crude ascitic fluid 
against GFAP was determined to be 1 50,000 (Table 3 4 )  and the working dilution was 
1 10,000 The working dilution of the SAS-treated 2DH5 ascitic fluid was 1 7,500
3 8 Screening the anti-G-CCM antibody by ELISA against other ceJJ lines.
The following cell lines G-CCM, G-UVW, MCF-7, HL-60, LOVO, K562, T-24, E J-  
138, A549, H5683, HL-60 and B21 (Table 2 2) were grown in culture and used to coat 
96-well plates for use in ELlSAs (Section 2 3 1 6 1 )  These cell lines were also used in 
Western immunoblottmg (Section 2 3 22 1), immunocytochemistry (Section 2 3 20 3) 
and FACS (Section 2 3 20 8 )  The results of the ELISAs using these cell lines are given 
in Table 3 5 These antibodies showed no cross-reactivity by ELISA with any other 
tumour cell line available in the laboratory The anti-G-CCM  antibody binds strongly 
to the astrocytoma cell lines, G-CCM and G-UVW, as would be expected The anti- 
GFAP antibody binds to a lesser extent to these two astrocytoma cell lines
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Table 3 3 Investigation of the binding activity of the 3BH2 monoclonal antibody. 
Crude, SAS-precipitated and protein G affinity chromatography-treated ascitic 
fluid were screened by ELISA against G-CCM, G-UVW and pure, lyophilised 
GFAP, respectively The results for each antibody fraction were determined by 
serial dilution of the ascitic fluid (1 10 - 1 500,000) in 0 01M PBS, pH 7 3 A 
suitable working dilution and titre was obtained for each antibody. The absorbance 
was read at 620nm (A620nm) and n=l
Test
Fraction
Crude 
ascitic fluid
SÆS-
treated
Protein G - 
treated
SA S- 
treated
SA S-
treated
Antibody
dilution
G-CCM coated G-UVW
coated
GFAP
coated
1 10 0 583 0 465 0139 0 364 0 554
1 50 0 522 0 417 0149 0 336 0 349
1 100 0 471 0 389 0136 0 284 0 306
1 500 0 364 0 312 0 083 0 259 0 228
1 1000 0 284 0 317 0 022 0 249 0 201
1 5000 0177 0 238 0 000 0151 0116
1 10000 0149 0162 0 000 0108 0110
1 50000 0115 0 077 0 000 0 000 0 085
1 100000 0104 0 013 0 000 0 000 0 000
1 500000 0 096 0 000 0 000 0 000 0 000
Negative controls for this assay (n=3) gave readings of < 0 05 and included 0 01M PBS, 
pH 7 3 and DMEMS10, normal mouse scrum (1 100 dilution) and SP2/0 supernatant 
The positive control was commercially available anti-GFAP (1 400) against GFAP and 
was 0 126 (0 004), n=3
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Table 3 4 Investigation of the binding activity of the 2DH5 monoclonal antibody 
Crude, SAS-treated and protein G affinity chromatography-treated ascitic fluid 
were screened against G-CCM, G-UVW and pure, lyophilised GFAP, respectively 
The results for each antibody were determined by serial dilution of the ascitic fluid 
(1 10 - 1 100,000) in 0 01M PBS, pH 7 3 A suitable working dilution and titre was 
obtained for each antibody The absorbance was read at 620nm (A620nm) and n=l
Test
Fraction
Crude 
ascitic fluid
SA S-
treated
Protein G -  
treated
SA S-
treated
SA S-
treated
Antibody
dilution
GFAP coated G-UVW
coated
G-CCM
coated
1 10 0 654 0 333 0 347 0 243 0 248
1 50 0 533 0 328 0 366 0 262 0 255
1 100 0 440 0 278 0 287 0 240 0192
1 500 0 341 0 242 0 224 0179 0165
1 1000 0 242 0197 0149 0172 0142
1 5000 0 250 0 205 0157 0149 0 111
1 10000 0197 0140 0124 0 053 0 035
1 50000 0127 0108 0 074 0 000 0 000
1 100000 0 060 0 011 0 014 0 000 0 000
Negative controls were as described for Table 3 3
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Table 3.5. Examination of the bmding activity of the 3BH2 and 2DH5 monoclonal 
antibodies to the following cell lines, G-CCM, G-UVW, MCF-7, HL-60, LOVO, 
K562, T-24, EJ-138, A549 and H5683. A dilution of 1:100 for each antibody m 
0.01M PBS, pH 7.3, was used m each case. The absorbance was read at 620nm 
(A^ onm) &ttd n = l.
Cell line 3BH2 2DH5
G-CCM 0 471 0 144
G-UVW 0 284 0 140
MCF-7 0 021 0 024
HL-60 0 028 0 059
LOVO 0 011 0 033
K562 0 089 0 094
T-24 0 021 0 034
EJ-138 0 005 0 021
A549 0 034 0 050
H5683 0 018 0 029
Negative controls were as described for Table 3 3 
3.9. Isotypmg of the monoclonal antibodies obtamed.
The monoclonal antibodies obtained were isotyped according to Section 2 3 18 
Supernatant and ascitic fluid were used in the determination of class, subclass, where 
appropriate, and light chain determination The determination of the subclass of the 
light chain was done using the indirect ELISA (Section 2 13 18 2) and was found to be 
kappa for all the antibodies isotyped The results obtained using supernatant from the 
anti-G-CCM and anti-GFAP antibodies with isotyping strips from Sigma (Section 
2 3 18 3 ) are shown in Figure 3 1 Using this method, 3BH2 isotyped as IgGl and 
IgM 2DH5 isotyped as IgM The Serotec isotyping kit (Section 2 3 18 4 ) gave an
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isotype of IgG l and IgM for anti-G-CCM and IgGl and IgM for anti-GFAP monoclonal 
antibodies Each of the nearly 100 antibody-producing positives obtained for the 6 
fusions performed during this project was isotyped by various methods (Section 
2 3 18 ) All isotyped as IgM This was an extraordinary result, considering the mice 
had been hypenmmumsed (Section 2 3 6 3 and Section 2 3 7 1 ,  respectively) and 
considering an anti-IgG assay (Section 2 3 18 2 ) had been used for screening 
However, other researchers in D C U involved in monoclonal antibody production 
were obtaining similar results at the time The probability of infection of the balb/c 
colony with mouse hepatitis virus (MHV) was suspected and confirmed This is 
discussed in Section 3 19
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Figure 3.1.
Results obtained using isotyping strips from Sigma of neat supernatant from (a) 3BH2 
clone A3 and (b) 2DH5 clone A10. 3BH2A3 isotyped as IgGl and IgM. 2DH5 isotyped 
as IgM.
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3 1 0  Purification of ascitic fluid from the anti-G-CCM and anti-GFAP 
monoclonal antibodies
The 3BH2 and 2DH5 antibodies were purified by a series of methods, each with a view 
to increasing the purity and specificity of the resulting immunoglobulins The protein 
concentration was determined following each stage of the purification procedure 
The ascitic fluid was treated with saturated ammonium sulphate (SAS) (Knutson et a l , 
1991) (Section 2 3 19) SAS precipitation was used to isolate all immunoglobulins, but 
this sample may contain some contaminating proteins from the ascitic fluid Protein G 
Sepharose Fast Flow (Section 2 6 3 )  affinity chromatography was used to purify the 
sample further With this method of purification only antibodies are eluted from the 
column The remaining contaminating proteins are washed through the column The 
results were compared by ELISA (Tables 3 3 and 3 4 )
Initially it was thought that many problems would be encountered in purifying ascitic 
fluid of the IgM isotype and purification using a Bio-Sil SEC 400 column from Bio- 
Rad (Shen et a t , 1989) was considered However, on examining even crude ascitic fluid 
on a Protein Pak HPLC column it was seen that the antibody had a retention time of 
16 21mm with very little contaminating proteins (Figure 3 2 1 )  Possible alternative 
methods of IgM antibody purification are discussed in Section 3 19 
The concentration of the ascitic fluid and the purified antibody fractions were found 
using the Bradford assay (Section 2 4 9 3 )  with mouse IgG or IgM as the protein 
standard The results are given in Table 3 6
A study of the crude and SAS-treated ascitic fluid from 3BH2 and 2DH5 showed that 
at -20°C, the antibody activity of both antibodies decreased over a period of 6 months, 
but the purified, SAS-treated sample was less stable The activity of the crude ascitic 
fluid, as determined by ELISA, decreased by 22% and the SAS-treated sample 
decreased by 60%, m the same period
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Table 3 6 Concentrations of crude and purified 3BH2 and 2DH5 ascitic fluid as 
determined by the Bradford assay The absorbance was read at 595nm
Antibody fraction
Concentration (mg/ml)
Anti-G-CCM (3BH2) Anti-GFAP (2DH5)
Crude ascitic fluid 315 20 0
SAS-treated 6 0 7 9
Protein-G treated 2 2 1 7
3 11 HPLC analysis of crude and purified ascitic fluid
HPLC chromatograms were preformed using a lOj^ im Protein Pak SW 300 column with 
a mobile phase of 0 1M phosphate buffer, pH 7 0, and a flow rate of 0 5ml/min 
Absorbance was detected at 280nm
The anti-G-CCM  and anti-GFAP monoclonal antibodies, 3BH2 and 2DH5, were grown 
as ascitic fluid in mice (Section 2 3 17) and were analysed on HPLC, along with 
commercial mouse IgG and IgM as standards for comparison In this system, mouse IgG 
standard gave a peak at 16 21min (Figure 3 2 1 ) Mouse IgM standard gave a major peak 
at 10 01mm, which represents protein eluting outside the resolution range of the column, 
and a minor peak at 18 97min, which may depict IgM subunits (Figure 3 2 2 )
When fresh, crude 3BH2A3 ascitic fluid was examined, a minor peak at 10 16min was 
seen This corresponds to protein eluting in the void volume of the column and may be 
IgM However, a major peak at 16 36 was also observed, which corresponds to the 
retention time of 16 21min of mouse IgG in this system The protein G affinity 
chromatography-purified sample gave one peak at 16 55mm The presence of only one 
peak in this sample indicated a high level of purity The results are given in Figures 3 3 
Fresh, crude 2DH5 ascitic fluid gave peaks at 9 73min and 16 69min The first peak was 
protein eluting in the void volume and the second peak corresponds to the elution time 
of IgG The SAS-treated sample gave a major peak at 16 86 and a minor peak at 9 85 
The protein G affinity chromatography-purified sample gave one peak at 16 59min 
These results are presented in Figures 3 3 (1 -5 ) and discussed in Section 3 19
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Figure 3.2,1.
HPLC chromatogram of commercial mouse IgG (2mg/ml) The column used was a 
10/xm Protein Pak SW 300 column with a mobile phase of 0 1M phosphate buffer, pH 
7 0, and a flow rate of 0 5ml/min Absorbance was detected at 280nm One major peak 
was detected with a retention time of 16 21mins This is representative of IgG (ISOkD)
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Figure 3.2.2.
HPLC chromatogram of commercial mouse IgM (2mg/ml). The column used was a 
lOjitm Protein Pak SW 300 column with a mobile phase of 0 .1M phosphate buffer, pH 
7.0, and a flow rate of 0.5ml/min. Absorbance was detected at 280nm. One major peak 
was detected with a retention time of lO.Olmins. This is representative of IgM 
(approximately 900kD) which eluted outside the resolution range of the column. A 
minor peak was detected at 18.97min which may represent IgM subunits.
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Figure 3.3 1.
HPLC chromatogram of fresh, crude 3BH2A3 ascitic fluid (2mg/ml) The column used 
was a 10/xm Protein Pak SW 300 column with a mobile phase of 0 1M phosphate 
buffer, pH 7 0, and a flow rate of 0 5ml/min Absorbance was detected at 280nm One 
major peak was detected with a retention time of 16 36mins This is representative of 
IgG (180kD) The minor peak at 10 16min was outside the resolution range o f the 
column and may have been IgM antibody The minor peak at 24 72min possibly 
identifies denatured protein
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Figure 3.3.2.
HPLC chromatogram of SAS-treated 3BH2A3 ascitic fluid (2mg/ml) The column used 
was a lOixm Protein Pak SW 300 column with a mobile phase o f 0 1M phosphate 
buffer, pH 7 0, and a flow rate of 0 5ml/min Absorbance was detected at 280nm One 
major peak was detected with a retention time of 16 42mins This is representative of 
IgG (180kD) The protein in the minor peak at 10 Olmin eluted outside the resolution 
range of the column
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Figure 3.3.3.
HPLC chromatogram of SAS-treated 3BH2A3 ascitic fluid (2mg/ml) incubated with 
GFAP (20/ig/ml) for 30mm at 37°C The column used was a 10/xm Protein Pak SW 300 
column with a mobile phase of 0 1M phosphate buffer, pH 7 0, and a flow rate of 
0 5ml/mm Absorbance was detected at 280nm One major peak was detected with a 
retention time of 17 OOmins This represents IgG (180kD) An extra peak was observed 
at 14 02min which distinguishes the GFAP-3BH2A3 complex which has a molecular 
weight of approximately 232kD (IgG =  180, GFAP=52kD) The minor peaks at 
9 86min eluted in the void volume of the column and may be IgM antibody The peak 
at 24 6min possibly identifies denatured or contaminating protein
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Figure 3.3.4.
HPLC chromatogram of SAS-treated 2DH5 ascitic fluid The column used was a l()/xrn 
Protein Pak SW 300 column with a mobile phase o f 0 1M phosphate buffer, pH 7 0 and 
a flow rate o f 0 5ml/mm Absorbance was detected at 280nm One major peak was 
detected with a retention time of 16 86mins which is representative of IgG (180kD) 
The minor peak at 9 85min was outside the resolving range o f the column
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Figure 3.3.5.
HPLC chromatogram of SAS-treated 2DH5 ascitic fluid (2mg/ml) incubated with GFAP 
(20/ig/ml) for 30min at 37°C The column used was a lOfim Protein Pak SW 300 
column with a mobile phase of 0 1M phosphate buffer, pH 7 0, and a flow rate of 
0 5ml/min Absorbance was detected at 280nm The major peak at 16 94mins 
represents IgG (180kD) An extra peak was observed at 14 99min which distinguishes 
the GFAP-2DH5 complex which has an approximate molecular weight o f 232kD 
(IgG =  180kD, GFA P=52kD) The minor peaks at 9 88min was outside the resolution 
range of the column and the peak at 23 95mm possibly identifies denatured protein 
GFAP had a retention time of 22 91min
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3 12 Dot immunobots used for initial screening of the anti-G-CCM and anti- 
GFAP antibodies
Dot immunoblotting was a relatively quick method for determining if the antigen of 
interest was present and if the test antibody reacted with this antigen GFAP was 
supplied by ICN Immunobiologicals (Table 2 3 )  Dot immunoblotting was performed 
prior to carrying out electrophoresis and Western immunoblotting A lot variation was 
noticed between the GFAP used to initially immunise and screen the anti-GFAP 
monoclonal antibodies, called GFAP "A", up to and including lot 16 and lots of GFAP 
obtained subsequently, were called GFAP "B" This variation was first noticed by 
ELISA (Section 3 6 )  and was confirmed using a dot blot (Section 2 3 2 1 ) The results 
are shown in Figure 3 4 1
It was found that the monoclonal antibodies 1BC6, 2BC7 and 3EG7 gave a better 
response with GFAP "A,r than 2DH5, which reacted with GFAP "B", which was used 
for the latter immunisations ICN Immunobiologicals, California, confirmed a change 
in source after lot 16
The positive control used throughout there experiments was the mouse monoclonal anti- 
GFAP, clone G -A -5, also from ICN Immunobiologicals (Table 2 3 )  This product was 
immunoglobulin ascitic fluid containing a mouse IgGl antibody produced by mice 
immunised with purified GFAP from porcine spinal cord It had also been tested for 
immunocytochemial localisation of GFAP from man, pig and rat The information sheet 
supplied with this antibody preparation states that in indirect immunofluorescence 
labelling on alcohol fixed paraffin embedded sections or frozen sections this antibody 
stains astrocytes and Bergmann glia cells This antibody also localises GFAP m the 
immunoblot technique, as can be seen in Figure 3 4 1
The dot blots shown in Figure 3 4 1 were treated as follows, (l) with 10ml of a 1 400 
dilution of commercially available anti-GFAP which reacts with GFAP "B" only, (11) 
the negative control, where PBS, pH 7 3, is subsituted for the commercially available 
antibody, (111) 10ml of a 1 5 dilution of 2DH5 clone A10 supernatant which can be seen 
to react with GFAP This reaction was not seen in (iv) the negative control which had 
DMEMS10, added instead of hybridoma supernatant
Fresh membrane preparations were prepared for use in dot-immunoblottmg and Western 
immunoblotting A serine protease inhibitor, phenyl-methyl-sulphonal fluoride, PMSF 
(Section 2 3 22 ), was added to the preparations (Barrand and Twentyman, 1992) Protein
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concentrations were determined using the BCA assay (Section 2 4 9 3 )
These dot blots were performed to confirm if the membrane preparations had been 
prepared correctly and to venfy that 3BH2 clone A3 recognises the cell lines G-CCM 
and G-UVW and does not react with the cell lines EJ-138, K562, A549 and T-24 The 
results are shown m Figure 3 4 2 A positive result for IJK^ can be seen on ail blots 
UK(t) was subsequently shown to be cross contaminated with C6 rat glioma cells, either 
before or during its deposition in the European Collection of Animal and Cell Cultures 
(Table 2 2 ) ,  and non-specific binding of the secondary antibody to these cells would 
explain this result
3,13. SDS-PAGE was performed on crude and purified antibody from ascitic fluid
SDS-PAGE was earned out according to Section 2 4 17 and the results are shown in 
Figure 3 5 These results show that an antibody band was observed at 150,000 daltons 
for commercial IgG and a band was observed in the protein G-punfied ascites This 
shows that the concentration of the antibody in this sample was low, confirming the 
results obtained by ELISA
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Figure 3.4.1.
Dot blots were performed to show that 2DH5 clone A10 recognises the GFAP 
GFAP "A" was used as the antigen on the upper portion of each dot blot and the same 
quantity of GFAP "B" was used on the bottom portion. The dot blots were treated as 
follows; (i) with 10ml of a 1:400 dilution of commercially available anti-GFAP in 
0.01M PBS, pH 7.3. It can be seen that this reacts only with GFAP "B", (ii) the negative 
control, using 0.01M PBS, pH 7.3, (iii) with 2DH5 clone A10 supernatant (1:5 dilution 
in 0.01M PBS, pH 7.3), this reacted with the GFAP "B" also and (iv) the negative 
control, with DMEMS10 added instead of antibody.
(i) (ii)
(iii)
G-CCM  - 
G-UVW - 
LA T
EJ-138 -
- K562
- A549
- T-24
< -  UK,t)
(iv)
n ;
Figure 3.4.2.
Dot blots performed to show that 3BH2 clone A3 recognises the G-CCM and G-UVW 
cell lines. The following cell lines were included on each dot blot; G-CCM, G-UVW, 
LAT, EJ-138, K562, A549, T-24 and UK(t). The dot blots were treated as follows: (i) 
the negative control, with DMEMS10 added instead of antibody, (ii) the negative 
control, with 0 .0 1M PBS, pH 7.3, (iii) with a 1:20 dilution of 3BH2 clone A3 
supematent diluted in 0.01M PBS, pH 7.3, and (iv) with a 1:400 dilution of 
commercially available anti-GFAP antibody in 0.01M PBS, pH 7.3.
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Figure 3.5.
A 5-20% (w/v) gradient PAGELR precast polyacrylamide gel from ATTO was loaded 
as follows; Lane (1) molecular weight markers,in daltons, (2) [anti-Ricin-A chain, SAS- 
treated], (3) mouse IgG standard, 2mg/ml, (4) anti-G-CCM (3BH2) ascitic fluid, protein 
G-treated, (5) anti-G-CCM, ascitic fluid SAS-treated, (6) anti-G-CCM, ascitic fluid (1:10 
dilution in 0.01M PBS, pH 7.3). The gel was run at 20mAmps per gel.
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3,14. Western blotting to determine the specificity of the anti-G-CCM and anti- 
GFAP antibodies.
SDS-PAGE gels containing commercial GFAP were transferred onto nitrocellulose m 
the same manner as preparations from cell membranes (Section 2 3 22 1 ) These blots 
were probed with supernatant from 3BH2 clone A3 and 2DH5 clone AIO (Figure 
3 6 1 ) or ascitic fluid from these monoclonal antibodies (Figure 3 6 2 ) A positive 
control, commercially available anti-GFAP monoclonal antibody, was also used In 
Figure 3 6 1 ,  blot A was treated with a 1 100 dilution of commercially available anti- 
GFAP in 2% (w/v) BSA, 0 01 % (v/v) Tween-20 in 0 01M PBS, pH 7 3 Blot B was 
tested with a 1 5 dilution of 3BH2 clone A3 supernatant
Commercially available anti-GFAP reacts strongly with an antigen of approximately 
45kD, which is, presumably, GFAP Other bands were seen at molecular weights of 
approximately 145kD and 295kD These bands may be due to the antibody reacting 
with contaminating protein in the GFAP preparation or they may be due to, perhaps, 
the antibody reacting with multimers (tnmer or hexamer aggregates) of GFAP The 
commercially available anti-GFAP antibody did not react with G-CCM or G-UVW 
3BH2 clone A3 gave a faint band at the same molecular weight for G-CCM, G-UVW 
and GFAP Faint bands can be seen at molecular weights of 145kD and 295kD also 
This Western blot was repeated with a dilution of ascitic fluid and a clearer result was 
obtained in Figure 3 6 2 The anti-G-CCM blot was tested with a 1 100 dilution of 
SAS-treated anti-G-CCM (3BH2A3) ascitic fluid m 0 01 % (v/v) Tween-20 m TBS The 
anti-GFAP ( D C )  blot was examined with a 1 100 dilution of 2DH5A10 ascitic fluid 
in 0 01 % (v/v) Tween-20 in TBS The anti-GFAP blot was investigated with a 1 300 
dilution of commercially available anti-GFAP in 0 01% (v/v) Tween-20 in TBS The 
negative (-ve) control blot was analysed with 0 01% (v/v) Tween-20 in TBS instead of 
primary antibody and shows no non-specific binding of the secondary antibodies used 
On each of the test blots [anti-G-CCM, anti-GFAP ( D C )  and anti-GFAP], the lane 
which was loaded with commercially available GFAP shows a large band in the 40kD 
to 50kD range A faint band was also seen with all three of these antibodies at 
approximately lOOkD A band was seen at approximately 150kD m the GFAP lane of 
this Western blot which was treated with the anti-G-CCM antibody Each of the three 
antibodies also pick up a band at approximately 50kD on the lanes loaded with G-UVW 
and G-CCM From the result of this Western blot, it was deduced that the 2DH5
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antibody reacts with GFAP and the 3BH2 antibody reacts with GFAP and to a GFAP- 
like antigen on G-CCM and G-UVW cells at a molecular weight o f 50kD With anti-G- 
CCM and anti-GFAP (D C ), in Figure 3 6 2 ,  faint bands are also seen at the top of 
each lane This may have been due to either (1) these antibodies reacting with 
aggregates o f the cell membrane preparations o f G-CCM and G-UVW which were not 
properly separated by somcation and, therefore, were o f a much larger molecular 
weight, or (11) GFAP is also found as multimers m these cell lines and the antibodies 
are reacting with these multimers
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Figure 3.6.1.
Westerns immunoblots using cell membranes and GFAP, as follows; Blot A was treated 
with a 1:100 dilution of commercially obtained anti-GFAP in 2% (w/v) BSA, 0.01% 
(v/v) Tween-20 in 0.01M PBS, pH 7.3. Blot B was examined with a 1:5 dilution of 
3BH2 clone A3 supernatant. The lanes were loaded as follows;
Blot A : (1) G-UVW, (2) G-CCM and (3) GFAP. Blot B : (4) G-CCM  (5) G-UVW 
(6) GFAP (7) IJK(t) and (8) MWM, in daltons (Table 2.10.).
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Figure 3.6.2.
Westerns blots of purified GFAP and membrane proteins from G-CCM  and G-UVW 
cell lines. The anti-G-CCM  blot was examined with a 1:100 dilution of SAS-treated 
anti-G-CCM  (3BH2A3) ascitic fluid in 0.01% (v/v) Tween-20 in TBS. The anti-GFAP 
(D.C.) blot was tested with a 1:100 dilution of 2DH5 ascitic fluid in 0.01% (v/v) 
Tween-20 in TBS. The anti-GFAP blot was tested with a 1:300 dilution of commer­
cially available anti-GFAP in 0.01% (v/v) Tween-20 in TBS. The negative (-ve) 
control blot was treated with 0.01% (v/v) Tween-20 in TBS instead of primary antibody 
and shows no non-specific binding of the secondary antibodies used.
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3 15 Analysis of the affinity constant of 3BH2A3 for GFAP using BLAcore
With BIAcore, the optical phenomenon used for detection is surface plasmon resonance 
(SPR) The SPR response is correlated to changes in refractive index at a sensor chip 
surface The difference in refractive index is caused by mass changes on this surface, 
for example when the analyte binds to the immobilised ligand The SPR signal is 
monitored continuously so that chemical interactions between biomolecules can be 
studied in real time (Borrebaeck et a l , 1992, VanCott et a l , 1992)
The 3BH2A3 sample used in the BIAcore was SAS-treated ascitic fluid diluted 1 1 in 
0 01M PBS, pH 7 3, with 0 05% sodium azide The GFAP sample was 100(xg of 
unreconstituted, commercially available GFAP from ICN Immunobiologicals (Table 
2 3 )  The samples were prepared (Section 2 3 24 1 )  The results were obtained by Paul 
Roben while he was at the Scnpps Institute in La Jolla, California and his assistance is 
gratefully acknowledged
The association/dissociation rate constants and affinity constants for (a) the 3BH2A3 
antibody and (b) the commercially obtained anti-GFAP antibody against GFAP were 
analysed using a BIAcore machine (Section 2 3 24 )
The equilibrium constant KA is the ratio of the association k ^  and dissociation rate 
constants kd)SS
— ^ass/^diss
To measure association, a low flow rate of antibody passing over a high concentration 
of bound antigen is used, to ensure that each antigen will be bound by an antibody To 
measure the rate of association the concentration of antibody bound is plotted against 
time From this graph the relative responses at different concentrations can be calculated 
If this is plotted against time, the slopes obtained can be plotted against concentration 
to obtain k ^
In Figure 3 7 1 , a sensogram shows the real time binding of the anti-G-CCM  
(3BH2A3) monoclonal antibody to surface GFAP, m BIAcore Response Units (RU) An 
average slope, read every 5 seconds, was calculated at each of the time points (crosses) 
along the binding curve To measure the rate of association, the concentration of 
antibody was plotted against time, from this graph the relative responses of the 3BH2A3 
antibody at different concentrations can be calculated (Figure 3 7 2 )  These results were 
plotted against time and the slopes obtained were plotted against concentration to obtain 
the association constant, k^, which was found to be 2 95x107M-1
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To measure dissociation, the antigen was coated at a low concentration to ensure that 
all the antigens present are bound to the surface of the sensor chip The low concentra­
tion of coating antigen also ensures that if the antibody was washed off, there will not 
be other antigens available for it to bind to At high antibody concentrations and high 
flow rate, all the antigens present will be bound by antibody When the sample pulse 
passed the sensor surface and was replaced by buffer, the concentration of free analyte 
(antibody) dropped suddenly to zero The derivative of the response curve then reflected 
the dissociation rate, 
dR = -kd]SSRt 
dt
This was only valid under the assumption that re-association of released analyte was 
negligible, 1 e analyte was efficiently removed by the buffer flow Integrating with 
respect to time gives,
— ^ d ]s s (tn - tl)
Rtn
where Rtn is the response at time n and R(1 is the response at an arbitary starting time 
of 1 The dissociation rate constant kdlss can be obtained by plotting the log of the drop 
m response against the time interval
The affinity constants were calculated automatically by the BIAcore system using the 
results given in Figures 3 7 The affinity constant for commercially available anti-GFAP 
against GFAP was found to be 9 6xl08m or1 and the affinity constant for 3BH2A3 
against GFAP was 2 95xl07m or1 The affinity constant for the commercial antibody was 
high, as expected The affinity of the 3BH2A3 antibody for GFAP was also satisfactory, 
considering the immunogen was the anaplastic astrocytoma cell line, G-CCM  The 
2DH5A10 antibody was not determined due to insufficient time being available
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Figure 3 7 1
An example of a sensogram showing real time binding of the anti-G-CCM  (3BH2A3) 
monoclonal antibody to surface GFAP, in BIAcore Response Umts (RU) An average 
slope, read every 5 seconds, was calculated at each of the time points (crosses) along 
the binding curve
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Figure 3.7.2.
The results from Figure 3.7.1. were plotted against time and the slopes obtained were 
plotted against concentration to obtain the association constant, k ^ , which was found 
to be 2.95xl07M_1. The results are discussed in Section 3.15.
167
Name:3B1500FF.BLR: Sensorgram 1
Figure 3.7.3.
To measure antigen-antibody dissociation, the antigen was coated at a low concentration 
to ensure that at the high antibody concentrations and high flow rate used, all the 
antigens present are bound. When the sample pulse has passed the sensor surface and 
is replaced by buffer, the concentration of free analyte drops suddenly to zero (arrow). 
The derivative of the response curve then reflects the dissociation rate.
168
I/
3BGFF XIC
Infro/rfinl.IQOE 0t»t1 to*}.005377
Figure 3 7 4
The dissociation rate constant, K ^ ,  can be obtained by plotting the log of the response 
curve (Figure 3 7 3 )  against the time interval (VanCott et a l , 1992 ) This is discussed 
in Section 3 15
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3 1 6  Characterisation of the anti-G-CCM and anti-GFAP antibodies by 
immunocytochemistry
A photograph of the G-CCM cells in culture is shown in Figure 3 8 1  The staining of 
G-CCM  cells by Romanowsky staining, as described in Section 2 3 20 3 ,  is seen in 
Figure 3 8 2
Immunocytochemistry was used to determine the specificities of the anti-G-CCM  and 
anti-GFAP antibodies with respect to G-CCM and G-UVW cell lines The SAS-treated 
anti-G-CCM  and anti-GFAP ascitic fluid samples were used in the lmmunocyto- 
chemical studies The optimum dilution of the antibodies was determined by initially 
examining a series of dilutions A stock of 2mg/ml of each purified antibody was used 
at a dilution of 1 10 to 1 100 The preparation of cytospin samples using cell lines is 
outlined in Section 2 3 20 2 The staining of the cytospin preparations employing the 
APAAP detection system (2 3 30 4 ) was determined using (i) a 1 100 dilution of SA S- 
treated 3BH2A3 ascitic fluid in 0 01M PBS on G-CCM and G-UVW cells (Figures 
3 8 3 and 3 8 4 , respectively), and (11) SAS-treated 2DH5 ascitic fluid, similanly 
diluted, was tested against G-CCM and G-UVW (Figures 3 8 5 and 3 8 6 )  Strong 
staining with 3BH2A3 and 2DH5 on the cell membrane was observed and, in some 
cells, cytoplasmic staining and staining of astrocytic processes were also seen (Figure 
3 8 7 )  Negative samples were prepared by substituting the primary antibody with 
0 01M PBS, pH 7 3 (Figure 3 8 8 )  Normal tissues were not studied due to the difficulty 
of obtaining such samples
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VFigure 3.8.1.
G-CCM  cells in culture at 40x magnification, photographed using a Nikon type ELWD 
0.3 inverted phase contrast microscope.
Figure 3.8.2.
G-CCM  cells stained by Romanowsky staining (Section 2.3.20.3.) at 400x magnifica­
tion, photographed as in Figure 3.8.1.
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Figure 3.8.7. 3BH2A3 (1:100 dilution) was incubated with a cytospin preparation of G - 
CCM cells which were then detected using the APAAP system (lOOx magnification), 
showing staining of the astrocytic proccesses. The cells were counterstained with methyl 
green.
Figure 3.8.8.
Negative samples were prepared by substituting the primary antibody with 0.01M PBS, 
pH 7.3. The cells were counterstained with methyl green.
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Figure 3.8.5. 2DH5 (1:100 dilution) was incubated with a cytospin preparation of G - 
CCM cells which were then detected using the APAAP system (lOOx magnification). 
The cells were counterstained with methyl green.
Figure 3.8.6. 2DH5 (1:100 dilution) was incubated with a cytospin preparation of G - 
UVW cells which were then detected using the APAAP system (lOOx magnification). 
The cells were counterstained with methyl green.
Figure 3.8.3. 3BH2A3 (1:100 dilution) was incubated with a cytospin preparation of G - 
CCM cells which were then detected using the APAAP system (lOOx magnification). 
The cells were counterstained with methyl green.
Figure 3.8.4. 3BH2A3 (1:100 dilution) was incubated with a cytospin preparation of G - 
UVW cells which were then detected using the APAAP system (lOOx magnification). 
The cells were counterstained with methyl green.
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/3 17 Characterisation of the anti-G-CCM antibody by immunofluorescence.
Indirect immunofluorescence enables the detection of surface antigens on live cells This 
method may be performed on single-cell suspensions or on cells attached to a culture 
dish (Section 2 3 23 2 ) When immunofluorescence is carried out on live and viable 
cells, only cell surface components are recognised (Schachner, 1982) Using this method, 
the first specific antibody is applied, followed by treatment with a second antibody 
carrying fluorescein as the detectable label The second antibody reacts with the first, 
thereby visualising indirectly the antigen of study
When the G-CCM  cells were treated by direct immunofluorescence using 3BH2, as the 
primary antibody, a green-yellow ring around the cell surface was clearly seen when 
photographed under ultraviolet light (Figure 3 9 1 ) This is indicative of cell surface 
localisation of the antigen recognised (Schachner, 1982) When the G-CCM  cells were 
tested with the 2DH5 monoclonal antibody a fainter fluorescent ring was also seen On 
testing G-CCM  cells with commercially obtained anti-GFAP monoclonal antibody by 
this method, no fluorescent ring was visible around the cell surface This result was 
expected as GFAP is intracellular m location and therefore would not be detected in live 
cells by this method These results show that the 2DH5 monoclonal antibody is 
immunologically similar to the commercially available anti-GFAP monoclonal antibody, 
but they are not identical in their reactivities
This result indicate that the antigen recognised by these antibodies is located on the cell 
membrane Cytoplasmic staining of some cells would indicate that the antigen 
recognised by these two antibodies may also be intracellular in location It was not 
possible to detect intracellular binding on live cells by immunofluorescence, but it was 
possible to detect intracellular binding on fixed, cytospm preparations
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Figure 3.9.1. 3BH2A3 incubated with live G-CCM cells and treated with an FITC- 
labelled secondary antibody, at 400x magnification, photographed under ultraviolet light 
using a Nikon Optiphot microscope.
Figure 3.9.2. 3BH2A3 antibody incubated with live G-CCM  cells and treated as in 
Figure 3.9.1, photographed under visible light using a Nikon Optiphot microscope, at 
400x magnification.
3 18 Characterisation of the anti-G-CCM and anti-GFAP antibodies by FACS
For FACS analysis, the availability of single-cell suspensions with a high degree of 
viability is required to permit the recognition of cell surface components only 
The FACS procedure was carried out as described in Section 2 3 20 8 and the results 
are shown in Figures 3 10 (1 - 7 )  All samples in each experiment are measured at the 
same gain settings Arbitrary thresholds were established, and the relative frequencies 
of cells with the same or higher fluorescent intensities are computed In this way, direct 
comparisons can be made between populations of interest to determine the relative 
frequency of cells with the same fluorescent intensities in different samples The 
selection of the arbitrary threshold is determined on the basis of the shape of the 
frequency distribution
Two negative controls were used for each experiment, (i) using PBS instead of the 
primary antibody, labelled as "FITC ONLY" and (11) using PBS instead of both the 
primary antibody and the FITC-labelled secondary antibody, labelled as "NO FITC" 
If the cells have been prepared and blocked properly, these two peaks should be 
identical (Figure 3 10 1 ) The results of the binding of a 1 10 dilution of the SA S- 
treated 3BH2 and 2DH5 ascitic fluid incubated with G-CCM  cells is shown in Figures 
3 1 0  1 and 3 10 2 The results of the binding of a 1 10 dilution of the SAS-treated 
3BH2 and 2DH5 ascitic fluid incubated with G-UVW cells is shown in Figures 3 10 3 
The positive control was a dilution of G12 ascitic fluid which reacts with the K562 
human erythroleukennc cell line (Figure 3 10 4 )  This was kindly obtained from Orla 
Nolan, D C U  Positive binding activity of 3BH2 and 2DH5 against the K562 
erythroleukaemia cell line was not considered unusual as the expression of common 
surface antigens by the brain and lymphoid cells and tissues has been reported 
(Wilkstrand and Bigner, 1985) The profiles obtained when using the 3BH2 and 2DH5 
antibodies with various cell lines (Table 2 2 ) are given (Figures 3 10 5 1 and 3 10 5 2 ) 
The results of the FACS analysis using crude antibody supernatant from the 3BH2 and 
2DH5 hybndomas are shown in Figures 3 10 6 and 3 10 7
The FACS analysis confirmed the western and immunofluorescence results, that the 
3BH2 and 2DH5 antibodies appear to be directed to a common antigen which is 
lmmunologically similar to GFAP, but appears to be a cell membrane antigen These 
two antibodies gave similar FACS results throughout
\
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#12: ^/DOL001\FL1-HNFL1-Height.
G-CCM
FITC ONLY
#12: /'3^DOL0S1\FL1 -HxFLl-Heigh t
G-CCM
Figure 3.10.1. The FACS analysis of the binding of SAS-treated 3BH2 and 2DH5 
ascitic fuid (1:10 dilution) incubated with G-CCM cells is shown in (b) and (c) 
respectively. Also shown, in (a), are the two negative controls used for each 
experiment; (i) using PBS instead of the primary antibody, labelled as "FITC ONLY" 
and (ii) using PBS instead of both the primary antibody and the FITC-labelled 
secondary antibody, labelled as "NO FITC". These two peaks are identical showing that 
the cells have been prepared and blocked properly and that there is no non-specific 
binding of the FITC-labelled antibody.
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(a)
# 12! /3,'OOL624\FL 1-H^FL 1-He i gh t
(b)
(c)
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(d)
Figure 3.10.2. The FACS analysis of the binding of (a) neat SAS-treated 3BH2 ascitic 
fluid, (b) a 1:10 dilution of SAS-treated 3BH2 ascitic fluid, (c) neat SAS-treated 2DH5 
ascitic fluid and (d) 1:10 dilution of SAS-treated 2DH5 ascitic fluid incubated with G - 
CCM cells is shown.
# 12: .'3»'DOL024\FL 1 -H"-FL 1 -He i gh t
Q-CCil
FITC ONLY
1.» 10 3BHS + FITC
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Figure 3.10.3. The FACS analysis of the binding of (a) neat SAS-treated 3BH2 ascitic 
fluid, (b) a 1:10 dilution of SAS-treated 3BH2 ascitic fluid, (c) neat SAS-treated 2DH5 
ascitic fluid and (d) 1:10 dilution of SAS-treated 2DH5 ascitic fluid incubated with G - 
UVW cclls is shown.
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Figure 3.10.4. The FACS analysis of (a) the negative control sample (0.01M PBS, PH 
7.3, instead of primary antibody), (b) the positive control sample, a 1:10 dilution of G12 
ascitic fluid which reacts with the K562 human erythroleukemic cell line, (c) a 1:50 
dilution of SAS-treated 2DH5 ascitic fluid incubated with the K562 cell line.
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FITC ONLY
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Figure 3.10.5.1. The FACS analysis of a 1:10 dilution of SAS-treated 3BH2 and 2DH5 
ascitic fluid with the (a) T-24, (b) LOVO, (c) E J-138 and (d) A549 cell lines (Table
2.2.) are given, which show that there is no specific binding between the 3BH2 or 2DH5 
antibodies and these cell lines.
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Figure 3.10.5.2. The FACS analysis of a 1:10 dilution of 3BH2 and 2DH5 SAS-treated 
ascitic fluid with the (a) SP2/0, (b) H5683, (c) M CF-7 and (d) HL-60 cell lines (Table
2.2.) are given, showing that there is no specific binding between the 3BH2 or 2DH5 
antibodies and these cell lines.
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Figure 3.10.6. The results of the FACS analysis using neat antibody supernatant from; 
(a) 3BH2 and (b) 2DH5 hybridomas against G-CCM cells and (c) 3BH2 and (d) 2DH5 
hybridomas against G-UVW cells.
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3 19 Discussion.
The aims of this research were achieved, as monoclonal antibodies against the anaplastic 
astrocytoma cell line, G-CCM, and against commercially available GFAP were 
produced, purified and characterised
An anti-GFAP antibody was produced as GFAP is one of the well characterised nervous 
system markeis Others include the three protein subunits of neurofilaments, neuro- 
specific enolase, myelin basic protein and S-100 protein The most important and 
reliable of these nervous system markers is GFAP which is a well characterised marker 
for the immunohistochemical diagnosis and classification of brain tumours of the glial 
group
This protein was isolated from fibrous astrocyte-rich multiple sclerosis plaques by Eng 
et al (1971) GFAP is apparently composed of 1-7 peptides in the range of 40,500 to 
54,000 daltons and it is a definitive marker of astrocytes and their processes GFAP is 
a cell-specific intermediate filament protein and is the major protein constituent of 
astroglial filaments It plays a major role in defining and maintaining astrocyte shape 
under normal conditions as well as during astrocyte response to CNS injury (Noetzel,
1990)
Human GFAP is 52,000 daltons and it has been cloned by Bongcam-Rudloff et a l ,
1991) The complementary DNA (cDNA) of a human GFAP has been cloned and 
sequenced and the ammo acid sequence deduced This sequence permitted the prediction 
of the complete amino acid sequence of the GFAP monomer subunit and showed its 
sequence homology with vimentm (67%) and desmin (65%) The chromosomal location 
of the GFAP gene has been established (17q21) by Southern blot hybrids and by in situ 
hybridisation (Bongcam-Rudloff et a l , 1991)
GFAP shows species-specific amino acid sequence heterogenity, and its molecular 
weight ranges from 48kD for mouse, 49kD -  52kD for human, 50kD for bovine and 
51kD for rat Comparison of the nucleic acid sequences between human and mouse 
cDNA revealed near 90% identity overall Except for small mterspecies polypeptide 
sequence variations, GFAP appears to be a conserved protein, as its phenotypic 
expression is unaffected by central nervous system (CNS) mutations (Jimpy mouse) or 
oncologic events (human glioma) (Eng and Shiurba, 1988) Brenner et al (1994) studied 
the transcriptional regulation of the GFAP gene to gain insight into astrocyte function 
and also to develop an astrocyte-specific expression system They have produced
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transgenic mice carrying the bacterial lacZ reporter gene linked to a 2 2kb 5-flanking 
sequence derived from the human GFAP gene that previously had been shown to direct 
astrocyte-specific transcription m cultures In this study, they reported that this promoter 
also directs expression to astrocytes in the CNS This specific expression of the GFAP- 
lacZ transgene means that it is now possible to target expression of other heterologous 
genes to astrocytes in vivo, and to study the mechanisms of reactive gliosis at the DNA 
level
GFAP immunoreactivity in the mature CNS is restricted to glial filaments within 
protoplasmic astrocytes in grey matter and fibrous astrocytes in white matter At the 
surface of the brain, GFAP immunoreactivity is especially concentrated in astrocytes 
which form the outer limiting membrane, the glia limitans GFAP has a slower rate of 
turnover than any of the neurofilament proteins and this is consistent with a possible 
structural role for glial filaments (Smith et a l , 1984)
In this project, fusions were performed in the hope of obtaining a monoclonal antibody 
which would react specifically against GFAP A second set of fusions were performed 
to produce a monoclonal antibody which would bind an antigen on a human astrocytoma 
cell line These antibodies could be used to aid in the classification of brain tumours 
and/or to target immunoconjugates to tumour cells to assist in the localisation and 
treatment of brain tumours (Section 1 7 )  The tumour cell line used, G-CCM , was 
diagnosed as grade IV malignant glioma and as such was probably relatively strongly 
antigenic Eng (1982) stated that GFAP is very antigenic, since samples heavily 
contaminated with tubulin elicited antibodies primarily to GFAP and not to tubulin 
Hybndomas secreting antibody which reacted strongly with G-CCM  were produced 
from fusions following immunisation with this cell line The antibody 3BH2 was 
selected on the basis of this initial screening and results of its purification, binding 
activity to a range of cell types, class and characterisation were presented The 
monoclonal antibody designated 2DH5 was produced following immunisation with the 
commercially available GFAP, both in vivo and in vitro, and was chosen for further 
study for the corresponding reasons as 3BH2 Both monoclonal antibodies reacted 
strongly to their antigens, were stable to freeze-thawing, produced large amounts of 
antibody and grew well m culture
Since G-CCM  proved to be a GFAP-positive cell line, all the antibodies produced from 
the fusions involving G-CCM immunised spleen cells were screened against GFAP for
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binding activity by the ELISA method to determine if any of the hybndomas obtained, 
produced an antibody which reacted with G-CCM and GFAP As whole cells were used 
for immunisation purposes, it was not expected that antibodies to an intracellular 
component, such as GFAP, would be produced However, since the 3BH2 antibody 
recognised epitopes similar to GFAP, the possibility was investigated These monoclonal 
antibodies were initially screened against G-CCM, G-UVW and GFAP by ELISA and 
the results are given in Tables 3 3 and 3 4
The titres and working dilutions of the 3BH2 and 2DH5 antibodies were outlined in 
Section 3 7 These two monoclonal antibodies were screened against other cell lines 
available in the laboratory (Table 3 5 )  The only cell line which showed some cross- 
reactivity with the anti-G-CCM antibody was K562
As part of the initial screening, the supernatants from the positive hybndomas produced 
during this project were isotyped All of the antibodies produced were IgM However, 
using the isotypmg strips from Sigma (Figure 3 1 ), 3BH2 isotyped as IgG and IgM, 
with kappa light chains The Serotec isotyping kit (Table 2 1 )  consistently gave an 
isotype of IgG I and IgM for both 3BH2A3 and 2DH5A10
When these monoclonal antibodies isotyped as IgM, it was, initially, considered a 
surprising result as the mice used to produce these monoclonal antibodies had been 
hypenmmuniscd However, at this time, other researchers in D C U  attempting to 
produce monoclonal antibodies were obtaining similar results The possibility of 
infection of the balb/c colony with the mouse hepatitis virus (MHV) was suspected Ten 
serum samples from mice from the D C U mouse colony were tested by the Microbiol­
ogy Laboratories, 56 Northumberland Road, Middlesex HA2 7RE, and two mice tested 
positive, by ELISA, for MHV
MHV is a single-stranded RNA virus, family Coronavindae, genus Coronavirus MHV 
is described as being extremely contagious It is one of the most ubiquitous infections 
of laboratory mice worldwide, with reported prevalence rates often exceeding 80% 
(Committee on infectious diseases of mice and rats, 1991) MHV is a frequent 
contaminant of transplantable tumours and cell lines It has been reported to alter many 
experimental results including alterations in immune function In immunocompetent mice 
MHV infection causes, among a range of symptoms, immunosuppression or lmmuno- 
stimulation during acute infection and chronic immunodepression in persistent infection 
(Committee on infectious diseases of mice and rats, 1991) There is widespread belief
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that coronaviruses can cause asyptomatic persistent infection with virus shedding over 
a period of months In an MHV epidemic in a mouse colony, the spectrum of diseases 
range from inapparent infection to overwhelming infection and death (Holmes et a l , 
1986) MHV epidemics in laboratory animal colonies have been implicated as a possible 
cause of variability in diverse experimental protocols
MHV can infect ascitic fluid and lymphoid cells Viruses remaining in a cell, without 
overtly damaging or destroying it, can sometimes alter its specialised functions These 
features enable certain viruses to invade the very tissues and cells in which the immune 
responses are generated, causing alterations in immune function B cells can also be 
rendered immunologically ineffective by exposure to large amounts of virus (Mims, 
1986) The extensive use of mice for the production of hybridoma antibodies m ascitic 
fluid may present an opportunity for dissemination of MHV in animal colonies One 
strain of MHV (MHV-A59) can readily infect hybridoma cells generated by fusion of 
munne splenic lymphocytes with myeloma cells (Holmes et a l , 1986) It is therefore 
possible that hybndomas may become infected when, during the preparation of 
hyperimmune ascitic fluid, they are passaged in the peritoneal cavity of mice with 
inapparent MHV infections The contaminated hybridoma cells might then transmit 
MHV to other mice, thus becoming a source for spread of infection within a mouse 
colony This illustrates the importance of eliminating MHV from mouse colonies in 
order to prevent compromise of research data There is currently a commercially 
available MHV antibody test ELISA system from Organon Tekmka (Science Park, 
Milton Road, Cambridge CB4 4BH) which could be used to routinely test for the 
presence of MHV
An alternative to using mice for the production of ascitic fluid could be systems like 
Technomouse This is a recent in vitro ccll culture system from Northumbria Biologicals 
that is designed to provide an economical and automated alternative for the production 
of large amounts of monoclonal antibodies The system consists of five bioreactor 
cassettes, each equivalent in production terms to 20 laboratory mice (Product review,
1992)
It was thought initially when these antibodies isotyped as IgM that problems would be 
experienced storing and purifying the ascitic fluid obtained using these monoclonal 
antibodies However, few problems were experienced m purifying and using the ascitic 
fluid obtained from the 3BH2 and 2DH5 hybndomas In fact, when SAS-treated ascitic
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fluid from these monoclonal antibodies was examined by HPLC only one major peak 
was obtained, at 16 42mins for anti-G-CCM (Figure 3 3 2 )  and 16 86 for anti-GFAP 
(Figure 3 3 4 )  This corresponded to mouse IgG This result was confirmed by SD S- 
PAGE (Figure 3 5 )
If required, however, IgM monoclonal antibodies could have been purified by a method 
based on the low solubility of IgM in dilute salt solutions and on the ability of gel- 
permeation matrices to desalt protein solutions (Bouvet and Pires, 1991) Knutson et al 
(1991) described a method for the purification of murine monoclonal antibodies of the 
IgM class, where ascitic fluid was subjected to ammonium sulphate precipitation, gel 
filtration chromatography on Ultrogel AcA22 and finally ion exchange chromatography 
on DEAE-sepharose They found that although the antibody was greater than 85% pure 
after gel filtration and greater than 95% pure after ion exchange chromatography, only 
50% of the antibody activity was recovered after the gel filtration purification and only 
10% of the initial antibody activity was recovered after the ion exchange chromatogra­
phy Therefore, since the recovery of immunoreactive IgM antibody was the goal in this 
project, and similar findings were obtained using the protein G-purified sample in this 
study, the ammonium sulphate-treated ascitic fluid was used for applications with these 
antibodies (Knutson et a1 , 1991) Only small amounts of ascitic fluid were used for 
purification purposes as, on storage, crude ascitic fluid was found to be more stable at -  
20°C than purified antibody Crude ascitic fluid was probably more stable due to the 
higher protein concentration
It is also possible to purify IgM, and IgG, ascitic fluid using a hydroxylapatite HPLC 
under very mild conditions (Josic et a l , 1991) In their study, both types of monoclonal 
antibody were purified, the problem of precipitation of IgM antibodies at low salt 
concentrations at the beginning of a chromatographic run was avoided by adding sodium 
chloride to the separation buffers It could have also been possible to attempt to isolate 
IgGl-secreting switch variants from IgM hybndomas by a two-site ELISA (Mercken 
et a l , 1991) or by subcloning (Faguet and Agee, 1993)
The binding activity of the antibodies was initially checked by dot immunoblotting 
(Figures 3 4 1 and 3 4 2 )  A change in the commercial GFAP purchased from ICN 
Immunobiologicals (Section 3 12) was suspected by ELISA and confirmed by dot 
blotting Figure 3 4 1 showed that 2DH5 reacted with GFAP from lot 17 Dot blotting 
confirmed that 3BH2 reacted specifically with G-CCM  A positive result was also
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observed for the cell line IJK^ on all blots, including the negative control (Figure 
3 4 2 )  IJK^ was subsequently shown to be cross-contaminated with the C6 rat glioma 
cells (Section 3 12 ) and this apparently positive reaction was probably due to non­
specific binding to these cells of the secondary antibody used 
The initial Western blot used a 1 5 dilution of the 3BH2 monoclonal antibody 
supernatant and only a faint, single band was obtained when this antibody was screened 
against the G-CCM  and G-UVW cell lines This band corresponds to the band obtained 
when GFAP was probed with the commercially available anti-GFAP monoclonal 
antibody (Figure 3 6 1 )
Another Western blot was prepared (Figure 3 6 2 )  using (i) SAS-treated 3BH2 and (11) 
2DH5 ascitic fluid and a single band was obtained when each antibody was screened 
against cell membranes prepared from G-CCM and G-UVW A large band at 
approximately 50kD was seen in all cases when these two antibodies, and the 
commercially available anti-GFAP antibody, were tested against GFAP This large band 
was due to denaturation of this protein on storage or the loading of too much protein on 
the gel This result suggested that the antigen(s) recognised by these two antibodies was 
similar in nature
The affinity constants for (a) the 3BH2A3 antibody and (b) the commercially available 
anti-GFAP, showing that both antibodies reacted with GFAP, were obtained using the 
BIAcore sensor system (Borrebaeck et a l , 1992, VanCott et a l , 1992) (Section 3 15 ) 
The affinity constant for commercially available anti-GFAP against GFAP was found 
to be 9 6x l08m or1 The affinity constant for 3BH2A3 against GFAP was 2 95xl07mol~1 
Using immunocytochemistry (Section 3 16), it was seen that the antigen recognised by 
3BH2A3 was found on the cell surface and in the cytoplasm of dead cells In Figure 
3 8 7 , a cytospin preparation of G-CCM cells, incubated with the 3BH2A3 monoclonal 
antibody and stained using the APAAP detection system, showed staining of the 
astrocytic processes of G-CCM cells Preliminary in situ hybridisation experiments 
performed on mouse cultured cells with biotinylated cDNA probes indicated that specific 
GFAP mRNAs are present along astrocytic processes, suggesting a subcellular sorting 
of the GFAP (Rataboul et a l , 1988) Iwa et al (1988) showed that in astrocytomas, 
using an avidin-biotin-peroxidase complex method with a monoclonal antibody against 
GFAP, the cell bodies and processes were positive with delicate fibrillary patterns, in 
anaplastic astrocytoma, the cytoplasm and the processes were intensively stained
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From immunofluorescence studies on live cells, it was seen that the antigen recognised 
by 3BH2A3 was on the cell surface (Figure 3 9 1 ) When the G-CCM  cells were tested 
by indirect immunofluorescence using 3BH2, as the primary antibody, a green-yellow 
nng around the cell surface was clearly seen (Figure 3 9 )  This is indicative of cell 
surface localisation of the antigen recognised (Schachner, 1982) When the G-CCM  
cells were tested with the 2DH5 monoclonal antibody a fluorescent ring was also seen 
On testing G-CCM  cells with commercially obtained anti-GFAP monoclonal antibody 
by this method, no fluorescent ring was visible around the cell surface This result was 
expected as GFAP is intracellular m location and, therefore, would not be detected in 
live cells by this method These results show that the reactivity of the 3BH2 monoclonal 
antibody is immunologicaliy similar to the anti-GFAP monoclonal antibody, but is not 
identical
Cytoplasmic staining of some cells would indicate that the antigen recognised by these 
two antibodies may also be intracellular in location It was not possible to detect 
intracellular binding on live cells by immunofluorescence, but it was possible to detect 
intracellular binding on fixed, cytospin preparations
From the FACS analysis it was seen that the two antibodies recognised antigens which 
were similar but not identical The results obtained when 3BH2A3 and 2DH5A10 were 
screened against G-CCM and G-UVW were very similar However, differences were 
noticed when these antibodies were screened against other cell line Although the 
antibody concentrations were the same, the anti-G-CCM antibody reacted more strongly 
to the K562 cell line than did the anti-GFAP monoclonal antibody (Figure 3 4 10 ) In 
Figure 3 10 5 2 , the anti-GFAP antibody reacted with the cell line HL-60 (Table 2 2 )  
whereas the anti G-CCM antibody did not
These results indicate that the antigen, or antigens, recognised by the 3BH2A3 
monoclonal antibody on the G-CCM and G-UVW is located on the cell surface This 
conclusion is substantiated by (i) the positive results obtained by Western blotting of cell 
membrane preparations, (11) the result obtained by indirect immunofluoresence on live 
cells, (111) FACS analysis of these two antibodies In the case of the antigen recognised 
by 3BH2A3, it is difficult to definately confum the exact nature of the antigen 
In a study by De Murait et al (1987), among the primary cultures analysed, cells from 
21/41 malignant astrocytomas were found to contain GFAP The synthesis of this protein 
was generally observed up to the fifth passage After more than ten passages only five
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lines out of 21 which were originally positive still retained the capacity to produce 
GFAP The reactivity spectrum of the three anti-ghoma monoclonal antibodies used m 
the study of DeMuralt and co-workers demonstrated that none of them were directed 
against a true tumour-specific antigen expressed only by gliomas and not by other 
tumours or normal tissue The two monoclonal antibodies described in this study 
appeared to be directed against two antigenic determinants on the same polypeptide 
chain with an apparent molecular weight of 48kD, with similar phenotypes to GFAP 
Immunocytochemical analysis, however, showed that two of the antibodies lmmuno- 
precipitated the same polypeptide chain with an apparent molecular weight of 48kD 
From these results, it was concluded that the two monoclonal antibodies recognise two 
different antigenic determinants present on the same molecule Experiments using 
immunoperoxidase staining of frozen tissue sections in the study of DeMuralt et al 
(1987) showed that the recognised antigen is expressed not only on the cell membrane 
but also in the cytoplasm of tumour astrocytes It is possible the monoclonal antibodies 
produced in this thesis recognise the same or a similar antigen to that of DeMuralt et 
al (1987) Further work needs to be performed to investigate the antigen or epitope on 
the astrocytoma cell lines used m this thesis which are recognised by 3BH2A3 and 
2DH5A10 study
Krauss et al (1994) produced a polyclonal against the high molecular weight 
neurofilament polypeptide obtained from cytoskeletal extracts of bovine spinal cord This 
antibody reacted with the immunogen, with the middle molecular weight neurofilament 
polypeptide and with a 51kD protein, GFAP, but not with the low molecular weight 
neurofilament polypeptide When this antibody was affinity purified with GFAP, it 
reacted with both purified GFAP and high molecular weight neurofilament polypeptide 
They reported that digestion with alpha-chcmotrypsin was used to determine the 
recognition site of the affinity purified antibodies and only fragments of the tail domain 
of the high molecular weight neurofilament polypeptide reacted with the antibody They 
proposed that common epitopes exist between the variable C-tcrmmal domains of this 
neurofilament polypeptide and GFAP
The majority of primary CNS neoplasms are anaplastic astrocytomas and supratentonal 
glioblastoma multiforme Even though these tumours generally do not metastasize 
outside of the cranial vault, they carry a grave prognosis The difficulty m discerning
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the margin between the growing tumour edge and normal brain parenchyma and the 
restricted permeability of the blood-brain barrier to imaging and chemotherapeutic 
agents contribute to the difficulty in managing these diseases (Section 1 8 )  Better 
visualisation techniques could potentially aid the neurosurgeon in (a) making a decision 
to attempt surgical resection, (b) visualising and removing classically described finger- 
like extensions of the glioblastoma, and (c) minimising the removal of normal brain 
parenchyma (Kornguth et a l , 1989) The improved definition of the tumour border and 
of the finger-like extensions of glioblastomas may also permit more effective 
stereotactic interstitial irradiation of the tumour
Malignant gliomas are invariably fatal Various therapeutic regimens have been 
developed as adjuvant therapy The preparation of biocompatible materials, which bind 
tumour cells to a greater extent than they bind to vascular endothelial cells, may permit 
the development of targeting agents for delivery of molccules that are effective in 
imaging and chemotherapy (Section 1 6 )  At best, however, these regimens have only 
been modestly successful at extending survival
It is now generally agreed that the GFAP antiserum stains only astrocytes of the CNS 
GFAP is proving to be of particular diagnostic importance m the following problems
(1) the demonstration of astrocytic cellular differentiation in either pnmitative or highly 
anaplastic CNS tumours, (2) the study of mixed tumours of the CNS, (3) the diagnosis 
of gliomas invading or metastasising to the meninges and in extra neural sites, and (4) 
the exclusion of non-glial tumours that may superfically resemble astrocytomas (Eng, 
1982) The immunohistochemical technique of Eng and Rubinstein (1978) has become 
an essential tool for the more precise identification of diagnostically difficult tumours 
The following lines of evidence indicate that GFAP is the principal protein constituent 
of the glial filament (1) GFAP can be isolated from nervous tissue preferentially 
enriched in fibrous astrocytes containing glial filaments (e g multiple sclerosis plaques),
(2) antibody specific for GFAP immunocytochemically labels only astrocytes at the 
light-microscopic level and glial filaments at the electron-microscopic level, (3) 
intermediate filaments isolated from normal bovine brain and spinal cord have chemical 
properties similar to GFAP from multiple sclerosis plaques
Since the initial reports describing the use of GFAP antiserum for tumour diagnosis 
(Deck et a l , 1976), polyclonal and monoclonal antibodies to GFAP are used routinely 
m medical centers throughout the world to assist in the diagnosis of human neoplasms
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For instance, an inverse relationship between the amount of GFAP and the degree of 
anaplasia has been found for astrocyte neoplasms including glioblastomas (Eng and 
Rubinstein, 1978) The presence of GFAP continues to be the main test for the degree 
of differentiation, the degree of anaplasia (dediffercntiation), and aberrant differentiation 
for those investigators studying molecular aspects of glial neoplasms 
Distinct antigenic heterogenity is evident among and within brain tumours, and patterns 
of antigenic expression can change continuously (Section 1 8 )  Monoclonal antibodies 
that recognise these antigens facilitate the objective typing of intracranial tumours It is 
possible that antibodies, including the anti-G-CCM  and anti-GFAP monoclonal 
antibodies developed during this project, could serve as carriers for radionuclides and 
cytostatic or cytotoxic agents The principal strategy for immunologic management of 
tumours is the development of corresponding complex immunologic probes for diagnosis 
and treatment Instead of using a single probe or carrier immune complex, panels of 
monoclonal antibodies may serve as carriers for agents to detect and destroy tumours 
(Section 1 9 )
In the past, a frequent problem with anti-GFAP polyclonal antibodies was the question 
of GFAP specifity With the development of GFAP-specific monoclonal antibodies, 
these questions have been largely resolved and those monoclonal antibodies with a high 
degree of specificity can be used in diagnosis of neurosurgical tumour biopsies and in 
experimental neurooncology A retrospective immunochemical survey of 71 intracranial 
and mtraspinal neoplasms with a "cocktail" of three monoclonal antibodies to GFAP 
yielded lmmunostainmg results, with one exception, identical to those obtained with a 
highly specific polyvalent GFAP antiserum (McLendon et a l , 1986) These three 
monoclonal antibodies represent a continuous supply of well-defined, monospecific 
reagents It is hoped that the antibodies produced and characterised during this project 
could contribute to the application of monoclonal anti-GFAP antibody "cocktails" which 
may provide a standard reagent for large, multi-institutional studies of human brain 
tumours
In summary, GFAP has become an immunohistochemical marker for determining glial 
origin of many human brain tumours In this project, monoclonal antibodies against 
GFAP and the brain tumour cell line, G-CCM, were produced, purified and 
characterised The long range experimental goals of this work are to use operationally 
specific anti-glioma monoclonal antibodies for in vivo imaging and therapeutic carrier
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studies in experimental animals prior to clinical investigation The future of 
immunotherapy in the management of patients with anaplastic gliomas remains to be 
defined, however, the multi-modality approach, combining radiotherapy, chemotherapy 
and immunotherapy has a strong appeal
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SECTION 4 PRODUCTION OF ANTI-IODINATED BOLTON HUNTER 
REAGENT (IBHR) ANTIBODIES
4 Outine
The aim of this project was to produce antibodies against the lodinated Bolton-Hunter 
reagent (IBHR) This was carried out as iodine's radioisotopes have the highest specific 
activity of any radioisotope If applied to the clinical situation, as an antibody against 
radiolabelled IBHR, it could be used in the detection and localisation of tumours 
(reviewed by O’Kennedy et a l , 1993)
In order to immunise animals to produce an anti-IBHR antibody, Bolton-Hunter reagent 
(BHR) was lodinated and this IBHR was conjugated to BSA, ovalbumin (IBHR-oval) 
and KLH The protein and iodide content of these conjugates were determined The 
IBH R-BSA  conjugate was then used as an immunogen to try to produce monoclonal 
antibodies against the IBHR hapten in five balb/c mice and one New Zealand White 
rabbit The IBHR-ovalbumin and IBHR-KLH conjugates were used to screen for these 
anti-IBHR antibodies The production of monoclonal anti-IBHR antibodies was not 
successful and the polyclonal approach was chosen This rabbit polyclonal antibody was 
purified and subsequently characterised by ELISA, HPLC and SD S-PAGE It was also 
used to produce heteroconjugates between this anti-IBHR polyclonal antibody and (1) 
the monoclonal anti-G-CCM, (11) monoclonal anti-GFAP and (111) monoclonal anti-r- 
Ricin A (Section 5 ) In order to detect the presence of the heteroconjugate, by a non- 
radioactive method, the IBHR-BSA and IBHR-KLH conjugates were further labelled 
with FITC and detected by immunofluorescence and FACS
4 1 Introduction
Isotopes conjugated to antibodies have distinct clinical applications, either m diagnosis 
by immunoscintigraphy or treatment by radioimmunotherapy (O'Kennedy et a l , 1993) 
Radioactive iodine (125I) could have been used during this project as it can be detected 
with great sensitivity by simple methods that arc virtually unaffected by the reaction 
milieu and independent of other environmental factors Proteins radiolabelled with (125I) 
have the advantage that they can be easily detected (Section 1 13 ), however they have 
the disadvantage that they tend to lose activity upon storage faster than dictated by the 
half-life of the isotope (Johnstone and Thorpe, 1982) This can be explained due to a 
number of factors, (i) Radiation Destruction the products of the radioactive decay can 
damage the protein (11) Loss of Iodine the protein-iodine molecule can break down to 
release free radioiodine and protein (111) Protein Deterioration some proteins tend to
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aggregate, with subsequent loss of activity upon lodination Furthermore, radiolabels 
have drawbacks associated with health risks and in the disposal of radioactive waste 
For these reasons, non-radioactively labelled iodide was used in this project The use 
of cold iodine as a label eliminated the problems associated with the use of radioactivity 
and with the stability of the isotope A molecule, which could be readily lodinated, was 
developed in 1973 by Bolton and Hunter The molecule they used was 3-(4-hydroxy p- 
henyl) propionic acid N-hyroxysuccmimide ester, now known as Bolton-Hunter reagent 
(BHR) The BHR was developed to carry iodine which may or may not be radioactively 
labelled In this project, the IBHR was not detected using radioactivity but by measuring 
the catalytic effect of iodide on the reduction of eerie ammonium sulphate by arsemous 
acid which was first described by Sandell and Kolthoff (1934) O'Kennedy et al (1989) 
described a microassay system for the determination of iodide and iodine-containing 
compounds based on the Sandell-Kolthoff reaction This was later optimised and applied 
(Keating et a l , 1991, O’Kennedy and Keating, 1993)
4 2 lodination of the BHR and testing the purity of the IBHR produced
There are many techniques to lodmate proteins, for example MacFarlane (1958) 
introduced the use of iodine monochloride (IC1) This method can be used to lodmate 
the BHR since it is a phenol and can be lodinated under the same conditions as the 
tyrosine in proteins (Section 2 4 1 ) The important advantages of this method is that the 
total amount of iodine incorporated into the lodinated material is known and can be 
controlled simply by limiting the amount of IC1 available for lodination (Doran and 
Spar, 1980) and that the protein to be conjugated is not exposed to harsh oxidising and 
reducing agents
The punty of the IBHR preparation was tested by thin-layer chromatography on
fluorescent silica gel plates developed m ethyl acetate toluene (1 1, v/v), where,
Rf = Average spot migration = 3 833cm = 0 46 
Average solvent front 8 3cm
This was compared on the same thin-layer chromatography plate with a previous
lodination of the same BHR, this gave an Rf of 0 46 The IBHR used in O'Kennedy et
al (1989) was run simultaneously and also gave an Rf of 0 46 The difference in the
reported Rf values was due to the use of different plates
*
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4 3 Conjugation of IBHR to proteins and purification of the IBHR-protein 
product
BSA, ovalbumin and KLH were labelled with IB HR The free IBHR was separated from 
bound IBHR by gel filtration according to O'Kennedy et al (1989) (Section 2 4 6 )  This 
was done using an Ultrogel AcA44 column and 1ml fractions were collected The 
fractions which contained the free IBHR and the IBHR-protein conjugate were 
determined using the Bio-Rad micro-Bradford assay (Section 2 4 9 3 )  The absorbance 
of every sample of the IBHR-protein conjugates was taken and the readings of every 
fifth fraction is shown in Figure 4 1 The first peak on this graph represents lodmated 
protein No protein was found in the second peak by the Bio-Rad micro-Bradford 
assay This peak represents unconjugated IBHR as detected using the iodide assay 
(Section 2 4 9 2 )
In the case of IBHR-BSA, samples 18 to 30 were pooled, for the IBHR-ovalbumin 
conjugate, samples 19 to 30 were pooled and with IBH-KLH, samples 16 to 28 were 
pooled, to provide the conjugate sample
4 4 Determination of the amount of iodine in the IBHR-protein conjugates 
produced
The iodine in the conjugate was detected using an iodine assay based on the Sandell- 
Kolthoff reaction, (Sandell and Kolthoff, 1934), who first reported that a minute quantity 
of iodide could be detected by measuring its catalytic effect on the slow cerium(IV) to 
arsemc(III) reaction,
2Ce4+ + As3+--------- > 2Ce3+ + As5+
The cerium (IV) is yellow m colour but the resulting product is colourless The reaction 
can be followed spectrophotometrically by measuring the intensity of the cerium yellow 
colour after a defined time period This means that the rate of catalysis, and thus the 
amount of iodine, can be calculated by the degree of colour present which is read at 
414nm A microassay was developed and later optimised by O'Kennedy et al (1989) 
The absorbances for this iodide microassay were read each minute for 5 minutes in order 
to correlate the best data for the assay The results obtained are shown in Figure 4 2
f
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Fraction Number
Figure 4.1. Isolation of IBHR labelled BSA, ovalbumin and KLH conjugates by 
chromatography on Ultrogel AcA44 (16mm internal diameter x 360mm) The eluant 
was 0 01M PBS, pH 9 0, the flow rate was lml/min and 1ml fractions were collected 
The absorbance reading of every sample was monitored at 280nm (A280) and the 
absorbance of every fifth sample is given The first peak (fractions 16-30) represents 
the lodinated protein No protein was found in the second peak (fractions 50-70) which 
represents unconjugated IBHR
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Figure 4.2. Calculation of Iodide concentrations using the Iodide assay Absorbance 
readings taken every minute for 5min measured at 414nm (A414) from the Iodide assay 
The number of determinations (n) was 3
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4.5 Determination of the amount of protein m the IBHR-protem conjugates pro­
duced
Since IBHR hapten conjugation introduces groups into the protein (Knight and Welch, 
1978) that absorb at 280nm, the use of absorbance at 280nm as a measure of protein 
concentration is no longer accurate The protein in the conjugate may be detected using 
a varity of protein assays IBHR was found to interfere with the BCA protein assay 
(Section 2 4 9 3 )  (Smith et a l , 1985)
The assay chosen to determine piotein concentration was the Bio-Rad micro-Bradford 
assay, (Section 2 4 9 3 )  (Bradford, 1976) BHR interferes with the Bio-Rad micro- 
Bradford assay To investigate this interference a standard curve was set up with two 
sets of BSA  standards, one being spiked with a known concentration of IBHR The 
results of the extent of this interference are shown in Figure 4 4 
In order to quantify the effect of the IBHR on the results of the Bio-Rad micro- 
Bradford assay, determinations of protein concentration were made using an IBHR 
concentration equivalent to that determined m the IBH R-BSA conjugate as a zero 
control in the assay, the protein concentration could then be directly measured
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Protein Concentration (|jg/ml)
(
Figure 4.3. Absorbances read at 595nm (A595) from the Bradford microassay procedure 
to determine protein concentrations in the range 0-20/zg/ml for BSA, KLH and 
ovalbumin, the number of determinations was 3 (n=3)
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Figure 4.4. Results from the Bradford microassay procedure to investigate the 
interference of IBHR with this assay Duplicate BSA standards (0-20/xg/ml) were 
prepared and one set was spiked with 2/ig/ml IBHR The absorbance was read at 595nm 
(A595) and the number of determinations was 3
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4 6 Determination of the concentration ratios of iodide and protein in each 
coi\jugate.
The molar ratios of iodine and protein in each conjugate were calculated based on the 
following molecular weights, BHR=263 25D, 1=126 92D, BSA=68kD, KLH=3,000kD 
and ovalbumin=45kD
The protein concentrations were found to be in the same range BSA  was 7 Omg/ml, 
ovalbumin was 12 Omg/ml and KLH gave a reading of 8 Omg/ml The iodide 
concentrations were also similar, with IBHR-BSA being 161 6mg/ml, IBHR-ovalbumin 
was 136 0 and IBHR-KLH was 144 8mg/ml The IBHR to protein ratios (jig mg) show 
that BSA  has the largest number of IBHR haptens per mg of protein (BSA  has 59 
lysines of which 30-35 are available for coupling) and was, therefore, chosen as the 
immunogen in the production of anti-IBHR antibodies as it had the largest IBHR 
concentration per mg of protein The results are shown in Table 4 1
Table 4 1  The concentration of iodide and protein in the coi\jugates produced were 
determined.
Coi\jugate Iodide Cone 
</ig/ml)
Protein Cone 
(mg/ml)
IBHR Protein 
/¿gIBHR/mg protein
IBHR Protein 
Molar Ratio
IBH R-BSA 1616 7 0 23 09 1 12 4 1
IBHR-oval 136 0 12 0 1133 1 4 1 1
IBHR-KLH 144 8 8 0 1 8 1 0 1 427 9 1
4 7 Immunisation schedule for balb/c mice immunised with IBHR-BSA coi\jugate
The immunisation of the five balb/c mice with the IBH R-BSA conjugate was carried 
out as outlined in Section 2 3 6 These mice were tail bled seven days after the third 
immunisation and the absorbances obtained are shown in Table 4 2
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Table 4 2 Screening of sera from mice immunised with the IBHR-BSA conjugate 
Sera (1 100 dilution) from five mice immunised with IBHR-BSA were tested by 
ELISA against IBHR-ovalbumin and ovalbumin-coated wells on the same plate 
The absorbance was read at 620nm The absorbance readings obtained from the 
ovalbumin-coated wells were subtracted from the absorbance readings obtained 
from the IBHR-ovalbumin-coated wells in order to determine the amount of 
antibody against IBHR present in the serum The data represents the mean values 
of triplicate determinations, with the standard deviation in brackets
IBHR-BSA-immunised 
mouse number
IBHR-otal coated 
plates
Ovalbumin coated 
plates
IBHR-oval -  oval
1 0 241 (0 023) 0 167 (0 009) 0 074
2 0 368 (0 02) 0 391 (0 009) 0 000
3 0 165 (0 006) 0 085 (0 005) 0 080
4 0 450 (0 03) 0 362 (0 013) 0 088
5 0 378 (0 062) 0 092 (0 017) 0 286
The controls (n=3) used for this ELISA, with standard deviations in brackets, included,
0 01M Phosphate Buffered Saline (PBS), pH 7 3, 0 004 (0 004)
normal mouse serum, diluted 1 100 with 0 01M PBS, pH 7 3 0 018 (0 006)
and SP2/0 supernatent 0 019 (0 009)
4 8 Production of monoclonal anti-IBHR antibodies in balb/c mice
Mouse number 5 was sacrificed and a splenectomy performed (Section 2 3 9 )  An in 
vitro immunisation (Section 2 3 11) was carried out (Section 2 4 10 ) The electrofusion 
was performed under the conditions in Section 2 3 13 2
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4 9 Summary of anti-IBHR fusion, screening and cloning
IN VITRO IMMUNISATION
I
ELECTROFUSION
1
15 plates made, 111 wells contained clones which produced mouse antibodies 102 
clones reacted strongly with IBHR-BSA, 9 clones did not react with IBH R-BSA
These 102 clones were screened against BSA, 17 clones appeared initially to react with 
IBH R-BSA and not to cross-react with BSA These clones were expanded into 24-well 
plates, 4 of these clones subsequently reacted with BSA
1
The 13 remaining clones chosen for further study were the following, A1B7, A6A9, 
A6B9, A6C9, A6D8, A7A12, A7B12, C1B10, C2D5, C2E10, C5A2, C5F2, C8E9 These 
were expanded and screened against ELISA plates coated with anti-mouse IgG, IBHR- 
BSA, BSA, IBHR-KLH, KLH, IBHR-ovalbumin, ovalbumin, poly-L-lysine and 
porcine thyroglobuhn
The positive control used in these ELISAs was sera obtained from these mice by tail 
bleeding (Section 2 3 8 )  before they were sacrificed Negative controls included pre- 
lmmumsation sera and 0 01M PBS, pH 7 3, used instead of the primary antibody in 
ELISA
i
On screening by ELISA, none of the antibody-secreting clones produced an antibody 
that reacted with the IBHR hapten on IBHR-BSA conjugates and which did not react 
with the protein carrier, BSA No clones were found to react exclusively with the IBHR 
hapten on ovalbumin or KLH conjugates that did not cross-react with the carrier 
protein
4 10 Production of polyclonal anti-IBHR antibodies
As the production of a monoclonal anti-IBHR antibody was unsuccessful, the polyclonal 
approach was undertaken Seven days prior to immunisation of the four month old male 
New Zealand White rabbit, serum was obtained and was assayed for non-specific
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antibodies (Table 4 3 )  Since the maximum titre of non-specific antibodies was only 
1 400, this rabbit was considered suitable for use in the production of polyclonal 
antibodies against the IBHR This pre-immunisation serum was used as a negative 
control in ELISAs during all stages of the experiment
4 11 Immunisation of the IBHR-BSA corrugate in a New Zealand White rabbit.
The rabbit was immunised (Section 2 4 11) over an 8 month period The rabbit was bled 
at intervals, its serum was obtained (Section 2 4 1 1 1 )  and ELISAs were performed to 
obtain the titre of specific antibody (Table 4 4 )
Table 4 3 Dilutions of normal rabbit serum, taken from a New Zealand White male 
rabbit before immunisation with IBHR-BSA This was screened by ELISA against 
plates coated with IBHR-BSA, BSA, IBHR-KLH, KLH, IBHR-ovalbumin, 
ovalbumin The absorbance readings obtained from the unconjugated protein- 
coated wells (e g BSA) were subtracted from the absorbance readings obtained 
from the IBHR-protein-coated wells (e g IBHR-BSA) m order to determine the 
amount of antibody against IBHR present in the serum The absorbance of one set 
of determinations was read at 620nm (A620)
Dilution IBHR-BSA IBHR-oval IBHR-KLH
1 2 5 0 014 0295 0 0 0 0
1 50 0146 0 251 0 086
1 75 0141 0 241 0 1 4 8
1 100 01 24 01 36 0 1 6 0
1200 0 001 0 021 0 092
1 400 0 016 0 008 0 011
The controls used for this ELISA were as described in Table 4 2
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Table 4 4 Dilutions of sera taken from a New Zealand White rabbit over a period 
of 8 months after immunisation with IBHR-BSA screened by ELISA against plates 
coated with IBHR-BSA, BSA, IBHR-ovalbumin, ovalbumin, IBHR-KLH and 
KLH The absorbance readings obtained from the unconjugated protein-coated 
wells (e g BSA) were subtracted from the absorbance readings obtained from the 
IBHR-protein-coated wells (e g IBHR-BSA) in order to determine the amount of 
antibody against IBHR present in the serum The absorbance of one set of 
determinations was read at 620nm (A620) and the reading taken in each instance is 
of a 1 1000 dilution (arbitrarily chosen)
Day IBHR-BSA IBHR-oval IBHR-KLH
1 0 071 0100 0 063
30 0165 0130 0079
50 0 206 0179 0 097
80 0183 0153 0 091
120 0 330 0 515 0 478
The controls used for this ELISA were as described in Table 4 2
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Table 4 5 Dilutions of the final serum taken from a New Zealand White rabbit 
after immunisation with IBHR-BSA The serum was screened by ELISA against 
plates coated with IBHR-BSA, BSA, IBHR-ovalbumin, ovalbumin, IBHR-KLH 
and KLH The absorbance readings obtained from the unconjugated protein-coated 
wells (e g BSA) were subtracted from the absorbance readings obtained from the 
IBHR-protein-coated wells (e g IBHR-BSA) in order to determine the amount of 
antibody against IBHR present in the serum The absorbance of one set of 
determinations was read at 620nm (A620)
Dilution IBHR-BSA IBHR-oval IBHR-KLH
1 100 0 075 0 276 0 299
1 250 01 39 03 70 0 305
1 500 0113 0 321 0 324
1 750 0133 0 335 0 307
1 1000 0159 0 278 0 345
1 2500 01 88 0 282 0 321
15000 01 67 0 296 0 313
1 7500 0 261 0 244 0 262
1 10000 0 257 01 79 01 07
1 25000 01 79 0109 0105
1 50000 0181 0 069 0101
1 75000 0 084 0 000 0 032
1 100000 0 073 0 000 0 000
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4 12 Determination of the polyclonal anti-IBHR antibody titre
By immunising with a conjugate, there are antibodies produced against the carrier 
protein and the IBHR The increase in titie was monitored by test bleeds during the 
period of the immunisation schedule (Table 4 4 )  The rabbit was bled 11 days after each 
immunisation The titre of the anti-IBHR antibody from this serum was taken as
1 50,000 as it gave a positive response with IBHR-contaming conjugates (Table 4 5 )  
As can be seen from the table, the final serum, obtained when the rabbit died, gave the 
highest response to IBHR and as a large volume of serum was recovered (50ml) This 
batch of serum was used for further purification and characterisation
4 1 3  Further purification and characterisation of the anti-IBHR polyclonal 
antibody
The antibody was purified by a series of methods, each with a view to increasing the 
purity and specificity of the resulting immunoglobulins The protein concentration was 
determined following each stage of the purification procedure (Table 4 6 )
The serum was initially treated with saturated ammonium sulphate (SAS) (Section
2 4 1 1 3 )  (Table 4 7 )  and subsequently this SAS-purified serum was further purified 
by either CNBr-activated sepharose affinity chromatography (Section 2 4 12) or by 
Protein A affinity chromatography (Section 2 4 13) and the results compared by ELISA 
(Tables 4 8 1, 4 8 2 and 4 8 3 )
SAS precipitation was used to isolate all immunoglobulins, but the SAS-precipitated 
sample may contain some contaminating proteins from serum Protein A affinity 
chromatography was used to purify 1ml of the SAS-precipitated sample (protein conc 
= 27 5mg/ml) further, as only IgG antibodies are eluted from this column The 
remaining contaminating proteins were washed through the column 
CNBr-activated sepharose coupled to IBHR-BSA was used to further purify the anti- 
IBH R-BSA antibodies using another 1ml of the SAS-treated sample (Table 4 6 )  The 
anti-IBHR antibodies were eluted from the column (Section 2 4 12)
After CNBr-activated sepharose affinity chromatography, protein was found in fractions 
7, 8, 9 and 10 Following protein A affinity chromatography, protein was found m 
fractions 4, 5 and 6 The protein concentration of the crude serum and the samples from 
the various stages of anti-IBHR antibody punficationwas found using the Bradford 
assay with rabbit IgG as standard and the results are given in Table 4 6
211
Table 4 6 Determination of the protein concentration of the anti-IBHR polyclonal 
antibody at different stages of purification
Stages of purification Concentration (mg/ml)
Crude serum 6 0
SAS-purified serum 27 5
CNBr-sepharose affinity 
chromatography-purified
0 4
Protein A affinity 
chromatography-purified
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The results of the titering of the SAS-treated sera are presented in Table 4 7 The results 
of the titering of the CNBr-activated affinity chromatography and protein A affinity 
chromatography samples against (i) IBHR-BSA and BSA are given in Table 4 8 1, (n) 
IBHR-ovalbumm and ovalbumin are given m Table 4 8 2 and (m) IBHR-KLH and 
KLH are given in Table 4 8 3
4 14 Analysis of ELISAs performed on purified anti-IBHR sera
As can be seen from Table 4 7 , some of the dilutions of the SAS-treated anti-IBHR 
serum gave an excellent response to the IBHR-BSA conjugate at a titre of 1 100,000 
A difference in absorbance (at 620nm) of 0 100 between the IBHR-protein reading and 
the reading obtained from the unconjugatcd protein alone was used as the cut-off 
absorbance It was expected that a high response would be obtained against BSA  since 
that was the carrier protein of the immunogen However, the antibody response obtained 
for the SAS-treated anti-IBHR serum screened by ELISA against IBHR-ovalbumm and 
IBHR-KLH were also 1 100,000
The maximum non-specific response to ovalbumin and KLH was negligible at a dilution 
of 1 7,500, and the difference between these and their corresponding IBHR-conjugates 
absorbance readings was 0 300 approximately
The antibody-containing serum was further purified by either CNBr-sepharose affinity 
chromatography or protein A affinity chromatography As is shown in Tables 4 8 1 ,
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4 8 2 and 4 8 3, the maximum titre of the affinity sample was only 1 250, again taking 
0 100 as the cut-off absorbance On protein A affinity chromatography purification, the 
titres obtained were higher, being 1 2500 for IBH R-BSA and only 1 100 for the other 
conjugates
Due to the higher antibody titre of the SAS-purified serum, the SAS-treated anti-IBHR 
serum was used in further experiments requiring this antibody and in the production of 
heteroconjugates
4 15 Competitive ELISA to test specificity and stability of the SAS-treated anti- 
IBHR antibody
The direct ELISA was routinely used to screen for the presence of anti-IBHR 
antibodies However, a competitive checkerboard ELISA was performed, with IBHR- 
KLH and KLH as the coating antigen at 10[Ag/ml The anti-IBHR antibody was diluted 
in a range from 1 100 to 1 10,000 with a free IBHR concentration of lOjig/ml to 
40p,g/ml of IBHR These results are shown in Table 4 8 4
The stability of the SAS-precipitated anti-IBHR antibody was determined at 4°C and 
25°C in PBS, pH7 2, to determine the stability of the antibody during storage at these 
temperatures The absorbance was compared to a similar dilution of antibody (1 1000) 
stored at -20°C, tested simultaneously The result for each temperature was calculated 
as a percentage of the control and is shown m Table 4 9 This table indicated that for 
long term storage -20°C give the best results If it is not possible to store the antibody 
sample at -20°C, then the antibodies should be stored at 4°C Storage at 25°C gave a 
significant deterioration in antibody activity
The purity of the antibodies were determined by HPLC and SDS-PAGE, under non- 
reducing conditions, (Sections 4 16 and 4 17, respectively)
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Table 4 7 Dilutions of SAS-treated anti-IBHR polyclonal serum (27 5mg/ml) were 
screened by ELISA against plates coated with IBHR-BSA, BSA, IBHR-ovalbumin, 
ovalbumin, IBHR-KLH and KLH The absorbance was read at 620nm ( \ 2o)*
Dilution IBHR-BSA IBHR-oval IBHR-KLH
1 100 0 085 0197 0 285
1 250 0 090 0153 0 2 1 9
1 500 0117 0129 01 67
1 7 5 0 01 00 01 18 0 219
1 1000 0132 0152 0 257
1 2500 0 1 2 2 0151 0 2 8 2
1 5000 0130 0164 0 342
1 7500 0 256 01 90 0 258
1 10000 0 271 0173 0 293
1 25000 0213 01 99 0 208
1 50000 0 218 0 085 0 1 2 3
1 75000 0 207 01 32 0133
1 100000 0 1 6 2 01 12 0 1 1 6
The controls used in this ELISA was as described in Table 4 2
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Table 4 8 1  Anti-IBHR serum (after SAS precipitation) was further purified by 
either CNBr-activated sepharose affinity chromatography or protein A affinity 
chromatography The results were compared by diluting the purified sample in 
0 01M PBS, pH 7.3, and screening by ELISA against plates coated with IBHR-BSA 
and BSA The results shown were acquired by subtracting the absorbance obtained 
from BSA coated wells from the corresponding IBHR-BSA coated wells The 
absorbance of one set of determinations was read at 620nm (A620)
Coating IBHR-BSA BSA
Dilution CNBr sepharose 
affinity sample
Protein A 
sample
CNBr sepharose 
affinity sample
Protein A 
sample
1 100 0 241 0 583 0 074 0 354
1250 0127 0 462 0 071 0 282
1500 0 092 0 365 0 044 0174
1 750 0 075 0 293 0 031 0135
1 1000 0 068 0 240 0 000 0119
1 2500 0 064 0 207 0 000 0108
1 5000 0 048 0116 0 000 0 077
1 7500 0 000 0 088 0 000 0 000
1 10000 0 000 0 000 0 000 0 000
The controls used in this ELISA were as described in Table 4 2
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Table 4 8 2 Anti-IBHR serum (after SAS precipitation) was further purified by 
either CNBr-activated sepharose affinity chromatography or protein A affinity 
chromatography The results were compared by diluting the purified sample and 
screening by ELISA against plates coated with IBHR-ovalbumm and ovalbumin. 
The absorbance was read at 620nm (A620)
Coating IBH-ovalbumin Ovalbumin
Dilution CNBr sepharose 
affinity sample
Protein A 
sample
CNBr sepharose 
affinity sample
Protein A 
sample
1 100 0138 0156 0 041 0 059
1250 0 056 0132 0 000 0 020
1500 0 000 0 063 0 000 0 000
1 750 0 000 0 000 0 000 0 000
The controls used in this ELISA were as described in Table 4 2
Table 4 8 3 Anti-IBHR serum (after SAS precipitation) was further purified by 
either CNBr-sepharose affinity chromatography or protein A affinity chromatog­
raphy The results were compared by diluting the purified sample and screening 
by ELISA against plates coated with IBHR-KLH and KLH The absorbance was 
read at 620nm (A620)
Coating IBHR-KLH KLH
Dilution CNBr sepharose 
affinity sample
Protein A 
sample
CNBr sepharose 
affinity sample
Protein A 
sample
1 100 0103 0 169 0 033 0 040
1 250 0 041 0 077 0 000 0 000
1500 0 000 0 000 0 000 0 000
The controls used m this ELISA were as described in Table 4 2
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Table 4 8 4 Competitive ELISA used to determine the specificity of anti-IBHR 
serum (after SAS precipitation) to the IBHR antigen Plates were coated with 
10/ig/ml of IBHR-KLH and KLH, the results shown are the subtraction of these 
readings (IBHR-KLH - KLH) A range of dilutions of the anti-IBHR antibody 
(1 100 to 1 1000) with a range of dilutions of IBHR also added (10^g/ml to 
40/ug/mI) The absorbance was read at 620nm (A^o)* n=2
Concentration of competing IBHR antigen
Antibody dilution 40/tg/ml IBHR 30/ig/ml IBHR 20/ig/mI IBHR lO^g/ml IBHR
1 100 0 340 0 352 0 397 0 413
1 250 0 288 0 294 0 335 0 365
1500 0 258 0 266 0 299 0 291
1 1000 0 212 0 243 0 248 0 267
The controls used in this ELISA were as described m Table 4 2
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Table 4 9 Stability study of the SAS-precipitated anti-IBHR serum determined at 
4°C and at 25°C The results were compared to a stock dilution of antibody (1*1000 
dilution stored at -20°C) These results were obtained by ELISA on plates coated 
with IBHR-KLH and KLH These absorbances were subtracted from each other 
and calculated as a precentage of the control antibody, treated similarity The 
absorbance was read at 620nm (A620), n=3 and the SD are in brackets.
Number of days 4°C, % of control 25°C, % of control
20 83 2 (0 091) 76 7 (0 107)
40 78 9 (0 088) 69 3 (0 059)
60 74 3 (0 026) 65 0 (0 070)
4 16 HPLC analysis of the purified anti-IBHR serum
The neat serum and each of the purified samples (i e SAS-precipitated, CNBr -  
activated sepharose affinity chromatography- and protein A affinity chromatography- 
treated samples), along with commercial rabbit IgG as a standard for comparison, 
underwent HPLC analysis using a lO i^m Protein Pak SW 300 column with a mobile 
phase of 0 1M phosphate buffer, pH 7 0 and a flow rate of 0 5ml/min The resulting 
chromatograms are shown in Figures 4 5 1 to 4 5 3
218
Retention time (mins)
Figure 4.5.1
HPLC chromatogram of commercial rabbit IgG The column used was a lO^m Protein 
Pak SW 300 column with a mobile phase of 0 1M phosphate buffer, pH 7 0 and a flow 
rate of 0 5ml/min Absorbance was detected at 280nm One major peak was detected 
with a retention time of 16 39mins This is representative of rabbit IgG (150kD) The 
minor peak at 13 93min may depict contaminating protein, perhaps used to stabilise this 
antibody
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Figure 4.5.2.
HPLC chromatogram of SAS-treated anti-IBHR serum The column used was a 10^m 
 ^ Protein Pak SW 300 column with a mobile phase of 0 1M phosphate buffer, pH 7 0 and 
a flow rate of 0 5ml/min Absorbance was detected at 280nm One major peak was 
detected with a retention time of 16 35mms This corresponds to rabbit IgG The minor 
peak at 10 27min corresponds to protein eluting in the void volume of the column, 
which may be due to contaminating proteins
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Figure 4.5.3.
HPLC chromatogram of protein A affinity chromatography-punfied anti-IBHR serum 
The column used was a 10^m Protein Pak SW 300 column with a mobile phase of 
0 1M phosphate buffer, pH 7 0 and a flow rate of 0 5ml/min Absorbance was detected 
at 280nm One major peak was detected with a retention time of 16 39mins which 
represents rabbit IgG
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4 17 Electrophoresis of the anti-IBH R neat and purified antibody samples
A 5-20% (w/v) SDS-PAGE non-reducing gel was used for the detection of the neat 
and purified anti-IBHR antibody samples (Section 2 4 17) Molecular weight markers 
were also included which would allow for the determination of molecular weights of the 
various bands seen on the gel With the knowledge that an IgG molecule is approxi­
mately 150kD, the molecular weights of the bands produced from the punfied samples 
can be calculated and compared with the true weights to identify the presence of 
antibodies
Figure 4 6 1 shows the stages of the purification of the rabbit polyclonal antisera, with 
results as would be expected There were a lot of proteins in the pre-immunised serum 
and m the crude serum The SAS-treated serum contains less contaminating proteins 
and, it appeared some large molecular weight protein, which might possibly be IgM, did 
not enter the gel The sample obtained following purification by protein A affinity 
chromatography was a pure IgG band as was expected from the HPLC result (Figure 
4 6 3) The CNBr-sepharose affinity chromatography-purified sample did not show up 
on the gel, which may be due to the very low protein concentration in this sample
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1 2  3 4 5 6
Figure 4.6. A 5-20% (w/v) gradient PAGELR precast polyacrylamide gel from ATTO 
was loaded as follows; Lane (1) Pre-immune serum from rabbit, (2) anti-IBHR crude 
serum, 1:10 dilution, (3) SAS-treated anti-IBHR serum, (4) protein A affinity 
chromatography-treated anti-IBHR serum, (5) CNBr-activated sepharose affinity 
chromatography-purified anti-IBHR sample, (6) Molecular weight markers. The gel was 
run at 20mAmps per gel.
125.000
86.000
65.000
48.000
38.000 
33,500
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4 18 Fluorescent labelling of IBH R -BSA  and IB H R -K LH  by F IT C
This procedure was carried out using the IBHR-BSA and IBHR-KLH conjugates 
(Section 2 3 23 ) Protein or antibody concentrations of greater than or equal to 10mg/ml 
relative to fluorochrome concentrations of 10-20|ig/mg, favour conjugation to antibody 
(up to 70%) as discussed in Section 2 3 23 and in Goding (1976) Lower antibody 
concentrations (lmg/ml) can be used if the fluorochrome concentration is correspon­
dingly increased (lOO^g/mg of protein)
The FITC protein ratio can be calculated using a simple formula proposed by The and 
Feltkamp (1970a,b) which included a correction factor for the contribution of FITC to 
the total absorbance at 280nm (Section 2 3 23 ) The fractions were collected from a 
Sephadex G-25 column (internal diameter 32cm x 3 2cm), the absorbances of each 
sample were read at 495 and 280nm (Harlow and Lane, 1988) The results obtained are 
shown in Table 4 10 and in Figure 4 8
As can be seen from Table 4 10 , the FITC protein ratios obtained for these conjugates 
were between an absorbance (A495 -  A2b0) of 0 3 and 1 0 (Section 2 3 23 1 ) This result 
signifies that the FITC protein ratios are in the correct range and may be used directly 
The FITC-labelled conjugates were used in the detection of bifunctional antibodies 
(Section 5 1 )
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Table 4 10 Results of the absorbance of the FITC labelled IB H R -B SA  and IB H R - 
K LH  conjugates measured at 495nm (A495) and 280nm (A280) to calculate the 
FITC protein ratio
Protein Fraction No A|»5 Am* A 4 9 5  -  Ajgo
FITC-IBH R- BSA 1 0 796 0 289 0 507
FITC-IBH R-BSA 2 1098 0 346 0 752
FITC-IBHR-KLH 1 1137 0 528 0 609
FITC-IBHR-KLH 2 1447 0 539 0 908
The eluate from the column, before the samples were loaded, was used as a blank when 
obtaining these readings
4 19 Electrophoresis of IBHR conjugates on SD S-PA G E
The following samples were analysed by SDS-PAGE, 1BHR-KLH-FITC, IBHR-KLH, 
KLH, IBHR-ovalbumin, ovalbumin, IBHR-BSA-FITC, IBHR-BSA, and BSA (Figure 
4 7 )  In this gel, the IBHR conjugated samples appear similar Neither of the IBHR- 
protem-FITC conjugates were detectable, due to the low concentration of protein in 
these samples which were then analysed by absorbance spectra (Figure 4 8 )
4 20 Analysis of absorption spectra of IBH R-protein-FITC  conjugates
Spectrum analysis was carried out using a Shimadzu UV-160A UV-Visible recording 
spectrophotometer over the range 200-580nm to determine the conjugation of the 
IBHR-protein conjugate to FITC The samples examined were BSA, IBHR-BSA, 
IBH R-BSA-FITC, KLH, IBHR-KLH and IBHR-KLH-FITC and the results are 
displayed in Figures 4 8
BSA  and KLH gave similar absorption spectra to their IBHR conjugates As can be 
seen, both FITC-labelled conjugates show distinct absorbance peaks at 492 5nm for 
IBH R-BSA -FITC and 493 0 for IBHR-KLH-FITC in close agreement with the 
expected absorption peak of 495nm for FITC These FITC-labelled conjugates were 
used in the detection of heteroconjugates containing anti-lBHR polyclonal antibodies 
by immunofluorescence and FACS (Section 5 1 )
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Figure 4.7. A 5-20% (w/v) gradient PAGELR precast polyacrylamide gel from ATTO 
was loaded as follows; Lane (1) Molecular weight markers, (2) IBHR-KLH-FITC, (3) 
IBHR-KLH, (4) KLH, (5) ffiHR-ovalbumin, (6) Ovalbumin, (7) IBHR-BSA-FITC, (8) 
IBHR-BSA and (9) BSA. The gel was run at 20mAmps per gel.
Figure 4 8 1  Absorption spectrum of an IBH R-BSA -FITC sample analysed on a 
Shimadzu UV-160A UV-Visible recording spectrophotometer m the range 200-580nm
2 0 0  0 5 0  0< N M / D I U  > 5 8 0  0
1 9  4 2  8 ^ 1  1 9 3  1 5 8 0  0 NM 0  0 0 9 f l |
Figure 4 8  2 Absorption spectrum of an IBH R-KLH -FITC sample analysed on a 
Shimadzu UV-160A UV-Visible recording spectrophotometer in the range 200-580nm 
The lower line in the figure represents the absorption spectrum of the IBHR-KLH 
conjugate
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4.21 Discussion
The first aim of this project was to lodinate BHR, conjugate the IBHR to the following 
proteins, BSA, ovalbumin and KLH and to characterise the resulting conjugates 
BHR was lodinated using IC1 (Doran and Spar, 1980) and was found by thin-layer 
chromatography to be pure (O’Kennedy et a l , 1989, Section 4 2 )  The IBHR molecule 
was conjugated to BSA, KLH and ovalbumin thus circumventing the problems with 
direct lodination of proteins (Section 4 1 )  This alternative method of detecting iodine 
in the IBHR-protein conjugates has proved invaluable during this project 
For conjugation to proteins, the lodinated reagent reacts with the lysyl residues present 
in most proteins and peptides to form amide bonds (Section 4 3 )  Knight and Welch 
(1978) reported that using this method, lysine residues were labelled predominately but 
lodinated histidine and tyrosine were also produced For the production of monoclonal 
and polyclonal antibodies, this method also has the advantage that the introduction of 
the IBHR will occur at the surface lysyl moieties, and in large proteins this should occur 
randomly Therefore, the IBHR hapten should be easily recognised by the immune 
system of the injected animal
ELISAs were used extensively for the characterisation of the anti-IBHR antibodies 
produced (Section 2 4 15) This IBHR was then conjugated to BSA, ovalbumin and 
KLH (O’Kennedy et a l , 1989) and the free IBHR was separated from bound IBHR by 
gel filtration and the absorbance reading monitored The first peak was lodinated protein 
and the second peak represented unconjugated IBHR (Figure 4 1 )  These fractions from 
the first peak were pooled to give the IBHR-protein sample These conjugates were 
characterised for iodide and protein content The amount of iodide was determined using 
the Sandell-Kolthoff reaction (Sandell and Kolthoff, 1934) and the iodide microassay 
(O’Kennedy et a l , 1989)
The oxidation of arsenic by cerium is catalysed not only by inorganic iodide but also 
by iodine-containing compounds such as thyroxine, proteins and drugs (reviewed by 
Keating, 1990, O'Kennedy et a l , 1989) The Sandell-Kolthoff reaction is very sensitive 
and is, therefore, often used to determine micro amounts of these species by kinetic 
methods It has been found that the catalytic activity of iodide in organic compounds is 
inferior to that of inorganic iodide (Pantel and Wiesz, 1977) This is due to the nature 
of the side groups attached to the iodine atom on the parent molecule This has resulted 
m the concept of a relative molar coefficient of catalytic activity', F (Pantel, 1982) This
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is a measure of catalytic activity of lodo compounds in comparison to that of inorganic 
iodide Timotheou-Potamia (1988) introduced the K coefficient which is defined as the 
'catalytic activity per iodine atom of the compound', the K  value of IBHR is 33%
The readings fiom this assay at 2 minutes gave the best regression (0 995) (Table 4 2 )  
and were used to determine the IBHR content of the conjugate, assuming the catalytic 
activity of the iodine atom is not greatly affected by the nature of side groups attached 
to the benzene ring (Timotheou-Potamia, 1988) Since these side groups do not change 
appreciably when a protein is conjugated using IBHR, it is expected that the catalytic 
activity of the iodine atom attached to the protein should be similar to IBHR 
(O'Kennedy et a l , 1989)
Since IBHR hapten conjugation introduces groups into the protein (Knight and Welch, 
1978) that absorb at 280nm, the use of absorbance at 280nm as a measure of protein 
concentration was no longer accurate The protein in the conjugate may be detected 
using a vanty of protein assays IBHR was found to interfere with the BCA protein 
assay (Smith et a l , 1985), and the one chosen to determine protein concentration was 
the BioRad micro-Bradford assay, (Figure 4 3 )  (Bradford, 1976)
In order for the dye to bind, the molecule must possess a macromolecular form and an 
active aromatic functional group This makes the assay suitable for protein determina­
tion, but as BHR also satisfies this criteria, it interferes with this assay To investigate 
this interference a standard curve was set up with two sets of BSA standards, one being 
spiked with a known concentration of IBHR, the results of the extent of this interference 
are shown in Figure 4 4 This interference was found to result in a uniform increase in 
absorbance of between +0 005 and +0 022 Considering this result, determinations of 
protein content were made using an IBHR concentration equivalent to that determined 
in the conjugate as a zero control in the protein assay It would be more accurate if a 
protein assay which was not subject to IBHR interference was used The relative 
IBHR protein concentrations were obtained from these results and the IBH R-BSA 
conjugate was found to contain the highest ratio of iodine to protein (Table 4 5 )  This 
was used as immunogen in the production of anti-IBHR antibodies 
The second aim of the project was to produce, purify and characterise antibodies against 
the IBHR hapten 5 balb/c mice were immunised with IBH R-BSA in order to produce 
monoclonal anti-IBHR antibodies Their anti-IBHR titres were assayed by ELISA, the 
mouse with the highest titre was selected for monoclonal antibody production An in
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vitro immunisation was performed on the spleen cells of this mouse, followed by an 
electrofusion The clones obtained were assayed by ELISA against IBHR-BSA, BSA, 
IBHR-ovalbumin, ovalbumin, IBHR-KLH and KLH No hybndoma was obtained which 
was specific for IBHR, all reacted to some extent with the carrier protein This may 
have been because the IBHR, with a molecular weight of 390D, was too small to elicit 
an adequate immune response for monoclonal antibody production 
The polyclonal antibody approach was, therefore, undertaken and was successful A 
rabbit was immunised with IBHR-BSA over a period of 8 months The pre- 
lmmumsation serum gave a maximun non-specific anti-IBHR titre of 1 400 Following 
immunisation, the serum was purified using SAS and was then screened by ELISA, a 
titre of up to 1 100,000 was obtained However, 1 50,000 was considered the titre of this 
SAS-treated sera since it gave a positive response with IBHR-containmg conjugates and 
did not cross-react with their carrier proteins (Table 4 9 )
This serum was further purified by either protein A affinity chromatography or CNBr- 
activated affinity chromatography, which did not provide improved results Both of these 
purification techniques resulted in a much lower antibody titre against IBHR 
The purity of the antibodies were determined by HPLC and SDS-PAGE, under non­
reducing conditions, (Sections 4 16 and 4 17, respectively) The commercial rabbit IgG 
gave a large peak at 16 39min which corresponds to IgG (150kD) by HPLC (Section 
4 16 ) A minor peak at 13 93min was also observed by HPLC which may correspond 
to larger proteins introduced to stabilise this antibody The SAS-treated anti-IBHR 
serum gave a large distinct band at 16 35min, in excellent agreement with the 
commercial rabbit IgG A smaller peak was seen at 10 27min, this represents proteins 
eluting m the void volume of the column The protein A affinity chromatography-  
treated sample produced a HPLC chromatogram with a single peak at 16 32min which 
corresponds to purified IgG This showed that the sample was pure but, as was observed 
in the ELISAs (Section 4 14 ), this sample had lost most of its anti-IBHR antibody 
activity For these reasons, the SAS-purified sample was used in further applications 
with this antibody, including the production of heteroconjugates (Section 5 1 )
The purification stages of the polyclonal anti-IBHR antibody loaded on an SDS-PAGE 
gel are shown in Figure 4 6 Some contaminating proteins were seen in the SA S- 
precipitated sample The protein A-purified sample gave one band at 150,000 daltons 
which agrees with the results obtained by HPLC However, as previously mentioned, this
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sample had lost most of its activity and was not used The CNBr-activated sepharose 
affinity chromatography sample was too dilute to be seen on the gel 
The stability of this antibody was analysed and, on storage at 4°C for two months, its 
activity was shown to decrease to 74 3% of the activity of a control stock of antibody 
stored at -20°C At room temperature, its activity decreased to 65% over the same 
period Therefore, the optimum storage temperature for this antibody is -20°C but for 
short periods it may be stored at 4°C
The IBH R-BSA and IBHR-KLH conjugates were further labelled by FITC (Goding, 
1976) The fluorescein coupling was estimated by measuring the absorbance at 495nm 
and at 280nm (Harlow and Lane, 1988) (Table 4 10) The fluorescein coupling was 
confirmed by absorption spectra analysis (Figure 4 8 )  and by the use of these FITC- 
labelled conjugates in the detection of the heteroconjugates (Section 5 1 )
In summary, some of the aims of this project were achieved BHR was lodinated and 
the IBHR was conjugated to three proteins These conjugates were characterised and 
used to produce anti-IBHR antibodies The production of monoclonal anti-IBHR 
antibodies was, however, unsuccessful A polyclonal antibody was produced against the 
IBHR hapten, purified and characterised The titre of this anti-IBHR polyclonal antibody 
was 1 50,000 This purified antibody was used in the construction of heteroconjugates 
which were detected by immunofluorescence and FACS (Section 5 1 )
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SECTION 5 BISPEC IFIC  AND G EN ETICALLY EN GINEERED ANTIBO DIES
5 Outline
This portion is divided into two sections and illustrates the development of monoclonal 
antibody based reagents and their potential applications
The aim of the first section (Section 5 1 )  was to produce the following bispecific (or 
heteroconjugate) antibodies, (1) monoclonal anti-GFAP (2DH5) x polyclonal IBHR, (11) 
monoclonal anti-G-CCM (3BH2) x polyclonal IBHR, (111) monoclonal anti-GFAP x 
monoclonal anti-rRicin-A chain and ( i v )  monoclonal anti-G-CCM  x monoclonal anti- 
rRicin-A chain These heteroconjugates were characterised by ELISA, HPLC, SD S- 
PAGE and FACS
The potential of genetic engineering (Sections 1 21 to 1 24) for solving many of the 
previous problems associated with the use of murine monoclonals is encouraging In the 
second section (Section 5 2 ), an attempt was made to express the anti-G-CCM  
monoclonal antibody (Section 3 )  in E coh Messenger RNA (mRNA) from the anti-G- 
CCM hybndoma was isolated and its complementary DNA (cDNA) was produced This 
was made using specifically developed primers to amplify the regions of interest 
Following Polymerase Chain Reaction (PCR), the purified DNA was ligated and 
transformed into E coh and screened for inserts in the correct orientation
5 1 Production of bispecific antibodies
5 1 1  Introduction
Since the ability of antibodies to be therapeutically or diagnostically efficient on their 
own has been limited (Section 1 1 9 ), efforts have been made to increase the efficiency 
of monoclonal antibodies by attaching them to various agents, such as bacterial or plant 
toxins (Section 1 11), radionuclides (Section 1 13 ) and cytotoxic drugs (Section 1 7 )  
Research in the past has been concentrated on using reagents derived mainly from the 
direct conjugation of antibodies to the effector compounds These immunoconjugates 
have now been used for diagnosis and therapy (Section 1 9  to 1 12 ) Direct coupling 
of antibodies to effector compounds has some major disadvantages Chemical 
manipulation can inactivate antibody binding sites as well as cause crucial alterations
in the effector agents, thus decreasing the efficiency of the immunoconjugates
C
(Goldenberg, 1993)
These probcms have led to the development of an alternative approach for tumour
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targeting in which, instead of coupling'effector compounds directly to antibody, a multi­
stage delivery system is employed Bispecific antibodies which have two different 
antigen-specific binding binding sites, one for tumour-associated antigen and the other 
for the effector compounds, have been developed The precisely designed bispecific 
antibody is firstly targeted to the tumour site by its tumour specificity After allowing 
a suitable period of time for the non-specifically bound antibody to be cleared, the 
effector compound, which is recognised by the second specificity of the targeted 
antibody, is then injected separately, leading to its specific localisation to the tumour 
This system may minimise the toxicity in therapy and maximise the quality of tumour 
imaging These bispecific antibodies also have many potential uses, ranging from 
immunodiagnosis to targeted delivery of toxic substances to tumours (Kuzel et a l , 1993, 
Phillips et a l , 1994) They have been studied for targeting effector cells (Morelli et a l , 
1994, Weiner et a l , 1994) or toxins to tumours and initial results look very promising 
(Tepler et a l , 1994) Progress towards an understanding of the construction and use of 
bispecific antibodies in the therapy of tumours has been reviewed by Fanger et al 
(1993)
The production, purification and characterisation of the anti-GFAP and anti-G-CCM  
monoclonal antibodies was detailed in Section 3 and the description of the anti-IBHR 
polyclonal antibody can be found m Section 4 A diagram of the anti-G-CCM  x anti- 
IBHR heteroconjugate is shown in Figure 5 11  The anti-recombinant Ricin-A chain 
(rRicin-A) monoclonal antibody (608/7) used in this project was obtained from Dr 
Malcolm V Pimm (Embleton et a l , 1991), following permission to use anti-ricin-A 
chain antibody, by Dr Partick Trown, Xoma Corporation (Table 2 3 )  The rRicin-A 
chain was a gift from Dr Denis Thatcher, Zeneca Corporation (Table 2 3 )
Initially, it was planned to produce an anti-drug antibody using drugs like methotrexate, 
daunomycin ar adnamycin which have been previously used to kill cancer cells (Section 
1 7 )  and to use these antibodies in the production of heteroconjugate antibodies with the 
anti-G-CCM  antibody (Section 3 )  However, in 1992, the laboratory of Dr Ellen 
Vitetta in the University of Texas Southwestern Medical Centre at Dallas, was visited 
with the aim of learning how to handle toxins and how to assay the activity of 
immunotoxins
Immunotoxins are conjugates of a plant or animal toxin and an antibody which are 
designed for cell specific killing (Section 1 11) A commonly used toxin is ncin which
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Figure 5 .1 .1 . A diagram of the anti-G-CCM x anti-IBHR heteroconjugate antibody 
produced
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can be purified from seeds of the castor bean Ricinus communis These toxins are made 
up of two chains, A and B The A chain is responsible for the toxin’s enzymatic activity 
and the B chain is responsible for binding the toxin to receptors on the cell surface If 
the B chain is replaced by an antibody, resulting in an immunotoxin, the A chain alone 
is not toxic The preparations of lm mu noconjugates and the method for the indirect 
immunotoxin assay, which tested the antibody specificity of cultured supernatants was 
learnt in Dr Vitetta's laboratory, along with how to prepare IgG -A  and IgG -B  chain 
conjugates
It was decided that it would not be feasible to accomplish this work in D C U as the 
preparation of an immunoconjugate is tedious, difficult and expensive with lg  of Ricin- 
A chain costing $60,000 m 1992 The preparation and characterisation of any A and B 
chain would have involved testing the lethal dose (LD50) in mice, the LD50 A chain 
should be l-2m g and the LD50 B chain should be 0 5 -lm g  The immunoconjugates 
prepared using these chains would have to have been checked by radioimmunoassay or 
indirect assay In the indirect assay the immunoconjugate is incubated with cells The 
number of cells killed should be 20% greater than the number of cells killed m the 
negative control (i e antibody without toxin), to be considered specific It was therefore 
decided to obtain the anti-rRicin-A chain from Dr M V Pimm and to obtain a small 
quantity of the rRicin-A chain as a gift from the Zeneca Corporation and to use this in 
the production and initial characterisation of bifunctional antibodies 
Unfortunately, it took over two years to obtain permission from the Xoma Corporation 
to use the anti-Ricm A chain antibody for research in D C U  Owing to this, only 
limited characterisation of the heteroconjugate antibodies produced was possible
5 1 2  Production of a bispecific antibody
Bispecific antibodies are produced mainly by two methods, fusion of two different 
hybndoma cell lines, or chemically linking two antibody molecules or their derivatives 
The production and applications of bispecific antibodies have been reviewed by Nolan 
and O'Kennedy (1990) (Section 1 1 5 )
In this project, two antibodies were linked using the heterobifunctional cross-linker N - 
succinimidyl-3-(2-pyridyldithio) propionate (SPDP) This is a quick method and was 
prepared according to Bush and Winkler (1989) (Section 2 5 1 )
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5.1.3. Characterisation, by ELISA, of the bispecific heteroconjugate antibodies 
produced.
ELISAs were performed to characterised the activity of the parent antibodies and the 
heteroconjugates produced, as outlined in Section 2.3.16.3. The ELISAs procedure 
chosen depended on the target antigens and on whether the parent antibodies were of 
mouse or rabbit origin. The results are shown in Tables 5.1.1. to 5.1.4.
Table 5.1.1. Results of ELISA s to demonstrate the binding of the an ti-G -C C M  x 
anti-IBH R  bispecific heteroconjugate to G -C C M  cells, GFAP and IBHR. The 
reading for IBHR is the result of the subtraction of the absorbance obtained for 
K LH -coated wells from the absorbance obtained for IBH R -K LH -coated  wells. The 
heteroconjugate was diluted 1:1000, using 0.01M PBS, pH 7.3. The absorbance was 
read at 620nm (A620) and the number of determinations was two (n=2).
Screening of the an ti-G -C C M  x anti-IBH R heterocoi\jugate
Dilution G -CC M -coated GFAP-coated IBH R-coated
1:1000 0.391 0.204 0.263
Table 5.1.2. Results of ELISA s to demonstrate the binding of the an ti-G -C C M  x 
anti-rRicin A chain bispecific heteroconjugate to G -C C M  cells, GFAP and rRicin 
A chain. The parent antibody, at the same dilution gave a reading of 0.378 against 
rRicin A-chain. The heterocoi\jugate was diluted 1:1000, using 0.01M PBS, pH 7.3. 
The absorbance was read at 620nm (A620) and n=2.
Screening of the an ti-G -C C M  x anti-rRicin A heteroconjugate
Dilution G -CC M -coated GFAP-coated rRicin-coated
1:1000 0.345 (0.018) 0.172 (0.005) 0.244 (0.026)
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Table 5 1 3  Results of ELISA s to demonstrate the binding o f the anti-G FA P x 
anti-IBH R  bispecific heteroconjugate to G -C C M  cells, GFAP and 1BHR The 
reading for 1BHR is the result of the subtraction of the absorbance obtained for 
K LH -coated wells from the absorbance obtained for IBH R -K LH -coated  wells The 
heteroconjugate was diluted 1 1000, using 0 01M PBS, pH 7 3 The absorbance was 
read at 620nm (A620), and n=2
Screening of the anti-GFAP x anti-IBH R heteroconjugate
Dilution G -CC M -coated GFAP-coated IBH R-coated
1 1000 0140 0186 0 233
Table 5 1 4  Results of ELISA s to demonstrate the binding of the anti-G FA P x 
anti-rRicin A chain bispecific heteroconjugate to G -C C M  cells, GFAP and rRicin 
A chain The parent antibody, at the same dilution gave a reading of 0 378 against 
rRicin A-chain The heteroconjugate was diluted 1 1000, using 0 01M PBS, pH 7 3 
The absorbance was read at 620nm (A620), n=2
Screening of the anti-GFAP x anti-rRicin A heteroconjugate
Dilution G -CC M -coated GFAP-coated rRicin-coated
1 1000 0121 0 202 0186
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5 1 4  Characterisation, by HPLC, of the bispecific heterocoiyugate antibodies 
produced
The heteroconjugate antibodies were characterised by HPLC following dialysis against 
the HPLC mobile phase The column used was a lO^im Protein Pak SW 300 column 
with a mobile phase of 0 1M phosphate buffer, pH 7 0 The result of a typical hetero- 
conjugate antibody chromatogram, the anti-G-CCM  x anti-IBHR, is shown in Figure 
5 1 2  The peak at 9 95min was protein eluting m the void volume Any bifunctional 
antibody would have eluted here The peak at 16 llm in  was the parental IgG antibodies 
or breakdown of antibodies which had been in the bispecific antibody
5 1 5  Characterisation, by SD S-PAGE, of the bispecific heteroconjugate antibodies 
produced
The heteroconiugate antibodies were characterised by SDS-PAGE, the gels used were 
PAGELr precast polyacrylamide gels for electrophoresis (Section 2 1 )  The results are 
shown in Figures 5 1 2
5 1 6  Characterisation, by FACS, of the bispecific heterocoi\jugate antibodies 
produced
The heteroconjugate antibodies were characterised by FACS (2 3 20 8 )  The results are 
shown in Figures 5 2 3 The anti-G-CCM x anti-IBHR and anti-GFAP x anti-IBHR 
heteroconjugate antibodies had previously been incubated with either (l) IBH R -BSA - 
FITC or (11) IBHR-KLH-FITC (Section 2 4 18 and 4 1 8 )  The negative controls for this 
experiment are control serum (l e pre-immune serum) pre-incubated with the FITC- 
labelled IBHR-protein conjugate and the anti-IBHR antibody, pre-incubated with the 
FITC-labelled IBHR-protein conjugate Both of these controls showed no non-specific 
binding to the G-CCM or G-UVW cell lines used (Figures 5 2 3 1 and 5 2 3 2 )  The 
anti-G-CCM  or anti-GFAP arm bound the heteroconjugate to the cell and fluorescence 
was detected using the FITC-labelled IBHR-protein conjugate, no secondary antibody 
was required (Figures 5 2 3 3  to 5 2 3 6 )  The results are discussed in Section 5 2 7
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Figure 5.1.2.
HPLC chromatogram of the anti-G-CCM x anti-IBHR heteroconjugate antibody The 
column used was \0fxm Protein Pak SW 300 column with a mobile phase o f 0 1M 
phosphate buffer, pH 7 0 and a flow rate of 0 5ml/mm A major peak was detected 
with a retention time of 9 95min and a second peak was seen at 16 llm in  The peak 
at 9 95min represents proteins eluting in the void volume of the column The peak at 
16 llm in  represents the individual unconjugated parental antibodies
10
240
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Figure 5.1.2.
HPLC chromatogram of the anti-G-CCM x anti-IBHR heteroconjugate antibody The 
column used was \0fxm Protein Pak SW 300 column with a mobile phase of 0 1M 
phosphate buffer, pH 7 0 and a flow rate of 0 5ml/min A major peak was detected 
with a retention time of 9 95min and a second peak was seen at 16 11mm The peak 
at 9 95min represents proteins eluting in the void volume of the column The peak at 
16 llm in represents the individual unconjugated parental antibodies
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1 2 3 4 5  6  7 8 9  10 11 12
Figure 5.I.2 .I. A 5-20% (w/v) gradient PAGELR precast polyacrylamide gel from 
ATTO was loaded as follows; Lane (1) SAS-treated anti-IBHR rabbit antibody, (2) SAS- 
treated anti-G-CCM antibody, (3) anti-G-CCM x anti-IBHR heteroconjugate antibody, 
(4) mouse IgG standard, (5) rabbit IgG standard, not visible as may have been too 
dilute, (£) molecular weight markers, arrowed from the top (in kD) 125, 86, 65, 48, 38 
and 35.5, (7) SAS-treated anti-GFAP, (8) empty lane, (6) anti-GFAP x anti-IBHR 
heteroconjugate antibody, (10) SAS-treated anti-rRicin, (11) anti-G-CCM x anti-IBHR 
heteroconjugate antibody and (12) anti-GFAP x anti-rRicin heteroconjugate antibody. All 
samples were brought to 2mg/ml. The gel was run at 20mAmps per gel.
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(a)
CONTROL SERUM +  IB H -B S A - F IT C
W T I - I B W  ♦. IBH-BSA-PTTC
• U s/V (^ 0 6 7 V F L 1 -H N F U .-+ Ie ia h  t (b)
CONTROL SERUM + IB H -K L N - F IT C
ANT I —IfiHft -k  IB H -K L M -F IT C
#11 r .'S 'D0L868\FL 1 -H \F U  ~H« i  gh  t
(c)
*Ut /5-D0L967NFLI -HsFL I -Hei&  X
CONTROL SERUM +  IB H -B S A - F IT C  
CONTROL SERUM + IBH-k'LM-FITC 
A N T I- IB H R  ♦  IB H -B S A - F IT C  
A N T I- IB H R  + IB H -B S A - F IT C
Figure 5 ,1 .3 .1 . FACS analysis showing the negative controls used in this experiment. 
These included (i) control serum pre-incubated with the FITC-labelled IBHR-protein 
conjugate and (ii) the anti-IBHR antibody pre-incubated with the FITC-labelled IBHR- 
protein conjugate, these were then incubated with G-CCM cells. No non-specific 
binding of these negative controls were observed.
G-CCM
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(b) g-
CONTROL SERUM + IB H -K L M -F IT C
ANTI-ISHR + ISH-KLM-FITC
*-11:,/5x DOU0!88\FL 1 -H \FL  1-H®igh ».
(c)
»1.1: .'5'DOL0?9\FL!-4H\FL1-Hed gh t
CONTROL SERUM + IB H -B S A - F IT C  
CONTROL SERiJH + IB H -kL M -PiT C  
A N T I- IB H R  ♦  IB H -B S A - F IT C  
ANT I  -  IB H R  +• IS H - e ^ A r ^ IT C
Figure 5 .I .3 .2 . FACS analysis showing the negative controls used in this experiment. 
These included (i) control serum pre-incubated with the FITC-labelled IBHR-protein 
conjugate and (ii) the anti-IBHR antibody pre-incubated with the FITC-labelled IBHR- 
protein conjugate, these were then incubated with G-UVW cells. No non-specific 
binding o f these negative controls were observed.
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Figure 5.I.3.3. FACS analysis of the binding of the anti-G-CCM  (3BH2) x anti-IBHR 
heteroconjugate antibodies against G-CCM cells. The heteroconjugate had previously 
been incubated with either IBH R-BSA-FITC or IBHR-KLH-FITC. Fluorescence was 
detected using the FITC-labelled IBHR-protein conjugate, no secondary antibody was 
required.
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(a)
G-UUW
CONTROL SERUM + IB H -B S A - F IT C
3BH£.>"ANTI-IBH + IBH-BSA-FITC 
A N T I- IB H R  + IB H -B S A - F IT C
(b)
# 1 i : -''5XDCR.080VFL 1-H v F L  1-H e  i g h  i
G-UUW
CONTROL SERUM + IB H -K L M -F IT C
SBHEj 'AMT I -  IBH + IBH-KLW-FUC. 
A N T I- IB H R  ♦  IB H -K L M -F IT C
,. f 'W  W/»l"
w
Figure 5.I.3.4. FACS analysis of the binding of the anti-G-CCM  (3BH2) x anti-IBHR 
heteroconjugate antibodies against G-UVW cells. The heteroconjugate had previously 
been incubated with either IBH R-BSA-FITC or IBHR-KLH-FITC. Fluorescence was 
detected using the FITC-labelled IBHR-protein conjugate, no secondary antibody was 
required.
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Figure 5.I.3.5. FACS analysis of the binding of the anti-GFAP (2DH5) x anti-IBHR 
heteroconjugate antibodies against G-CCM cells. The heteroconjugate had previously 
been incubated with either IBHR-BSA-FITC or IBHR-KLH-FITC. Fluorescence was 
detected using the FITC-labelled IBHR-protein conjugate, no secondary antibody was 
required.
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Figure 5.I.3.6. FACS analysis of the binding of the anti-GFAP (2DH5) x anti-IBHR 
heteroconjugate antibodies against G-UVW cells. The heteroconjugate had previously 
been incubated with either IBHR-BSA-FITC or IBHR-KLH-FITC. Fluorescence was 
detected using the FITC-labelled IBHR-protein conjugate, no secondary antibody was 
required.
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5 1 7  Discussion
Targeting of toxic substances to tumour cells has been discussed (Section 1 6 )  Using 
the heteroconjugate antibody produced in this section, it would be possible to target ncin 
A-cham (Section 1 1 1 )  or radiolabelled IBHR (Section 1 1 3 )  to astrocytoma cells 
(Section 3 )  (Figure 5 1 1 )  Bifunctional antibodies have potential for many uses 
including diagnostic imaging of tumour cells, therapy and in diagnostic kits, reviewed 
by Fanger et al (1993)
In this section, bispecific heteroconjugate antibodies were made to show the potential 
application of the monoclonal antibodies produced during this project Heteroconjugate 
antibodies were generated using anti-G-CCM x anti-IBHR and anti-GFAP x anti- 
IB HR, as well as anti-G-CCM x anti-rRicin A-chain and anti-GFAP x anti-rRicin A - 
chain by the method of Bush and Winkler (1989) (Section 2 5 1 )  These antibodies were 
initially screened by ELISA (l) to determine if, m fact, heteroconjugate antibodies had 
been produced and (11) to determine if the heteroconjugate bound to both parental 
antigens In all cases (Tables 5 1 1  to 5 1 4 ), it was seen that heteroconjugate antibodies 
bound to both antigens The parental, unconjugated antibodies were not separated from 
the heteroconjugate antibodies in this system, which is a disadvantage as this may result 
in erroneous results, especially m ELISAs This was particularly a problem where both 
of the paternal antibodies were of mouse origin, in the case of anti-G-CCM  x anti- 
rRicin A-cham and anti-G-CCM x anti-rRicm A-chain In these cases, it was only 
possible to show separately that both paternal binding activities were retained in the 
heteroconjugate
It was simplei to demonstrate that a heteroconjugate antibody had been produced 
involving the rabbit anti-IBHR antibody and the murine anti-G-CCM  and anti-GFAP 
This was achieved by coating the ELISA plates with G-CCM  or GFAP and using 
alkahne-phosphatase-labelled anti-rabbit antibody as the secondary antibody The 
results in Tables 5 11  to 5 1 4 suggest that heteroconjugate antibodies were produced 
which retained binding affinities for (i) IBHR and G-CCM  and (11) IBHR and GFAP 
The unconjugated parent antibodies were also screened against the opposite antigen of 
the heteroconjugate to ensure there was no non-specific cross-binding In all cases, 
non-specific binding was seen up to a dilution of 1 200, this was due to the high 
concentration of antibody No non-specific binding was seen at the 1 1000 dilution used 
This method (Bush and Winkler, 1989) using the hctcrobifunctional cross-linker, SPDP,
248
was fast and reliable A disadvantage of this method is the large size of the resultant 
heteroconjugate antibodies and, as already mentioned, the heteroconjugate antibodies 
were not separated from the parental antibodies The bispecific heteroconjugate 
antibodies were then assessed by HPLC In all cases, following dialysis against the 
HPLC mobile phase buffer, 0 1M phosphate buffer, pH 7 0, a peak was seen at 
approximately ten minutes and sixteen minutes It was considered the first peak, which 
eluted in the void volume, may have been the heteroconjugate antibody and the second 
peak was unconjugated, parental antibody as it eluted at the same retention time as 
rabbit and mouse IgG
This assumption was confirmed by SDS-PAGE (Figure 5 1 2 )  where, on lanes 
containing heteroconjugate antibody samples, bands were seen corresponding to IgG and 
protein was seen at the top of the heteroconjugate lanes which may have been the 
heteroconjugate antibody which was too big, at 300 kD, to enter the gel 
The heteroconjugate antibodies were analysed by FACS (Section 2 3 20 8) The negative 
controls used in this experiment (Figures 5 1 3 1  and 5 13  2 )  were the G-CCM  (or G - 
UVW) cells incubated with rabbit control serum (Section 4 ) which had previously been 
incubated with either IBHR-KLH-FITC or IBH R-BSA-FITC It was seen that the peak 
obtained was exactly the same as the peak obtained when 0 01M PBS, pH7 2, was used 
A  similar result was seen when the anti-IBHR antibody was premcubated with IBHR- 
BSA -FITC or IBHR-KLH-FITC
In Figures 5 13  3 and 5 1 3 4 ,  the binding of the anti-G-CCM  (3BH2) x anti-IBHR 
heteroconjugate antibody was assessed against the G-CCM  and G-UVW cell lines It 
was seen that a broad peak was obtained, which was quite distinct from the negative 
control peak This is the type of band obtained with a heteroconjugate antibody (Dr 
Tom Cotter, St Patrick's College, University of Maynooth, personal communication) 
This result was important as it showed definitively that (l) the anti-G-CCM  antibody 
bound to G-CCM  and G-UVW cells, (11) the anti-IBHR antibody bound to the IBHR 
present in the IBHR-piotein-FITC conjugate, as the FITC-labelled protein was the 
detection method used by FACS in this experiment, and (m) that heteroconjugate 
antibodies involving the anti-G-CCM x anti-IBHR antibodies were produced A similar 
result was observed when the anti-GFAP (2DH5) x anti-IBHR heteroconjugate 
antibody, demonstrating that although this antibody was against GFAP, it also bound to 
a GFAP-hke antigen on live G-CCM and G-UVW cells (Section 3 19 )
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The bispecific antibodies produced m this project could be used to target radiolabelled 
131I to astrocytoma cells, if radiolabelled iodine was subsituted for non-radiolabelled 
iodine in the IBHR A pre-targeting method could be used where the heteroconjugate 
could be introduced in vivo and given time to localise to the tumour and its metastases, 
if present When the non-specifically bound heteroconjugate was eliminated, the 
131IBHR could be administered and localised by tomographic scanning or imaging Such 
heteroconjugates could be clinically applied in diagnosis by immunoscintigraphy or 
treatment by radioimmunotherapy
Bispecific antibodies have potential for a wide range of clinical applications (Fanger et 
a l , 1993) It is hoped that the potential uses of monoclonal antibodies can be fully 
exploited, both therapeutically and diagnostically, in the future using heteroconjugate 
antibodies
In summary, heteroconjugate antibodies were produced during this project using the 
anti-G-CCM , anti-GFAP, anti-IBHR and anti-Ricin A chain antibodies These 
heteroconjugate antibodies were characterised by ELISA, SDS-PAGE, HPLC and 
FACS
V
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5 2 Genetic engineering of monoclonal antibodies
5 2 1  Introduction
The potential of genetic engineering for solving many of the previous problems associ­
ated with the use of murine monoclonal antibodies has been discussed in Sections 1 21 
to 1 24 This area has been reviewed by Hand et al (1994)
Antibodies are humanised (Section 1 2 3 ) by grafting the murine CDRs onto a human 
variable region framework (Reichmann et a l , 1988) Roguska et al (1994) achieved a 
further advance by "resurfacing" or replacing only the surface residues of the mouse 
variable framework region with those from a human variable region (Section 1 2 4 ) 
These techniques also allow for the creation of novel antibodies, such as catalytic 
(Section 6 ) and bifunctional antibodies and can optimize the performance of existing 
antibodies (Section 5 1 )
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5 2 2 Large scale production of antibodies or antibody fragments
The genetics of antibody production have been reviewed by O'Kennedy and Roben 
(1991), a diagram of the antibody domains is shown in Figure 5 2 1  At present, the 
major production methods for monoclonal antibodies involve the use of animals for 
ascites fluid generation and large scale cell culture Although the production of ascites 
fluid gives good yields difficulties exist, which are discussed m Section 1 5 These 
difficulties have resulted in research aimed at the generation of antibodies by genetic 
means using a range of expression systems including yeast, bacteria, baculovirus and 
plants While these technologies are still to be optimised they offer exciting new 
methods for antibody production on a large scale (Cahill et a l , m press)
The use of bacteriophage systems may prove more powerful than bacterial expression 
systems for the generation of high—titre combinatorial libraries (Cunningham and Hams, 
1992) (Figure 5 2 2) The expression of Fv or Fab antibody fragments on the surface of 
bacteriophage has facilitated efficient screening of large numbers of phage clones (>107) 
for antigen-binding activity Phage which binds specifically to antigen-coated plates or 
columns can then be eluted, propagated and re-screened against antigen Mark et al 
(1991) reported the screening of 2xl07 cloned human immunoglobulin genes from an 
ummmumsed human donor by this method, obtaining antigen-specific antibody 
fragments of moderate affinity The production of human antibodies using bacteriophage 
enables human antibody fragments of high affinity and specificity to be produced 
without immunisation This area has been reviewed by Griffiths (1993)
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1HEAVY
Figure 5 2 1. Diagram of antibody domains The variable and heavy chains of a 
complete antibody are shown The protein regions of a mature antibody corresponding 
to the DNA regions amplified by the PCR primers used in this study (Table 5 2 1 ) are 
shown with arrows (not to scale) The explaination of symbols are, H =  heavy chain, 
L  =  light chain, C =  constant region, V =  variable region, J  =  joining region, D =  
diversity region, CDR =  complementary determining region and FR =  framework region
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Figure 5.2.2. Overview of the Recombinant Phage Antibody System from Pharmacia 
(1992).
Purification and 
into pCANTAB 5 E
into 
E. coli TG1
Rescue
Phage
against Antigen
of E. coll TG1 
Eluted Phage
Plate Rescue 
and Growth 
of Colonies
Plate Rescue (cont.) 
Phage Rescue and 
Recombinant Phage 
Antibody Expression
Blots,
ELISAS,
Western Blots with Antigen
K07 helper
of £. coli HB2151
of Culture 
Colony
of
Antibodies
Blot Analysis
K07 helper
254
5 2 3 Vectors and hosts in the cloning of antibody genes
To engineer antibodies, the antibody genes to be used are first cloned into eukaryotic 
expression vectors The most commonly used are the pSV2 plasmids (Mulligan and 
Berg, 1981) as they contain (1) a plasmid origin of replication, (11) a marker for selection 
in bacteria and (111) a dominant selection marker for eukaryotic cells A  common 
selection marker for eukaryotic cells is the E coh gene encoding the xanthine-guamne 
phosphoribosyltransferase This allows cells to grow in the presence of mycophenohc 
acid, provided xanthine is present, which inactivates G418, an antibiotic that prevents 
eukaryotic cell synthesis (Tan and Morrison, 1988) In this project, the plasmids used 
for the initial phases were pTACOlH for the heavy chain gene and pTCOl for the light 
chain (Figure 5 2 3 (a) and (b)) These could then be excised and re-ligated sequentially 
into the pComb3 system (Figure 5 2 4 )  which enables the expression of engineered 
antibodies m E coh This pComb3 vector was constructed to fuse antibody Fd chains 
(comprising of VH and CH1 domains with the C-ternnnal domain of cpIII (Figure 5 2 5 )  
The Fd/cpIII fusion and light chain proteins were placed under the control of the lac 
promoter/operator sequences and directed to the periplasmic space by pelB  leader 
sequences for functional assembly on the membrane
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EcoR I Hind m
Figure 5.2.3.(a) and (b). The plasmids pTACOlH and pTCOl The heavy chain PCR 
fragments were ligated to the pTACOlH plasmid, which cam es the carbemcilhn 
resistance gene and the light chain PCR fragments were ligated to pTCOl which cames 
the chloramphenicol resistance gene
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Figure 5.2.4. A detailed diagram of the pComb vector showing the regions where DNA 
fragments for the antibody heavy and light chain can be inserted when used to secrete 
antibody fragments
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Figure 5.2.5.
The pComb vector showing how it can be used as a phagemid expressing soluble Fab 
fragments
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5 2 4 Overview of expression of murine monoclonal antibodies in E coll.
The 3BH2A3 hybndoma cells (Section 3 )  were grown in culture and the mRNA 
isolated using oligio-(dT)-cellulose spun columns This mRNA was used as a template 
for the synthesis of the first cDNA strand using reverse transcriptase This mRNA- 
cDNA hybrid was used as the template for PCR By developing probes specific for the 
conserved sequences in antibodies, only the required DNA was amplified and could be 
subsequently purified by column chromatography or electrophoresis In this way, the 
specific antibody DNA can be isolated from hybndoma cells If a mouse-human 
chimaeric antibody was obtained, it could be detected by ELISA (Mixter et a l , 1986)
5 2 5 Purification and quantification of the PCR primers
The primers were purified from their columns (Section 2 3 30 7 )  and quantified (Section 
2 3 30 8 ) To confirm these primers were purified correctly from their columns, they 
were run on a 4% Nusieve agarose gel (Figure 5 2 5 )
5 2 6  Results of mRNA isolation
In order to genetically engineer or humanise the mouse monoclonals produced against 
G-CCM  (Section 3 )> mRNA was isolated from the rapidly growing hybndoma cell line, 
3BH2 clone A3, at a cell count of 1 59xl07 using the QuickPrep mRNA punfication kit 
from Pharmacia, according to Section 2 3 30 3 This kit is designed for the direct 
isolation of polyadenylated RNA from eukaryotic cells and tissues, bypassing the need 
for intermediate purification of total RNA
The precautions regarding removal of all RNAses from glassware, plastics and reagents 
to be employed in the isolation and use of mRNA were strictly followed These are 
outlined in Section 2 3 30 1
The mRNA was quantitated using the Shimadzu UV-160A UV-Visible recording 
spectrophotometer Knowing that for RNA, 1 A260 unit = 40fxg/ml, the concentration of 
the RNA present, was calculated using the following formula 
[RNA] = A260 x D x 40(iig/ml
where D = final dilution factor, in the simpliest case above, this would be 2 
If the absorbance of the diluted sample was greater than or equal to 0 5, the sample may 
be used directly for cDNA synthesis (Section 2 3 30 9 ) If the absorbance was less than 
0 5, the sample must be precipitated and redissolved at a higher concentration to ensure
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efficient cDNA synthesis (Pharmacia, 1991) This method is rapid, but has the 
disadvantage that it requires 1/3 of the mRNA sample A total of 4 71fxg mRNA was 
obtained This was sufficient, as 0 5jig was required per cDNA reaction
5 2 7 Results of cDNA synthesis and PCR
The mRNA was immediately used as a template for the synthesis of the first strand of 
cDNA using reverse transcriptase (Section 2 3 30 9 ) The primers were used m the 
combinations outlined in Table 5 2 1  for the three PCR reactions (Section 2 3 30 6 ) As 
a negative control, the PCR reactions were preformed without template DNA The 
results of these PCR reactions are shown in Figure 5 2 7
Table 5 2 1  Primer combinations used in the three cDNA and PCR reactions (RXN)
RXN 1 RXN 2 RXN 3
VKFOR
VKCBAC2
1 HEAVY 
HCH1BAC2
1 HEAVY 
HCH2
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Figure 5 2 6  Determination of the presence of the 5 different DNA primers following 
their elution from primer columns The primers are as follows, Lane (1) HCH2, (2) 
VKCBAC2, (3) 1 HEAVY, (4) VKFOR and (5) HCH1BAC2
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1353 bp 
1078 
872 
603 
310
271, 281
1 2 3 4 5 6 7 8 9  10
Figure 5 2 7 Results of the initial PCR experiments to amplify regions of the 3BH2A3 
genomic DNA The gel was loaded as follows, Lane (1) RXN3, (2) RXN3, negative 
control, (3) RXN2, (4) RXN2, negative control, (5) RXN1, (6 ) RXN1, negative control, 
(7) <j)X174¡Hae III MWM, in base pairs (bp), (8 ) and (9) Positive controls and (10) 
Negative control
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5 2 8  Optimisation of PCR reactions
From Figure 5 2 7 ,  a band can be seen for reactions 2 and 3 and no band is seen in 
their negative controls, these bands correspond to 660 and 735 base pairs (bp), 
respectively, which agree with the base pair lengths of the corresponding amplified DNA 
regions shown in Figure 5 2 2 The light chain reaction was initially unsucessful, which 
could be due to an inability of the light chain primers to bind the template DNA The 
three PCR reactions were optimised and the results are shown for the heavy chain 
reactions in Figure 5 2 7 and for the light chain reactions in Figure 5 2 8 
The heavy chain reactions both gave one defined band on a gel (Figure 5 2 7 )  and were 
purified from contaminating amplification primers and nucleotides using the Magic PCR 
preps™ purification system from Promega (Section 2 3 30 16 ) Due to the lack of 
success in the PCR amplification of the light chain reaction in Figure 5 2 8 , the DNA 
from the band corresponding to the molecular weight of this fragment (660bp) was 
excised carefully from the gel and was also purified using the "Magic" PCR preps™ 
purification system (Section 2 3 30 16 ) This was used as a template for PCR but again 
no band was seen
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Figure 5.2.8. Results of the optimised PCR experiments to amplify regions of the 
3BH2A3 heavy chain genomic DNA. The gel was loaded as follows; Lane (1) RXN3,
(2) RXN2, (3) and (4) RXN3, (5) and (7) RXN2, (6) <|>X174iHae III MWM (bp), (8) 
and (9) negative controls for RXN3 and RXN2 respectively. Both PCR reactions in lanes
(1) and (2) produced one clear band at a molecular weight of approximately 735bp, in 
lane 1, and 660bp, in lane 2. The PCR reactions in lanes (3), (4), (5) and (7) were under 
different conditions to those in lanes (1) and (2) and were unsuccessful.
1 2 3  4 5  6 7 8 9
Figure 5.2.9. Results of the optimised PCR experiments to amplify regions of the 
3BH2A3 light chain genomic DNA. The gel was loaded as follows; Lane (1), (2) and
(3) RXN1, (4) and (5) RXN1, which showed a series of bands (6) RXN1, negative 
control, (7) and (8) negative controls, (9) <t>X174IHae III MWM (bp).
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5 2 9 Results of the cloning of the amplified DNA
The purified PCR fragments were digested with their appropriate restriction enzymes 
(Section 2 3 30 6 )  before being ligated to their respective plasmids (Section 2 3 30 19 ) 
The heavy chain reactions were ligated to the pTACOlH plasmid, which carries the 
carbemcillin resistance gene and the light chain was ligated to pTCOl which carries the 
chloramphenicol resistance gene These plasmids were specially prepared for ligation by 
treatment with calf intestinal phosphatase (Section 2 3 30 18 ) which is shown in Figure 
5 2 10
The plasmids were prepared according to Section 2 3 30 18 (Bimboim and Doly, 1979) 
20ng were used at lOng/jil in the electroporation procedure (Section 2 3 30 2 1 ) Positive 
and negative controls were performed at all stages of the experiment The ligated 
plasmids were transformed by electroporation (Section 2 3 30 2 1 ) into electrocompetent 
E  coh TGI cells (Section 2 3 30 20 ) Antibiotics were prepared according to Section 
2 3 30 23 and the transformed E coh cells were spread onto agar plates containing the 
appropriate antibiotic
Colonies were obtained on the test antibiotic plates and these were screened for inserts 
according to Section 2 3 30 22 by punfying the plasmid DNA from the E coll cells, 
restricting the plasmid with the appropriate restriction enzymes and observing the 
digestion pattern on a 4% agarose gel The orientation of the insert in the plasmid is 
also important The antibody fragments will only be produced if the insert is in the 
correct orientation and position with regard to the promoter (Figure 5 2 4 (b)) The 
orientation of inserts can be found by PCR cloning (Innis et a l , 1988) and analysis of 
their restriction patterns (Sambrook et a l , 1989) However, of the clones obtained, no 
clone contained the heavy chain insert in the correct orientation Due to time constraints, 
this transformation was not repeated These results are further discussed in Section 
5 2 10
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Figure 5.2.10. Gel showing preparation of plasmids pTACOlH and pTCOl for ligation 
with purified PCR fragments. Lane (1) MWM (Gibco 1Kb ladder), (2) pTCOl, (3) 
pTCOl RNase treated, (4) pTCOl RNase treated cut with Xbal and SacI, (5) pTCOl 
RNase treated cut with Xba I and Sac I and treated with calf intestine phosphatase, (6) 
pTACOlH, (7) pTACOlH RNase treated, (8) pTACOlH RNase treated cut with Xho 
I and Spe I, (9) pTACOlH RNase treated cut with Xho I and Spe I and treated with calf 
intestine phosphatase.
5 2 17 Discussion
Hand et al (1994) reviewed the development of novel immunoglobulin forms and 
proposed that such genetic modifications may result in more useful diagnostic reagents 
and in the production of more stable immunoconjugates with the characteristics of more 
efficient tumour cell killing While the use of phage to express antibodies is still a new 
technology, many groups are already using bacterial expression vectors for the 
production of antibody fragments Using the phage system (Cunningham and Hams, 
1992) (Figure 5 2 2), each phage mimics a B cell in that each phage displays an 
antibody fragment on its surface Only l-10m g of antibody fragments per litre of culture 
broth could be produced using routine laboratory culture methods Antibody-fragment 
production in the gram per litre range appears to be achieveable when fermentor systems 
are used The combination of using technology for generating novel antibodies and 
bacterial-host expression systems using fermentation techniques to produce large 
quantities of Fab or Fab'2 fragments could mean that, before long, traditional munne 
immunisation protocols may become redundant Pharmacia, in collaboration with 
Cambridge Antibody Technology L td , U K , have developed a Recombinant Phage 
Antibody System designed for the cloning and expression of recombinant antibody 
fragments in bacteria This approach is based on that developed by McCafferty et al 
(1990) and Winter and Milstcin, (1991) This approach relies on a phage-display system 
in which fragments of antibodies are expressed as fusion protein on the phage surface 
The outline of this system is shown in Figure 5 2 2 (Pharmacia, 1992)
The choice of host for the antibody genes is paramount In eukaryotes, the heavy and 
light chains arc secreted into the lumen of the endoplasmic reticulum where folding and 
disulphide bond formation occurs (Piuckthun et a l , 1988) The host cell should, if 
possible, mimic this process if functional antibody products are to be obtained 
For a bacterial host to express functional antibodies or antibody fragments it must, (l) 
synthesise approximately equal numbers of heavy and light chains, (11) transport the 
chain precursors to the periplasm (functionally equivalent to the endoplasmic reticulum), 
(in) align the chains correctly, ( i v )  fold correctly, (v) form disulphide bonds and (vi) 
form heterodimers These criteria were realised in E coh (Piuckthun, 1990) It is also
important that the gene sequences transfected contain many unique restriction sites and
f
do not contain any codons consideied foreign to E coh
Yeast could also be used as a host since it does not have the problems associated with
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folding, bond formation, etc as m ‘'É' coh, and its expression systems are well 
understood The secreted antibody from yeast has, however, been found not to bind to
P
the antigen (Horowitz et a l , 1988) Further studies have been undertaken using insects 
(Hasemann and Capra, 1990) and transgenic plants with varying degrees of success 
Hiatt et al (1989) showed that it was possible to express antibodies m plants with 1 3% 
of total leaf protein found to be functional antibody
Transfection is another difficulty, especially with yeast cells The whole process is very 
inefficient with less than 10~4 cells being stably transformed Calcium phosphate 
precipitation of the DNA (Chu and Sharp, 1981) is a common method but the success 
rate is very low (Oi and Morrison, 1986) Protoplast fusion provides a better method (Oi 
and Morrison, 1986) with frequencies of up to 10“3 and better were obtained with the 
myeloma line J558L (Gillies et a l , 1983) Electroporation is another technique that can 
be used It is quick and simple but the DNA has to be specially prepared (Toneguzzo 
et a l , 1986)
In this project, mRNA from the 3BH2A3 hybridoma (Section 3 )  was successfully 
isolated using the QuickPrep mRNA purification kit from Pharmacia (Section 2 3 30 9) 
This was quantified spectrophotometncally and a total of 4 71[xg mRNA was obtained 
This was sufficient, as only 0 5^ig was required per cDNA reaction The cDNA was 
prepared immediately, as RNA is less stable than DNA The cDNA was amplified using 
specifically developed primers to amplify the regions of interest (Table 5 2 1 )  by PCR 
Following PCR, it was seen that single bands were obtained for reactions 2 and 3, both 
heavy chain reactions No band was seen for the light chain reactions (RXN1) This 
could be due to the degradation of the mRNA for this reaction, or more probably, the 
light chain primers were not specific for this region (Section 2 3 30 5 ) Since it has been 
reported by Orlandi et al (1989) and Ward et al (1989) that much of the specific 
antigen-binding capability resides in the variable region of the heavy chain, and they 
have produced single domain antibodies, consisting only of the variable heavy chain 
region (Figure 5 2 1 ), it was decided to attempt to clone and express the heavy chain 
The plasmid DNA was prepared (Figure 5 2 9) and the purified DNA was ligated and 
transformed into E coh The plasmid DNA from the clones produced (Section 
2 3 30 2 2 ) was screened for the presence of inserts in the correct orientation by 
restriction enzyme analysis (Sambrook et a l , 1989) No inserts in the correct orientation 
were obtained
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This transformation was not repeated*due to insufficient time Future work would 
involve repeating the transformation to obtain a clone containing the DNA encoding the 
variable regions of the 3BH2A3 monoclonal antibody heavy chain, with and without the 
hinge region (Figure 5 2 1 ) Had an insert m the correct orientation been found, it would 
have been digested with the appropriate restriction enzymes and would be cloned into 
the pComb expression vector The clones which contained the VH and V* gene inserts 
would have been confirmed by sequencing as most of the recombinants would be 
expected to carry the correct inserts Any functional antibody obtained, would have been 
detected by ELISA (Mixter et a l , 1986) and the results compared to the parent anti-G- 
CCM antibody (Section 3 )  As an alternative to sequencing independent clones, the 
amplified cDNA could be sequenced directly (Innis et a l , 1988) Work was halted on 
this project due to insufficient time and may be resumed in the future
Antibody engineering has created new exciting fields of study and is helping to optimise 
the older ones Bifunctional antibodies have potential for many uses including imaging, 
therapy and diagnostic kits (Section 118) There are two mam methods for their 
production, chcmical and biological The chemical method involves the chemical linkage 
of two F(ab’) fragments (Nolan and O'Kennedy, 1990, Section 5 1 )  and the biological 
is based on somatic cell hybridization Such bifuctional antibodies are active in their 
native state and need no chemical alteration to bind either the target or the functional 
agent In the future, it may also be possible to create tn— and multi-functional 
antibodies using antibody engineering
In summary, an unsuccessful attempt was made to express the anti-G-CCM  antibody, 
3BH2A3, (Section 3 ) in E coh (Section 5 2 )  mRNA was isolated from the hybndoma 
cells, cDNA was produced Primers weie constructed to amplify the regions encoding 
the antibody heavy and light chains from the cDNA by PCR This was successful for 
the heavy chain PCR reactions but not for the light chain reactions The DNA from the 
heavy chain gene reactions was ligated to the pTAOlH plasmid and transformed into E  
coh No inserts m the correct orientation were obtained
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SECTIO N  6  PRODUCTION AND CHARACTERISATION OF CA TA LYTIC 
ANTIBODIES
6  Outline
This section is concerned with the application of polyclonal and monoclonal catalytic 
antibodies which would catalyse the hydiolysis of the mixed aryl 4-mtrophenyl 
carbonate (1), but would not catalysis the hydrolysis of the isomeric 2-mtrophenyl 
carbonate (II) The polyclonal antibody raised in sheep which catalysed this reaction was 
obtained from Dr Gerry Gallacher (Table 2 3 )  and was purified and analysed for 
catalysis The results obtained were in close agreement with those obtained by Gallacher 
et al (1991) A number of attempts were made to produce monoclonal antibodies of the 
IgG isotype, but only IgM antibodies were obtained The most promising of these were 
grown as an ascites (Section 2 3 17), the antibody was purified and characterised by 
ELISA, HPLC, SDS-PAGE and catalytic activity
i
6  1 Catalytic antibodies, transition states and their analogues
Recent developments and applications of catalytic antibodies have been discussed 
(Section 1 2 0 ) In the short period of time which has elapsed since the first reports of 
antibody catalysis in 1986 (Pollack et a l , 1986, Tramontano et a l , 1986) a considerable 
number of leactions have been catalysed using antibodies The substrate specificities of 
antibody catalysed reactions are high and rate accelerations of up to 106 have been 
achieved (Tramontano et a l , 1988) A number of general stratagies have also evolved 
for generating catalytic antibodies including transition state stabilisation, catalysis by 
approximation, introduction of catalytic groups via hapten-antibody complementarity 
and chemical modification, generation of cofactor binding sites and site-directed 
mutagenesis (Shokat and Schultz, 1990) Characterisation of catalytic antibodies is 
providing insights into fundamental notions of enzymatic catalysis 
The concept of catalytic antibodies is by no means a new one In 1946, Linus Pauling 
hinted at the possibility (Pauling, 1946) In 1952, Woolley suggested that if 'antibodies 
were challenged continuously and for long periods of time, they might evolve to become 
enzymes' (Woolley, 1952) In 1969, Jenks stated that it should be possible to find 
antibodies with catalytic properties The first attempts to elicit such antibodies were 
made by Raso and Stollar in 1975 Although unsuccessful, their research prompted other 
groups to begin working in the area but it was not until Kohen et al (1980) demon­
strated that monoclonal antibodies against 2,4,-di-mtro-phenyl (DNP) were able to 
enhance the hydiolysis of DNP-e-amino-caproyl-umbelliferone conjugate implying that
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these antibodies have quasi-enzymatic properties akin to those observed m anti-steroidal 
antibodies Apart from their fundamental importance, such antibodies are interesting as 
they may prove useful as ’made-to-measure’ reagents to induce specific hydrolytic 
reactions The first catalytic antibodies were produced by Tramontano et al (1986) and 
Pollack et al (1986) Since then, antibodies have been generated against a variety of 
haptens to catalyse various leactions including carbonate, ester and amide hydrolysis 
(reviewed in Nakayama and Schultz, 1991) Antibodies which catalyse Claisen 
rearrangements (Hilvert et a l , 1988), redox reactions (Shokat et a l , 1988), disfavoured 
reactions (Danishefsky, 1993, Janda et a l , 1993) and cationic cyclisation (Li et al, 
1994) have now been produced
Pauling stated that the fundamental difference between antibodies and enzymes was that 
enzymes bind transition states while antibodies bind ground states (Pauling, 1946) He 
also predicted that a stable substance might mimic the transition state in shape and 
charge He suggested that one way in which enzymes lower the activation energy of a 
reaction is to bind most strongly to the tiansition state and, thereby, stabilising it Less 
energy is then needed for its formation and thus, the reaction is accelerated (Lerner and 
Tramontano, 1988) Enzymes use a variety of methods to lower the activation energy 
of a reaction including transition state stabilization, general acid-base catalysis, strain 
and proximity effects Although enzymes use several of these mechanisms simulta­
neously, catalytic antibodies usually employ just one However, the specificity of 
antibody-catalysed reactions may be very high and oftens rivals or even exceeds that 
of enzyme-catalysed reactions (Lernei et a l , 1991) The reactions are not catalysed to 
the same extent as enzymatic reactions as yet, but typically they proceed 103-106 times 
faster than the uncatalysed reactions
The whole idea of catalysis is to lower the activation energy of a given reaction 
Without a catalyst, most biochemical reactions would be impossibly slow Many 
enzymes have evolved to provide an active site environment that is sterically and 
electronically complementary to the rate determining transition state (Pauling, 1946) 
Enzymes catalyse chemical reactions without being used up themselves and antibodies 
recognise a diversity of substances, yet both exert their effect by binding to another 
molecule Some antibodies may bind more readily and stabilise the transition state of 
a reaction to be catalysed, in prefeience to the resting or ground state, thereby 
decreasing the energy needed foi the reaction and, thus, increasing its rate Whereas
*
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intermediate and ground state species of a chemical reaction lie in the free energy wells 
and correspond to structures in which bonds are fully formed or fully broken, the 
transition state configuration corresponds to a species in which bonds are partially 
formed and partially bioken (Schatz, 1993, Section 1 20 )
The transition state can be defined as being located at a free-energy minimum along a 
reaction pathway between reactants and products (Schatz, 1993) It is the highest energy 
species in the reaction, has a lifetime on the order of a bond vibration (10'13sec) and is, 
therefore, unable to act as an immunogen However, antibodies with such specificities 
for this transition state can be produced by immunising with a transition state analogue 
During the transition state period, the length of the bonds from the central carbon 
increase to 120% of their normal size To provide an analogue for this, phosphorous is 
substituted for the central carbon Its bonds are roughly 20% longer than those of 
carbon and the resulting compound, known as the phosphate ester, is stable
6.2 Initial investigations with catalytic antibodies
In the initial stages of this project, in collaboration with Dr Mark Searcy, St Lukes 
Cancer Research Institute, an attempt was made to produce a monoclonal antibody to 
a transition state analogue Our proposed phosphate ester, was a prodrug that could be 
cleaved on interacting with an appropriate monoclonal to 7-OH-coumann (Figure 6 1 )  
It was envisaged that the proposed catalytic antibody would cleave the prodrug (Figure 
6 1 (a)) resulting in free 7-OH-coumarin The applications of 7-OH-coumann as an 
anti-cancer agent have been reviewed by Egan et al (1990)
Had this antibody been produced, it could have been a novel method to target drugs to 
the tumour site, if the catalytic antibody and the anti-G-CCM  antibody were used to 
make a heteroconjugate, the anti-tumour part of this heteroconjugate could localise it 
to the tumoui in vivo and the catalytic side could catalyse the prodrug to drug 
conversion at the tumour site The prodrug, being non-toxic, would not damage non­
tumour tissue However, Dr Searcy's group failed to produce such a transition state 
analogue and this work was discontinued The assistance and encouragment of Dr 
Searcy is gratefully acknowledged and appreciated
Dr Geraid Gallacher’s group in London have produced a transition state analogue which 
was prepared by substitution of a phosphorous atom for a central carbon atom in the 
transition state's tetrahedral group of atoms to form a stable phosphate ester (Gallacher
*
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Figure 6.1. postulated scheme of prodrug to drug conversion using catalytic 
monoclonal antibodies (a) Phosphate ester attached to KLH, the carrier protein This 
is the putative prodrug (b) Postulated scheme of prodrug to drug conversion using 
catalytic antibodies resulting in 7-OH-coumann
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et a l , 1991) This was conjugated to KLH and was known as the phosphate immunogen, 
compound (XI) The distribution of charge on the oxygen resembles that of the transition 
state, in addition, the phosphorus-oxygen bonds are about 20% longer than ordinary 
carbon-oxygen bonds, which enables the analogue to mimic the elongated bonds of the 
transition state Further work in this area was continued using this transition state 
analogue
6  3 Polyclonal catalytic antibodies
The first incidence of the pioduction and characterisation of a catalytically competent 
polyclonal antibody prepaiation from a sheep was by Gallacher et al (1991) In this 
instance, a sheep was immunised with the hapten-KLH conjugate (Phos-KLH) (sheep 
271) and this preparation of IgG catalysed hydrolysis of the mixed aryl 4-mtrophenyl 
carbonate (I) but not of the isomeric 2-nitrophenyl carbonate (II)(Figure 6 2 )  The 
catalysed reaction obeys Michaelis-Menten kinetics
This result demonstrates that, whatever structural heterogemty exists in the IgG, the 
catalytic characteristics of the active IgG species are all sufficiently similar that 
differences between them aie not leadily detected as deviations from a single-site 
saturation model
Gallacher argued that the polyclonal method was preferable as it is easier to produce 
polyclonal antibodies and that the investigation of catalytic antibody responses in 
animals could also be studied The incidence of contamination with enzymes was ruled 
out in this study after extensive analysis
The structures of the phosphate immunogen (XI), the carbonate substrate (I), the amide 
substrate (III), the inhibitor and the alternative substrate are shown in Figure 6 2 and 
are described below
The phosphate immunogen (Figure 6 2 (a)), known as compound (XI) (all compounds 
are as described in Gallacher et a l , 1991, unless otherwise referenced) and compound
(II) (Gallacher et a l , 1992), involved the carboxy group of 4-nitrophenyl 4'-carboxy- 
methylphenyl phosphate and an amino group of KLH and was designated 4-nitrophenyl 
4'-(3-oxa~2-oxobutyl)phenyl hydrogen phosphate The carbonate substrate (Figure 6 2 
(b)), known ax> compound (1), was labelled 2-nitrophenyl 4'-3(-aza-2-oxoheptyl) 
phenyl carbonate This is a chromogemc substrate for the investigation of catalytic 
activity The amide substrate (Figure 6 2 (c)), known as compound (III), was called N -
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H(d)
NHa
Figure 6.2. The structures of (a) the phosphate immunogen (XI), (b) the carbonate 
substrate (I), (c) the amide substrate (III), (d) the inhibitor and (e) the alternative 
substrate are shown Detailed descnptions are given m Section 6  3
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(4-mtrophenyl)N!-butyl-l,4--phenylenediacetamide The inhibitor (Figure 6 2 (d)) was 
termed compound (XXI) This acts as a competitive inhibitor of the catalysed hydrolysis 
of compound (I), the carbonate substrate The alternative substrate is shown in Figure 
6 2 (e) Hydrolysis of this substrate could be catalysed by contaminating enzymes, like 
esterases, but will not be catalysed by antibodies (G Gallacher, personal communica­
tion)
6 4 Techniques used in the characterisation of polyclonal and monoclonal catalytic 
antibodies
In order to detect catalysis of the monoclonal antibodies produced during this project, 
it was first necessary to repeat the procedure outlined m Gallacher et al (1991) to 
determine the kinetics of hydrolysis of the carbonate ester (Figure 6 2 (b)) In order to 
do this, the crude normal sheep serum and the antibody fraction from the serum of the 
immunised sheep 271 was isolated by sodium sulphate precipation and chromatography 
on Protein G- Sepharose (Sections 2 61  and 2 6 3 ,  respectively) (Gallacher et a l , 
1991) Kinetics of the hydrolysis of the carbonate ester were monitored by the release 
of 4-mtrophenolate from the carbonate ester in sodium phosphate buffer, pH 8 0, 
containing 0 67% (v/v) acetomtnle at 25°C by recording the increase in the absorbance 
at 400nm (A ») with the use of a Shimadzu UV-160A UV-Visible recording 
spectrophotometer and quantified by using e400= 1 65xl04M1cm 1 Stock solutions of the 
substrate were prepared in acetomtnle and their concentrations were adjusted so that, by 
addition of stock substiate solution and acetomtnle solvent to 20pl in a final reaction 
volume of 3ml, final concentrations in the approximate range of 0 2-16|liM were 
achieved (Section 2 6 4 )  In some cases, reaction mixtures also contained 0 2|xM IgG 
prepared from sheep 271 or 0 2[iM IgG prepared from the non-immunised sheep or 
from hybndoma serum or from mouse ascitic fluid, control or sample
6  5 Initial evaluation of sheep polyclonal catalytic antibody
The kinetic data presented below weie obtained for an IgG preparation of sheep 
antiserum (number 271) supplied by Dr Gallacher, which had been immunised with the 
Phos-KLH immunogen Sheep were chosen as the source of IgG because of the large 
volumes of antiserum they can provide
The concentration of IgG in the elutatc from the Sephadex G-25 column was
%
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4determined by using 8^=2 0\105M ‘cm 1 and was found to be approximately 3\iM from 
Gallacher et al (1991), using the following equation,
A=ecl
where e is the extinction coefficient of proteins (M ’em'1), 
c is the concentration (M)
1 is the path length = 1cm 
A is absorbance
The concentration of IgG obtained using the procedure outlined in Section 2 6 4 was 
determined to be 3 86(xM} as an absorbance of 0 077 was obtained at 280nm To 
calculate the total background hydrolysis, this was repeated for 20(jil of the lmg/ml stock 
of the substrate m acetonitrile in 3ml of carbonate buffer, pH 12 0, at 400nm (Section 
2 6 4 )  This was repeated for the same concentration of substrate in the same buffer at 
pH 8 0  at 400nm, which was used to determine background hydrolysis The concentra­
tion of substrate was calculated by subtracting the value at pH 8 0 from the value at pH 
12 0 using e^oo-l 65xlO'4M1cm 1
The total background hydrolysis was obtained by monitoring the absorbance at 400nm 
of carbonate buffer pH 12 0 with 20[xM substrate and repeating this for carbonate buffer 
pH 8 0  with 20\xM substrate The results obtained were as follows,
A,oo(pH 12 0) = 0 0210,
c = 1 273\10^M,
A J p H  8 0) = 0 0149,
t  = 903x10 7M
The total background hydrolysis was 1 273x10 6M -  9 03xl0'7M = 3 07xl0'7M
Initial rates (ft) were determined from slopes of linear progress curves From Gallacher’s 
paper, ft=/c[S], since the same [S] is used throughout the experiment, it is assumed that 
Thus, foi the reactions carried out (i) in the absence of IgG, in the presence of 
carboxylesterase, DMEMS0, control ascitic fluid (Section 2 3 17 ) or control whole sera 
or (11) in the presence of IgG prepared from non-immunised sheep, the initial change 
in absorbance increased 1 meanly with increased substrate concentration [S] and were 
closely similar at any given [S] The initial rates obtained in the presence of IgG from 
non-immumsed sheep were subtracted from those obtained at the same values of [S] in
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the presence of the IgG prepared from sheep number 271 to provide the rates of the 
polyclonal catalytic antibody-catalysed reaction Other parameters such as and Ka 
can be calculated (Gallacher et a l , 1991)
In this system, the apparent background first order rate constant for hydrolysis in pH 8 0 
buffer at 400nm was detcinnned as follows, 20jli1 of substrate was added to 3ml 
carbonate buffer, pH 8 0, and the change in absorbance at 400nm (dA) was monitored 
over 40 seconds (s,dt) dA/dt=(0 0071-0 0001)/40s = 1 75x10V 1 This compares well 
with the 1 87xl0^s1 obtained by Gallacher The next step was to do the same experiment 
with 0 2\xM IgG from the purified normal sheep serum which was found to be [(0 0081- 
0 0002)/40s] 1^975x10^ 1 again comparing with 1 99xl0^s 1 in Gallacher’s paper Then 
the same experiment was carried out using purified sheep 271 serum and the results 
obtained are shown in Table 6 3 It was hoped a monoclonal catalytic antibody would 
improve on these results
6  6  Advantages of catalytic monoclonal antibodies
Characterisation of the kinetic parameters, specificity, mechanism and structural 
properties of catalytic antibodies is complicated and difficult to mtrepret unless a 
monoclonal antibody is used In addition, reproducibility becomes an important concern 
when a polyclonal antibody preparation is generated It should be noted that nearly 20 
years ago, Raso and Stollar (1975) attempted to use pyridoxamine binding antibodies to 
catalyse Schiff base formation and transamination reactions Their lack of success may 
have been due to the use of polyclonal rather than monoclonal antibodies The 
importance of monoclonal antibodies is further discussed in Section 6 19
6  7 Immunisation of mice with the phosphate immunogen, Phos-K LH  (XI)
The protocols used m this project to generate catalytic monoclonal antibodies are 
generally no different than those used for the production of monoclonal antibodies for 
other uses (Kohler and Milstein, 1975, Goding, 1986), and are described in Section 
2 6  5 An amide conjugate involving the carboxy group of the 4-mtrophenyl 4 -  
carboxy-methylphenyl phosphate and an ammo group of KLH was synthesised as 
outlined (Gallacher et a l , 1991) This phosphate immunogen (Phos-KLH) (XI) used to 
immunise the 6 balb/c mice was produced and supplied by Dr Gerard Gallacher (Table 
2 3) The mice were tail bled (Section 2 3 7 )  and their sera tested by ELISA on Phos-
*
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Table 6  1 Testing of sera (1 100 dilution) from 6  mice immunised with Phos-K LH , 
used in the 6  fusions performed during this project, by ELISA  against Phos-BSA  
and BSA coated plates read at 620nm (A«J Standard deviations are in brackets, 
(n=3)
BSA and BSA coated plates The îesuîts obtained are shown in Table 6 1
Fusion number Phos-BSA coated 
plates (lO/xg/'ml) (A ,J
BSA coated plates
(1 0 /ag/ml) ( A J
1 0 474 (0 009) 0 002 (0 001)
O 0 114 (0 003) 0 002 (0 000)
3 0 108 (0 004) 0 004 (0 000)
4 0 101 (0 003) 0 008 (0 001)
5 0 087 (0 012) 0 037 (0 007)
6 0 072 (0 001) 0 003 (0 000)
The controls (n=3) used for this ELISA, with standaid deviations in brackets, included, 
PBS 0 0036 (0 0035),
normal mouse serum, diluted 1 100 with 0 01M PBS, pH 7 3, 0 0125 (0 008), 
DMEMS0 0 0175 (0 003) and 
SP2/0 supernatant 0 014 (0 006)
6  8  Results of the initial fusions and screening of anti-Phos monoclonal antibodies
Of the six mice immunised, initially thiee were used An in vitro immunisation was also 
performed as outlined m Section 2 3 115 The spleen cells from this in vitro 
immunisation were fused with SP2/0 cells using the PEG method (Section 2 6 5 )  
(Fusion 1) The success of this in vitro immunisation was assessed using the ELISA - 
spot assay This assay showed that 131 hybndoma cells producing the desired antibody 
were obtained by this method For the other two fusions performed, PEG was also used 
These results are outlined in the following scheme
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I
PEG FUSIONS
I
FUSION 1 5 plates, 164 clones 
FUSION 2 5 plates, 74 clones 
FUSION 3 5 plates, 79 clones
4
These 317 clones were scicened by ELISA using anti-mouse IgG as antigen (Section 
2 3 16 4 ) , the clones which gave positive ELISA values (> 0150) on the sandwich 
ELISA were expanded further and screened against BSA, KLH, Phos-BSA and Phos- 
KLH The most interesting clones are outlined below,
FUSION 1 PL2G7 and PL4B1
FUSION 2 PL1E7, PL3A10, PL3C8, PL3D1, PL4C2, PL4D2, PL4F6, PL5C4 and 
PL5H2
FUSION 3 PL1E4, PL1E7, PL1F5, PL2A10, PL2C5, PL2D5, PL3D1, PL3D7, PL3D8, 
PL4A2, PL4C3, PL4D2, PL5B2 and PL5E11
1
These antibodies were screened by ELISA foi cross-reactivity with BSA-hapten, for 
inhibition of binding to the BSA-hapten conjugate by free hapten and for lack of cross- 
reactivity with KLH Those with maximum binding affinity for the hapten carrier 
conjugate were further characterised
I
9 clones were found to be positive against the phosphate antigen In order to find which 
of these antibodies may be catalytic, an attempt was made to detect hydrolysis of the 
carbonate ester by the monoclonal as described for sheep polyclonals (Gallacher et a l ,
1991) (Section 6 4 )
i
The most interesting antibodies were F1PL4B1, F2PL1E7, F3PL1E4, F3PL1F5, 
F3PL2C5, F3PL2D5, F3PL4C3, F3PL5B2, F3PL5E11 These hybndomas were cloned 
according to Section 2 3 15 and the results of their screening by ELISA against Phos- 
BSA, BSA, Phos-KLH and KLH are shown in Table 6 2
IN VITRO IMMUNISATION
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These results indicate that these antibodies may be against the phosphate immunogen 
and an attempt was made to determine whether they catalysed the hydrolysis of the 
carbonate ester (Figure 6 2 (b)) as described in Section 6 9
Table 6  2 Supernatants taken from cloned hybridomas, diluted 1 100 with 0 01M 
PBS, pH 7 3, were screened by ELISA  against plates coated with Phos-BSA , BSA, 
Phos-K LH  and KLH  The absorbance was read at 620nm (A^J and n = l
Clone Phos-BSA BSA Phos-K LH K LH
F1PL4B1 0107 0101 0 029 0 054
F2PL1E7 0103 0 095 0 036 0119
F3PL1E4 0117 0 057 0 026 0 011
F3PL1F5 0 313 0 217 0194 0 322
F3PL2C5 0 268 0 062 0130 0 071
F3PL2D5 0 096 0118 0 074 0 092
F3PL4C3 0 032 0 072 0 010 0 043
F3PL5B2 0 087 0 025 0 050 0 073
F3PL5E11 0 006 0 000 0104 0 021
The controls used for this ELISA were as described for Table 6 1
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6  9 Detection of catalysis in hybndoma supernatants
Following the choice of hapten, the hybridoma selection procedure is the most crucial 
phase in the successful production of catalytic monoclonal antibodies The generation 
of catalytic antibodies makes use of the same basic procedures that have been used for 
the generation of binding monoclonal antibodies, yet the process involves an additional 
crucial step screening for catalytic activity Tawfik et a l , (1992) addressed the unique 
problems involved in the detection of inefficient catalytic activity that is accompanied 
by uncatalysed background reactions, as discussed in Section 6 19 
In order to ascertain if it is possible to detect the hydrolysis of the carbonate substrate 
(I) (Figure 6 2 (b)) by monoclonal antibodies in the supernatant of the hybridomas 
produced from these fusions, initial rates (ft) were determined from slopes of linear 
progression curves These are slopes of curves obtained when 20jxM of substrate was 
added to 3ml of control or sample and blanked against carbonate buffer or DMEMSi0, 
as appropriate The absorbance was read at 400nm and the change in absorbance taken 
for a time period of 40 seconds (s, dA/dt) 40s was chosen as the absorbance remained 
constant after this time The supernatants from the hybridomas which appeared
a
interesting by ELISA were monitored to ascertain if it was possible to detect a potential 
catalytic antibody using this method If this procedure was successful, it would save 
time, money, animals and expertise, in that only the interesting hybridomas would be 
grown in ascitic fluid (Section 2 3 17 ), purified and characterised The results are shown 
m Table 6 3
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Table 6 3 Determination of monoclonal antibody-catalysed hydrolysis o f the 
carbonate substrate (20fd) by detecting a change m absorbance at 400nm (dA) over 
40s (dt) of controls and sample supernatants, at pH 8 0, unless otherwise stated.
Sample (pH 8 0) + 20/xl 
substrate
Change in Absorbance 
at 400nm (dA)
ft = dA/40s =dA/dt
(s')
Normal sheep serum 0 0079 1975x10"
271 Sheep serum 0 0796 199x103
Carbonate buffer 0 0070 1 75x10"
Carbonate buffer (pH 12 0) 0 2147 5 368x10"
DMEMS,„ 01307 3268x101
F1PL4B1 01457 3 643xl0-3
F1PL4B1 (pH 7 2) 0 0158 1 295x101
F2PL3C8 0 2444 6 1 1 x 1 0 ’
F3PL1E4 01228 3 0 7 x 1 0 3
F3PL1E4 (pH 7 2) 0 0726 1 8 1 5 x l0 3
F3PL1F5 01845 4 62x101
F3PL2A10 0 2428 60 7 x1 0 3
F3PL2C5 0 1666 4165x103
F3PL2C5 (pH 7 2) 0 0473 118 x1 0 1
F3PL1E4 (pH 7 2) 0 0726 1 815x103 r
F3PL2D5 0 0426 1065x103
F3PL2D5 (10nl) 0 0228 5 7x10"
F3PL4C3 0 0524 131 x1 0 3
F3PL5B2 0 2476 6 1 9 x 1 0 3
F3PL5E11 0 2300 5 7 5 x 1 0 3
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u6  10 Discussion of the results obtained in Table 6  3
The results obtained for (i) the apparent background first order rate constant for 
hydrolysis in pH 8 0 buffer was 1 75xl0^s 1 concurring with that obtained by Gallacher 
et al (1991) of 1 87xl(Ts 1 and (11) normal sheep serum of 1 975xl0^s1 agrees well with 
that obtained by Gallacher et al (1991) of 1 99x10^ 1 The result obtained using purified 
271 sheep serum was 1 99x10 3s 1 These results are further discussed m detail in Section 
619
6  11 Isotyping of the initial anti-Phos monoclonal antibodies
These antibodies weie isotyped according to Section 2 3 18 and all were shown to be 
IgM, probably due to MHV contamination (Section 3 19 ) For this reasons discussed 
in Section 6 19 , it was decided an IgG antibody was preferable and, therefore, a number 
of strategies were tried to produce an anti-Phos monoclonal antibody which was IgG, 
including using the Cel Prime in vitro immunisation ’High IgG Yield* kit from Immune 
Systems (Section 2 3 1 1 6 )
6  12 Attempts to produce IgG anti-Phos monoclonal antibodies
One of the certified disease-free mice purchased from Harlan and Olac was used in an 
in vitro immunisation (Section 2 3 115, Fusion 4) The fifth fusion was carried out using 
the Cel-Prime High IgG yield' kit from Immune Systems (Section 2 3 1 1 6 , Fusion 5) 
This kit advocated the discarding of any excess support cells but instead these cells were 
frozen and used in the sixth fusion with 95% viability
Fusion 6 used the same procedure as Fusion 5 except, since the immunisation medium 
supplied with the kit had been exhausted, the immunisation medium used in Fusion 4 
was used instead The support cells were incubated in this medium with antigen as 
outlined in Section 2 3 116 and the spleen cells were incubated as for Fusion 5 for a 
further 3 days
All fusions were performed using PEG 1500 (Section 2 3 13 1) and the clones were 
selected using HA (Section 2 3 14) This sixth fusion proved to be the most successful 
The spleen used in Fusion 4 had only been immunised once with 50p,g of Phos-KLH 
before the in vitro immunisation whereas Fusions 5 and 6 had been immunised twice 
with 50(^g of Phos-KLH The results of the ELISA on the pre-immunised sera for these 
mice are given in Table 6 1
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For each fusion, the spleen cells were counted (Section 2 3 3 ), pooled and were fused 
using the PEG method
8 56xl07 spleen cells were fused with 1 22\107 SP2/0 cells at a 7 1 ratio of spleen cells 
to myeloma cells (Fusion 4)
Fusion 5 was a fusion of 3 7xl07 spleen cells and 3 72xl07 SP2/0 cells, at a 10 1 
spleen myeloma cell ratio
Fusion 6 was a fusion of 6 7\107 spleen cells and 1 OxlO7 SP2/0 cells, at a 6 7 1 
spleen myeloma cell ratio
The cells from each of these three fusions were plated onto 5 plates which were 
monitored for growth of clones after 10 days The hybridomas were screened by ELISA 
against Phos-BSA, BSA, Phos-KLH and KLH (Section 2 3 16 3 and 6 13)
6  13 Results of in vitro immunisations and fusions
The results of the second set of anti-Phos fusions are outlined below 
IN VITRO IMMUNISATIONS 
1
PEG FUSIONS 
1
FUSION 4 5 plates, 52 wells contained clones 
FUSION 5 5 plates, 64 wells contained clones 
FUSION 6 5 plates, 77 wells contained clones
1
These 193 clones were expanded into 24 well plates, and were screened by ELISA using 
anti-mouse IgG as antigen
i
40 clones gave positive ELISA values (> 0 150), these were expanded and screened 
against Phos-BSA, Phos-KLH, BSA and KLH
1
FUSION 4 A10E5
FUSION 5 E7C11, F5C11
FUSION 6 B2C7, B2D6, D5A6, D5A10
These 7 clones were found to be the most promising as they gave positive results against 
the phosphate antigen and not against the earner proteins Their initial screening of
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hybridoma supernatants against Phos-BSA, Phos-KLH, BSA and KLH are shown in 
Table 6.4. for a dilution of 1:100.
1
A10E5, B2C7, B2D6, D5A6, D5A10, E7C11 and F5E11 were found to be stable, 
specific and good producers of antibody. These hybridomas were subcloned twice, 
screened for anti-Phos activity, grown in ascitic fluid, frozen as stocks and initially 
characterised by HPLC, with B2C7 being analysed by SDS-PAGE and for catalytic 
activity.
Table 6.4. Supernatants taken from cloned hybridomas from the second set of 
fusions, diluted 1:100 with 0.01M PBS, pH7.3, were screened by ELISA against 
plates coated with Phos-BSA, BSA, Phos-KLH and KLH. The absorbance of one 
reading, at 620nm (A*w), is presented.
Clone Phos-BSA BSA Phos-KLH KLH
A10E5 0.247 0.127 0.198 0.130
B2C7 0.271 0.074 0.222 0.091
B2D6 0.237 0.070 0.231 0.118
D5A6 0.192 0.155 0.214 0.184
D5A10 0.165 0.064 0.078 0.097
E7C11 0.253 0.140 0.212 0.163
F5E11 0.065 0.062 0.101 0.064
The controls for this ELISA were as described for Table 6.1.
6.14. Results of isotyping the second set of anti-Phos monoclonal antibodies.
A10E5, B2C7, B2D6, E7C11 and F5E11 were found to be the best producers and the 
most stable during freeze-thawing. These antibodies were further characterised and will 
be referred to as the 'anti-Phos' antibodies. These antibodies were isotyped using the 
SEROTEC isotyping kit (Section 2.3.18.4.) along with the isotyping strip method
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Figure 6.3.
Results obtained using isotyping strips from Sigma of neat supernatant taken from (a) 
B2C7 and (b) B2D6. Neat hybridoma supernatant was added to a tube provided and the 
procedure was as outlined in Section 2.3.18.4. Both hybridomas isotyped as IgM. 
(Section 2.3.18.3.) and all of the clones tested isotyped as IgM.
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B2C7 and B2D6 were isotyped twice as they showed some positivity for IgG2b when 
the SEROTEC kit was used, but on repeating the test using the isotyping strips, both 
these hybridomas gave a definite IgM result This result was disappointing, especially 
as it was obtained despite importing certified mice and using the Cel-Prime 'High IgG 
yield7 kit from Immune Systems (Section 2 3 1 1 6 )  (Fusion 5) which claimed a 55% 
IgG yield, without prior immunisation These isotyping results are shown in Figure 6 3
615  Results of ELISA s on purified polyclonal and monoclonal anti-Phos 
antibodies
The anti-Phos monoclonal antibodies were grown as ascitic fluid (Section 2 3 17 ) and 
purified according to Gallacher et al (1991) The results of screening crude and Protein 
G-purified (l) normal sheep serum, (11) catalytic serum, and crude and Protein G - 
punfied ascitic fluid from (111) A10E5, ( i v )  B2C7, (v) B2D6 and (v i)E 7C ll are shown 
in Table 6 5 All samples were adjusted to a stock concentration of 2mg/ml before 
dilution and the results using a 1 1000 dilution is given Each antibody shows cross- 
reactivity with KLH, as would be expected, and all show some reactivity against BSA
Table 6  5 1 1000 dilution of Protein G -punfied polyclonal and monoclonal anti- 
Phos antibodies screened against Phos-BSA, BSA, Phos-K LH  and K LH  All 
samples were brought to a stock concentration of 2mg/ml The absorbance was read 
at 620nm (A6J
Sample Phos-BSA BSA Phos-K LH K LH
Normal sheep serum 0 044 0 007 0 065 0 011
271 Sheep serum 0 253 0 017 0 414 0136
A10E5 0 389 0 099 0 412 0108
B2C7 0 372 0 077 0 344 0183
B2D6 0 282 0 063 0 308 0 086
E7C11 0 347 0133 0 408 0104
The controls used in this ELISA were as described in Table 6 1
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6  16 HPLC analysis with anti-phosphogen antibodies
Seven monoclonal antibodies, A10E5, B2C7, B2D6, D5A6, D5A10, E7C11 and F5E11, 
were grown as ascitic fluid in mice (Section 2 3 17) and were analysed by HPLC, along 
with mouse IgM and IgG as standards for comparison
When commercial IgM was loaded on the HPLC, two peaks were obtained at 10 08mins 
and 17 25mins (Figure 3 2 1 ) IgM has a molecular weight of 900kD which is higher 
than the fractionation range of the column used and, therefore, it comes off the HPLC 
column m the void volume (10 08min) The first peak represents intact IgM (900kD) and 
the second peak may represent the breakdown of IgM into its component of five IgGl 
immunogloubhns which have a molecular weight of 180kD each A peak at 16 21min 
was observed when commercially available IgG was loaded (150kD)
SAS-precipitated B2C7 antibody-containing ascitic fluid was loaded on to the HPLC 
column and the result is shown in Figure 6 4 1 The major peak detected had a retention 
time of 17 Olnnns which may represent the IgGl constituents of the IgM antibody The 
peak at 9 92min represents proteins eluting m the void volume and may contain the 
intact IgM antibody A small peak was seen at 24 70nnn and may be denatured or 
contaminating protein If this analysis of the HPLC chromatogram presented in Figure 
6 4 1 is correct, it would imply that this ascitic fluid may contain a mixture of IgM and 
IgG molecules which would correspond to these two peaks
SAS-precipitated ascitic fluid from the following hybndomas, A10E5 (16 49min), B2D6 
(16 51mm), D5A6 (16 52mm), D5A10 (16 64mm), E7C11 (16 48mm) and F5E11 
(16 82min) were also examined by HPLC The respective major peak retention times are 
given m brackets
A second set of experiments were performed to analyse the interactions of these 
antibodies with the Phos-protein conjugates The binding of the antibody to the 
unconjugated phosphogen or the carbonate substrate were not used, as the change m 
molecular weight would not be detected by HPLC
All samples were adjusted to 2mg/ml and were incubated with the Phos-protein 
conjugate (20^g/ml) for 30min at 37°C
SAS-treated B2C7 antibody-containing ascitic fluid was incubated with Phos-BSA for 
30min at 37°C and the major peak detected had a retention time of 16 94mins (Figure 
6 4 2) which may represent the IgGl constituents of the IgM antibody, as previously 
discussed The peak at 9 85mm lepresents pioteins eluting in the void volume and may
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contain the intact IgM antibody A small peak was seen at 25 21min and may be 
denatured or contaminating protein An extra peak was observed at 14 03mm which 
distinguishes the Phos-BSA-B2C7 complex which has a molecular weight of 
approximately 250kD (180kD for IgGl + 70kD for Phos-BSA)
A similar chromatogram was obtained when B2C7 was incubated with the Phos-KLH 
conjugate, while no peak at a retention time of 14 Omin was observed when B2C7 was 
incubated with KLH or BSA
This experiment was also carried out using A10E5, which was incubated with KLH and 
BSA  The chromatograms obtained were scrutinised for a new peak at the retention time 
of 13 6mm -  14 lmin which would indicate the formation of an antibody-antigen 
complex BSA gave no new peak but KLH gave a peak at 13 70min A distinct peak 
was seen when incubated with Phos-KLH at 13 66min and a broader, less distinct peak 
was observed on incubation with Phos-BSA (13 75min)
B2D6 gave no peak when incubated with KLH or BSA, a distinct peak was seen when 
incubated with Phos-KLH (14 05mm) and a larger one was seen on incubation with 
Phos-BSA (1 4 11mm) This result suggests that this antibody reacts with the 
phosphogen portion of the Phos-piotem conjugate
D5A6 ascitic fluid showed a distinct new peak at 14 34min and 14 46 when incubated 
with Phos-KLH and Phos-BSA, respectively D5A10 ascitic fluid showed a distinct new 
peak at 14 29min and 13 75 when incubated with Phos-BSA and Phos-KLH, 
respectively E7C11 ascitic fluid was treated as above but no Phos-protein-antibody 
conjugate was observed F5E11 gave a new peak at 13 88min and 13 99mm when 
incubated with Phos-KLH and Phos-BSA, respectively
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Figure 6.4.1.
HPLC chromatogram of SAS-precipitated B2C7 antibody-containing ascitic fluid. The 
column used was a 10/xm Protein Pak SW 300 column with a mobile phase of 0.1M 
phosphate buffer, pH 7.0 and a flow rate of 0.5ml/min. Absorbance was detected at 
280nm. The major peak detected had a retention time of 17.01mins which may 
represent the IgG l constituents of the IgM antibody. The peak at 9.92min represents 
proteins eluting in the void volume and may contain the intact IgM antibody. A small 
peak was seen at 24.70min and may be denatured or contaminating protein.
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Figure 6.4 2. HPLC chromatogram of SAS-punfied B2C7 antibody-containing ascitic 
fluid (2mg/ml) incubated with Phos-BSA (20/xg/ml) for 30min at 37°C The column 
used was as described in Figure 6 4 1 Absorbance was detected at 280nm The major 
peak detected had a retention time of 16 94mms The peak at 9 85mm represents 
proteins eluting in the void volume A small peak was seen at 25 21min and may be 
denatured or contaminating protein An extra peak was observed at 14 03min which 
distinguishes the Phos-BSA-B2C7 complex which has a molecular weight o f approxi­
mately 250kD (180kD for IgGl +  70kD for Phos-BSA)
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6.17 Electrophoresis of B2C7 ascitic fluid purified by SD S-P A G E
B2C7 was punfied using anhydious sodium sulphate (Section 2 6 1 )  and protein G 
affinity chromatogiaphy (Section 2 6 3 )  and was analysed by SD S-PA G E (Section 
2 4 17 ) The results aie shown in Figure 6 5 and are discussed in Section 6 19
6 18 Detection of catalytic activity using the purified anti-Phos ascitic fluid
The antibody fraction from the anti-Phos ascitic fluid was precipitated using anhydrous 
sodium sulphate and Protein G 20jxl of carbonate substrate was added to 20pi of A10E5 
and read for 40sec (and lOnnns) on a Shimadzu UV-160A UV-Visible 
spectrophotometer and the results obtained are presented in Table 6 6 These results are 
discussed in Scction 6 19
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Figure 6.5. A 5-20% (w/v) gradient PAGELR precast polyacrylamide gel from ATTO 
was loaded as follows, Lane (1) protein G-punfied B2C7 monoclonal antibody- 
containing ascitic fluid, (2) anhydrous sodium sulphate-precipitated B2C7 antibody 
fraction, (3) IgG standard, this sample was too dilute to be seen on the gel, the bands 
seen may be protein which leaked from lane 2, and (4) molecular weight markers (in 
daltons) The gel was run at 20mAmps per gel and the results are discussed in Section 
6 17
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Table 6 6 Determination of monoclonal antibody-catalysed hydrolysis of the 
carbonate substrate (20/xl) by detecting a change in absorbance at 400nm (dA) over 
40s (dt) of protein G-purified ascitic fluid, at pH 8 0
Sample (pH8 0) + 20/il 
substrate
Change in Absorbance 
at 400nm (dA)
ft = dA/40s =dA/dt
(s'1)
A10E5 0 0015 3 6 6 x 1 0 V
B2C7 0 0012 3 01x10 Ss 1
B2D6 0 0014 3 42x10 V
The controls for this experiment are as described in Table 6 3 
6 19 Discussion
Two unique points are crucial for the successful production of catalytic monoclonal 
antibodies (l) the design of the hapten and (11) the process of selecting the few 
monoclonal antibodies that are catalytic from among the many antibodies which bind 
the hapten but do not catalyse the reaction The attempts to produce a transition state 
analogue for the proposed phosphate ester by Dr Mark Searcy (Figure 6 1 ) ,  which 
would have been catalysed to produce 7-OH-coumarm as the post-catalysed product, 
were unsuccessful It was decided to produce monoclonal antibodies which catalysed the 
hydrolysis of the mixed aryl 4-nitrophenyl carbonate (I) (Gallacher et a l , 1991) instead, 
as this phosphate ester was readily available
Once the methods of catalytic screening were established in this project (Section 6 5 ) , 
it was possible to screen hybndoma supernatants and ascitic fluid to determine the rate 
of hydrolysis of the amide substrate by an antibody Catalytic antibodies are currently 
raised by immunisation of mice with a transition-state analogue-protein carrier 
conjugate and subsequent fusion, the resulting hybndoma cells are then screened in 
order to select those antibodies exhibiting binding affinity for the hapten An alternative 
method for selecting potential catalytic monoclonal antibody-secreting clones is on the 
basis of their affinity to a short "transition state analog" (Tawfik et a l , 1990) These 
potentially positive clones are then piopagated in large quantities, generally as ascitic 
fluid preparations, and the antibodies purified to allow their screening for catalytic
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In this project, fusions weie peifoimed using PEG (Section 6 7 and 6 8 )  and the nine 
most interesting hybridomas were cloned and their supernatants were screened by ELISA 
(Table 6 2 )  and for catalytic activity The techniques used in the characterisation of 
polyclonal and monoclonal catalytic antibodies were as described by Gallacher et al 
(1991) The concentration of the piotein G-punfied sheep serum (271) obtained during 
this project was in agreement with the value of 'approximately 3^M' found by Gallacher 
et al (1991) Then the total background hydrolysis was determined to be 3 07x10 7M 
The apparent background fust order rate constant for hydrolysis obtained was 1 75xlO"V 
(Section 6 5 )  This is in excellent agreement with the value of (1 87xlO",s 1) obtained by 
Gallacher Repeating this experiment using purified normal sheep serum the value 
obtained (1 975x10^ ‘) compares well with the 1 99xl0 ‘4s 1 in Gallacher's paper This 
experiment was repeated using purified sheep 271 serum and 1 99x10 3s_1 was obtained 
(Section 6 5 )
The selection of hybndoma supernatant, by screening for catalytic activity, is crucial in 
the successful production of catalytic antibodies Since the hybridomas were grown m 
DMEMS10, the next measurements were to detect the apparent background first order rate 
constant for hydrolysis in DMEMSI0 (pH 8 0) The pH of this medium decreased when 
exposed to the air for any length of time, which made the accurate attainment of these 
results difficult It was found that when 20^ x1 of substrate were added to the DMEMS10, 
and this was blanked against DMEMS10, an initial rate of 3 268x10 3s 1 was obtained To 
eliminate this, each hybndoma sample was blanked against DMEMS10 which had 20|il 
of substrate added at the same time as the substrate was added to the sample and the 
readings were then taken (Table 6 3 )  This represents the rate of hydrolysis of the amide 
substrate When supernatant from the anti-G-CCM hybndoma, 3BH2A3 (Section 3 ), 
was tested in a similar mannei, the change m absorbance was 0 025 and the initial rate 
was 6 25xl0 ‘4s 1
The hybridomas which appeared interesting from ELISA gave initial rates of hydrolysis 
of the substrate [Figure 6 2 (c)] by the antibody m the supernatant in the order of 
4 x l0 "V 5 which was higher than the result obtained for the polyclonal sheep catalytic 
antibody (1 99x10 3s l) This initial result showed that perhaps the antibody in this 
hybndoma supernatant was catalysing this reaction The initial rate was, however, in the 
same order as the polyclonal antibody
activity
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The results obtained in Table 6 3 may, or may not be, due to catalysis For a single 
substrate concentration, the expected obseivation would be a rapid reaction that slows 
as the substrate is used up A reaction burst, as was seen here, might indicate that 
substantial amounts of substrate are used up quickly due to very rapid reaction Because 
this was the case the initial rate (d) was taken from a linear part of each graph near the 
origin, (1 e the first 40 seconds) If the reaction slows down while there is still a 
substantial (90%) amount of substrate, this may be a catalysed reaction that is not 
turning over (1 e it is stoichiometric)
The hybridoma supernatants weie isotyped (Section 2 3 18) and all were IgM The 
reasons for this are discussed in Section 3 19 At a discussion at the Ciba Foundation 
catalytic antibody symposium (1991), Janda and Lerner stated that both their groups had 
obtained some catalytic activity with IgM antibodies but they were orders of magnitude 
lower m affinity At this meeting, Schultz stated that of all the IgM antibodies obtained 
in his group, none were catalytic For this reason it was decided an IgG antibody was 
preferable and therefore, a number of strategies were tried to produce an anti-Phos 
monoclonal antibody which was IgG Despite the attempts to produce anti-Phos 
catalytic antibodies of the IgG isotype, the isotyping results obtained using hybndoma 
supernatant fiom B2C7 and B2D6 were also IgM (Figure 6 3 )  This result was 
unexpected since the Cel-Pnme 'High IgG yield' kit from Immune Systems was used 
which claimcd a 55% IgG yield, without prior immunisation
The ascitic fluid from the best four hybndomas was purified according to Gallacher et 
al (1991) and was screened by ELISA (Table 6 5 ), which showed continued reactivity 
against the phosphogen hapten The reaction of the phosphate immunogen with the seven 
monoclonal antibodies was analysed by HPLC (Section 6 1 6 )  and demonstrated in the 
cases of B2C7 B2D6, D5A6 and D5A10 that these antibodies were indeed reacting with 
the phosphogen immunogen
The results of the SDS-PAGE analysis of the protein G-purified B2C7 ascitic fluid, 
under non-reducing conditions, showned one band at 150kD (Figure 6 5 )  corresponding 
to the molecular weight of IgG Since this antibody isotyped as IgM, this band may be 
due to the breakdown of the IgM antibody into its constituent IgGl antibodies B2C7, 
B2D6 and A10E5 were then tested for catalytic activity and the results are shown in 
Table 6 6 These results were in the order of the results obtained using the polyclonal ( 
antibody, which indicate that these antibodies bind the phosphate immunogen but are not
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catalytic as a sharp increase in the initial rate would be expected if these antibodies 
catalysed the of the mixed aryl 4-nitrophenyl carbonate (I) substrate (Dr G Gallacher, 
personal communication)
These antibodies isotyped as IgM but on HPLC and SDS-PAGE analysis the appeared 
to be IgG It is speculated that perhaps these antibodies were a mixture of IgM and IgG 
and that the isotype was not the reason that these antibodies did not catalyse the desired 
reaction Much more than seven monoclonal antibodies would need to be screened in 
order to find a catalytic monoclonal antibody (Shokat and Schultz, 1990) Since an IgG 
antibody was required, perhaps it would have been more successful if the immunisation 
scheme proposed by Tawfik et al (1990) had been tried using certified mice immunised 
m isolatois Tawfik et al (1990) used a short immunisation protocol using two foot pad 
injections of balb/c mice over an 18 day period (25jig/mjection), followed three days 
later by draining lymph nodes and fusing these cells to NSO myeloma cells (Eshhar, 
1985) Draining lymph node cells was found to yield a greater repertoire of clones than 
spleen cells when a short immunisation protocol was used Perhaps this method would 
give better results if another attempt is made to produce this monoclonal antibody It 
would have a high probability of success if it was used with certified mice in an 
isolator
Relative to enzymes, antibody-mediated catalysis in still very modest, the largest 
turnover number, Kctl, reported for a catalytic monoclonal antibody is 0 3 m m 1 
(Tramontano et a l , 1986), while values as high as lO ^in '1 are not uncommon for 
enzymes (Feisht, 1985) In addition, the nature of most of the reported antibody 
catalysed reactions is such that they proceed with measurable rates even in the absence 
of any catalyst The catalytic power is generally described m terms of K J K WM9 l e the 
rate enhancement of the reaction, rather than the absolute rate, commonly used to 
describe enzymatic activity Rate enhancements by catalytic monoclonal antibodies are 
generally in the range of 10z -  105, which is still lower than those of enzymes by orders 
of magnitude The detection of catalysis by antibodies therefore presents unique 
difficulties which were addressed by Tawfik et al (1992)
The most important factors involved m being able to detect antibody-mediated catalytic 
activity are (l) the concentration and purity of the monoclonal antibody in the 
preparation used for the assay and (n) the choice (structure) and concentration of the 
substrate Tawfik et al (1992) showed that the detection of antibody-mediated catalysis
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requires not only relatively high concentrations of purified monoclonal antibodies but 
also the use of an appiopnately designed substrate Unlike enzymes, catalytic antibodies 
are tailormade catalysts The structure of the substrate must obviously be related to the 
structure of the hapten used and the reaction that is to be catalysed by the resulting 
antibodies, yet various possibilities foi the design of the substrate always exist Other 
important points involved in the detection of catalytic antibodies include the sensitivity 
of the assay to be used, the solubility and reactivity of the substrate, the pH and the 
buffer
If it is known that an enzyme catalyses the reaction of interest, it is important to purify 
the antibody to1 ensure any catalysis of the fraction observed is due only to the antibody 
and not due to a contaminating enzyme For example, if the turnover number, k^, for 
a catalytic (IgG) antibody is lm in1, and a natural enzyme has a k^ of SxlO'min'5, 
contamination of the antibody with 1x10 3% (on a mol/mol basis) of the natural enzyme 
would lead to the deduction that the antibody is catalytic when in fact the contaminating 
enzyme is responsible for the rate enhancement observed Kinetic analysis, specificity 
or inhibition data cannot always distinguish between catalysis by an antibody and 
catalysis by an enzyme impurity Rigorous checks of specific activity must be performed 
after each purification step, along with a comparison between different methods of 
purification and comparison of whole antibody versus isolated ¥tb For example, Shokat 
and Schultz (1990) found it very difficult, even after considerable purification, including 
affinity chromatography, to remove glycosidase, adenosine deaminase and nbonuclease 
impurities from what appeared, by gel electrophoresis, to be homogeneous antibody 
The long-range goal is to be able to directly screen the antibodies present m each of the 
hybridoma supernatant solutions for catalysis However an analysis that takes into 
account the amount of antibody present in such supernatants, the detection sensitivity, 
and the degree of non-specific reaction (Tawfik et a l , 1990) indicates that (a) a reaction 
which proceeds at any appreciable rate without antibody catalysis (as a result of non­
catalysed reaction, enzyme impurities in the medium, etc) cannot be considered for 
direct screening of catalytic monoclonal antibodies at the low antibody concentration in 
the media and (b) if no background reaction exists, direct screening for catalysis is only 
possible for efficient catalytic monoclonal antibodies and when a particularly sensitive 
as well as selective assay (able to detect small amounts of product in the presence of a 
104-106 excess of unreactcd substiate) is used Other stratagems to screen for potential
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catalytic clones must therefore be sought
Novel methods, such as combinatorial vanable-region cloning in phage (Winter and 
Milstein, 1991), have been used to generate catalytic antibodies (Section 5 2 )  Yet future 
application of these methodologies for obtaining catalytic antibodies depend upon 
appropriate sciecning Analysis of the unique problems involved in direct screening of 
hybndoma supernatants for antibody-mediated catalysis led Tawfik's group to develop 
an ELISA to detect catalytic antibodies in supernatant, called catELISA (Tawfik et a l ,
1992), an assay involving a substrate-*protein conjugate immobilised on microtitre plates 
Antibody-catalysed conversion of any "solid phase" substrate to a product is then 
detected by oidinary ELISA, using binding anti-product antibodies Employing this 
catELISA, Tawfik's group were able to rapidly screen thousands of hybndoma clones 
elicited against both a phosphate transition state analog and an amide substrate to detect 
catalytic cleavage of the corresponding/>-mtrobenzyl ester
A prerequisite to the design and engineering of catalytic antibodies is the knowledge of 
their structuie and in paiticular which residues are involved in binding and catalysis 
Individual residues important for ligand binding and catalytic activity have been 
identified by site-directed mutagenesis and computer modelling, using a three- 
dimensional model of the antibody variable region using an antibody structural database 
(Stewart et a1 , 1994, Roberts et a ! , 1994) The results of these studies allow the 
reaction mechanism of antibody catalysed reactions to be elucidated 
The three-dimensional stiucture of a catalytic antibody with chorismate mutase activity
o
has been deteimined to 3 OA resolution as a complex with a transition state analogue 
(Haynes et a l , 1994) The structural data suggest that the antibody stabilizes the same 
conformationally restricted pencycle transition state that occurs in the uncatalysed 
reaction The structure of this antibody-hapten complex provides confirmation that the 
properties of an antibody catalyst faithfully reflect the design of the transition state 
analogue which could be an aid in detei mining their structure
Genetic selections or screens have yet to be exploited for the generation of catalytic 
antibodies which may allow the generation of catalytic antibodies from substrate specific 
antibodies However this approach will require more efficient yeast and bacterial 
expression systems Clearly the most promising method for the generation of new 
catalytic antibodies with rate enhancements comparable to enzymes is the combination 
of two or more highly successful strategies New approaches will become increasingly
302
important as different strategies aie combined to make efficient, tailorable catalysts for 
application in biotechnology, chemistry and medicine and for environmental and 
industrial applications
The paradigm of Jencks (1969), " it should be possible to synthesise an enzyme 
by [preparing] an antibody to a haptemc group which resembles the transition state of 
a given reaction " is proving to be very fruitful for an increasing variety of model 
reactions The use of improved technologies combined with direct screening methodol­
ogies such as those presented in Tawfik et a l , (1993) promises to afford useful 
antibody-based catalysts for moie demanding chemical reactions and challenging 
biomedical applications
In summary, monoclonal antibodies weie produced which reacted with the phosphate 
immunogen (XI) (Gallachcr et a l , 1991) The sheep polyclonal antibody obtained from 
Dr Gallacher was purified and the results obtained for the catalysis of the hydrolysis 
of the mixed carbonate substrate (1) were m close agreement with those obtained by 
Gallacher et a l , 1991 Monoclonal antibodies were produced which reacted by ELISA 
with the phosphate immunogen (I) and did not react with the carrier proteins, KLH or 
BSA  These monoclonal antibodies isotyped as IgM An attempt was made to detect 
catalysis of these antibodies m cell culture supernatants, which was unsuccessful Ascitic 
fluid was produced, purified and characterised by ELISA, SDS-PAGE and HPLC This 
fluid was analysed for catalytic activity
&
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